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Abstract 
As the prevalence of Chronic Myeloid Leukaemia (CML) grows, due to the therapeutic 
success of tyrosine kinase inhibitors (TKI), we are witnessing increased incidences of drug 
resistance. Some of these patients have failed all currently licensed TKIs and have no 
mutational changes in the kinase domain that may explain the cause of TKI resistance. 
This poses a major clinical challenge as there are currently no other drug treatment 
options available for these patients. Therefore, our aim was to identify and target 
alternative survival pathways against BCR-ABL in order to eradicate TKI-resistant cells. 
To investigate alternative survival mechanisms in TKI-resistant CML cells, ponatinib-
resistant cell line models were generated, which show resistance to all current TKIs, 
despite complete inhibition of BCR-ABL activity. Additionally, DNA sequencing revealed 
no mutational changes within the BCR-ABL kinase domain, which may explain TKI 
resistance and RNA-sequencing showed an impaired transcriptional response following 
ponatinib treatment when compared with parental TKI-sensitive cells. 
Using these models, we demonstrated that the TKI-resistant cells acquired alternative 
activation of mTOR. Using clinically relevant dual PI3K and mTOR inhibitors; NVP-Bez235, 
VS-5584, apitolisib and gedatolisib, we validated the PI3K-AKT-mTOR pathway as a 
therapeutic target in vitro in TKI-resistant CML cell lines and more importantly in bone 
marrow derived mononuclear cells from CML patients resistant to TKIs and with no 
known kinase domain mutational changes.  
We demonstrated in vitro that TKI-resistant cell lines are highly sensitive to PI3K and 
mTOR inhibitors, with EC50 values less than 30 nM compared to ponatinib, 647.3 nM. 
These inhibitors reduced cell viability by causing a significant induction of apoptosis and 
significant decrease in the clonogenic growth of primary TKI-resistant CML patient 
samples.  
Furthermore, we showed that NVP-Bez235 induced autophagy as a protective mechanism 
following PI3K/mTOR inhibition. The combination of NVP-Bez235 with pharmacological 
(Hydroxychloroquine (HCQ)) or specific autophagy inhibition, via ATG7 knockdown, the 
efficacy of NVP-Bez235 was enhanced shown by the dramatic reduction in clonogenic 
growth of TKI-resistant CML patient cells. In addition, we validated this in vivo using a 
murine model by transplanting luciferase tagged TKI-resistant cells, treated with NVP-
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Bez235 in combination with HCQ, which significantly reduced tumour burden and 
increased survival rates compared to controls.  
These data suggested that the PI3K-AKT-mTOR pathway may be a key player responsible 
for TKI-resistance and that pharmacological inhibition of this pathway, with the additional 
inhibition of autophagy, may represent a potential new treatment option for TKI-resistant 
CML patients, when resistance is driven by a BCR-ABL-independent mechanism.  
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1 Introduction 
 
1.1 History of haemopoietic stem cells  
 
Haemopoiesis is a beautiful example of the human body’s ability to orchestrate highly 
complex and regulated processes that are vital for the maintenance of life. The 
haemopoietic system is responsible for producing blood cells from all blood cell lineages 
and replenishing these cells throughout an individual’s lifetime. Most mature blood cells 
have short lifespans and therefore maintaining blood homeostasis relies heavily on the cells 
ability to self-renew and differentiate. These unique biological properties are held by a 
very rare but long lived cell population known as haemopoietic stem cells (HSCs).  
HSCs stand at the apex of the hierarchy of the haemopoietic system and have the ability to 
maintain themselves and generate all types of mature blood cells through a series of 
progenitor cells that become progressively restricted to several or single lineages (Orkin, 
2000). These progenitors create blood precursors devoted to unilineage differentiation and 
production of mature blood cells, including red blood cells, megakaryocytes, myeloid cells 
(monocyte/macrophage and neutrophil), and lymphocytes (figure 1-1). 
 
 
 
Figure ‎1-1: The Haemopoietic Hierarchy. 
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1.1.1 Development of the haemopoietic system 
In mammals, the production of haemopoietic cells is accomplished in two waves of 
haemopoietic activity; a primitive wave and a definitive wave (Galloway and Zon, 2003). 
The primitive wave begins early in embryonic development, within the yolk sac. The 
purpose of this wave is to produce erythrocytes which are able to oxygenate the embryo 
and to support its rapid proliferation (Orkin and Zon, 2008). Although blood cells are 
produced during this wave, they are transitory and are only produced to provide support to 
the embryo within its early development. 
The definitive wave is the first major phase of haemopoietic cell production and this occurs 
in the aorta, gonads and mesonephros (AGM) region.  This occurs around day 23 during 
human gestation, where the initial transient progenitors are produced (Bertrand et al., 2007, 
McGrath et al., 2011). By day 27 cells with the characteristic hallmarks of a HSC begin to 
emerge from the human embryonic aorta (Tavian et al., 2001). The HSCs divide and soon 
after migrate to the primary foetal haemopoietic centre, the liver. The HSCs continue to 
divide in the foetal liver and migrate through to the spleen and thymus, and just before 
birth the HSCs migrate to the primary adult haemopoietic centre, the BM, where they 
engraft, self-renew and differentiate (Cumano and Godin, 2007). 
1.1.2 Haemopoietic hierarchy 
Human and mouse haemopoiesis are historically described as cellular hierarchies, which 
are maintained by HSCs that reside at the apex of the pyramidal structure of differentiating 
blood cells. In murine haemopoiesis the HSC pool has two functionally distinct 
subpopulations, long-term HSCs (LT-HSCs) and short-term HSCs (ST-HSCs) (Morrison 
and Weissman, 1994). LT-HSCs have an extensive renewing potential and provide long-
term reconstitution of HSCs, while ST-HSCs have a limited self-renewal capacity.  
The standard haemopoietic model begins with a single LT-HSC and upon activation can 
give rise to a less primitive ST-HSC. The HSC population produces stem cell intermediates 
with less durable self-renewal, termed multipotent progenitor cells (MPPs). This is the 
final step before oligopotent and unipotent progenitors are produced, which have shorter 
life spans, are of higher frequency and differentiate into many functional blood cell types. 
MPPs can differentiate into two different common lineages; one for myelopoiesis; a 
common myeloid progenitor (CMP) or one for lymphopoiesis; a common lymphoid 
progenitor (CLP) (Akashi et al., 2000, Kondo et al., 1997). CLPs then differentiate and the 
potential to produce B-cells, T-cells, Natural Killer (NK) cells and dendritic cells. During 
25 
 
myelopoiesis the CMP population, produce more mature lineage restricted progenitor 
populations, such as megakaryocyte and erythroid progenitors, which go on to make 
platelets and red blood cells (RBCs). CMPs also produce granulocyte and monocyte 
progenitors, which differentiate into mast cells, eosinophils, basophils, neutrophils, 
monocytes, dendritic cells and macrophages (figure 1-1). 
 
1.1.3 HSC identification and isolation 
The human haemopoietic hierarchical model was based on a similar differentiation scheme 
as that of mouse haemopoiesis. Human HSCs were isolated and validated using the same 
isolation strategy previously used for mouse HSCs using immunophenotypic cell surface 
markers (Table 1-1). Cell populations were isolated using FACS analysis against the cell’s 
immunophenotypes and their activity was measured by conducting BM repopulation 
assays and methylcellulose colony-forming cell (CFC) assays. These experiments 
identified that different populations of cells vary in terms of their ability to reconstitute the 
haemopoietic system. However, the current model that human blood development occurs 
progressively through a series of multipotent, oligopotent, and then unilineage progenitor 
stages is being challenged (Notta et al., 2016).  Recent studies in John Dick’s Laboratory 
have proposed a redefined model, which includes a developmental shift in the progenitor 
cell architecture from the foetus, where many stem and progenitor cell types are 
multipotent, to the adult, where the stem cell compartment is multipotent but the 
progenitors are unipotent (Notta et al., 2016). Since the original experiments were carried 
out to identify and isolate haemopoietic cells, new markers have been identified and new 
isolation strategies are being proposed (Notta et al., 2016). 
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Cell Type Phenotype 
LT-HSC CD34+ 
CD38- 
CD90+ 
CD45RA- 
CD49f+ 
Lineage - 
MPP CD34+ 
CD38- 
CD90- 
CD45RA- 
CD49f- 
Lineage - 
CMP CD34+ 
CD38+ 
CD45RA- 
CD135+ 
CD7- 
CD10- 
CLP CD34+ 
CD38+ 
CD45RA+ 
CD7- 
CD10+ 
Mature cells CD34- 
Lineage+ 
Table ‎1-1: Immunophenotypes of haemopoietic cell populations 
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1.1.4 Haemopoietic stem cell characteristics and regulation 
The HSCs are the most important cells in haemopoietic cell production, as these cells are 
ultimately responsible for repopulating the whole haemopoietic system throughout life. 
Although HSCs are a very rare cell population, accounting for only 0.05% of cells within 
total BM population (Morrison et al., 1995), they have the capacity to produce all types of 
mature blood cells due to their multipotency and ability to self-renew. In order to do so, 
HSCs can either divide asymmetrically; producing one daughter cell that differentiates and 
becomes a committed progenitor cell and one daughter cell that retains HSC characteristics 
or HSCs can divide symmetrically producing two daughter cells that are committed 
progenitor cells or two new HSCs (Marley and Gordon, 2005). The combination of 
asymmetric and symmetric cell divisions controls haemopoiesis by maintaining the stem 
cell pool and the producing more mature progenitors. The daughter cell’s fate is highly 
regulated by many intrinsic factors as well as extrinsic factors, which are believed to come 
from the BM microenvironment, known also as the stem cell niche (Schofield, 1978).  
Another fundamental characteristic of HSCs is quiescence. HSCs exist in a quiescent state 
within the BM microenvironment. Cellular division is very infrequent and it is thought a 
single cell division occurs every 40 weeks (Catlin et al., 2011). Therefore, HSCs 
predominantly reside outside of the cell cycle in the G0 phase. However, HSCs can be 
rapidly activated to enter the cell cycle to regulate haemopoiesis following physiological 
demands. 
The maintenance of HSCs demands strict regulation between HSC quiescence and 
proliferation, which is maintained by a complex network of intrinsic and extrinsic factors. 
Essential intrinsic factors include cell cycle regulators, such as cyclin-dependent kinase 
(CDK) inhibitor p21
Cip1
 (Cheng et al., 2000), Rb family (Viatour et al., 2008), p53 (Liu et 
al., 2009), c-myc (Laurenti et al., 2008), PTEN (Yilmaz et al., 2006), RUNX1 (Jacob et al., 
2010), FOXO (Miyamoto et al., 2007), PU.1 (Staber et al., 2013), C/EBPa (Ye et al., 2013) 
and epigenetic regulators; Bmi1 (Park et al., 2003) and Dnmt3a (Challen et al., 2012). 
Extrinsic factors also have an important role in the maintenance of quiescent HSCs. It is 
believed that osteoblasts within the niche produce growth factors, extracellular matrices 
and other intracellular signals that are crucial for the long-term maintenance of HSC 
quiescence. Various signalling pathways have been implicated such as; Wnt/β-catenin 
signalling (Fleming et al., 2008), Notch signalling (Varnum-Finney et al., 1998), as well as 
Tie2/Angiopoietin-1 (Arai et al., 2004) and Mpl/Thrombopoietin (Qian et al., 2007, 
Yoshihara et al., 2007) interactions. The hypoxic environment of the niche is also a key 
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regulator of HSCs.  Hypoxia-inducing factors, such as HIF-1 (Takubo et al., 2010) 
contribute to the maintenance of HSC quiescence (Simsek et al., 2010). Due to low levels 
of oxygen in the BM microenvironment HSCs have a low oxidative metabolism and 
therefore use glycolysis  for energy production (Simsek et al., 2010). This also results in 
reduced reactive oxygen species (ROS) production, which is required to maintain self-
renewal and genomic stability (Suda et al., 2011).  
Another mechanism has been identified which allows HSCs to evade metabolic stress 
within the stem cell niche. It has been shown that quiescent HSCs require the efficient 
process of autophagy. Autophagy is a catabolic pathway, which sequesters unwanted 
cellular components into characteristic double-membrane vesicles, called autophagosomes, 
and delivers them to lysosomes for degradation (He and Klionsky, 2009). The energy 
produced through the degradation of the cellular components can then be used to maintain 
nutrient and energy levels during periods of metabolic starvation or stress (He and 
Klionsky, 2009). Through the ablation of essential autophagy gene, ATG7, it has been 
shown that efficient autophagy is required in order for quiescent HSCs to control 
mitochondrial mass, ROS levels, and genomic integrity (Mortensen et al., 2011). Warr and 
colleagues showed that autophagy was essential in protecting quiescent HSCs from growth 
factor fluctuations and nutrient deprivations that naturally occur in the BM 
microenvironment, especially after haemopoietic injury (Warr et al., 2013a). Any 
imbalance in these mechanisms could cause haematological disorders; (1) insufficient 
proliferation would impair haemopoiesis and cause BM failure, (2) whilst increased 
proliferation might lead to exhaustion of the HSC pool and therefore overproduction of 
various blood lineages, which could lead to the development of a haematological 
malignancy (Pietras et al., 2011).  
1.1.5  CML is a stem cell disease 
The concept of a cancer causing stem cell was first proposed in 1997 by Bonnet and Dick, 
when they were able to isolate different populations of haemopoietic stem and progenitor 
cells from acute myeloid leukaemia patients and assess their capacity to initiate leukaemia 
in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice or more commonly known as the NOD scid 
gamma (NSG). Their study showed that only the most primitive stem cell population 
(CD34
+
CD38
- 
) had the potential to induce leukaemia (Bonnet and Dick, 1997). Leukaemic 
stem cells (LSCs) have a similar phenotype to normal HSCs. It is thought that in CML the 
LSC arises from a HSC that has acquired mutations that promote leukaemic 
transformation, as LSCs retain stem cell characteristics such as the ability to self-renew, 
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but have also developed the ability to initiate leukaemia and cause metastasis and drug 
resistance (Reya et al., 2001). 
1.2 Chronic Myeloid Leukaemia 
Chronic myeloid leukaemia (CML) is one of the biggest success stories of modern 
medicine. Research in this field was the first to provide evidence of a genetic link to 
cancer. Historically, in 1960 Peter Nowell and David Hungerford identified that leukaemic 
leukocytes from patients suffering from CML had “small but definite chromosomal 
changes”. This study revealed an abnormally short chromosome 22, which they called the 
Philadelphia (Ph) chromosome (Nowell and Hungerford, 1960). Initially, Ph chromosome 
was thought to be caused by a genetic deletion, however in 1973, due to the development 
of new cytogenetic techniques, Dr. Janet Rowley karyotyped CML patients cells and 
demonstrated that the Ph chromosome developed as a consequence of a specific 
chromosomal translocation (Rowley, 1973). This abnormality resulted from the reciprocal 
translocation of the long arm of chromosome 9 replacing the long arm of chromosome 22, 
t(9:22)(q34:q11) (Rowley, 1973) (figure 1-2). Consequentially, this leads to the generation 
of an abnormal fusion between c-Abl
+
 (human homologue of the Abelson Murine 
Leukaemia virus) a tyrosine kinase encoding oncogene, native to chromosome 9 and Bcr
+
 
(Breakpoint Cluster Region), native to chromosome 22
 
(Groffen et al., 1984). This 
chimeric fusion gene encodes a 210 kDa oncoprotein (p210 BCR-ABL), which possesses 
increased and constitutively active tyrosine kinase activity (Konopka et al., 1984, Daley et 
al., 1990). It is this abnormal activity, which promotes cellular transformation and 
ultimately the development of leukaemia (Konopka et al., 1984, Daley et al., 1990).  
The most striking evidence of this was shown by various mouse model experiments, where 
murine BM was infected with retrovirus encoding p210 BCR-ABL and was transplanted 
into recipient mice. Transplant recipients developed a myeloproliferative syndrome closely 
resembling the chronic phase (CP) of human CML. Therefore demonstrating that BCR-
ABL is necessary and sufficient for the development and maintenance of the disease 
(Daley et al., 1990, Elefanty et al., 1990, Heisterkamp et al., 1990, Kelliher et al., 1990). 
The origin of this myeloproliferative disorder has been shown to arise as a consequence of 
a rare event in a single haemopoietic stem cell. Evidence that CML is a clonal disease was 
first demonstrated in 1967 following a study of three female CML patients. These patients 
were heterozygous for an X-linked gene, glucose-6-phosphate dehydrogenase, however the 
CML cells from the patients only expressed one of the genes suggesting that these cells 
originated from a common stem cell and that CML cells are  clonal in origin, which leads 
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to the expansion of transformed, primitive haemopoietic progenitor cells (Fialkow et al., 
1967, Fialkow).  
 
Figure ‎1-2: The Philadelphia Chromosome.  
This mutation develops due to a translocation involving the long arm of chromosome 9 replacing 
that of chromosome 22 t(9:22)(q34:q11) and vice versa. In doing so leads to the fusion of two 
genes Bcr+ and Abl+, which encodes oncoprotein BCR-ABL. 
1.2.1 CML epidemiology and clinical characteristics 
The annual incidence rate of CML varies between countries, however current data from 
large scale studies, such as the European study EUTOS, showed an incident rate of 0.99 
per 100,000/year (Hoffmann et al., 2015) and in the USA study, SEER, it was published 
that an incidence rate as high as 1.8 per 100,000 was predicted (Chen et al., 2013). 
However closer to home in the UK and more particularly Scotland it has been reported that 
incident rates are 0.7 per 100,000 (Smith et al., 2014) and 0.64 per 100,000 per year 
(Harrison et al., 2004) respectively, which is much lower than predicted globally. These 
incidences of CML account for 15% of all adult leukaemia diagnosed globally (Faderl et 
al., 1999b). The median age for patients at diagnosis is 45 to 55 years (Faderl et al., 
1999b), however in the UK, Cancer Research UK state that 50% of diagnosed patients are 
65 and over. It is thought that about 50% of these cases are diagnosed through routine 
check-ups as a significant number of patients are asymptomatic or present with mild 
symptoms, such as fatigue, weight loss, fever, abdominal fullness, bleeding, purpura, 
splenomegaly, leukocytosis, anaemia, and thrombocytosis, which are fairly general and 
could account for a number of benign disorders.  
CML is characterised by its biphasic or triphasic progression and approximately 90% of 
patients who are newly diagnosed are in the first phase of the disease, known as chronic 
phase (CP). Patients in CP have fairly mild symptoms, if not asymptomatic. However, as 
CML develops leukaemic cells lose the ability to differentiate resulting in an expansion of 
primitive blast cells rather than mature granulocytes. CP patients typically have less than 
10% blasts in their peripheral blood or BM, therefore the blood cells are mainly 
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differentiated and minimally invasive (Faderl et al., 1999b). Unless controlled, 3-5 years 
after the onset of CML the disease will progress. CP patients can advance to an 
intermediate phase called accelerated phase, however a quarter of patients are thought to 
progress straight to blast crisis (Kantarjian et al., 1993). Accelerated phase (AP) is 
characterised by 10-20% blasts in the peripheral blood and BM, a high basophil count of 
20% or more in the peripheral blood and BM, a high WBC, thrombocytopenia, 
thrombocytosis, splenomegaly and cytogenetic clonal evolution (Kantarjian et al., 1993). 
Eventually patients progress to the terminal stage, blast crisis (BC), which can display as 
either myeloid or B-lymphoid. In this phase there is a further increase in the cellular 
expansion of the immature blasts to 30% or more in the peripheral blood and BM, due to 
newly developed cytogenetic changes. Blast cells also exhibit enhanced proliferation and 
have acquired the ability to evade apoptosis. At this end stage, blast cells have become so 
aggressive that they have infiltrated extramedullary sites. Patients in BC have a very poor 
prognosis with a median survival rate of 3-6 months (Kantarjian et al., 1987).  
CML disease progression is a complex process characterised by the increase in 
proliferation, a block in differentiation and cytogenetic clonal evolution. Genomic 
instability causes the continuous generation of subclones (Jiang et al., 2007, Bolton-
Gillespie et al., 2013), and inevitably the progression to BC. However, the molecular 
events that occur to trigger disease progression from CP CML to advanced AP or BC are 
unknown.  The accumulation of various different chromosomal abnormalities have been 
implicated in the transition from CP to an advanced disease (AP or BC), such as double Ph 
chromosome, trisomy 8, and isochromosome 17 (Spiers and Baikie, 1968, Rowley, 1975). 
These abnormalities are found in 50-75% of advanced stage patients (Muehleck et al., 
1984, Rowley, 1975, Spiers and Baikie, 1968, Spiers, 1979). As well as these 
chromosomal rearrangements, gene deletions, insertions and point mutations are also 
involved, which may suggest that a second hit is important for the transformation to an 
acute leukaemia.  At the molecular level, the most common mutations to occur are of p53, 
RUNX1, CDKN2A/B and IKAROS. More recently Jak1, Flt3, Nf1, Erg and Mll3 have also 
been implicated in disease progression (Giotopoulos et al., 2015). However, as these 
genetic changes are relatively common and none of these lesions occur solely in the 
majority of patients, it is likely that it is a combination of different mutations that result in 
BC (Perrotti et al., 2010).  
One of the main markers of aggressive progression into BC is the overexpression of BCR-
ABL1 in committed progenitors, this leads to various genetic and epigenetic events. This 
has been shown to impact upon the transcriptome, resulting in altered gene expression of 
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SOC-2 (Schultheis et al., 2002), which is involved in PI3K and MAPK signalling, IGF-1, 
which is involved in RAS signalling, as well genes involved in the WNT/β-catenin 
pathway,  all of which may play a role in BC (Radich et al., 2006). Overexpression of 
BCR-ABL1 may also result in the constitutive activation of factors involved in mitogenic, 
anti-apoptosis and anti-differentiation, such as MAPKERK1/2, MYC, JAK2, YES-1, LYN, 
hnRNP-E2, MDM2, STAT5, BMI-1, and Bcl-2,  as well as, inhibiting key tumour 
suppressors such as p53, C/EBPa and PP2A (Calabretta and Perrotti, 2004a, Melo and 
Barnes, 2007, Chang et al., 2007).  
1.2.2 Diagnosis and monitoring 
As previously discussed, the symptoms of CML are not specific and include; weight loss, 
weakness, fever, night sweats, and malaise. Therefore, an assumed diagnosis is usually 
made via blood counts indicating leukocytosis with basophilia with a more in depth 
assessment made with a blood film demonstrating immature granulocytes, mainly 
metamyelocytes, myelocytes and promyelocytes, and few or occasional myeloblasts being 
indicative of CML.  
However the gold standard diagnostic observation for CML is the detection of the Ph 
chromosome, which is found in 95% of CML patients (Faderl et al., 1999b). The most 
sensitive methods for the identification of the Ph chromosome are cytogenetic analysis and 
fluorescence in-situ hybridization (FISH). Cytogenetic analysis allows for the screening of 
additional chromosomal abnormalities, which may be indicative of a more advanced stage 
of disease (Egan and Radich, 2015). Therefore these methods help establish a diagnosis of 
CML, the disease staging and the potential response to therapy (Egan and Radich, 2015). 
Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) testing is the 
most sensitive method for detection of BCR-ABL mRNA. BCR-ABL transcripts in a 
single CML cell in a background of up to at least 100,000 normal cells can be detected 
using current methods (Egan and Radich, 2015). This high level of sensitivity allows for 
less invasive monitoring within the peripheral blood. BCR-ABL transcript levels 
determined by qRT-PCR are highly correlated with disease burden and is used along with 
FISH to monitor patients response after stem cell transplantations or the efficacy of 
treatment (Faderl et al., 1999b).  
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1.2.3 BCR-ABL structure 
The Ph translocation forms the aberrant fusion gene BCR-ABL by adding a 3’ end fragment 
of the ABL gene to part of the 5’ end of the BCR gene. The BCR gene is located on 
chromosome 22 and spans over 130 kilobases (kb) and encodes two proteins, which are 
160kDa and 130kDa in size. BCR is expressed ubiquitously, but the highest levels of 
mRNA are found in the brain and haemopoietic cells (Collins et al., 1987, Frit et al., 1999, 
Maru et al., 1999). Although the function of BCR is still not very well defined, it has been 
associated with the XPB protein, which has a role in DNA repair, transcription initiation 
and cell cycle regulation. The c-ABL (Abelson) gene is located on chromosome 9, it has 11 
exons and is over 230 kb long. It encodes for a 145 kDa protein, which is a member of a 
family of non-receptor kinases (Kurzrock et al., 1988). c-ABL is also ubiquitously 
expressed and has a major role in regulating cell cycle progression (Van Etten, 1999). In 
quiescent cells retinoblastoma (Rb) protein binds to the ABL protein to inhibit ABL 
activity. When cells re-enter the cell cycle Rb is phosphorylated and dissociates from ABL, 
which then becomes activated and is subsequently phosphorylated by CDC2 kinases to 
allow progression through the cell cycle (Sawyers et al., 1994).  
The break point of ABL usually occurs 5’ of exon 2 and therefore exons a2-a11 are 
transposed into the major breakpoint cluster region of BCR. This usually occurs between 
exon 12 and 16, also known as b1 to b5. The breakpoint locations on BCR usually occur 
between b2 and b3 and this creates a BCR-ABL fusion gene with a b2a2 or b3a2 junction, 
which is transcribed into an 8.5 kb mRNA. The mRNA is then translated into a chimeric 
protein of 210 kDa called p210 BCR-ABL (Kurzrock et al., 1988).  
1.2.4 BCR-ABL functional domains 
Both BCR and ABL proteins possess structural elements, which work together or 
individually to promote the leukaemogenic transformation. ABL has important roles in 
regulation of cell growth but also in signal transduction, due to three functional domains at 
the N-terminus that have a similar homology to Scr family kinases. These are termed SCR 
homology domain (SH) 1, 2 and 3. SH1 possesses the tyrosine kinase activity of p210 
BCR-ABL, and plays an important role in phosphorylating proteins. SH1 is flanked by 
SH2 and SH3, at the N-terminal end, and are both involved in protein-protein interactions 
required for the protein signalling (Pawson, 1995, Feller et al.).  
In addition, at the c-terminus of ABL there is a nuclear localisation domain, DNA binding 
domain and actin binding domain (Van Etten et al., 1994). BCR has multiple functional 
domains, the most critical are; the dimerization domain, which has a coiled-coil (CC) 
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motif, and has been shown to increase tyrosine kinase activity (McWhirter et al., 1993), a 
serine-threonine kinase domain, which activates signalling pathways regulated by ABL 
tyrosine kinase activity, as well as BCR-ABL (Reuther et al., 1994). BCR also has a Rho 
guanine-nucleotide exchange factor (Rho-GEF) domain, a calcium- dependent lipid 
binding site and a Rac GTPase activating protein (Rac-GAP) domain (Boguski and 
McCormick, 1993, Diekmann et al., 1991).  
The N-terminal fusion of BCR to ABL appends a large amino acid sequence to the SH2 
domain of ABL, this deregulates the SH3 domain and allows the tyrosine kinase activity of 
ABL to become constitutively active (Pendergast et al., 1991, Kurzrock et al., 1988). 
As well as being constitutively active, BCR-ABL has much higher tyrosine kinase activity 
compared to the native c-ABL protein (Kurzrock et al., 1988).  
It is this constant high level of tyrosine kinase activity which causes malignant 
transformation. In order to understand the underlying molecular mechanisms that lead to 
this transformation, experiments have been performed mainly using retrovirally transduced 
cellular models (Daley et al., 1990). It has been shown that BCR-ABL has many targets 
and activates many signalling pathways to protect the cells from apoptosis and maintain 
their pathogenicity by altering cellular mechanisms such as proliferation and 
differentiation, cell adhesion and survival (Afar et al., 1994, Jiang et al., 2000, Puil et al., 
1994, Sawyers, 1993, Bhatia et al., 1999, Gordon et al., 1987, Bedi et al., 1994, Cortez et 
al., 1995, Cotter, 1995, McGahon et al., 1994). This comes as no surprise, due to the 
number of diverse binding domains BCR-ABL possesses.  
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1.2.5 BCR-ABL oncogenic pathway 
BCR-ABL targets a large variety of signalling pathways, however the major contributors 
to malignant transformation include; the Janus-activated kinase (JAK)-STAT pathway, 
which effects transcriptional response, Ras-mitogen-activated protein kinase (MAPK), 
effects proliferation, and the phosphoinositide 3-kinase (PI3K)/AKT/mTOR, which effects 
apoptosis (Raitano et al., 1995, Skorski et al., 1997, Skorski et al., 1995a, Warmuth et al., 
1999, 1995).  
It is a combination of these cellular signals, which leads to the characteristic phenotype of 
CML cells; increased proliferation, ability to evade apoptosis, growth factor independence 
and genomic instability.  
BCR-ABL also effects adaptor proteins such as CRKL, c-CBL and cytoskeleton and cell 
membrane mediating proteins, such as actin, paxillin and FAK/PYK2, which cause cell 
adhesion  and cytoskeleton defects and results in the abnormal entry of immature cells into 
the peripheral blood and extramedullary tissues (Salgia et al., 1997, Sattler et al., 2002b, 
Salesse and Verfaillie, 2002). 
 
1.2.5.1 JAK-STAT pathway  
The JAK-STAT pathway is an important signalling pathway, which regulates the 
transcription of genes in normal haemopoiesis. This pathway is activated when 
haemopoietic growth factors bind to their receptors. This in turn activates the intracellular 
tyrosine kinase JAK2, which subsequently phosphorylates the signal transducer and 
activator of transcription factor 5 (STAT5). JAK2 and STAT5 form a dimer and 
translocate to the nucleus, where STAT5 can regulate transcription (Ward et al., 2000). 
The importance of the JAK2/STAT5 pathway in haemopoiesis has been demonstrated in in 
vivo studies, as it was shown that JAK2
-
/
- 
embryos become anaemic and die around day 
12.5 postcoitum(Neubauer et al., 1998, Grundschober et al., 2014, Park et al., 2013). 
Several studies have shown that both JAK2 and STAT5 are constitutively active in BCR-
ABL+ cells (Chai et al., 1997, 1996) and that this abnormal activity promotes 
leukaemogenesis. More specifically, STAT5 has been shown to support leukaemogenesis 
by assisting in the inhibition of apoptosis via the Bcl-2 family proteins such as MCL-1 and 
Bcl-XL (Gesbert and Griffin, 2000, Mei Huang, 2002). Whereas, JAK2 has been reported 
to activate c-myc mRNA expression and protect c-myc protein from degradation, therefore 
acting as a cooperative oncogene (Shanhai Xie, 2002). JAK2 has also been implicated in 
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promoting leukaemogenesis in a study where BCR-ABL+ cells were transduced with an 
inactive form of JAK2, which reduced clonogenic potential and disease burden (Shanhai 
Xie, 2001). 
1.2.5.2 The GRB2 adaptor  
One of the most critical pathways for leukaemic transformation is induced by BCR via the 
tyrosine residue at position 177 (Y177). BCR-ABL induces autophosphorylation of this 
site, which has been identified as a major Grb-2-binding site (Pendergast et al., Puil et al., 
1994). Grb-2 acts as an adaptor molecule, which activates the Ras and PI3K signalling 
pathways (Cortez et al., 1995, Goga et al.). 
The importance of this process was shown in vivo where a mutation at the Y177 site, 
changing tyrosine to phenylalanine (Y177F) abolished Grb-2 binding and turns off BCR-
ABL-driven activation of Ras, which extended the life expectancy of the mice (Million and 
Van Etten, 2000).  
1.2.5.3 Activation of the RAS pathway  
Ras proteins are responsible for regulating cell signalling pathways involved in cell 
growth, migration, adhesion, cytoskeletal integrity, survival and differentiation. Ras was 
first discovered as a retroviral oncogene in a study of the Harvey sarcoma virus and 
Kirsten sarcoma virus (Chang et al., 1982). Ras proteins sit at the top of a signalling 
cascade known as the Ras-Raf-MEK-MAPK pathway, which is thought to be deregulated 
in approximately 20% of all human cancers, promoting tumour growth and disease 
progression (Rajalingam et al., 2007). 
As explained the Grb-2 adaptor molecule binds to the Y177 residue of BCR-ABL to create 
the BCR-ABL-Grb-2 complex, which recruits Son of Sevenless (SOS) (David Cortez, 
1997). The BCR-ABL-Grb-2- SOS complex then stimulates the conversion of the inactive 
GDP-bound form of Ras to its active GTP bound form (Ren, 2005). The BCR-ABL-Grb-2-
SOS complex also activates Grb-2-associated binding protein 2 (GAB2), which is also 
recruited to the complex. As a result, the Grb-2/GAB2/SOS complex is formed, and this 
causes a constitutive activation of Ras and its signalling pathway (Sattler et al., 2002a). 
The pathway begins with the active form of Ras activating a serine/threonine-selective 
protein, Raf. Raf then phosphorylates MEK and ultimately leads to the activation of ERK, 
now known as MAP kinase (MAPK). MAPK is involved in regulating transcription and 
translation of genes important for the cell cycle, via an indirect activation of the ribosomal 
protein S6 (RPS6). Therefore, deregulation within this pathway will alter cell cycle 
regulation and promote abnormal cell proliferation.  
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1.2.5.4 PI3K-AKT-mTOR signalling pathway 
The PI3K-AKT-mTOR signalling pathway is involved in many essential cellular processes 
such as survival, proliferation, differentiation, metabolism and motility (Fruman et al., 
1998). It has been found to be deregulated in a high percentage of human cancers (Kapeller 
and Cantley, 1994), including CML, where PI3K has been shown to play an essential role 
in BCR/ABL leukaemogenesis. The major mode of activation of the PI3K signalling 
pathway in CML is via the Grb-2 adaptor molecule. As previously described Grb-2 binds 
to the Y177 residue of BCR-ABL, this leads to the recruitment of GAB2. GAB2 possesses 
a YXXM motif, which is phosphorylated by BCR-ABL and this then acts as a binding site 
for PI3K regulatory subunits, which activates the PI3K/AKT/mTOR pathway (Sattler et 
al., 2002a). PI3K is an intracellular lipid kinase that phosphorylates phosphatidylinositol. 
There are various classes of PI3Ks; however, the ones involved in BCR-ABL signalling 
are class IA. PI3Ks are heterodimers consisting of a catalytic and a regulatory subunit. 
There are three genes that code for the 110-kDa catalytic subunits (p110α, p110β, and 
p110δ) and three genes that code for regulatory subunits (p85α, p85β, and p55γ) (Kharas 
and Fruman, 2005). It is not yet clear, which PI3K isoforms are essential for BCR-ABL 
transformation as haemopoietic cells express all three class IA PI3K catalytic isoforms as 
well as the class IB isoform (p110γ) (Gritsman et al., 2015). Once activated via the 
regulatory subunit, PI3K, with the use of the catalytic domain, converts phosphoinositide-
4,5-bisphosphate (PIP2) to phosphoinositide-3,4,5-trisphosphate (PIP3), an important 
second adaptor molecule (Vanhaesebroeck et al., 2001). PIP3 creates a docking site for 
proteins that contain pleckstrin homology domains, such as AKT and PDK1 (Divecha and 
Irvine, 1995). AKT is localised to the lipid membrane and binds to PIP3, this allows PDK-1 
to activate AKT via phosphorylation at the threonine 308 residue (Alessi et al., 1996, 
Alessi et al., 1997). 
AKT is a serine/threonine kinase and was first isolated in its active form from the cells of 
leukaemia and lymphoma prone mice (Staal, 1987, 1988). AKT has a number of 
potentially important substrates that link it to a number of biological processes, which may 
be important in leukaemogenesis. Such substrates include; the forkhead box subgroup O 
(FOXO) transcription factors, which regulate cell cycle and promote cell survival, growth 
and proliferation in CML cells (Komatsu et al., 2003). Bad, which inhibits apoptosis via 
Bcl-2 and Bcl-XL dissociation, which allows Bcl-XL to bind to Bax molecules and prevent 
the formation of pro-apoptotic Bax homodimers (Datta et al., 1997, M Andreeff, 1999). 
Murine double mutant 2 (MDM2) oncogene, which is phosphorylated by AKT to suppress 
p53 expression, which inhibits p53 mediated apoptosis (Mayo and Donner, 2001, Goetz et 
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al., 2001, Trotta et al., 2003). However, the substrate of AKT, which is most important in 
CML leukaemogenesis, is Tuberous Sclerosis-2 (TSC-2) as it activates the Mammalian 
Target of Rapamycin (mTOR) pathway. Active AKT phosphorylates TSC-2, which blocks 
TSC-1/2 complex formation and therefore its ability to inhibit Rheb. Rheb is then free to 
activate mTOR. mTOR is a highly conserved serine threonine kinase, which is composed 
of two complexes. The first is mTOR complex 1 (mTORC1), which is made up mTOR, 
regulatory-associated protein of mTOR (RAPTOR), the mammalian LST8/G-protein β-
subunit like protein (mLST8/GβL), PRAS40 and the DEP domains interactor of mTOR 
(DEPTOR) (Kim et al., 2003, Kim et al., 2002). mTORC1 is a master growth regulator that 
senses diverse nutritional and environmental cues, including growth factors, energy levels, 
cellular stress, and amino acids (Koo and Squazzo, 1994). It then uses these signals to 
promote cell growth by phosphorylating substrates that potentiate anabolic processes, such 
as mRNA translation and lipid synthesis, as well as processes such as autophagy (Bhaskar 
and Hay, 2007, Wullschleger et al., 2006).  
Two important targets of mTOR are ribosomal S6 kinase (RPS6K) and the eukaryotic 
translation initiation factor 4E-binding protein 1 (4E-BP1). mTOR phosphorylates 4EBP-1, 
which blocks its ability to inhibit eIF4E. This releases the eIF4E protein, which is then free 
to bind to the 5′-cap structure of mRNAs and increase in cap-dependent translation 
efficiency (Pause et al., 1994).  
mTOR also phosphorylates RPS6K and is further phosphorylated by PDK1 to initiate 
activation of RPS6K (Pullen et al., 1998). This then activates RPS6 protein of 40S 
ribosomes to allow protein synthesis (Peterson and Schreiber, 1998). RPS6K can also 
feedback to mTORC1 to stimulate mTOR activity (Chiang and Abraham, 2005).  
The second complex, mTOR complex 2 (mTORC2), is composed of mTOR, (RAPA; aka 
sirolimus)-insensitive companion of mTOR (RICTOR), mLST8/GβL and the mammalian 
stress-activated protein kinase interacting protein 1 (mSIN1) (Frias et al., 2006, Dos et al., 
2004). mTORC2 promotes cell survival by forming a feedback loop, which phosphorylates 
and activates AKT via the serine 473 residue (Sarbassov et al., 2005). It also regulates 
cytoskeleton dynamics by activating protein kinase Cα (PKCα) and the small GTPases 
(RHOA, CDC42 and RAC1) as well as controlling ion transport and growth via SGK1 
(Mori et al., 2014). 
The importance of PI3K-AKT-mTOR pathway in CML leukaemogenesis has been shown 
in a study expressing an inactive form of AKT, which greatly diminished BCR-ABL-
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dependent myeloid colony formation (Skorski et al., 1997) It has also been discussed that 
cancer cells that are highly dependent of AKT, also rely on the subsequent activation of 
mTOR for tumourigenesis and are thought to be addicted to mTOR activity (Guertin and 
Sabatini, 2007).  
The PI3K pathway is negatively regulated by phosphatases, specifically PTEN. PTEN is a 
lipid and protein phosphatase that removes the 3-phosphate from the PIP3 to produce PIP2, 
which prevents AKT activation (Wu et al., 1998). PTEN is considered a tumour suppressor 
and is frequently mutated in human cancer (Dahia et al., 1999).  
1.2.5.5 CRKL adaptor protein 
CRKL is an adaptor protein for BCR-ABL (ten Hoeve et al., 1994). It is ubiquitously 
expressed and expresses high tyrosine phosphorylation activity during embryogenesis, 
however this activity becomes more restricted in adult tissues (de Jong et al., 1995). 
However, in CML patients, CRKL is constitutively tyrosine phosphorylated (ten Hoeve et 
al., 1994, Oda et al., 1994, Nichols et al., 1994). CRKL contains an SH2 domain and two 
SH3 domains and has been shown to be an important BCR-ABL target, as its high 
phosphorylation activity was found in neutrophils from the peripheral blood of CML 
patients (Oda et al., 1994). Since this study, further information has been elucidated, and it 
has been demonstrated that CRKL interacts with BCR-ABL through a SH3 domain and is 
phosphorylated on tyrosine 207 (de Jong et al., 1995). Although the main function of 
CRKL in CML is still unknown, it has been linked to paxillin, which may imply a role in 
cytoskeleton reorganization and integrin-mediated signalling pathways (Salgia et al., 
1995). CRKL has also been implicated in PI3K binding and therefore may also initiate the 
PI3K/AKT/mTOR signalling pathway (Sattler et al., 1997). Despite the main function of 
CRKL in CML being unknown, it is still a prominent substrate of BCR-ABL and is the 
gold standard marker for measuring BCR-ABL activity (Grumbach et al., 2001, Druker et 
al., 2001b). 
1.2.6 BCR-ABL mimics growth factor signalling  
Another survival mechanism used by CML cells to promote cell proliferation and survival 
is growth factor mimicking. Normal haemopoietic cells cannot survive without the support 
of growth factors. They use cytokines, such as Interleukin-3 (IL-3) and granulocyte colony 
stimulating factor (G-CSF), which bind to receptors on the cells and upon activation of 
signalling pathways such as RAS-MEK-ERK, PI3K-AKT-mTOR and JAK-STAT, 
promote proliferation and differentiation. However, one very obvious feature observed in 
vitro when studying the effect BCR-ABL has on normal cytokine-dependent cell lines is 
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they no longer need cytokines to proliferate (Daley and Baltimore, 1988, Lugo and Witte, 
1989, Kabarowski et al., 1994). This observation was further supported by later studies, 
which showed in vivo that mice with a CML-like disease induced by BCR-ABL have 
developed an autocrine mechanism to produce IL-3 and GM-CSF (Zhang and Ren, 1998, 
Li et al., 1999). In order to prove this mechanism was also true for primary CML cells 
proved difficult. However, in 1986 Eaves and colleagues showed that CML cells were 
actively cycling, whether cultured in the presence of supportive stromal cells or as a single 
cell suspension. Since this observation and due to the generation of more sensitive 
techniques it was found that CD34
+ 
CML cells from CP patients had consistent activation 
of IL-3 and G-CSF associated with growth factor independent proliferation (Jiang et al., 
1999). Mimicking of physiological growth factor stimulation, obviously gives cells a 
growth advantage and must play a significant part in malignant transformation and 
maintenance of CML cells (Jiang et al., 1999). 
1.2.7 BCR-ABL alteration of the HSC niche  
Increasing evidence from current research shows that the BM microenvironment is also an 
important factor to consider in order to fully understand leukaemic cells survival 
mechanisms. It has been shown that LSCs can reprogram the environment in order to 
favour their growth above normal HSCs. An example of this was shown when Schepers 
and colleagues found that when BCR-ABL is expressed in haemopoietic cells secondary 
genetic changes occur within the microenviromental cells which would support the 
survival of the leukaemic cells. They demonstrated that upon BCR-ABL transformation 
there was a marked decrease in osteolineage mesenchymal cell expression of molecules 
that support normal haemopoiesis, such as CXCL12 and Kit ligand  (Schepers et al., 2013). 
This shifted the balance in favour of leukaemic cells and provides evidence that BCR-ABL 
cells can effectively remodel the niche for their advantage adding more complexity to the 
molecular mechanisms used by leukaemic cells for their survival.   
Furthermore, a recent study conducted by Welner and colleagues showed that the exposure 
to chronic myeloid leukaemia (CML) caused normal mouse hematopoietic progenitor cells 
to increase division, alter their differentiation, and reduce their reconstitution and self-
renewal potential. They also reported that the normal cells also acquired gene expression 
patterns similar to that of the CML cells, which implied the leukaemia signature was 
mediated by extrinsic factors. In this study, IL-6 was deemed responsible for most of these 
changes as neutralization of IL-6 prevented these changes and treated the disease (Welner 
et al., 2015).  
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1.3 History of CML treatment  
The first known treatment of a CML patient was described in 1882 by Arthur Conan 
Doyle, a physician from Birmingham, UK. He described his patient as presenting with 
“leucocythaemia”, which was thought to be due to malaria. He first prescribed a malaria 
treatment of quinine and iron for the anaemia; however, no change was seen in the 
patient’s symptoms. Another known treatment at that time, for malaria, was a 1% arsenic 
trioxide solution. The arsenic solution was reported to improve the clinical condition of 
CML patients, as at an appropriate dose it controlled fever, reduced the white blood cell 
count, reduced the size of the spleen, relieved pruritus, and reduced the degree of anaemia 
(CE, 1938), however for the treatment of CML these effects were short-lived. 
In the early 1900s with the discovery of x-rays, it was found that if irradiation was directed 
to the spleen of patients with CML it reduced splenomegaly and to a degree normalised the 
patient’s blood cell counts and general health status (WA, 1902, Senn, 1903). Although 
this treatment gave patients a better quality of life it did not cure patients nor prolong the 
life expectancy of these patients (Hoffman and Craver, 1931, Minot et al., 1924).  
The increased understanding of cancer biology throughout the 1900s led to cancer drug 
discovery programmes becoming more focused on DNA synthesis and cell division. This 
resulted in the generation of chemotherapeutic agents. The first chemotherapy used to treat 
leukaemia came from chemical weapons created in WWII. It was known that mustard gas 
had myleosuppressive effects and therefore provided a good rationale for its use in the 
treatment of leukaemia (Goodman et al., 1984, Jacobson et al., 1946).  Although it showed 
some efficacy, it was highly toxic. Therefore, this spurred on studies to produce a variety 
of antimetabolites, alkylating agents and microtubule destabilizers that were less toxic, 
such as busulphan. Although they proved highly effective in controlling clinical features of 
CML for long periods of time, they were still highly toxic due to their non-specificity, 
which left patients with severe side effects (Galton, 1953, Galton, 1959, Haddow and 
Timmis, 1953). 
In the 1979, the first successful BM transplantations were recorded in CML patients. They 
were treated with high-dose chemoradiotherapy followed by a transfusion of BM cells 
from their genetically identical, normal twins (Fefer et al., 1979). This led to the initiation 
of programs for treating CML patients by allogeneic stem cell transplantation (Champlin et 
al., 1982, Clift et al., 1982, Goldman et al., 1982, McGlave et al., 1982). Although, 
transplantation resulted in great survival rates, it could only be offered to 20% of CML 
patients due to limitations, in age, physical health, and donor availability (Goldman, 1998). 
42 
 
It also only showed high 5-year survival rates in low-risk patients, 72%, which was 
reduced to 20% in high-risk patients (Gratwohl et al., 1998). Patients undergoing 
transplantation also demonstrated increased morbidity and mortality due to infections, 
mucositis, graft failure or graft-versus-host disease (Faderl et al., 1999a, Sawyers, 1999). 
In the 1980s, came the discovery of biological agents, interferons which have 
immunomodulatory, antiviral, and antiproliferative properties, all of which make them 
highly attractive prospects for anti-cancer therapy. The cytokine interferon α (IFNα) 
offered an alternative less toxic treatment for the management of CML, compared to 
previous chemotherapies. IFNα effectively stabilised CML symptoms and prolonged life 
expectancy. One of the most significant observations in patients following IFNα treatment 
was that many patients became Ph negative and transformation rates into BC were much 
reduced (Talpaz et al., 1983). 
 However, the most significant breakthrough occurred due to the discovery of BCR-ABL 
and its constitutive tyrosine kinase activity being the driving force of cellular 
transformation in CML. The enzymatic activity of this deregulated gene could plausibly be 
defined as an attractive drug target for addressing BCR–ABL-positive leukaemia (Lugo et 
al., 1990). In 1992 it was reported that by treating CML cells with tyrphostin, a tyrosine 
kinase inhibitor, it was possible to inhibit the tyrosine kinase activity of BCR-ABL. This 
discovery opened up the possibility of creating an ABL specific drug for the treatment of 
ABL-associated human leukaemia (Anafi et al., 1992, Anafi et al., 1993). 
1.3.1 The development of tyrosine kinase inhibitors (TKIs) 
The discovery of BCR-ABL meant that for the first time a drug target was identified that 
distinguished between normal cells and leukaemic cells. BCR-ABLs enzymatic activity 
functions by transferring a phosphate from ATP to tyrosine residues of its protein 
substrates and this could be targeted pharmacologically.  
In the late 1980s Lydon and Matter from Novartis, initiated projects to identify compounds 
with inhibitory activity against protein kinases. They profiled a library of compounds and 
initially focused on a Protein Kinase C inhibitor. However low potency and poor 
specificity led to further tweaks in the compound, such as: the addition of a 3′-pyridyl 
group at the 3′-position of the pyrimidine, which enhanced potency. The introduction of a 
benzamide group at the phenyl ring, which enhanced the activity specifically against 
tyrosine kinases. The addition of a flag-methyl group at the anilino phenyl ring, which led 
to the loss of activity against PKC, but further enhanced activity against tyrosine kinases 
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and finally with the attachment of a highly polar side chain, N-methylpiperazine for 
solubility, imatinib was born (Zimmermann et al., 1996, Zimmermann et al., 1997). 
Imatinib is a competitive ATP inhibitor and has the ability to inhibit c-ABL kinase at a 
concentration of 85 nM (Sandra et al., 2004). Imatinib interacts with ABL via its kinase 
domain, when ABL is in its kinase inactive confirmation and therefore the A-loop and the 
major regulatory element occlude the catalytic centre. This specific way of binding is 
important for imatinib’s selectivity towards ABL, as there is higher structural diversity in 
kinases in their inactive state (Nagar et al., 2002, Manley et al., 2002, Schindler et al., 
2000). Therefore, imatinib stabilises the inactive form of BCR-ABL and inhibits 
autophosphorylation, which blocks the kinase activity and the subsequent phosphorylation 
of downstream substrates.  
In collaboration with Brian Druker, the selective inhibitory activity of imatinib was shown 
at the cellular level on the constitutively active p210BCR–ABL tyrosine kinase in in vitro 
and in vivo studies (Druker et al., 1996). Further studies revealed that the inhibition of 
BCR-ABL autophosphorylation was closely related to the anti-proliferative activity of 
imatinib. These also showed that even treatment with low micromolar concentrations of 
imatinib, was enough to selectively induced apoptosis in BCR–ABL+ cell lines, and 
induced cell death in primary leukaemia cells from patients with Ph+ CML. In vivo 
treatment with 160 mg/kg–1 daily of imatinib over three doses for 11 days inhibited p210 
BCR-ABL tyrosine phosphorylation, and resulted in tumour free survival. This was 
specific for BCR-ABL positive cells, as minimal toxicity was seen in BCR-ABL negative 
cells (Druker et al., 1996, Beran et al., 1998, Gambacorti-Passerini et al., 1997, Deininger 
et al., 1997, Shingo Dan, 1998, le Coutre et al., 1999). 
As well as imatinib’s ability to potently inhibit all of the ABL tyrosine kinases, including 
c-ABL, v-ABL, and BCR-ABL (Buchdunger et al., 1996, Druker et al., 1996, Buchdunger 
et al., 2000), it has also been shown that it can target c-KIT and ligand-activated platelet-
derived growth factor (PDGF) receptor (Buchdunger et al., 2000, Heinrich et al., 2000). 
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1.3.2 Imatinib in clinical trial 
Due to its success in in vitro and in vivo models of CML, imatinib entered clinical trials. A 
phase I clinical trial began in 1998 in order to assess the maximal tolerated dose that would 
produce a clinical benefit. Patients eligible for the trial were CP CML patients, who had 
failed IFN-α. Patients were treated with imatinib as a daily oral therapy, with doses ranging 
from 25 to 1000 mg. Imatinib treatment was well tolerated and had remarkable affects. Out 
of 54 patients receiving at least 300 mg/day, 53 achieved a complete haematological 
response (CHR). Even more impressive was that at doses of 300 mg/day and higher, 
cytogenetic responses (CyR) were achieved in 31% of patients, with 13% achieving a 
major cytogenetic response (MCyR) (Druker et al., 2001b).  
The success of the Phase I trial moved imatinib into a Phase II trial in late 1999. This study 
involved using imatinib as a single agent for all stages of CML (Sawyers et al., 2002). 
Treatment with imatinib in late CP CML patients, that had previously failed IFNα , 
allowed 95% of the patients to achieve a MCyR and, after an 18 month follow up, 89.2% 
of the patients had not progressed to AP or BC (Kantarjian et al., 2002). Unsurprisingly as 
disease progressed the efficacy of imatinib on patients decreased (Talpaz et al., 2002). 
In 2000 a Phase III trial began to assess the efficacy of imatinib versus the current standard 
therapy for CML patients. The trial was called International Randomized Study of 
Interferon and STI571 (IRIS) trial. In this trial newly diagnosed CP CML patients received 
either 400 mg/ day of imatinib or the standard treatment of IFN-α and cytarabine, a 
chemotherapeutic agent that inhibits DNA synthesis. This trial recruited 1106 patients from 
16 different countries. In the 19 month follow up patients treated with imatinib had gained 
much higher MCyR rates, 87.1%, versus 34.7% in the IFN-α and cytarabine treated group. 
Even more encouraging was that 76.2% of imatinib treated patients had achieved a 
complete CyR (CCyR) compared to 14.5% in the IFN-α and cytarabine treated. In 2001, 
with the success in clinical trial, imatinib received approval from the United States Food 
and Drug Administration (FDA) to be used as a frontline treatment for Ph+ CML (O'Brien 
et al., 2003, Hochhaus et al., 2009, O'Brien and Deininger, 2003).  
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1.3.3 Treatment responses  
Although TKIs are highly effective in treating CML, some patients fail to respond, respond 
sub-optimally or can relapse due to acquired resistance. Patients are monitored closely, by 
cytogenetic and molecular techniques, during treatment to ensure an optimal response is 
being achieved. If patients become unresponsive this can be caught early and treatment 
regimens can be changed to control disease progression.  
Treatment responses have been officially categorised by the European Leukemia Net 
(ELN) and the U.S. National Comprehensive Cancer Network (NCCN) guidelines 
(Baccarani et al., 2009, (NCCN), 2010). Response profiles are categorised into 
haematological, cytogenetic and molecular. A haematological response indicates an 
improvement in the peripheral blood cell counts. A complete haematological response 
(CHR) indicates normalised peripheral blood counts; a white blood cell count below 
10×10
9
/L, platelets below 450×10
9
/L, immature cells absent or normalized differential and 
no signs and symptoms of disease. A CyR refers to the amount of Ph+ cells in the BM or 
peripheral blood. A complete or major cytogenetic response (CCyR) is the complete 
absence of Ph+ cells. The loss of a CyR is indicated by an increase in Ph+ cells to 30% or 
more in the BM or PB. A molecular response is the level of BCR-ABL transcripts relative 
to an established baseline, which is determined by measuring BCR-ABL transcripts levels 
in the blood of the patient upon diagnosis. The transcript level is then standardised 
according to an international scale (Hughes et al., 2006). A complete molecular response 
(CMR) indicates the absence of transcripts and a major molecular response (MMR) is 
defined as a 3-log decrease or a reduction to 0.1% compared with the baseline level of 
BCR-ABL transcripts (Hughes et al., 2006). The time a patient takes to respond to 
treatment haematologically, cytogenetically and molecularly is also very important in 
determining whether drug therapy is effective. The ELN also provide guidelines for the 
times that it should take to reach certain levels of response and warning signs of 
suboptimal responses or relapses (Baccarani et al., 2009). Patients that do not achieve a 
timely response to drug treatment are at higher risk of disease progression due to 
ineffective drug treatment. Failure to respond to TKI is indicated by the patient not 
achieving a CHR by 3 months, or having BCR-ABL transcripts >10% and/or Ph
+
 >35% at 
6 months, or at 12 months BCR-ABL transcripts >1% and/or Ph
+
 >0%. Then at any time 
loss of CHR, CCyR, loss of MMR and the detection of mutations all indicate TKI failure. 
Failure to respond is also indicated in relapse if there is a loss of CHR or CCyR at any 
point. If this occurs, it means continuing with the current treatment regime is no longer 
appropriate. A suboptimal response is defined by the patient having BCR-ABL transcripts 
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>10% and Ph
+
 36-95% at 3 months, or at 6 months having BCR-ABL transcripts 1-10% 
and Ph
+
 1-35%, or at 12 months having BCR-ABL transcripts 0.1-1% (Baccarani et al., 
2013).  
The current practice for CML patients is to continue treatment indefinitely as the ability of 
imatinib to completely eradicate the CML clone is uncertain. However, it was thought that 
patients who had achieved a CMR for at least 2 years may have completely eradicated 
CML cells from their body and could potentially discontinue treatment. Therefore, the 
STIM and the Australian TWISTER studies were launched. In the STIM study, imatinib 
was discontinued in 69 patients and of these 61% of them relapsed (Mahon et al., 2010). 
Similar results were obtained in the TWISTER study, which also demonstrated that all 
patients in the trial, even patients that did not relapse after stopping imatinib treatment, still 
harboured residual leukaemia (Ross et al., 2013). These two trials support the hypothesis 
that there is a population of leukaemic stem cells (LSCs) that are resistant to TKI and their 
persistence can replenish the leukaemic cell pool upon drug withdrawal and cause relapse. 
However, it is still thought that imatinib can be safely discontinued in patients, which have 
achieved a CMR for at least 2 years’ duration, as imatinib discontinuation in this type of 
patient population has resulted in molecular relapse-free survival for many patients in the 
trial. These patients potentially could be cured of CML by TKI. Additionally, patients who 
did suffer a relapse still responded well to the reintroduction of imatinib (Ross et al., 2013, 
Mahon et al., 2010, Nicolini et al., 2013). 
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1.4 Mechanisms of resistance 
Although the majority of CML patients have excellent response rates to imatinib, there is a 
significant subset of patients who experience primary or secondary resistance to imatinib 
treatment. Primary or intrinsic resistance is the lack of efficacy of imatinib from the outset. 
Secondary resistance is an acquired resistance which occurs following an initial response 
to imatinib treatment. A significant amount of research has been directed towards 
understanding the mechanisms that cause imatinib resistance. Initial studies were 
conducted using BCR-ABL+ cell line models that had been exposed to prolonged and 
progressive escalation dosing of imatinib in order to cause a cellular change, which may 
resemble resistance seen in the clinic (le Coutre et al., 2000, Mahon et al., 2000b, 
Weisberg and Griffin, 2000). This has led to the discovery of numerous mechanisms which 
are associated with resistance, and can be classified into BCR-ABL-dependent and 
independent. Resistant mechanisms classed as BCR-ABL-dependent include; genetic 
mutations in BCR-ABL, BCR-ABL amplification and drug trafficking. Those associated 
with BCR-ABL-independent mechanisms are epigenetics, clonal evolution and activation 
of alternative signalling pathways.  
 
1.4.1 Intolerance and non-compliance 
A very simple and yet unfortunate reason that a patient may suffer from a sub-optimal 
response to imatinib treatment is poor compliance or intolerance. A large study conducted 
in 2011, showed that out of 422 patients that took part in the study, 25-30% of the patients 
suffered quite highly from side effects, which ranged from fatigue, muscle cramps, 
musculoskeletal pain and oedema (Efficace et al., 2011). Only 20% of patients in this study 
reported not to experience any side effects (Efficace et al., 2011). Continuous side effects 
of this nature are enough to impact upon a patient’s ability to comply with their treatment 
regime. A study conducted in 2009, the Adherence Assessment with Glivec: Indicators and 
Outcomes (ADAGIO) demonstrated that although 15% of patients on imatinib took more 
than the prescribed dose, 71% of patients took less than their prescribed dose (Noens et al., 
2009). This information is very disconcerting as there is a very strong negative correlation 
between patients taking less than 90% of their imatinib dosage compared to patients taking 
over 90% and reaching an optimal MMR, 28.4% and 94.5% respectively (Marin et al., 
2010). This is also even more apparent in patients’ ability to achieve a CMR, 0% and 
43.8% respectively (Marin et al., 2010). Although these side effects can be fairly 
manageable, patients can suffer more serious life threatening complications after long term 
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treatment with TKIs. These complications include myelosuppression and infection, fluid 
retention including pleural and pericardial effusions, liver toxicity, pancreatitis, cardiac 
effects such as; cardiac failure, arrhythmias, vascular events including hypertension, 
myocardial infarction, peripheral vascular occlusion and stroke, pulmonary hypertension, 
and gastrointestinal bleeding. If these sorts of life threatening events occur, TKI treatment 
must be discontinued, however the frequency of occurrence and severity are associated 
with the more potent inhibitors (Holyoake and Helgason, 2015).  
1.4.2 BCR-ABL-dependent mechanisms of resistance 
1.4.2.1 BCR–ABL amplification 
One of the first mechanisms of resistance to be established using TKI-resistant CML cell 
line models, was increased levels of BCR-ABL kinase activity compared to the original 
TKI sensitive CML cell lines. This was shown to be due to BCR-ABL gene amplification 
and was shown in three independent studies (le Coutre et al., 2000, Mahon et al., 2000b, 
Weisberg and Griffin, 2000). Although this had only been shown in cell lines, Gorre and 
colleagues performed cytogenetic testing on 11 samples collected from patient resistant to 
imatinib and showed that 3 of these had multiple copies of the BCR-ABL gene (Gorre et 
al., 2001). In all three cases, additional copies of the Ph chromosome were observed as 
imatinib treatment was continued. Quantitative PCR analysis of genomic DNA (gDNA) 
obtained from these three patients confirmed increased ABL gene copy number at relapse 
when compared to a patient without BCR-ABL gene amplification (Gorre et al., 2001). 
This drug resistance mechanism is associated with BCR-ABL signal transduction at higher 
levels. It is possible that the original imatinib dose is no longer sufficient to inhibit the 
higher levels of BCR-ABL signalling therefore allowing cells to continue proliferating. 
High levels of BCR-ABL activity are also associated with genomic instability, due to 
increased levels of ROS (Sattler et al., 2000, Koptyra et al., 2008). This would increase the 
likelihood of a mutation to occur, which may lead to the development of imatinib 
resistance. However, there is a low frequency of CML patients who are found with BCR-
ABL gene amplification (A Hochhaus, 2002). This may be due to high levels of BCR-ABL 
being toxic to CML cells and these cells die before analysis. With this in mind it has been 
hypothesised that the first step in the development of imatinib resistance is the 
overexpression of BCR-ABL, which subsequently leads to a mutation. It is thought that the 
highly expressing BCR-ABL clone dies and leaves the clones which have lower levels of 
BCR-ABL and a mutation which gives them a growth advantage and drives imatinib 
resistance (Tang et al., 2011). 
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1.4.2.2 Mutations affecting the BCR-ABL kinase domain 
The most common cause of imatinib resistance is due to the cells ability to evolve and 
develop point mutations. These mutations usually cluster within the kinase domain of 
BCR-ABL, which is the binding site for imatinib. This disrupts the contact points between 
imatinib and BCR-ABL or induces conformational changes from inactive to active, which 
makes imatinib no longer able to bind to BCR-ABL and renders it ineffective (von 
Bubnoff et al., 2002, Gorre et al., 2001, Branford et al., 2003, Shah et al., 2002). BCR-
ABL mutations are found in 50–80% of patients with CML at time of development of 
resistance (Gorre et al., 2002, Soverini et al., 2005, Jabbour et al., 2006, Jones et al., 2008). 
The list of point mutations in BCR-ABL has grown to include more than 90 which confer 
imatinib resistance. Some of these occur at a higher frequency than others and cause 
varying degrees of imatinib resistance (Corbin et al., 2003, Soverini et al., 2011). The 
degree of resistance caused depends on the proximity to the kinase domain, ranging from 
moderate to severe resistance, which significantly increases imatinib’s IC50, half the 
maximal inhibitory concentration. Mutations that are associated with high levels of 
resistance to imatinib include mutations on the P-loop of BCR-ABL, specifically between 
amino acids 244 and 255, such as; Q252R/H, Y253F/H, E255K/V (O'Hare et al., 2005). 
However the most common mutation, which causes a high level of imatinib resistance and 
occurs within the BCR-ABL kinase domain, is the T315I mutation and is known as the 
‘gatekeeper’ mutation (O'Hare et al., 2005). Of all the CML patients that develop an 
imatinib resistant mutation, 20% will develop the T315I mutation (Aaron Shaver, 2014). 
The development of mutations not only affects imatinib binding, but also causes genomic 
instability, which promotes DNA damage and impairment of DNA repair mechanisms 
(Stoklosa et al., 2008).  
In the majority of CML patients, 1 mutation will occur in the BCR-ABL kinase domain. 
However, there is a subset of patients susceptible to ≥ 2 mutations, which can be caused by 
multiple BCR-ABL clones, polyclonal mutations, or ≥ 2 mutations in the same BCR-ABL 
molecule, which are termed compound mutations. Each of the individual mutants from the 
polyclonal mutant population is expected to retain a certain amount of sensitivity to 
imatinib, depending on the mutation. However, compound mutations, due to the multiple 
mutational changes, impose a higher risk of dramatic changes to BCR-ABL, which can 
have extremely negative effects in terms of drug binding and therefore imatinib sensitivity 
(Shah et al., 2007, Eide et al., 2015). Patients harbouring highly imatinib resistant 
compound mutants, such as BCR-ABL
E255V/T315I
, have limited therapeutic options (Eide et 
al., 2015). 
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1.4.2.3 Pharmacokinetics & drug delivery issues 
Another proposed mechanism underlying resistance to imatinib can be due to 
pharmacokinetics and ineffective drug delivery. One simple reason for a suboptimal 
response to imatinib may be due to low imatinib plasma levels resulting from exposure to 
inadequate imatinib dosage. Metabolism of imatinib occurs through the cytochrome (CYP) 
P450 system to which CYP isoenzyme 3A4 (CYP3A4) is the major enzyme that 
metabolises imatinib and its levels can vary highly between patients, therefore it is 
important to monitor plasma levels carefully (Larson et al., 2008, Peng et al., 2004, Picard 
et al., 2007). 
However low plasma levels could also be due to dysfunctional drug import and export 
pumps on the target cell membrane. The multidrug efflux transporter, ATP-binding 
cassette subfamily B member 1 (ABCB1), also known as P-glycoprotein and MDR1, has 
been implicated in imatinib resistance in CML (Mahon et al., 2003). ABCB1 is a 
transmembrane protein that belongs to the ATP-binding cassette subfamily (ABC). ABC 
transporters use ATP hydrolysis to open and close ion channels to allow the movement of 
endogenous substrates across the plasma membrane. ABC transporters also participate in 
the movement of most drugs and their metabolites across cell surface and cellular organelle 
membranes and therefore defects in these genes have been implicated in drug resistance 
(Vasiliou et al., 2009). ABCB1 has been shown to mediate multidrug resistance by 
increasing the efflux of imatinib from haemopoietic cells (Raaijmakers, 2007, Burger et al., 
2004). Mahon and colleagues showed that overexpression of the MDR1/ABCB1 gene in a 
CML cell line led to imatinib resistance, which could be reversed by treatment with a P-
glycoprotein inhibitor (Mahon et al., 2003). To further understand this mechanisms in a 
clinical setting, a study was conducted analysing 33 CML patients which concluded that 
overexpression of ABCB1 was linked to more advanced phases of disease, such as AP and 
BC CML patients (Mahon et al., 2000a, Galimberti et al., 2005). However, the importance 
of this has been put into question due to later studies from our laboratory, which 
demonstrated that inhibition of ABCB1 could neither enhance the effect of imatinib nor 
did it significantly increase imatinib’s efficiency in eliminating CD34+ CML cells, which 
was thought to be due to low expression levels of ABCB1 in this primitive cell fraction 
(Hatziieremia et al., 2009).  
A second membrane transporter that has been implicated in imatinib resistance is human 
organic cation transporter 1 transporter (hOCT-1), which has been shown to induce 
imatinib influx into cells and its inhibition was shown to directly impact imatinib uptake in 
leukaemic cells (Thomas et al., 2004). In clinical studies, the activity of hOCT-1 and the 
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mRNA expression of OCT-1 correlate with the imatinib response (White et al., 2010, 
Wang et al., 2008, Eechoute et al., 2011). Patients with high hOCT-1 expression achieved 
superior response  rates to imatinib, with regards to CCyR and progression-free and overall 
survival (Wang et al., 2008). However, patients with imatinib resistant CML have been 
shown to have lower levels of hOCT-1 (Kim et al., 2014). In addition, a study analysing 33 
newly diagnosed CML patients identified a hOCT-1 single nucleotide deletion, M240del, 
which was associated with an increased probability of imatinib treatment failure 
(Giannoudis et al., 2013). Dose escalation of imatinib may overcome the pharmacokinetics 
and drug influx and efflux issues to increased imatinib plasma levels and allow the patient 
to achieve better response (White et al., 2007).  
1.4.3 BCR-ABL-independent mechanisms of resistance 
However, there are a sub set of patients who are treated with TKI and despite BCR-ABL 
inhibition the CML cells retain the ability to survive and proliferate. These patients are 
described as having a BCR-ABL-independent resistance to TKIs. This can either occur due 
to epigenetic changes, clonal expansion, microenviromental factors or by activation of a 
secondary oncogenic mechanism. Patients with BCR-ABL-independent TKI resistance are 
of major clinical concern. As unlike BCR-ABL-dependent resistance mechanisms, these 
patients have very limited treatment options and it is thought that 50% or more imatinib 
resistant CML patients may develop BCR-ABL-independent imatinib resistance 
mechanisms. Therefore, increased effort is being made to investigate these alternative 
mechanisms of resistance. 
1.4.3.1 Clonal evolution  
As CML progresses patients acquire additional cytogenetic anomalies, which has been 
coined “clonal evolution”. The most frequent abnormalities that are associated with clonal 
evolution are trisomy 8 (34%), isochromosome 17 (20%), and duplicate Ph chromosome 
(38%) (Johansson et al., 2002).  These aberrations have been linked to c-myc 
overexpression, loss of p53 and BCR-ABL overexpression, respectively (Jennings and 
Mills, 1998, Calabretta and Perrotti, 2004b, Gaiger et al., 1995). Loss of p53 occurs at a 
high rate and is found mutated in 25-30% of BC CML patients (Calabretta and Perrotti, 
2004b). The inactivation of p53 has also been shown to augment disease progression by 
blocking the response to imatinib and therefore causing imatinib resistance (Wendel et al., 
2006). Clonal evolution reflects the high level of genetic instability that occurs during 
disease progression and ultimately leads to advanced stages of CML. 
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1.4.3.2 Epigenetic modifications  
Recent evidence suggests that abnormal epigenetic regulation of the expression of CML-
associated genes may play a critical role in its pathogenesis and in the mechanisms 
modulating therapeutic responsiveness (Jelinek et al., 2011, Machova Polakova et al., 
2013). Epigenetic events include; DNA methylation and post-translation modifications in 
histone, including acetylation, deacetylation and phosphorylation (Jenuwein and Allis, 
2001, Matzke et al., 2001). 
DNA methylation of CpG islands is a transcription inhibiting mechanism that balances the 
levels of gene expression that is frequently deregulated in leukaemia. A large number of 
genes, which are mostly tumour suppressors, are inactivated by hypermethylation of CpG 
islands mainly in the promoter regions, while other genes, such as oncogenes are 
hypomethylated. Hypomethylation has been shown to cause genomic instability in CML 
and leads to disease progression (Roman-Gomez et al., 2008). Genes that have been found 
to be hypermethylated in CML and correlate with a poor prognosis are HOXA4 and 
HOXA5 (Strathdee et al., 2007), and DNA-damage-inducible transcript 3 (DDIT3) gene, 
from the CEBP family of transcription factors (Wang et al., 2010), which are associated 
with cell growth and differentiation in haemopoiesis. As well as tumour suppressor genes 
p15, a cyclin independent kinase inhibitor (Nguyen et al., 2000), Cadherin-13, responsible 
for selective cell recognition and adhesion (Roman-Gomez et al., 2003), Metastasis 
suppressor 1 (MTSS) (Schemionek et al., 2016) and SHP1 (Esposito et al., 2011b).  
Further epigenetic mechanisms that are important for cellular transformation in leukaemia 
are histone acetylation and deacetylation. Studies have shown that alterations in the pattern 
of acetylation of non-histone proteins can promote abnormal cellular proliferation and 
resistance to apoptosis. Using imatinib resistant CML cell line models it was shown that 
these cells undergo aberrant acetylation of nonhistone proteins, such as p53, Ku70, and 
Hsp90, which was due to upregulation of histone deacetylases (HDACs) and down-
regulation of histone acetyltransferase (HAT) (Lee et al., 2007). This occurs due to 
upregulation of HDAC1, 2, and 3 and SIRT1 and the down regulation of CBP/p300 and 
PCAF with HAT. The aberrant acetylation therefore down-regulates p53 and cytoplasmic 
Ku70 (Lee et al., 2007). Ku70 is a known acetylation-sensitive binding partner for pro-
apoptotic protein, Bax. This allows Ku70 to sequester Bax and inhibit stress-induced 
apoptotic cell death (Sawada et al., 2003, Cohen et al., 2004). 
Treatment of CML cells with the HDAC inhibitors restores the acetylation of several 
proteins and the cell’s ability to undergo apoptosis. In addition, the use of HDAC inhibitors 
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in combination with TKIs showed a synergistic effect by increasing the level of apoptosis 
in primary cells isolated from CML patients (Kircher et al., 2009, Fiskus et al., 2006). One 
phase II/III clinical study has been conducted using HDAC inhibitors for the treatment of 
patients suffering from CP CML with resistant disease following treatment with at least 
two BCR-ABL targeting TKIs, NCT00451035. The results of this trial have not yet been 
published. However, toxicity of HDAC inhibitor to normal stem cells is a potential 
concern. Another potential therapeutic option is to target SIRT1 (Li et al., 2012). Currently 
available HDAC inhibitors do not target SIRT1, which has been shown to play an 
important role in maintaining self-renewal and differentiation of HSC especially under 
conditions of stress (Narala et al., 2008, Ou et al., 2011, Han et al., 2008). SIRT1 is over 
expressed in CML stem cells and as discussed is associated with aberrant acetylation of 
p53 (Luo et al., 2001), Ku70 and Foxos (Brooks and Gu, 2009). Inhibition of SIRT1 was 
shown not to affect normal HSC but importantly, increase apoptosis and reduce 
proliferation of CML stem cells and this effect was significantly enhanced by the addition 
of imatinib (Li et al., 2012).  
An interesting study was performed using a BCR–ABL positive CML cell line (KBM7), to 
generate iPSCs, which showed that when the KBM7 cells were reprogrammed they lost 
their dependency on BCR-ABL and became insensitive to imatinib. The authors 
hypothesise that imatinib must target cells in a specific epigenetic context, which may 
contribute to the inability of imatinib to fully eradicate CML cells (Carette et al., 2010). 
However a similar study performed more recently by Amabile and colleagues shows that 
reprogramming CML cells back to an iPSC state erased the CML DNA-methylation 
signature and these cells were no longer effective in producing CML when subsequently 
transplanted into immunocompromised mice (Amabile et al., 2015).  This shows the 
complexity involved of epigenetic mechanisms in CML and that it is context dependent.   
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1.4.3.3 Activation of alternative signalling pathways  
Aberrant activation of alternative cellular pathways can also be responsible for BCR-ABL-
independent imatinib resistance. The exact mechanism that may cause this is unclear, 
however it seems to vary depending on the individual as studies conducted with mouse 
models and human primary samples have shown much variability. The main pathways and 
their associated mechanisms that have been implicated so far include; (1) deregulation of 
apoptotic proteins, such as down-regulation of pro-apoptotic protein BIM (Ng et al., 2012) 
or up-regulation of anti-apoptotic protein Bcl-2 (Dai et al., 2004), (2) down-regulation of 
SH2-containing tyrosine phosphotase 1 (SHP-1) (Esposito et al., 2011a), (3) over-
expression of SRC kinases, such as LYN, HCK and FYN, which promote survival and 
proliferation (Donato et al., 2003, Grosso et al., 2009)
 
and (4) maintenance of survival 
signals such as the activation of the PI3K/AKT/mTOR pathway (Quentmeier et al., 2011), 
FOXO1and FOXO3A (Wagle et al., 2016, Pellicano et al., 2014), STAT3 (Eiring et al., 
2015) and RAS-independent activation of RAF (Hentschel, 2011) and Wnt/β-catenin 
(Zhang et al., 2013, Neviani et al., 2013, McWeeney et al., 2010). Despite the complexity 
of this type of resistance it is hoped that through further research a common alternative 
drug target will be identified that can be exploited for treatment of this patient population. 
The PI3K/AKT/mTOR pathway is a frequently deregulated pathway in cancer (Gallardo et 
al., 2012, Shukla et al., 2007). Activation of this pathway has been shown to positively 
regulate cellular proliferation, differentiation, survival and mRNA translation, which is 
regulated via phosphorylation of the mTOR complex 1 (mTORC1), which phosphorylates 
the downstream targets ribosomal protein S6 (RPS6) and eukaryotic translation initiation 
factor 4E- binding factor (4E-BP1) in CML cells (Ly et al., 2003). In CML, it has been 
shown that BCR-ABL can regulate the activity of the PI3K/AKT/mTOR pathway (Skorski 
et al., 1995b) and the aberrant activity was important for supporting BCR-ABL mediated 
cellular transformation and disease progression (Skorski et al., 1997). It has also been 
reported that the PI3K/AKT/mTOR pathway is involved in promoting TKI-resistance. A 
studying conducted using BCR-ABL-independent imatinib resistant CML cell line models, 
showed that after treatment with imatinib, ERK1/2 and STAT5 were dephosphorylated, 
however PI3K/AKT1/mTOR activity remained unaffected. In addition, targeting this 
pathway with inhibitors against PI3K, AKT or mTOR, induced a high level of apoptosis 
(Quentmeier et al., 2011, Okabe et al., 2014). This makes the PI3K/AKT/mTOR pathway 
an attractive signalling pathway for investigation of TKI-resistance in CML patients. 
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1.5 Strategies to combat TKI resistance  
1.5.1 Imatinib dose escalation  
In the first instance, to overcome TKI resistance a dose escalation of imatinib can be given 
to patients. This can be beneficial to patients who have BCR-ABL over expression, an 
amplification of BCR-ABL transcripts, BCR-ABL mutation and drug influx and efflux 
issues, which can be targeted at higher imatinib concentrations. 
The standard of care for imatinib treatment is 400 mg daily. If a patient is having a slow or 
inadequate response to 400 mg of imatinib then dose escalation to a daily dose of 600-800 
mg daily has been shown to benefit  a proportion of patients (Kantarjian et al., 2003).  
106 patients from the IRIS clinical trial experienced a suboptimal cytogenetic response or 
resistance to the 400 mg imatinib treatment. These patients were then entered into a trial to 
assess the effects of dose escalation to either 600 mg or 800 mg of imatinib daily. Dose 
escalation was beneficial as 42% of these patients achieved a cytogenetic response. The 
dose increase also prevented disease progression to AP or BC in 89% of patients and 
overall survival was 84% following 3 years of increased imatinib treatment. Imatinib dose 
escalation was deemed an appropriate initial treatment option for patients with CP CML 
who had experienced suboptimal CyR or resistance (Kantarjian et al., 2009). 
1.5.2 TKIs 
Resistance to TKIs is one of the primary reasons for the failure of therapy in patients with 
CML. In an effort to overcome this more potent and mutation targeted TKIs have been 
designed. Second generation TKIs, dasatinib and nilotinib, were designed to be more 
potent than imatinib, to bind more effectively to the BCR-ABL kinase domain and allow 
binding to BCR-ABL mutant isoforms. Although very effective the elusive T315I BCR-
ABL mutation was not targeted by second-generation TKIs. This led to third generation 
TKIs, bosutinib and ponatinib, which exhibited increasing specificity and potency towards 
BCR-ABL. Ponatinib, was specifically designed to overcome resistance-inducing 
mutations, including the T315I mutation, in the ABL kinase domain. 
1.5.3 Second-generation TKIs  
1.5.3.1 Dasatinib  
Dasatinib was developed as a more advanced BCR-ABL kinase inhibitor than imatinib and 
differed due to dasatinib’s slightly less stringent binding requirements. This enables 
dasatinib to bind to both the inactive and the active confirmations of BCR-ABL. It can also 
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bind the Src family kinases given their similar geometry to the Abl active conformation, 
and maybe most importantly it has activity against many imatinib-resistant kinase domain 
mutations of BCR-ABL. In vitro studies using cell line models showed that dasatinib could 
inhibit 18-19 known imatinib-resistant BCR-ABL mutations, within a narrow clinically 
achievable concentration range. The only mutation that is able to evade dasatinib treatment 
is a single point mutation deep within the ATP-binding domain, T315I. It has been shown 
to have a high resistance against imatinib and second generation TKIs. It is thought that 
this occurs as all current TKIs directly interact with threonine-315 via hydrogen bonding, 
therefore if this site is mutated the inhibitors can no longer bind (Shah et al., 2004, 
Lombardo et al., 2004, O'Hare et al., 2005, Tokarski et al., 2006).  
Dasatinib went into a dose escalation Phase I clinical trial in 2003 and patients were 
recruited in various stages of CML disease progression that were resistant to imatinib. 
Patients received 15 to 240 mg/day in four-week treatment cycles, once or twice daily. The 
results of this trial showed that 37 out of 40 CP CML patients achieved a complete 
haematological response, with 95% of patients maintaining their response at 12 months 
(Talpaz et al., 2006). 
A phase II trial followed recruiting 387 CP CML patients resistant to imatinib. Patients 
were dosed at 70 mg twice daily and after a median follow-up of 15.2 months 91% of 
patients had attained and maintained a CHR, 59%  achieved a MCyR and of these patients 
49% achieved CCyR (Hochhaus et al., 2008).  
The efficacy of dasatinib versus imatinib treatment was then evaluated in newly diagnosed 
CML patients in the DASISION trial (Kantarjian et al., 2010). In this trial 519 CP CML 
patients were recruited and randomised into two groups. One group received 100 mg of 
dasatinib and the second 400 mg of imatinib per day.  After 12 months a higher percentage 
of patients treated with dasatinib achieved CCyR at a much faster rate than imatinib treated 
patients (dasatinib 77%, imatinib 66%; p = 0.007). Also a higher percentage of dasatinib 
treated patients achieved a Major Molecular Response (MMR) compared to imatinib 
(Dasatinib 46%, imatinib 28%; p < 0.0001) (Kantarjian et al., 2010). After a 5 year follow 
up, the final results from the trial continue to support dasatinib 100 mg once daily as a safe 
and effective first line therapy for the long-term treatment of CP CML (Cortes et al., 2016). 
In 2006, with the success of the clinical trials dasatinib was approved by the FDA for the 
treatment of newly diagnosed CML patients and patients who were resistant to previous 
therapy. Although dasatinib treatment had enhanced effects over imatinib in CP CML 
patients, in more progressive phase of the disease, these effects were limited and response 
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rates were poor and short lived (Cortes et al., 2008, Apperley et al., 2009). Dasatinib has 
also been shown, due to its increased potency,  to target an earlier CML progenitor 
population than imatinib, however it still fails to eliminate the persistent LSCs within the 
BM (Copland et al., 2006a). 
1.5.3.2 Nilotinib  
It was hypothesized that more potent and selective compounds could be developed by 
reengineering the structure of imatinib to incorporate elements designed to capitalise upon 
the elucidation of the imatinib-ABL binding mode (Manley et al., 2004). Nilotinib is based 
on the chemical structure of imatinib and exhibits the same binding mode (Sandra et al., 
2004). Nilotinib has one important structural difference, which is the replacement of an N-
methylpiperazinyl group, which gave nilotinib a slightly different structure to fit better 
within the kinase domain of BCR-ABL and therefore enhances binding efficiency. This 
increased potency of nilotinib by 30-fold compared to imatinib. It also increased its 
binding affinity for BCR-ABL compared to other kinases, such as c-KIT and PDGFR. The 
enhancement in binding affinity also improves inhibitory activity against most of the 
common kinase domain mutations that cause imatinib resistance, with the exception of the 
T315I mutation (Weisberg et al., 2005, Bradeen et al., 2006, Ray et al., 2007). 
Through Phase I and II clinical trials nilotinib has shown greater efficacy than imatinib in 
newly diagnosed CP CML patients. A phase III trial ENESTnd further emphasised this 
effect, as patients in a three arm randomised trial where patients were treated with either 
300 mg nilotinib or 400 mg nilotinib twice daily or 400 mg imatinib daily. A 2 year follow 
up of this trial concluded that significantly more patients treated with nilotinib had 
achieved a MMR compared to imatinib; 71% of 300 mg nilotinib treated patients, 67% 400 
mg nilotinib and 44% of 400 mg imatinib patients. Overall a significantly higher number 
of nilotinib treated patients achieved CMR compared to imatinib (Kantarjian et al., 2011, 
Hochhaus et al., 2016). In 2010, with the success shown in the clinical trials, the FDA 
granted accelerated approval for nilotinib treatment in patients with newly diagnosed CP 
CML. However, like imatinib and dasatinib, nilotinib is also unable to eliminate the 
persistent population of LSCs (Jørgensen et al., 2007b).  
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1.5.4 Third-generation TKIs  
1.5.4.1 Ponatinib 
Ponatinib was designed though computational modelling and structure-based experiments 
in order to develop a TKI that could inhibit BCR-ABL, including the T315I mutation. To 
overcome this problematic mutation, ponatinib has a novel triple-bond linkage that avoids 
the steric hindrance caused by the bulky isoleucine residue at position 315 in the BCR-
ABL T315I mutant (Zhou et al., 2011). Ponatinib is therefore a pan-TKI inhibitor, which 
can inhibit all known BCR-ABL mutants; it also targets Flt3 and SRC kinases. 
Additionally preclinical experiments showed that ponatinib could suppress tyrosine to 
phenylalanine (T177F) the emergence of any mutation at a low concentration of 40 nM 
(O’Hare et al., 2009).  
A phase I clinical trial was conducted in 2008 to evaluate the toxicity and safety of 
ponatinib for clinical use. This dose escalation trial recruited CML patients who had 
previously failed at least two TKIs. 43 CP CML patients entered this trial and of these 
patients 98% achieved a CHR, 63% a CCyR and 44% MMR. Ponatinib was generally well 
tolerated and on the basis of the safety, pharmacokinetic, and pharmacodynamic data, 45 
mg of ponatinib was determined to be the maximum tolerated dose suggested for further 
clinical studies (Cortes et al., 2012b). 
The encouraging phase I results led to the launch of a phase II clinical trial in 2010, the 
Ponatinib Ph+ ALL and CML Evaluation (PACE) trial. PACE recruited 271 CP CML 
patients and 79 AP CML patients, who had experienced resistance to or unacceptable side 
effects from dasatinib or nilotinib or harboured the T315I mutation. Patients received 45 
mg/day of ponatinib and the results showed that ponatinib had significant anti-leukaemic 
activity across categories of disease stages and especially with patients harbouring the 
T315I mutation. Overall 46% of the CP CML patients achieved a CCyR response of whom 
34% achieved a MMR (Cortes et al., 2013). 
Ponatinib was becoming a very attractive treatment option for patient’s resistant to all 
current TKIs. Further clinical studies were performed to assess whether ponatinib would 
result in a superior outcome compared with imatinib in newly diagnosed CP CML patients. 
A phase III trial commenced in 2012, called the Evaluation of ponatinib versus imatinib in 
CML (EPIC) trial. 307 patients were entered into randomised groups and either treated 
with 45 mg of ponatinib or 400 mg imatinib daily. However, the trial was terminated early, 
following concerns about thrombotic vascular adverse events that were observed in 
patients given ponatinib in other trials. The trial termination meant limited data was 
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available for the primary endpoint of the trial, MMR at 12 months. Only 10 patients in the 
ponatinib arm and 13 in the imatinib could be assessed at the 12 month time point. The 
small number of patients means interpretation of the data was taken with caution, however 
the preliminary data suggested ponatinib maybe more beneficial. 80% of ponatinib patients 
and only 38% of the imatinib patients achieved MMR within 12 months (Lipton et al., 
2016).  
Due to the concerns of thrombotic vascular events, ponatinib was briefly withdrawn from 
the US market in October 2013 on the recommendation of the FDA, however it was soon 
re-introduced in January 2014. Ponatinib is currently approved for CML patients with the 
T315I mutation or for CML patients who are unresponsive to all TKIs (National Institute 
of Health, 2013).  
1.5.4.2 Bosutinib  
Bosutinib is a dual inhibitor of ABL and SRC kinases, which showed potent inhibitory 
activity against BCR-ABL in imatinib-resistant CML cell lines. It is a much more potent 
inhibitor than imatinib, with several studies showing a 15-100 fold lower IC50(Puttini et al., 
2006, Golas et al., 2003).  
Unlike other TKIs bosutinib exhibits a lower activity against c-Kit or PDGFR, which are 
non-specific targets of TKIs, which are thought to be associated with toxicities (Puttini et 
al., 2006, Remsing Rix et al., 2008, Konig et al., 2008, Bartolovic et al., 2003). 
The FDA approved Bosutinib in 2012 for the treatment of CP, AP and BC CML patients 
with resistance to prior therapy.  
An on-going phase III clinical trial BELA is evaluating the efficacy of bosutinib compared 
to imatinib in newly diagnosed CP CML patients. The patients were randomised into two 
groups one received 500 mg of bosutinib and the other 400 mg of imatinib. Data from a 2 
year follow-up showed that the CCyR rates were the same for the two treatment groups; 
50% for bosutinib and 49% for imatinib. However a higher percentage of bosutinib treated 
patients achieved MMR compared to imatinib, 59% and 49%, respectively (Brümmendorf 
et al., 2015). 
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1.5.5 An alternative experimental BCR-ABL inhibitor 
1.5.5.1 ABL001 
ABL001 is an allosteric inhibitor of BCR-ABL. It binds to the myristoyl pocket of the 
BCR-ABL kinase domain. The normal substrate for this pocket is the myristoylated N-
terminus of ABL, which serves as an autoregulatory mechanism for ABL signalling, 
however this domain is lost in the formation of BCR-ABL. Therefore, ABL001 has been 
designed to fit the myristoyl pocket to mimic the autoregulatory role of the myristoylated 
N-terminus of ABL and restore negative regulation of kinase activity. As this inhibitor 
does not bind with the kinase domain of BCR-ABL, where many mutations occur to cause 
TKI resistance, it is thought this could potentially be an alternative drug treatment for TKI-
resistant patients. 
Preclinical studies showed that ABL001 was potent and selectively inhibited the growth of 
BCR-ABL+ CML cells. These inhibitory effects were also extended to mutated isoforms 
of BCR-ABL, including T315I. In vivo treatment of xenograft models with ABL001 
revealed potent anti-tumour activity and complete tumour regression (Ottmann et al., 
2015). Additionally, a combination treatment of ABL001 and nilotinib achieved sustained 
tumour regression even after treatment discontinuation (Wylie et al., 2014). ABL001 is 
currently undergoing a phase I dose-escalation study to examine the safety of the drug in 
the clinic. Patients have been recruited who have CP or AP CML that is not responding to 
two or more TKIs due to resistance. The patients have been treated with ABL001 in doses 
ranging from 10 to 150 mg twice daily (Ottmann et al., 2015).  
Thirty-five patients were recruited to the study, however at the time of publication data 
was only available for 20 of the patients. Patients had received treatment for ≥ 3 months at 
the time of analysis and evidence of BCR-ABL inhibition was observed in doses ≥ 10 mg. 
Five of these patients had suffered a haematological relapse and all of these patients 
achieved a CHR within three months of ABL001 treatment. Nine of the 20 patients that 
were in cytogenetic relapse at trial entry achieved a MCyR by 3 months, and 6 of these 
patients also achieved CCyR. Five of the 20 patients achieved a MMR after 5 months of 
ABL001 treatment. All patients that achieved a CHR, CCyR or MMR maintained their 
responses. Therefore ABL001 has proven itself to have rapid dose-dependent anti-tumour 
activity and to-date has been well tolerated in CML patients, providing evidence that 
ABL001 could have the potential to benefit CML patients resistant to TKIs (Ottmann et al., 
2015). 
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1.5.6 Omacetaxine 
Omacetaxine also known as homoharringtonine is an alkaloid derived from the plant 
Cephalotaxus harringtonia, which has anti-tumour properties.  It has been reported that 
omacetaxine has the ability to reversibly inhibit the initial stages of protein translation of 
important anti-apoptotic and cell cycle mediators, such as MCL-1, Cyclin D1, c-myc, 
XIAP and -catenin, and therefore promotes apoptosis and cell cycle arrest (Tang et al., 
2006, Meir and David, 2011). Although omacetaxine cannot selectively target cancer cells, 
protein translation has been shown to be markedly upregulated in cancer cells along with 
high levels of proteins involved in cell division and survival, compared to normal cells 
(Hershey and Miyamoto, 2000).  
Omacetaxine has been assessed in several phase II clinical trials involving CML patients, 
who are either TKI-resistant (ClinicalTrials.gov identifier: NCT00462943) or for CML 
patients that carry the BCR–ABL T315I mutation and have failed TKI treatment 
(ClinicalTrials.gov identifier: NCT00375219) (Cortes et al., 2012a). The study which 
assessed the effects of omacetaxine treatment in CML patients carrying the T315I mutation 
was carried out in the pre-ponatinib era, when no TKI was effective against the T315I 
mutation. 66 patients were enrolled in the study and 77% of the patients achieved a CHR, 
23% achieved a MCyR and 16% of these patients achieved CCyR. Omacetaxine was 
deemed a safe and effective treatment option for these patients. The clinical trial for CP 
and AP CML patients resistant to TKI recruited 46 CP-CML patients, who had received 2 
or more prior TKIs. Haematological response was achieved in 67%, however a CCyR was 
only achieved by 4% of patients. Although this treatment is not so effective in these 
patients it was given approval by the FDA in 2012 for treatment for CP or AP CML 
patients with resistance or intolerance to two or more TKIs, as treatment options were very 
limited for CML patients who were resistant to TKIs at that time. Omacetaxine is seen as a 
last resort treatment option for CML patients. Due to its non-specific mode of action it has 
the ability to potently target both normal and leukaemic cells (Allan et al., 2011). This 
makes it highly toxic and causes many adverse effects, such as cardiac toxicity, which 
raises concerns for its use as a CML treatment. However, there is another clinical trial still 
recruiting patients which hopes to evaluate the pharmacokinetics, safety, and efficacy of 
Omacetaxine to patients with CP or AP CML (Referred to as the SYNSINCT Study) 
(ClinicalTrials.gov identifier: NCT02078960). 
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1.6 Autophagy 
Eukaryotic cells orchestrate many finely balanced biological processes in order to maintain 
cellular homeostasis. One of the main regulators of cellular homeostasis is the lysosome. 
The lysosome contains acidic hydrolases, which the cell utilises to degrade unwanted 
materials. In stressful conditions, such as nutrient deprivation, cells can employ a highly 
regulated self-eating process called autophagy. Autophagy is an intracellular recycling 
mechanism that regulates lysosomal degradation of organelles, protein aggregates, 
cytoplasmic proteins and lipids (DeBerardinis et al., 2008). This allows for the generation 
of new cellular building blocks, such as amino acids, fatty acids and acetyl-CoA, that can 
be utilised by the cell for energy and the synthesis of macromolecules (DeBerardinis et al., 
2008).  
Autophagy is an essential mechanism for the maintenance of cellular homeostasis 
(Amaravadi et al., 2011). Cells have a basal rate of autophagy that is critical is for the 
degradation and recycling of aberrant protein aggregates and damaged organelles that will 
otherwise accumulate and cause cellular damage (Amaravadi et al., 2011, Jung et al., 
2009). However in stressful cellular conditions, such as nutrient deprivation, hypoxia or 
following chemotherapeutic drugs, autophagy can be upregulated in order to maintain a 
balanced cellular environment (Amaravadi et al., 2011).  
The term autophagy was first introduced in 1963 by Christian de Duve, who used this word 
to describe observations from electron microscopy studies, which showed single or double 
membrane vesicles that contained parts of the cytoplasm, including organelles, in various 
degrees of degradation (Ashford and Porter, 1962, Clark, 1957, de Duve and Wattiaux, 
1966, Novikoff, 1959). However, it wasn’t until the late 1990s, that the molecular 
mechanisms of how autophagy functions began to become clearer. This started with 
genetic screens using budding yeast, Saccharomyces cerevisiae, which led to the 
identification of 32 autophagy (ATG) related genes. Of these genes 11 were found to have 
unambiguous orthologues in mammalian cells and most of these genes mediate the highly 
regulated autophagosome formation (Nakatogawa et al., 2009). 
There are three general types of autophagy; chaperone-mediated, microautophagy and 
macroautophagy (Huang and Klionsky, 2007, Majeski and Fred Dice, 2004, Reggiori and 
Klionsky, 2002, Wang and Klionsky, 2003). This piece of work focuses on 
macroautophagy, which will from hereon be referred to as autophagy. 
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The autophagy process begins with the formation of the phagophore, which is a cup shaped 
membrane that is generated upon induction of autophagy. The phagophore elongates to 
form a double membrane vesicle, known as an autophagosome. As it does so it engulfs 
cytoplasmic components that have been primed for degradation. Autophagosomes are able 
to move by sliding along cytoskeletal structures to deliver the waste material to the 
lysosome. The outer membrane of the autophagosome fuses with the lysosome to create an 
autolysosome. The inner membrane along with the waste cargo is then degraded by the 
acidic hydrolases from the lysosome. The broken down waste products can be recycled 
back to the cytosol for reuse (Tooze and Yoshimori, 2010). 
Basal levels of autophagy are low under normal conditions, but are upregulated following 
cellular stress. The autophagy pathway can be divided into sequential steps; initiation, 
autophagosome formation, fusion and degradation, each highly regulated by different 
protein complexes.  
1.6.1 Autophagy initiation 
The major regulator of autophagy in mammalian cells is mTORC1, which is activated in a 
Rheb-dependent manner under nutrient rich conditions to inhibit membrane targeting of 
the autophagic initiation complex (Hosokawa et al., 2009). The initiation complex is made 
up of several components; Unc-51- like kinase 1 (ULK1), ULK2, ATG13, ATG101 and 
FIP200.  mTORC1 is able to negatively regulate autophagy initiation by phosphorylating 
ULK1 and ATG13 (Jung et al., 2009). In stressful condition, such as nutrient deprivation, 
mTORC1 is inhibited and dissociates from the initiation complex, freeing the complex to 
allow energy sensor AMP-activated protein kinase (AMPK) to phosphorylate ULK1 and 
thereby induce autophagy (Kim et al., 2011). Activated ULK1, phosphorylates and 
activates ATG13 and FIP200, and the active ULK-ATG13-FIP200 complex is recruited to 
the phagophores (Hosokawa et al., 2009). 
1.6.2 Autophagosome formation 
The formation of the phagophore is regulated by a second multi-protein complex, referred 
to as the class III PI3K complex (Liang et al., 2008). This complex comprises the class III 
PI3K vacuolar protein sorting 34 (VPS34), the regulatory unit VPS15 and BECLIN1 
(Mizushima, 2007, Itakura et al., 2008, Simonsen and Tooze, 2009). VPS34 is essential for 
the developmental progression of a phagophore to an autophagosome (Liang et al., 2008).  
The PI3K complex has many different binding partners that regulate autophagy and 
depending upon the interaction the complex will function in a specific manner. Most of 
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these interactions occur via binding with BECLIN1 and therefore BECLIN1 is also an 
essential protein for autophagosome biogenesis. One such interaction occurs between 
BECLIN1 and ATG14L. It is believed that ATG14L targets the PI3K complexes to an 
endoplasmic reticulum (ER) subdomain and therefore mediates the localisation of the PI3K 
complexes to the site of the autophagosome formation (Itakura and Mizushima, 2010, 
Matsunaga et al., 2010). BECLIN1 can also form a complex with apoptosis regulators Bcl-
2 or Bcl-xL, via its BH3 domain, which has an inhibitory effect on BECLIN1 (Maiuri et 
al., 2007). However, upon starvation BECLIN1 disassociates and can induce autophagy 
(Levine et al., 2008). In addition, BECLIN1 can also form a complex with Activating 
Molecule in BECN1-regulated autophagy1 (AMBRA1). This interaction allows the PI3K 
complex to dock to the cytoskeleton via dyneins. However upon autophagy induction, 
ULK1 phosphorylates AMBRA1, which disrupts this interaction and allows the PI3K 
complex to detach and migrate to the ER to initiate autophagosome formation (Di 
Bartolomeo et al., 2010). Other BECLIN1 regulators include the UV radiation resistance-
associated gene (UVRAG) and Rubicon, which can either positively or negatively regulate 
autophagy (Yang and Klionsky, 2010). 
Although the autophagosome is thought to form near the ER, the origin of the 
autophagosome membrane is still unclear. However, studies have suggested the ER, Golgi 
apparatus, mitochondria or even de novo generation (Tooze and Yoshimori, 2010).  
1.6.3 Autophagosome completion 
Autophagosome completion is controlled by two essential ubiquitin-like conjugation 
systems: ATG12-ATG5 (Mizushima et al., 1998) and LC3-PE (Ichimura et al., 2000). The 
ATG12-ATG5 conjugation forms with the aid of a homodimeric E1-like enzyme, ATG7. 
ATG7 activates ATG12, which covalently conjugates ATG12 to ATG10, an E2-like 
enzyme, and then to ATG5. ATG10 then interacts with ATG16 to form the ATG12-ATG5-
ATG16 complex (Nakatogawa et al., 2009). This large complex promotes the recruitment 
and conversion of cytosolic-associated protein light chain 3 (LC3-I) to the membrane 
bound lipidated form; LC3-II (Matsushita et al., 2007, Kabeya et al., 2000). LC3-I 
conjugation begins with the cleavage of the carboxyl-terminal by cysteine protease ATG4. 
Upon autophagy activation, ATG7 activates LC3-I and transfers it to ATG3, an E2-like 
enzyme (Yamada et al., 2007). Finally, the ATG12-ATG5-ATG16 complex facilitates the 
conjugation of LC3-I to phosphatidylethanolamine (PE) to generate the lipidated form, 
LC3-II, which is integrated into the double membrane of the autophagophore. ATG4 can 
also cleave LC3 from the outer membrane of the autophagophore for recycling (Kirisako et 
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al., 2000). When autophagosome formation is complete the ATG proteins are recycled, 
with the exception of LC3-II, which remains bound to the mature autophagosome until 
fusion with a lysosome has been completed. LC3-II is the main marker of autophagy and it 
is the LC3 conversion that is used as a marker to monitor autophagy (Klionsky et al., 
2016).  
Although it is thought that autophagosomes engulf cellular material non-specifically, it can 
be semi selective. A cargo selector receptor, known as SQSTM1 (p62) delivers 
ubiquitinated substrates to the autophagosomes for autophagic degradation. p62 contains a 
c-terminal ubiquitin-associated domain that binds ubiquitin and also a LC3 interaction 
region the allows direct binding with LC3 (Pankiv et al., 2007). p62 is also useful when 
analysing autophagy as it is degraded during autophagy, but accumulates when autophagy 
is inhibited (Klionsky et al., 2016).  
1.6.4 Autolysosome formation 
Maturation of the autophagosome involves the fusion of the outer membrane of the 
autophagosome with a lysosome, to form an autolysosome (Liang et al., 2008). Upon the 
formation of the autolysosome the inner membrane and the sequestered cellular debris are 
lysed by lysosomal hydrolases, such as cathepsins, and are subsequently degraded to their 
monomeric units and released back into the cytosol. Therefore the cell gains new building 
blocks for energy generation and macromolecule synthesis (Xie and Klionsky, 2007). This 
maturation/degradative process is not fully understood, but is known to require lysosomal 
protein LAMP-2, the small GTPase RAB7 and UVRAG for completion (Rosenfeldt and 
Ryan, 2009) (figure 1-4). 
1.6.5 Autophagy and Cancer 
The first strong piece of evidence that linked autophagy to cancer was in 1999 when it was 
shown that BECLIN1 expression in MCF7 breast cancer cell line inhibited cell 
proliferation in vitro and inhibited tumourigenesis in nude mice (Liang et al., 1999). This 
data was interestingly supported by data showing that BECLIN1 was mono-allelically 
deleted in 40-70% of sporadic human breast and ovarian cancer patients (Aita et al., 1999).  
It was later shown that BECLIN1 haploinsufficient mice were prone to tumour 
development (Qu et al., 2003, Yue et al., 2003). Since these findings it has also been 
shown that other autophagy related genes have links to cancer. For example, frameshift 
mutations of ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers (Kang 
et al., 2009) and deletion of other key autophagy regulators, such as ATG7, in mice 
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promote malignant transformation in the liver and HSCs
 
 (Mortensen et al., 2011, 
Takamura et al., 2011).  
1.6.6 Autophagy and CML  
Increasing evidence is emerging that autophagy is an essential mechanism involved in the 
maintenance of HSCs
 
and may protect against leukaemia development (Liu et al., 2010, 
Mortensen et al., 2011, Warr et al., 2013b). The first studies to show this were conducted 
by Lui et al and Mortensen et al, which showed, that deleting essential autophagy genes 
FIP200 and Atg7 had negative effects on the function and maintenance of HSCs (Liu et al., 
2010, Mortensen et al., 2011). FIP200 was shown to be essential for foetal HSC 
maintenance and function, as its deletion caused increased mitochondrial mass and high 
levels of ROS production and as a consequence these mice suffered from severe anaemia 
and perinatal lethality (Liu et al., 2010). Similarly, the conditional deletion of ATG7 in the 
haemopoietic system led to the accumulation of mitochondria, increased ROS production, 
DNA damage and the loss of HSC function (Mortensen et al., 2011). The loss of ATG7 
also affected the production of myeloid and lymphoid progenitor cells and the mice 
developed a myeloproliferative disorder and only had a mean survival of 12 weeks 
(Mortensen et al., 2010), therefore suggesting that autophagy may protect the cells against 
leukaemogenesis. This has been supported more recently by Warr et al, who demonstrated 
that FOXO3A is essential for life-long maintenance of HSCs via its critical role in poising 
HSCs for rapid induction of autophagy upon starvation (Warr et al., 2013b). These data 
indicate just how important basal autophagy is to maintain homeostasis in normal cells, as 
it allows the cells to adapt to changing environments. 
Strong evidence linking autophagy with leukaemia development has led to several studies 
publishing links specifically to CML (Bellodi et al., Salomoni and Calabretta, 2009, Yan et 
al., 2006, Kamitsuji et al., 2008).  
As discussed CML cells depend on growth factoring mimicking of BCR-ABL for their 
survival. One major pathway which BCR-ABL signals through for growth and survival is 
the PI3K/AKT/mTOR pathway, therefore mTOR is constitutively active in CML cells. 
mTOR is a negative regulator of autophagy and an in vivo study has shown that BCR-ABL 
expressing haemopoietic precursor cells have low levels of autophagic activity, however, 
the cells are highly dependent on this process (Altman et al., 2011).  
Strong data shows that although standard treatments for CML cause apoptosis in the 
majority of cells, a small persistent reservoir of BCR-ABL expressing CML cells survive, 
which is responsible for disease progression. Treatment of CML cells with TKIs has been 
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shown to induce autophagy, presumably due to the inhibition of BCR-ABL signalling, 
which therefore leads to down regulation of the PI3K/AKT/mTOR pathway. The induction 
of autophagy is thought to make CML cells become metabolically inactive, which allows 
them to evade TKI stress. A hypothesis, was drawn by Calabretta and Salomoni, that if 
CML cells induce autophagy as a survival mechanism against TKI, the inhibition of 
autophagy would eliminate this pro-survival mechanism and could potentially restore TKI 
sensitivity in these CML cells (Calabretta and Salomoni, 2011). 
The first evidence of autophagy induction in CML cells was shown in 2006, when a lab 
used a neurotoxin; crotoxin, as an anti-cancer treatment against the CML cell line K562. 
They showed that crotoxin induced autophagy in the K562 cells and by blocking 
autophagy, this further sensitised the K562 cells to the crotoxin treatment, thereby 
increasing the cytotoxic effect (Yan et al., 2006). The following year, with the 
development of more specific CML therapeutics, it was shown that specifically inhibiting 
BCR-ABL induced autophagy in CML cells. This study used a potent c-ABL and LYN 
kinase inhibitor, bafetinib (INNO-406) to treat K562 cells and this led to the induction of 
autophagy (Kamitsuji et al., 2008). The autophagic response had a protective role in the 
surviving cell population as a treatment with autophagy inhibitor chloroquine (CQ) 
enhanced the cytotoxic effect of bafetinib. Upon the generation of imatinib this data was 
further supported as, imatinib was also shown to induce autophagy in CML cells and a 
combination treatment with CQ substantially enhanced imatinib-induced cell death 
(Mishima et al., 2008). However the strongest evidence that demonstrates that autophagy 
inhibition enhances imatinib treatment of primary CML cells was conducted by Bellodi 
and colleagues in 2009 (Bellodi et al,. 2009). They showed that combining a TKI, imatinib, 
dasatinib or nilotinib, with autophagy inhibition, enhanced TKI treatment to the extent that 
there was a near complete elimination of phenotypically and functionally defined CML 
stem cells (Bellodi et al., 2009). This was supported by an in vivo study, which 
conditionally deleted ATG3 to inhibit autophagy in BCR-ABL expressing haemopoietic 
cells (Altman et al., 2011). These cells were then transplanted into lethally irradiated mice 
and due to the ATG3 deletion the BCR-ABL cells failed to induce leukaemia (Altman et 
al., 2011).  
Studies within our own laboratory have shown that CD34
+
 CML cells express lower levels 
of essential autophagy genes compared to normal CD34
+
 cell populations. However, upon 
TKI treatment and subsequent BCR-ABL inhibition, these same genes are shown to be 
upregulated in the CD34
+
 CML cells. This suggests that BCR-ABL not only suppresses 
autophagy post-transcriptionally by increased PI3K/AKT/mTOR signalling, but also leads 
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to down-regulated transcription of key autophagy genes. This data further supports the 
hypothesis made by Bellodi et al, that at the primitive stem cell level, autophagy is induced 
as a protective mechanism specifically against TKI induced BCR-ABL inhibition (Bellodi 
et al., 2009).  
A collaboration between our laboratory and Calabretta and Salomoni, has identified 
autophagy as a potential survival pathway that CML stem cells activate in response to TKI-
induced cellular stress (Calabretta and Salomoni, 2011).  Autophagy is thought to help 
CML stem cells escape TKI induced death and there evade eradication. Therefore, 
autophagy has become a key research area in CML stem cell research. 
 
1.6.7 Autophagy inhibition in CML 
In the clinic the most common treatment given to patients to inhibit autophagy is an 
antimalarial drug called CQ, or its derivative, HCQ which is increasingly potent and 
associated with lower retinal toxicity (Solomon and Lee, 2009, Levy et al., 1997). 
HCQ is a lysosomotropic weak bases, which raises the pH within lysosomes and impairs 
lysosomal function.  This can therefore effect the end stage of the autophagy process; due 
to the inhibition of lysosomal acidification it can no longer degrade the autophagic cargo. 
In addition to this effect it can also inhibit autophagy flow by preventing the fusion of the 
autophagosome to the lysosome. HCQ’s primary use is as an anti-malarial drug, but it has 
also been used to treat patients with autoimmune diseases, such as rheumatoid arthritis. 
HCQ has been well tolerated in the clinic and due to its FDA approval it has allowed a 
number of clinical trials to be launched investing its efficacy in inhibiting autophagy 
function, either as a sole cancer treatment or in combination with cytotoxic agents.   
There are other pharmacological drugs that are available that can target the early stages of 
autophagy, such PI3K-III inhibitor, 3-methyladenine and wortmannin (Blommaart et al., 
1997). Chemical inhibitors are also available and these target the later stages of autophagy, 
such as lysosomal protease inhibitors E64d and pepstatin, which effects degradation of the 
autophagosome (Tanida et al., 2005).  However, none of these inhibitors are specific to 
autophagy and some of them are associated with high toxicity at clinically relevant doses.   
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1.6.8 CHOICES clinical trial 
The significance of the previously mentioned data has led to the initiation of the phase II 
CHOICES (CHlOroquine and Imatinib Combination to Eliminate Stem cells) randomised 
clinical trial (NTC01227135). CHOICES is a preliminary study evaluating the response of 
imatinib versus imatinib and HCQ, in CML patients who have been on imatinib for over 1 
year and are in MCyR with residual disease detectable by qRT-PCR. The primary 
objectives of this trial are (1) to determine if imatinib or imatinib in combination with 
HCQ is more effective in lowering BCR-ABL levels in patients with CML in MCyR with 
residual BCR-ABL positive cells detectable by qRT-PCR after at least one year of imatinib 
treatment, and (2) to determine the safety and tolerance of this treatment regime in CML 
patients. Patients were randomised into 2 different treatment arms; in arm A patients 
received oral imatinib daily and arm B patients received oral imatinib daily and oral HCQ 
twice daily. In both treatment arms the treatment was given continuously for up to 12 
months in the absence of disease progression or unacceptable toxicity. The patients then 
received oral imatinib daily for a further 12 months during the follow up period of the 
study. Patients’ blood samples will be analysed at baseline, during and upon completion of 
the treatment for pharmacological and laboratory testing. After the completion of the study, 
patients undergo follow-up testing at 3, 6, 9 and 12 months.   
Data from the CHOICES clinical trial will be invaluable in the understanding of the 
regulation of autophagy in CML and if this is an effective future therapeutic option for 
CML patients.  
 
1.6.9 New generation of autophagy inhibitors 
Although, HCQ has been shown to effectively inhibit autophagy in vitro there is 
uncertainty whether the same effect can be achieved in the clinic. Therefore, we are 
continuing to investigate different autophagy inhibitors, as more potent and specific 
compounds are becoming increasingly available. Currently we are interested in analysing 
the effects of Lys05, a CQ derivative, which has been shown to be 10x more potent than 
HCQ (McAfee et al., 2012) and therefore more likely to show the desired inhibitory effect 
needed for CML patients. Lys05 is an autophagy inhibitor, which has also shown to have 
single agent antitumour activity, unlike HCQ (McAfee et al., 2012). In vivo investigations 
using mouse models have shown that at a high dosage level Lys05 reproduced a similar 
phenotype as humans with genetic defects in autophagy gene ATG16L1, therefore 
supporting its specificity to autophagy inhibition (McAfee et al., 2012).  
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Figure ‎1-3: Autophagy activation.   
Autophagy is induced by the activation of the initiation complex. This occurs when mTOR is 
inhibited, as seen with the inhibition of BCR-ABL signalling by TKIs. This allows ULK1 and ATG13 to 
be phosphorylated by AMPK and activate the initiation complex, which is then recruited to the 
phagophore. 
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Figure ‎1-4:The molecular mechanism of autophagy.  
Activation of the initiation complex promotes autophagosome formation. An essential autophagy 
protein for autophagosome formation is VPS34, which forms a complex with VPS15, BECLIN1, 
UVRAG and AMBRA1. Autophagosome completion is regulated by LC3 and ATG12-ATG5 
conjugation systems, which mediate lipid modification of LC3-I, allowing LC3-II to bind to the 
autophagosomal double membrane. Completed autophagosomes contain cellular debris that is 
ready for degradation. The completed autophagosome fuses with a lysosome and forms an 
autolysosome, which uses the lysosomal enzymes to degrade and recycle the debris to allow for 
the generation of energy and new building blocks for protein synthesis. Adapted from (He and 
Klionsky, 2009b).   
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1.7 Summary 
As has been discussed in this chapter, TKIs have greatly improved the life expectancy of 
CML patients, however their success has been tarnished by the development of drug 
intolerance, CML stem cell insensitivity to TKIs (Graham et al., 2002, Jørgensen et al., 
2007a, Copland et al., 2006b, Corbin et al., 2011, Hamilton et al., 2012) and drug 
resistance (Karvela et al., 2012). A significant subset of CML patients suffer from TKI 
resistance and despite efforts to combat known resistant mechanisms such as ABL kinase 
domain mutations (Druker et al., 1996) with the development of more potent TKIs (Corbin 
et al., 2002, Lombardo et al., 2004, Brümmendorf et al., 2015, O’Hare et al., 2009) there is 
still a patient population, which have an acquired TKI resistance, which is not due to a 
kinase domain mutation and yet are resistant to all current TKI treatments. These patients 
are believed to have a BCR-ABL-independent mechanism of resistance. Evidence has been 
shown from several reputable publications (Thomas et al., 2004, Mahon et al., 2003, 
Mahon et al., 2008) that BCR-ABL-independent TKI resistance may stem from the 
activation of a secondary oncogenic mechanism. Patients with a BCR-ABL-independent 
mechanism of TKI resistance are of major clinical concern, as although a number of 
mechanisms have been proposed, not one common mechanism has been discovered, which 
leaves these patients with very limited treatment options. In this study we hope to gain a 
further understanding of the mechanisms causing BCR-ABL-independent TKI resistance. 
In order to do so we generate ponatinib resistant cell line models and attempt to 
characterise their mechanism of resistance using different screening methods. It is hoped 
that information gained from these experiments will guide us towards the identification of 
a common weakness in primary TKI-resistant CML cells. Results from our study propose 
the PI3K-AKT-mTOR pathway as a key player responsible for TKI resistance and that 
pharmacological inhibition of this pathway in combination with the inhibition of survival 
mechanism, autophagy, may represent a potential new treatment for TKI-resistant CML 
patients. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Small molecule inhibitors 
Imatinib and ABL001 were provided as a white powder under a Materials Transfer 
Agreement (MTA) from Novartis Pharma (Basel, Switzerland). Dasatinib was provided as 
a white powder under a MTA from Bristol-Myers Squibb (Princeton, NJ, USA). Ponatinib 
was provided as a white powder under a MTA from ARIAD Pharmaceuticals Inc. 
(Massachusetts, USA). Details of the suppliers, stock concentrations, and diluents of all 
drugs and inhibitors used are listed in Table 2-1. All stock aliquots were stored at -20°C, 
with the exception of HCQ and CQ, which were stored at 4°C. All small molecule 
inhibitors were made up fresh for each experiment and diluted to the appropriate 
concentration with appropriate medium prior to use. 
Molecule Vehicle
 
Stock Concentration Supplier 
Imatinib Water 100 mM Novartis 
Dasatinib DMSO
(a)
 20 mM Bristol-Myers Squibb 
Nilotinib DMSO 10 mM Novartis 
Ponatinib DMSO 10 mM ARIAD Pharma 
ABL001 DMSO 10 mM Novartis 
Omacetaxine DMSO 10 mM Chemgenex 
Chloroquine Water 100 mM Sigma-Aldrich 
Hydroxychloroquine PBS
(b) 
100 mM SigmaAldrich 
Rapamycin Ethanol 2 mM Sigma-Aldrich 
Rad001 DMSO 5 mM Novartis  (MTA) 
PP242 DMSO 10 mM Seleckchem 
AZD8055 DMSO 10 mM Seleckchem 
NVP-Bez235 DMSO 1 mM LC laboratories 
VS-5584 DMSO 10 mM Seleckchem 
Gedatolisib DMSO 1 mM Seleckchem 
XL765 DMSO 10 mM Seleckchem 
Apitolisib DMSO 10 mM Seleckchem 
BKM120 DMSO 10 mM Seleckchem 
PI-103 DMSO 10 mM Seleckchem 
AZD6244 DMSO 10 mM Seleckchem 
Trametinib DMSO 10 mM Seleckchem 
Vorinostat DMSO 10 mM Seleckchem 
Belinostat DMSO 10 mM Seleckchem 
Sunitinib DMSO 10 mM Seleckchem 
Table ‎2-1: Small molecule inhibitors (a)dimethyl sulfoxide; DMSO, (b)phosphate buffered saline; 
PBS 
 
2.1.2 Tissue culture materials 
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BD Biosciences, Oxford, UK  
20G needles 
Syringes: 1 mL, 5 mL, 10 mL, 20 mL, 50 mL 
 
Biolegend, London, UK  
Mouse recombinant IL-3 
 
Corning, Amsterdam, Netherlands 
Pipettes: 5 mL, 10 mL and 25 mL 
Sterile plastic falcon tubes: 15 mL and 50 mL 
Tissue culture flasks: 25 cm
2
, 75 cm
2
, 175 cm
2
 and 225 cm
2
. 
Tissue culture plates: 35 mm
2
, 10 cm
2
, 6-well, 12-well, 24-well and 96-well 
 
Chugai Pharma, London, UK  
Human recombinant G-CSF 
Gilson, Middleton, USA  
Yellow and blue pipette tips 
 
Greiner, Bio-One, Gloucestershire, UK 
BIJOU BOTTLE 7 mL 
Culture dish TC treated 145 mm deep base 20 mm 
Cryotubes 
EASYstrainer 40 µm mesh 
Eppendorf Tubes: 0.5 mL and 1.5 mL 
 
Hendley, Essex, UK  
Multi-spot microscope slides 
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Invitrogen, Paisley, UK  
Ampicillin 
Blastocidin  
Dulbecco’s modified eagle medium (DMEM) 
Dulbecco’s phosphate buffered saline (PBS) 
Foetal calf serum (FCS) heat inactivated 
Hank’s buffered salt solution (HBSS) 
Isocove’s modified Dulbecco’s medium (IMDM) 
L-glutamine (200 mM) 
Penicillin-Streptomycin (10,000 U/mL) 
Puromycin 
RPMI 1640 
Trypsin-EDTA (0.05%), phenol red 
 
Nalgene Labware, Roskilde, Denmark 
Cryo freezing container ‘Mr Frosty’  
Non-adherent tissue culture flasks: 25 cm
2
 and 75 cm
2 
 
Peprotech, London, UK  
Human recombinant FLT-3L 
Human recombinant granulocyte macrophage-colony stimulating factor (GM-CSF) 
Human recombinant IL-3 
Human recombinant IL-6 
Human recombinant LIF 
Human recombinant Macrophage inflammatory protein 1α (MIP-1α) 
Human recombinant Stem Cell Factor (SCF) 
 
Sartorius, Hannover, Germany  
Minisart 0.2 µM sterile filters 
Minisart 0.45 µM sterile filters 
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Sigma-Aldrich, Dorset, UK  
2-mercaptoethanol (2-ME) 
Bovine serum albumin (BSA) 
DMSO 
Ficoll/Histopaque®-1077 
Hydrochloric acid (HCl) 
Magnesium chloride (MgCl2) 
Potassium chloride (KCl2) 
Trypan blue 
XTT salt 
 
StemCell™ Technologies, Grenoble, France 
(DNase) 1 mg/mL 
BSA/insulin/transferrin (BIT) 
Low density lipoprotein (LDL) 
Methocult (human) H4034 
Methocult (human) H4230 
Methocult (murine) M3434 
 
2.1.3 Molecular biology supplies 
 
Applied Biosystems, Foster City, CA, USA 
GeneAmp® RNA PCR Core Kit 
 
Bioline, London, UK  
HyperPAGE prestained protein marker 
α-select competent cells (gold and silver efficiency)  
 
 
Bio-Rad Laboratories Ltd, Sussex, UK 
Precision plus protein dual xtra standard ladder  
Mini Trans-Blot® Cell 
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Cambridge bioscience, UK 
Endura™ ElectroCompetent Cells (DUOs) Lucigen 
 
Cell Signaling Technology®, New England Biolabs, Hitchin, UK 
100 BP DNA ladder 
1 kB DNA ladder 
Anti-rabbit IgG HRP linked secondary antibody 
Rabbit anti-human-p-CrkL antibody 
Rabbit anti-human p-ERK1/2 antibody 
Rabbit anti-human-LC3b antibody 
Rabbit anti-human-p-RPS6 antibody 
Rabbit anti-human-β-Tubulin antibody 
Quick DNA ligation kit 
T4 DNA ligase 
T4 Polynucleotide kinase 
 
Chemical Store, University of Glasgow, Glasgow, UK 
EtOH 
Methanol 
Isopropanol  
 
Epitomics-Abcam, Burlingame, CA, USA 
ATG7 antibody 
 
GE Healthcare Life Sciences, Buckinghamshire, UK 
Hybond-P (14 × 16 cm) PVDF membrane1 box 
 
IDT, Leuven, Belgium 
Oligonucleotides 
PCR primers 
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Invitrogen, Paisley, UK  
Agarose 
DH5 ALPHA CELLS SUBCLONING EFF/1 mL 
Empty Gel Cassettes, mini, 1.0  mm 
Empty Gel Cassette Combs, mini, 1.0 mm, 10 well 
NuPage® MES sodium dodecyl sulphate (SDS) running buffer (20x) 
NuPage® MOPS sodium dodecyl sulphate (SDS) running buffer (20x) 
Nupage® Novex® Bis-Tris 4-12% gel 
NuPage® transfer buffer (20x)  
SYBR®Safe  
XCell II
TM
 Blot module 
 
Qiagen, West Sussex, UK  
HiSpeed® plasmid maxi kit 
QIAamp DNA blood mini kit 
QIAquick gel extraction kit 
RNeasy mini kit 
 
Sigma-Aldrich, Dorset, UK  
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
Agar 
Ammonium persulfate (APS) 
Boric acid 
CaCl2*2H2O 
COMPLETE ULTRA, MINI, EDTA-Free easypack  
DTT 
EDTA 
Glucose 
Glycine 
PhosSTOP 
Potassium chloride 
SOC media 
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Sodium chloride 
Sodium phosphate 
Sodium dodecyl sulphate (SDS) 
Tetramethylethylenediamine (TEMED) 
Tris base 
TWEEN 20 
 
Thermo Fisher Scientific 
Bicinchoninic acid (BCA)™ protein assay kit 
CL-XPosure Film, 7 x 9.5 inches (18 x 24 cm) 
FastAP Thermosensitive Alkaline Phosphatase (1 U/L) 
FastDigest Esp3I (BsmBI) 
FILTER PAPER 3MM CHROMATOGRAPHY 46x57cm 
Pierce™ ECL Western Blotting Substrate 
Phusion Flash High Fidelity PCR Master Mix 
ProtoGel (30%) 37.5:1 Acrylamide to Bisacrylamide 
RIPA Buffer 
SuperSignal™ West Femto Maximum Sensitivity Substrate 
 
Thistle Scientific, Glasgow, UK 
PCR tubes 
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2.1.4 FACS 
 
BD Biosciences, Oxford, UK  
FACS flow/FACS clean 
Mouse Anti-Human-annexin-V-APC antibody 
Via-ProbeTM- 7 aminoactinomycin D (7-AAD) 
PerCP-Cy™5.5 Mouse Anti-Human CD45 
Sterile capped FACS tubes 
 
Elkay Laboratories, Basingstoke, UK 
FACS tubes 
 
Merck Millipore 
FlowCellect™ Autophagy LC3 Antibody-based Assay Kit 
 
2.1.5 Immunofluorescence  
 
Carl Zeiss, Jena, Germany  
AxioVision software 
 
Sigma-Aldrich, Dorset, UK  
Formaldehyde solution (36.5%) 
Poly-L-lysine 
 
Vector Laboratories Ltd, Peterborough, UK  
VECTASHIELD® mounting medium with 4',6-diamidino-2- phenylindole (DAPI) 
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2.1.6 Seahorse 
 
Corning, Amsterdam, Netherlands 
Cell Tak 
 
Seahorse Bioscience, Copenhagen, Denmark 
Seahorse XF96 Flux Analyser 
XF96-well plate 
XF Assay Medium  
XF Cell Mito Stress Test Kit 
 
Sigma-Aldrich, Dorset, UK 
Oligomycin 
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) 
Antimycin A 
Rotenone 
 
2.1.7 Animal work 
 
Perkin Elmer, Seer Green, UK 
D-Luciferin, Potassium salt 
 
Sigma-Aldrich, Dorset, UK  
Citric acid 
N-Methyl-2-pyrrolidone 
Sodium citrate 
Polyethylene glycol (PEG) 300  
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2.1.8 PCR primer sequences 
 
CRISPR Screen PCR 1 primers: 
v2Adaptor_F: AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG 
v2Adaptor_R: TCTACTATTCTTTCCCCTGCACTGTtgtgggcgatgtgcgctctg 
CRISPR Screen PCR 2 primers: 
Forward 
F01:AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATCTtAAGTAGAGtcttgtggaaaggacgaaacaccg 
F02:AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATCTatACACGATCtcttgtggaaaggacgaaacaccg 
F03:AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATCTgatCGCGCGGTtcttgtggaaaggacgaaacaccg 
F04:AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATCTcgatCATGATCGtcttgtggaaaggacgaaacaccg 
F05:AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATCTtcgatCGTTACCAtcttgtggaaaggacgaaacaccg 
F06:AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATCTatcgatTCCTTGGTtcttgtggaaaggacgaaacaccg 
F07:AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATCTgatcgatAACGCATTtcttgtggaaaggacgaaacaccg 
F08:AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATCTcgatcgatACAGGTATtcttgtggaaaggacgaaacaccg 
F09:AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATCTacgatcgatAGGTAAGGtcttgtggaaaggacgaaacaccg 
F10:AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATCTtAACAATGGtcttgtggaaaggacgaaacaccg 
F11:AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATCTatACTGTATCtcttgtggaaaggacgaaacaccg 
F12:AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT
CCGATCTgatAGGTCGCAtcttgtggaaaggacgaaacaccg 
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Reverse  
R01:CAAGCAGAAGACGGCATACGAGATAAGTAGAGGTGACTGGAGTTCAGAC
GTGTGCTCTTCCGATCTtTCTACTATTCTTTCCCCTGCACTGT 
R02:CAAGCAGAAGACGGCATACGAGATACACGATCGTGACTGGAGTTCAGAC
GTGTGCTCTTCCGATCTatTCTACTATTCTTTCCCCTGCACTGT 
R03:CAAGCAGAAGACGGCATACGAGATCGCGCGGTGTGACTGGAGTTCAGAC
GTGTGCTCTTCCGATCTgatTCTACTATTCTTTCCCCTGCACTGT 
R04:CAAGCAGAAGACGGCATACGAGATCATGATCGGTGACTGGAGTTCAGAC
GTGTGCTCTTCCGATCTcgatTCTACTATTCTTTCCCCTGCACTGT 
R05:CAAGCAGAAGACGGCATACGAGATCGTTACCAGTGACTGGAGTTCAGAC
GTGTGCTCTTCCGATCTtcgatTCTACTATTCTTTCCCCTGCACTGT 
R06:CAAGCAGAAGACGGCATACGAGATTCCTTGGTGTGACTGGAGTTCAGACG
TGTGCTCTTCCGATCTatcgatTCTACTATTCTTTCCCCTGCACTGT 
 
2.1.9 Equipment 
Kell-Strom, Wethersfield, USA  
Branson 200 Ultrasonic cleaner 
 
BD Biosciences, San Jose, CA, USA 
FACSAria II 
FACSCanto 
FACSVerse 
 
Gilson, Middleton, USA 
Gilson pipetman single channel pipettes 
 
Weber Scientific International, West Sussex, UK 
Hawksley Neubauer counting chamber 
 
Carestream Health, Rochester, NY, USA 
Kodak X-OMAT 1000 
 
Thermo Fisher Scientific, Loughborough, UK 
Bio-Rad Hercules, CA, USA PowerPac300 
NanoDrop ND-2000 spectrophotometer 
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Bio-Rad Laboratories Ltd., UK  
Molecular Imager® ChemiDocTM XRS 
 
Carl Zeiss, Jena, Germany  
Fluorescence microscope 
Light microscope 
 
2.2 Preparation of medium and solutions 
2.2.1 Tissue culture mediums and solutions 
 
RPMI media 
RPMI 1640 440 mL 
FCS 50 mL 
L-glutamine (200 mM) 5 mL 
Penicillin/streptomycin solution (10,000 UmL-1/10,000 gmL-1) 5 mL 
 
DMEM media 
DMEM 440 mL 
FCS 50 mL 
L-glutamine (200 mM) 5 mL 
Penicillin/streptomycin solution (10,000 UmL-1/10,000 gmL-1) 5 mL 
 
DAMP solution for thawing cryopreserved CD34+ or mononuclear cell (MNC) aliquots 
from -150°C 
DNase I (2 vials at approximately 2500 U/1 mL/vial) 2 mL 
Magnesium chloride (400X, 1.0 M stock) 1.25 mL 
Trisodium citrate (0.155 M) 53 mL 
Human serum albumin (20%, SNBTS) 25 mL 
Dulbecco’s PBS (magnesium/calcium free) 418.75 mL 
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Serum free medium (SFM) 
BIT (bovine serum albumin, insulin, transferrin) 25 mL 
L-glutamine (200 mM) 1.25 mL 
Penicillin/streptomycin solution (10,000 UmL-1/10,000 gmL-1) 1.25 mL 
2-mercaptoethanol (50 mM) 250 μL 
Low density lipoprotein (10 mg/mL) 500 μL 
IMDM 97.25 mL 
 
SFM supplemented with high five growth factors (SFM+5GFs) 
SFM 10 mL 
IL-3 (50 μg/mL) 4 μL 
IL-6 (50 μg/mL) 4 μL 
G-CSF (20 μg/mL) 10 μL 
FLT3L (50 μg/mL) 20 μL 
SCF (50 μg/mL) 20 μL 
*Filter through 0.22 μM filter 
 
SFM supplemented with physiological growth factors (SFM+PGFs) 
SFM 10 mL 
SCF (0.5μg/mL) 4μL 
G-CSF (2 μg/mL) 5 μL 
GM-CSF (0.1 μg/mL) 20 μL 
IL-6 (5 μg/mL) 2 μL 
LIF (0.1 μg/mL) 5 μL 
MIP-1α (0.1 μg/mL) 20 μL 
*Filter through 0.22 μM filter 
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IMDM for the maintenance of mouse c-kit enriched cells 
IMDM 440 mL 
FCS 50 mL 
L-glutamine (200 mM) 5 mL 
Penicillin/streptomycin solution (10,000 UmL-1/10,000 gmL-1) 5 mL 
Mouse SCF 50 ng/mL 
Mouse IL-6 25 ng/mL 
Mouse IL-3 10 ng/mL 
 
1% FBS/ PBS 
PBS 99 mL 
FBS 1 mL  
 
Freezing media 10% DMSO FBS 
DMSO 5 mL 
FBS 45 mL 
  
87 
 
 
2.2.2 Western blot solutions 
 
Lysis buffer for protein lysates (radio-immunoprecipitation assay; RIPA) 
Distilled sterile water (dsH2O) 7.75 mL 
1.5 M NaCl 1 mL 
1 M Tris-HCl 0.5 mL 
150 mM EDTA 333 μL 
NP-40 50 μL 
10% (w/v) Sodium deoxycholate 250 μL 
*Immediately prior to use, one protease inhibitor tablet added per 10 mL of buffer 
 
2x SDS Sample buffer (Laemmli) 
1.5 M Tris-HCl, pH 6.8 10 mL 
Glycerol 30 mL 
20% (w/v) SDS 6 mL 
Bromophenol blue 1.8 mg 
2-mercaptoethanol 15 mL 
Distilled H2O to 100 mL 
 
10X TBS buffer 
NaCl 8.76 g 
Tris 6.05 g 
In 800 mL upH2O 
Adjust pH to 7.5 with 1M HCL (9.5 mL) 
Adjust to 1 L with Ultra pure H2O 
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1x TBS-Tween (TBST) buffer 
10x Tris-buffered saline (TBS) buffer 100 mL 
TWEEN20 1 mL 
dH2O 899 mL 
 
Homemade gels - 1.5 mm mini gels 
10% Resolving gel  
30% Acrylamide 5 mL 
upH2O 4.35 mL 
1 M Tris (pH 8.8) 5.6 mL 
10% SDS 0.25 mL 
10% APS 0.1 mL 
TEMED 0.02  mL 
 
15% Resolving gel 
30% Acrylamide 10.0 mL 
dsH2O 2.5 mL 
1.5 M Tris (pH 8.8) 7.5 mL 
10% SDS 0.35 mL 
10% APS 0.1 mL 
TEMED 0.02 mL 
 
Stacking gel 
30% Acrylamide 1.67 mL 
dsH2O 6 mL 
1M Tris (pH 6.8) 1.25 mL 
10% SDS 0.15 mL 
10% APS 0.05 mL 
TEMED 0.02 mL 
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10x Tris-Glycine Buffer 
Tris 30.3 g  
Glycine 144.1 g 
Up H2O to 1 L 
 
1x Running buffer 
10x Tris-Glycine Buffer 100 mL 
10% SDS 10 mL 
upH2O 890 mL 
 
1x Transfer buffer 
10x Tris-Glycine Buffer 100 mL 
Methanol 200 mL 
upH2O 700 mL 
 
5% BSA/TBST blocking buffer 
1X TBST buffer 100 mL 
BSA 5 g 
 
5% Milk/TBST blocking buffer 
1X TBST buffer 100 mL 
Marvel 5 g 
 
 
 
 
 
 
90 
 
2.2.3 Flow cytometry 
 
Annexin-V and 7AAD solution per sample 
Annexin-V APC 2.5 µL 
7AAD 2.5 µL 
HBSS 45 µL 
 
2.2.4 Immunofluorescence solutions 
 
3.65% Formaldehyde 
36.5% Formaldehyde solution 1 mL 
PBS 9 mL 
 
2.2.5 PCR assay solutions 
 
10x Tris/Borate/EDTA (TBE) buffer 
Boric acid 55 g 
EDTA (0.5 M, pH 8.0) 40 mL 
Tris base 108 g 
Ultra pure (up)H2O to 1L 
 
2% Agarose gel 
1x TBE 200 mL 
Agarose 4 g 
* The solution was boiled using a microwave until the agarose powder was completely 
dissolved. After cooling, 20 µL of SYBR
®
Safe DNA gel stain was added to the solution 
and gel was poured into casting trays and allowed to set before use.  
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2.2.6 Transfection solutions 
 
2x HEPES-buffered saline (HBS) 
NaCl 8 g 
KCl 0.37 g 
Na2HPO4 0.2 g 
Glucose 1.0 g 
HEPES 5 g 
upH20 to 500 mL 
pH to 7.04 
*Sterile filter through 0.22 µM filter 
 
2 M CaCl2 
CaCl2*2H2O 147 g 
upH2O to 500 mL 
 
Transfection solution/10cm
2
 petri dish 
dsH20 1280 μL 
2X HBS 1.5 mL 
2M CaCl2 (dropwise) 183 μL 
psPAX2 plasmid 12.45 µg 
pCMV-VSV-G plasmid 4.5 µg 
Plasmid for transfection 14.2 µg  
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2.2.7 Microbiology solutions 
 
LB Broth 
LB broth 20 g 
upH2O to 1 L 
*Autoclave* 
Ampicillin (100 mg/mL) 1 mL 
 
LB Agar 
LB broth 20 g 
Agar 15 g 
upH2O to 1 L 
*Autoclave* 
Ampicillin (100 mg/mL) 1 mL 
 
30% Glycerol  
Glycerol 3 mL 
upH2O to 7 mL 
 
Bacterial glycerol stocks 
Bacteria in LB broth 500 µL 
30% glycerol 500 µL 
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2.3 Methods 
2.3.1 Cell Culture 
2.3.1.1 Culture of cell lines 
2.3.1.1.1 Suspension cells 
 
The human CML Blast Crisis cell line KCL22
WT
 was available from our own laboratory. 
KCL22 cells expressing BCR-ABL
T315I 
were kindly donated by Professor Bruno 
Calabretta. The murine haemopoietic cell line, BaF3
Parental
, is an IL-3 dependent pro-B cell 
cell line. BaF3
Parental
 transfected with a retroviral construct encoding BCR-ABL
p210
 or 
BCR-ABL
p210
 with the T315I kinase domain mutation to generate CML cell lines BaF3
WT
 
or BaF3
T315I 
respectively, were donated as a kind gift from Professor Junia Melo.  
2.3.1.1.2 Imatinib resistant cell lines 
 
KCL22 imatinib-sensitive (KCL22-S), KCL22 imatinib-resistant (KCL22
Im-Res
), human 
CML blast crisis cell lines K562-S, K562
Im-Res
, Lama88-S and Lama88
Im-Res
 were also 
kindly gifted by Professor Junia Melo. 
2.3.1.1.3 Ponatinib resistant cell lines 
 
Ponatinib resistant cell line models were generated in our own lab, using KCL22
WT
 and 
BaF3
WT
, which were grown in increasing concentrations of ponatinib, until 100 nM 
ponatinib resistant, for a prolonged period of time. KCL22
Pon-Res 
generated by Dr. G. V. 
Helgason and BaF3
Pon-Res 
generated by R. Mitchell.  
All suspension cells were cultured in complete RPMI 1640 media in tissue culture flasks. 
BaF3
Parental
 cells were supplemented with 10 ng/ml recombinant mouse IL-3. The cells 
were counted and passaged every two days with fresh warm medium, to maintain a density 
of between 0.1x10
6
-1x10
6
 cells/mL. 
2.3.1.1.4 Adherent cells  
 
Human Embryonic Kidney 293 (HEK 293) cells were available from our own lab. 
HEK293 cells were cultured in complete DMEM media in tissue flasks. The cells were 
passaged every two days with fresh warm medium, to maintain confluency between 50-
80%. 
All cell lines were maintained at 37°C with 5% CO2. 
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2.3.1.2 Isolating sub clones 
 
Background: KCL22
Pon-Res 
cells are made up of a heterogeneous cell population. In order 
for us to understand the underlying mechanism of resistance we isolated individual clones.  
Method: KCL22
Pon-Res
 cells were counted and 1000 cells were added to 1.5 mL of 
Methocult
TM
 (H4230), transferred to 35 mm tissue culture plates and incubated for 10 days 
at 37°C, 5% CO2. Following this incubation, individual colonies were plucked from the 
Methocult
TM
 and added to 100 µL of RPMI in a 96 well plate to allow for expansion of the 
clones. 
 
2.3.1.3 Primary samples 
 
All samples were collected with the approval of the Local Research and Ethics Committee 
(LREC) and all human participants gave written informed consent. 
Research Ethics Committee: West of Scotland REC 4  
Research Tissue Bank: Haematological cell research bank  
REC reference number: 15/WS/0077 
2.3.1.3.1 CML cells 
 
Peripheral blood or bone marrow samples from newly diagnosed untreated patients with 
CP CML, or patients with CML
T315I 
or TKI-resistant CML were collected and processed by 
Alan Hair or myself. Purification of the MNC fraction was performed using a method 
based on density gradients. The samples were diluted in PBS and layered onto 
Histopaque®-1077. The suspension was centrifuged at 400 x g for 30 min and the layer 
containing the MNC fraction was isolated and washed in PBS. This technique allows the 
isolation of MNC only, leaving the plasma, granulocytes and RBC. 
2.3.1.3.2 Non-CML samples 
 
Peripheral blood samples were obtained from patients undergoing autologous stem cell 
collection for either non-Hodgkin’s lymphoma or multiple myeloma. Patient stem cells 
were mobilised with G-CSF following chemotherapy and the excess cells remaining after 
those required for clinical use were donated for research purposes. 
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2.3.1.4 Cryopreservation of cells 
 
Primary CML, non-CML and cell lines were centrifuged at 300 x g for 10 minutes and 
resuspended by gently adding 10% DMSO/FBS dropwise with agitation. The cells were 
aliquoted into cryotubes and transferred to a cryofreezing container (“Mr Frosty”) and kept 
at -80°C overnight in order to lower the temperature slowly. The next day the cryotubes 
were transferred to a -150°C liquid nitrogen freezer for long-term storage. 
2.3.1.5 Recovery of frozen samples 
 
Primary CML and non-CML cells were removed from liquid nitrogen and immediately 
thawed at 37°C in a water bath until ice crystals disappeared. The cells were transferred to 
a 15 mL sterile tube and recovered by adding dropwise 10 mL of pre-warmed at 37°C 
DAMP thawing solution over 20 minutes. This step was performed at room temperature to 
enhance the activity of the DNase I, with constant agitation to avoid clumping of the cells. 
The cells were then centrifuged 250 x g for 10 minutes and the supernatant removed. This 
was repeated twice more, to remove traces of DMSO. Subsequently, the cells were 
transferred to appropriate volume of SFM with Physiological Growth Factors (PGF) for 
CML samples or SFM with a high growth factor (5GF) cocktail for non-CML samples. 
The cells were seeded in a 25 cm
2
 non-adherent tissue culture flasks at a cell density of 
1x10
6 
cells/mL and incubated overnight to allow the cells to recover. 
Cell lines were thawed immediately in a 37°C water bath and recovered by slowly adding 
RPMI with agitation. The cells were centrifuged at 300 x g for 5 minutes and the 
supernatant was removed. This step was repeated to wash off the DMSO. The cells were 
then resuspended in RPMI and seeded in a 25cm
2
 tissue culture flask. 
2.3.1.6 Primary cell culture 
 
Primary CML mononuclear cells (MNCs) were cultured in SFM comprising Iscove’s 
modified Dulbecco’s medium with BIT, 1 mmol/l glutamine, 1 mmol/l 
streptomycin/penicillin, 40 ng/ml low-density lipoprotein and 0.1 mmol/l 2-
mercaptoethanol (all, Invitrogen Ltd, Paisley, UK), further supplemented with a 
Physiological Growth Factor cocktail (0.2 ng/mL SCF, 1.0 ng/mL G-CSF, 0.2 ng/mL GM-
CSF, 1.0 ng/mL IL6, 0.05 ng/mL LIF and 0.2 ng/mL MIP-α; Stem Cell Technologies, 
Vancouver, BC, Canada). The cells were seeded in 25 cm
2
 or 75 cm
2
 non-adherent tissue 
culture flasks at an initial concentration of 1x10
6
cells/mL and maintained in an incubator at 
37°C, 5% CO2.  
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Non-CML cells are cultured in SFM supplemented with a high growth factor cocktail (20 
ng/mL IL-3, 20 ng/mL IL-6, 20 ng/mL G-CSF, 100 ng/mL Flt3-L, 100 ng/mL SCF). 
 
2.3.2 Cell proliferation assays 
 
2.3.2.1 Trypan blue dye exclusion method 
 
Background: The trypan blue dye exclusion method was used for cell counting and 
assessment of viability. Non-viable cells have damaged membranes, which are porous and 
can therefore absorb the trypan blue dye, appearing dark blue under a light microscope. 
Viable cells with an intact membrane do not absorb the dye. To determine the viable cell 
counts only the unstained cells were counted and the remaining stained dead cells were 
deemed non-viable. 
Method: Trypan blue dye was first diluted 1:10 with PBS and 50 μL was added to 50 μL of 
cell suspension to give a 1:1 dilution of cells. Approximately 10 μL of the mixture was 
transferred to a counting chamber, an improved Neubauer haemocytometer, and the four 
squares (1, 2, 3 and 4 indicated in figure 2-1) were counted to give a statistically significant 
count. The number of cells was determined by using the formula shown in figure 2-1. 
 
Figure ‎2-1: Trypan blue method for cell counting and viability assessment with improved 
Neubauer counting chamber. 
 
2.3.2.2 Automated cell counter using the CASY® Cell Counter and Analyser System 
 
Background: The Casy® cell counter and analyser system was also used to measure cell 
counts and cell viability. Casy® cell counter utilises electric current exclusion and pulse 
area analysis to count and analyse the cells in an efficient and precise manner. 
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2.3.3 Colony Forming Cell (CFC) assay 
 
Background: The CFC assay is an in vitro functional assay used to detect and quantify 
haemopoietic stem and progenitor cells, based on their ability to proliferate and 
differentiate into different cell lineages to produce colonies in semisolid medium. Each 
colony is derived from a single progenitor cell and the number of colonies provides a 
measure of the number of viable and functional progenitors in the cell sample being tested. 
This assay can be of particular use for monitoring the activity of cells in response to 
treatment in culture or genetic manipulation. We also use this assay with cell lines, to 
determine the functionality of a leukaemic cell after drug treatment and whether it still has 
leukaemic potential.  
Method: In order to carry out a CFC assay primary human cells or cell lines were cultured 
either in SFM with the addition of physiological growth factors or complete RPMI, 
respectively, with the appropriate drug treatment for 72 hours. After the 72 hour incubation 
cell counts were performed on all treatment arms. In order to gain a relative insight to the 
cell response to drug treatment, the number of cells were calculated so they were relative to 
the untreated arm, 100,000 cells in the case of primary samples and 1,000 cells for cell 
lines. Duplicate CFC assays were set up for each treatment arm, the appropriate volume of 
cell suspension was calculated and was added to 1.5 mL of Methocult
TM 
(H4434 for 
primary human samples, M3434 for mouse cells and H4230 for cell lines). Cell 
suspensions were then pulse vortexed to allow for homogenous mixing of the cells and left 
for 10 minutes for the bubbles to dissipate. The mixture was then transferred into 35mm 
tissue culture plates using a 1 mL syringe. Two 35mm plates plus one 35mm filled with 
sterile PBS were put inside a 10cm plate, to ensure a humid environment during the long 
incubation period.  The cells were incubated for 10-14 days at 37°C, 5% CO2. At the end 
of this time, the total number of viable colonies was counted in each dish and this allowed 
a comparison of the primitive cells present in the different treatment conditions. 
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2.3.4 Flow cytometry 
 
Flow cytometry is a laser based technology that can simultaneously measure and analyse 
multiple physical characteristics of a cell, such as size, using forward-angle light scatter 
(FSC) and granularity, using side angle light scatter (SSC). It can also determine the 
phenotype of the cell by staining with antigen specific fluorescent antibodies and 
measuring the fluorescence intensity. These cellular characteristics are determined by the 
way in which the cell scatters incident laser light and emits fluorescence. A flow cytometer 
is made up of three main components: (1) fluidics, which transports the cells in a stream to 
the laser beam, (2) optics, which is a complex system of lasers that illuminate the particles 
and optical filters that direct the light signals back to detectors, and (3) electronics, which 
converts the light signals to the computer for processing. All the flow cytometric analyses 
herein described were carried out on a Becton Dickinson FACSCanto or FACSVerse and 
the data was analysed using FlowJo software. 
2.3.4.1 Analysis of apoptotic and necrotic cell death  
 
Background: Apoptosis, or programmed cell death, is a normal process that occurs within a 
tissue to maintain homeostasis. This process is initiated when cells undergo stress that 
causes damage to the cells, such as cytotoxic drug treatments. One of the earliest features 
of apoptosis is the loss of asymmetry of the plasma membrane, during this event an 
important membrane phospholipid component phosphatidylserine (PS) translocates from 
the inner to the outer plasma membrane. Annexin V is calcium-dependent phospholipid 
binding protein that has a high affinity for PS and therefore binds to the exposed PS on 
apoptotic cells.  Annexin V can be conjugated to fluorochrome and still retain its integrity 
and binding affinity to PS, therefore Annexin V is a useful tool to analyse early apoptotic 
events by fluorescence-activated cell sorting (FACS). As the apoptotic pathway proceeds 
the plasma membrane becomes porous, this is indicative of late stage apoptosis or necrosis.  
By staining the cells with a nucleic acid dye, such as 7-Amino-Actinomycin D (7AAD), 
we can determine whether membrane integrity has been lost, as the dye can enter the cell 
through the damaged plasma membrane. Therefore, cells that are stained both with 
Annexin V and 7AAD are said to be in late apoptosis. This assay can distinguish between 
viable cells, (annexin V- 7AAD-) and cells in early (annexin V+ 7AAD-) or late (annexin 
V+ 7AAD+) apoptosis.  
Method: Apoptosis assay was used to analyse the effect of a drug on CML cells after 72 
hours. In cell line experiments, cells were plated at a concentration of 0.25x10
6
/mL and for 
primary samples MNC were plated at 1x10
6
/mL in multi-well plates. Cells were then 
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treated, in triplicate, with the appropriate drugs and incubated for 72 hours. After 72 hours, 
200 uL was taken from each well and transferred to FACS tubes, cells were centrifuged at 
300 x g for 5 minutes to remove the medium. The cells were resuspended in a solution 
made up of; 2.5 μL annexin-V-APC (BD, Cat no. 550475) and 2.5 μL 7-AAD (BD, Cat no. 
559925) in 45 μL 1x HBSS binding buffer (Thermo Fisher Scientific, Gibco Cat no. 
14025100). Cells were incubated for 20 minutes in the dark at room temperature, then 
washed with 500 μL 1x HBSS binding buffer and centrifuged at 300 x g for 5 minutes. The 
buffer was poured off and cells were resuspended in the residual buffer (~100 μL) and 
analysed by FACS within an hour, to identify percentages of necrotic and apoptotic cells. 
The lasers used for analysis of fluorochromes were 633nm Annexin V-APC, 488 nm for 
7AAD). 
2.3.4.2 Measurement of cell death using DAPI  
 
Background: 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) is a nucleic acid 
dye that binds to A-T rich regions of DNA. Like 7AAD, DAPI cannot permeate through an 
intact plasma membrane of a living cell. Therefore, DAPI can be used to measure viability 
to discriminate between live cells and membrane damaged cells, i.e. dead cells.  
Method: DAPI was used to analyse cell viability in cell lines post lenti-viral transduction or 
drug treatment. Cell line assays were set up at 0.25x10
6/mL, 200 μL of the cell suspension 
was taken for analysis, at each time point. The cells were transferred to FACS tubes and 
DAPI was added to the cells 1:100 dilution, making the final DAPI concentration 10 
ng/mL. The cells were incubated for 5 minutes and analysed by FACS using laser 405 nm, 
to identify the percentage of DAPI stained cells, non-viable. 
2.3.4.3 Flow cytometry cell sorting  
 
Cells were counted using the CASY® Cell Counter to get an approximate cell number, and 
then washed with 2%FCS/PBS, centrifuged at 300 x g for 5 minutes. The cells were 
resuspended in 2%FCS/PBS and filtered through a nylon sterile filter cup. Cells were 
sorted using a FACSAriaIII (BD Biosciences). Very stringent sorting parameters were set 
up with the help of FACS technician Jennifer Cassels. Cells were sorted back into a FACS 
tube containing 500 μL of 2%FCS/PBS. Cell numbers were taken by the FACSAriaIII and 
the cells were put in the appropriate volume of media and put back into culture overnight 
to recover from stress caused by sorting.  
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2.3.4.4 FlowCellect™ Autophagy LC3 Antibody-based Assay Kit (Millipore, Cat no. 
FCCH100171) 
 
Background: As previously described; when autophagy is induced the LC3 protein is 
translocated from the cytoplasm to the autophagosome, where it is then targeted by the 
lysosome for degradation.  
Autophagy is a hard process to analyse and interpret, however the FlowCellect™ kit 
allows us to specifically quantify lipidated LC3-II.  
The kit selectively permeablises the cell membrane and flushes out the cytosolic LC3 by a 
series of washing steps. However, the LC3 that has translocated into the autophagosome is 
protected and remains intact inside autophagosomes. The intact LC3 is stained with a FITC 
tagged LC3 antibody and the fluorescence is measured by flow cytometry. An increase in 
lipidated LC3 would imply an induction of autophagy. 
 
Method: KCL22
Pon-Res
 cells were seeded at 0.25x10
6
/mL in RPMI and incubated at 37°C at 
5% CO2 for 24 hours with the appropriate drug; 100 nM ponatinib, 100 nM NVP-Bez235 
or 4 hours with 10 µM HCQ. Each parameter was set up in triplicate. 100,000 cells were 
harvested per sample and collected into FACS tubes, the cells were centrifuged at 300 x g 
for 5 minutes and the supernatant was discarded. Wash cells with 1% FBS/PBS. Dilute 
Autophagy Reagent B at a 1:10 dilution in water and add 100 µL to each sample. 
Immediately centrifuge samples and discard the supernatant. The samples were then 
stained with anti-LC3-FITC antibody. The antibody is diluted 1:5 with assay buffer, with a 
final volume of 50 µL being added to each sample. The samples were incubated with the 
antibody for 30 minutes at 4°C. Following the incubation, the 150 µL of assay buffer was 
added to each sample and centrifuged at 300 x g for 5 minutes. The supernatant was 
discarded and the cells were resuspended in 200 µL of 1% FBS/PBS and analysed via 
FACS. 
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2.3.5 Immunofluorescence microscopy 
 
Poly-L-lysine coated multi-spot microscope slides were prepared in advance; poly-L-lysine 
is adhesive and it facilitates suspension cells binding to glass microscope slides. Poly-L-
lysine solution (Sigma-Aldrich, Cat no. P8920) was diluted 1:10 in distilled water, and 
multisport microscope slides were immersed in the dilution in a Coplin jar for 10 minutes. 
Excessive poly-L-lysine solution was removed, and the slides were air-dried and kept in a 
box for future use. 37,500 cells per treatment were added to each well of a poly-L-lysine-
coated multi-spot slide. The samples were allowed to adhere to the slide for 90 minutes in 
a tissue culture incubator. Following the 90 minutes, the excess medium was gently 
removed by blotting carefully with tissue paper. The cells were fixed by cross-linking 
protein molecules by adding 30 µL of 3.65% formaldehyde solution onto each well. The 
slides were incubated for 15 minutes at room temperature and washed 2x 5 minutes by 
spotting on PBS to the wells. The slides were then air-dried for 15 minutes and mounted 
with two drops of VECTASHIELD® mounting medium with DAPI (Vector, Cat no. H-
1200) added to the centre of each slide and a coverslip placed on the top. The coverslip 
was carefully placed over the wells, so that the mounting medium covered each well of the 
slide and the edges of the cover slip were sealed with nail varnish. The slides were stored 
at 4°C until analysis. All slides were analysed using a Zeiss Imager M1 microscope at 
100x magnification using oil immersion and AxioVision software. Images were captured 
with multiple layers from the top to the bottom of cells with optimal distance (0.25 µM) 
between adjacent layers. Captured images were subjected to deconvolution to remove non-
specific fluorescence and sharpen images. Deconvolution was performed by utilising the 
deconvolution program in the AxioVision software; the iterative algorithm and clip 
normalisation methods were used. 
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2.3.6 XTT cell viability assay 
 
Background: The XTT assay is a colorimetric assay that detects cellular metabolic 
activities. This type of assay is widely used in drug screening to test the effects of drugs on 
cell viability. XTT is a yellow tetrazolium salt. It is added to a cell suspension along with 
an electron coupling reagent, N-Methylphenazonium methyl sulphate (PMS). The XTT salt 
is reduced to a highly coloured formazan dye by dehydrogenase enzymes in metabolically 
active cells. This conversion only occurs in viable cells; therefore, the amount of the 
formazan produced is proportional to viable cells in the sample. The formazan dye can be 
quantified by measuring the absorbance at wavelength 490 nm using a spectrophotometer.  
Method: Using a 96 well plate 50 µL was dispensed into each well, apart from column 12 
which had 70 µL. 20 µM (final concentration 10 µM) of drug was added to column 12 and 
mixed thoroughly. Using a multichannel pipette 20 µL was taken from wells in column 12 
and transferred to the wells in column 11 and mixed well (Final drug dilution 1:5). In order 
to make a serial dilution this was repeated down to column 2. Column 1 was left as the no 
drug control. Cell lines were counted and resuspended in fresh RPMI at a cell 
concentration of 0.2x10
6
/ml. 50 µL of the cell suspension was aliquoted into each well 
using a multichannel pipette.  
 
Figure ‎2-2: 96 well plate XTT assay design for low concentration drug screening. 
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One row of wells was left free for 100 µL of media only so the background level of XTT 
absorbance could be established and subtracted from the final results. The cells were left to 
incubate for 72 hours at 37°C and 5% CO2. Following, the 72 hour incubation XTT salt 
was prepared: 1 mg XTT salt per 1 mL of media. The solution was placed at 37°C for 20 
minutes until the salt had dissolved. In the meantime, 1 mg of PMS was dissolved in 715 
µL of PBS. 5 µL of PMS is added to 1 mL of XTT solution. 25 µL of the XTT and PMS 
solution was added to each well and incubated for 2 hours at 37°C. After the 2 hour 
incubation period, the absorbance of the XTT salt was read via spectrophotometer at a 
wavelength of 490 nm. A high absorbance indicates cells are un-affected by the drug and 
able to reduce the formazan dye. A low absorbance means the cells are metabolically 
inactive and the drug has cytotoxic effects at that concentration. 
 
2.3.7 Repurposing NIH approved oncology drug screen 
 
Background: In collaboration with the Beatson Drug Screening facility, we screened a total 
of 119 clinically tested drugs from the DTP-Approved Oncology Library (NIH), and 14 
selected drugs of interest; dual PI3K/mTOR inhibitor: NVP-Bez235, apitolisib, VS-5584, 
voxtalisib (XL765) and gedatolisib; PI3K inhibitor: BKM120; mTORC1+2 inhibitor: 
AZD8055; MEK inhibitor: selumetinib (AZD6244); tyrosine kinase inhibitor: ponatinib; 
Autophagy inhibitors: hydroxychloroquine sulfate (HCQ), This library was screened 
initially in KCL22
WT
 and KCL22
Pon-Res
 cells. Prior to commencing screening, an 
appropriate cell seeding density for each cell line was determined in 96-well plate format, 
with minimal intra-plate variation. The appropriate cell density was 0.25x10
6
/mL. Internal 
plate controls were included to allow statistical assessment of screening performance, 
namely vehicle control (DMSO), a lethality control (omacetaxine (1 µM)), and a positive 
control (ponatinib (100 nM)). Cells were counted using a Countess Cell counting System 
(Invitrogen) and plated at 25000 cpw (+/- 100 nM ponatinib) using an XRD automated 
reagent dispenser (FluidX). Drugs were diluted in medium and added to cell plates at a 
final concentration of 10, 1, 0.1 and 0.01 µM using an automated JANUS system (Perkin 
Elmer). Drug effects were quantified by cellular metabolic output using resazurin, and 
scanning plates using an EnVision multiplate reader (Perkin Elmer). 
Secondary screen was carried out taking the top hits from the initial screen. These drugs 
were validated using Ba/F3
parental
, Ba/F3
p210
 and Ba/F3
Pon-Res
 cells. The same parameters 
were used as in the initial experiment; however, a drug curve was carried out with a larger 
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range of concentrations. Final drug concentrations were: 10, 5, 2.5, 1.25, 0.6, 0.3, 0.15, 
0.08, 0.04 and 0.02 µM.  
Drug toxicity was tested on normal blood cells, non-CML cells; non-CML024, 026 and 
027 samples gained from the Holyoake Bio-bank. Cells were thawed using DAMP, and 
cultured for 3 days in SFM supplemented with high growth factors. Cell density 
experiment had previously been performed by Dr. D. Vetrie’s group, using the same 
samples. Therefore, a seeding density of 0.5x10
6
/mL was used as per their experiment. 
Drugs tested included; omacetaxine (control), ponatinib (control), NVP-BEZ235, 
apitolisib, gedatolisib, VS-5584, AZD8055, rapamycin, RAD001, AZD6244 and 
trametinib. The same parameters were used as in the secondary experiment, with final drug 
concentrations of 10, 5, 2.5, 1.25, 0.6, 0.3, 0.15, 0.08, 0.04 and 0.02 µM.  
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2.3.8 Western blotting 
 
Western blotting is a molecular technique used to identify specific proteins from a complex 
mixture of proteins that have been extracted from cells. This technique uses three steps to 
accomplish this: (1) gel electrophoresis to separate the proteins by size, (2) transfer of the 
proteins from the gel to a solid support, in this case a PVDF membrane, and (3) staining of 
the target protein using a specific primary antibody and a secondary HRP tagged antibody 
to visualize the expression of the protein of interest. 
2.3.8.1 Protein lysate preparation 
 
In order to analyse the proteins of interest, first, the cells need to be lysed. However as 
soon as the cells are lysed; proteolysis, dephosphorylation and denaturation also initiate. 
These events can be significantly inhibited by keeping the samples on ice and by adding 
appropriate protease and phosphatase inhibitors to the lysis buffer. 
Ice-cold RIPA lysis buffer (Thermo-Scientific Cat no. 89900) was used for this application 
with an increased percentage of SDS from 0.1% to 1%, in order to increase the strength of 
the buffer and therefore enhance its ability to solubilise proteins. Protease and phosphatase 
inhibitors were added immediately prior to use. 
Method: An equal numbers of cells were washed twice with ice cold PBS (300 x g for 5 
mins). The cells were then transferred to a 1.5 mL eppendorf and washed again in ice cold 
PBS. RIPA buffer was added to the cell pellet, using approximately 100 μL per 1x106 
cells, homogenised by vigorous pipetting and incubated for 15 minutes on ice. Following 
the incubation, the cell lysates were centrifuged (21,000 x g for 20 minutes at 4°C) to 
pellet nucleic acids and cellular debris, leaving the supernatant containing protein. The 
supernatant was transferred to a new 1.5 ml eppendorf and stored at -20°C.  
2.3.8.2 Protein quantification 
 
Bicinchoninic acid (BCA
TM
) protein assay (Thermo-Scientific Cat no. 23227) was used to 
quantify RIPA-lysed protein sample concentrations according to the manufacturer’s 
instructions. This is a two-step process (1) reduction of Cu
2+
 to Cu
1+
 by protein in an 
alkaline medium to form a light blue complex. (2) Bicinchoninic acid (BCA) reacts with 
Cu
1+
 formed in step one. The intense purple colour produced is due to the chelation of two 
molecules of BCA with one Cu
1+ 
ion. The BCA/Cu
1+ 
complex has a strong absorbance at 
562 nm and correlates linearly with increasing protein concentrations from 20 to 2000 
μg/mL. 
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Method: BSA standards were prepared by serially diluting 2000 μg/mL BSA in dH2O. 
BSA concentrations were prepared: 2000, 1000, 400, 200, 100, 80 μg/mL and dH2O only 
as a blank. These BSA standards were stored at - 20°C and used multiple times.  
To a 96-well plate 10μL of each BSA standard concentration was added to each well in 
triplicate, and 10 μL of protein samples was added in duplicate. The BCA working solution 
was prepared according to manufacturer’s instructions by thoroughly mixing reagents A 
and B (50:1). 200μL of this solution was then added to each well of a 96-well plate and 
incubated at 37°C for 30 minutes. The colorimetric reaction was read by a 
spectrophotometer at absorbance 562 nm.  The protein concentrations were calculated 
according to the BSA standards and so equal quantities of protein from each lysate could 
be loaded for analysis by western blotting. 
2.3.8.3 Sample preparation for SDS-PAGE  
 
Background: 4X SDS sample buffer. 4x SDS sample buffer contains 4 main ingredients: 
SDS, 2-mercaptoethanol, glycerol and bromophenol blue.  
(1) SDS denatures proteins by binding around their polypeptide backbone in a mass ratio 
of 1.4:1, giving the protein a negative charge that is proportional to their length. Therefore, 
during gel electrophoresis separation is not only determined by intrinsic electrical charge 
but by molecular weight. (2) 2-mercaptoethanol is used as a reducing agent; it reduces 
disulphide bridges in proteins before they adopt the random-coil configuration so that all 
the constituent polypeptides can be analysed separately. (3) Glycerol is added to the buffer 
to increase the weight of the sample so when loading the sample stays at the bottom of the 
well. (4) Bromophenol blue is a dye that enables the visualisation of the migration of 
proteins during gel electrophoresis. 
An equal quantity of protein (20-30 μg) from each lysate was calculated from the BCATM 
assay. Protein samples were thawed on ice and the correct volume of lysates transferred 
into a new 1.5 mL eppendorf. Sample volumes were made up to 50 μL by adding 4x SDS 
sample buffer (12.5 μL) to each sample and the remaining volume made up with dH2O.  
Prior to loading the protein samples were boiled at 95
o
C for 10 minutes to denature the 
sample and briefly centrifuged.  
 
 
107 
 
2.3.8.4 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Background: SDS-PAGE is a denaturing separation method used for the analysis of 
protein. When carrying out electrophoresis the samples are loaded into the wells and an 
electrical current is applied, the negatively charge proteins will travel towards the positive 
electrode through a gel matrix, which can separate out the proteins according to size. This 
technique uses two different types of gel: (1) stacking and (2) separating gel, which makes 
up the composition of the gel 1:2. The proteins first migrate through the stacking gel. This 
is slightly acidic, pH 6.8, and has a lower acrylamide concentration making it a porous gel, 
which separates protein poorly but allows them to form thin, sharply defined bands. The 
lower gel is called the separating, or resolving gel, is basic, pH 8.8, and has a higher 
polyacrylamide content, which makes the gel's pores narrower. The proteins are therefore 
separated by their size more so in this gel, as the smaller proteins can travel more easily, 
and hence rapidly, than larger proteins.  
 
Method: SDS-PAGE method was used for the separation of proteins based on their size. 
Denatured protein samples were loaded into homemade 10% or 15% gels or into Nupage® 
Novex® Bis-Tris 4-12% (Invitrogen, Cat no. NP0321BOX) gradient gels. Alongside a pre-
stained protein standard ladder (Bio-Rad Cat no. 1610377 or Bioline, Cat no. BIO33066) 
to determine the molecular weight of the proteins within the samples. Gels were run in 1X 
NuPAGE® MOPS or MES SDS running buffer for the precast gels, or homemade 1X 
running buffer for the homemade gels, at 80V for the first 30mins and at 120V for the 
remaining time, in an Invitrogen XCell SureLock
TM
 mini-cell electrophoresis system. 
 
2.3.8.5 Transfer to PVDF membrane 
 
Following gel electrophoresis, proteins were transferred from the gel to a solid support, a 
PVDF membrane. The PVDF membrane was activated by soaking into methanol for 2 
minutes and then equilibrated in 1x transfer buffer for 15 minutes. The sponges, Whatman 
paper and the gel were also soaked in transfer buffer before use. Methanol is added to the 
transfer buffer, to maintain the stability of the gel, and also to remove SDS from proteins 
and increase protein binding to the membrane. The transfer sandwich was assembled inside 
the gel cassette. The transfer sandwich was built upon the cathode side (black); 1 soaked 
foam pad, 3 soaked Whatman papers, the equilibrated gel, the equilibrated PVDF 
membrane, 3 soaked Whatman papers and 1 soaked foam pad. A blot roller removed any 
trapped air between the layers, then the cassette was closed and locked. The cassette was 
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inserted into the blotting module, along with an ice pack and the tank was filled with 1x 
transfer buffer. A magnetic stirrer was added to the tank and the tank was placed on top of 
a magnetic stir plate. Proteins were transferred at 120V for 2 hours in a Mini Trans-Blot
® 
Cell module at 4°C. 
2.3.8.6 Immunolabelling 
 
Once the transfer was completed the membrane was blocked in either 5% Marvel/ 1xTBST 
or for the analysis of phospho-antibodies 5% BSA/1xTBST blocking buffer. This was 
performed at room temperature for 1 hour with constant agitation. Blocking is an important 
step as it prevents nonspecific binding of antibodies to unoccupied protein-binding sites on 
the membrane. After blocking, the membrane was incubated with a primary antibody 
solution diluted in the blocking buffer (e.g. p-CrkL, p-RPS6, p-ERK1/2, LC3B, ATG7, β-
Tubulin; 1:500-1000 dilution) overnight at 4°C with gentle rotation. The next day, the 
membrane was incubated in primary antibody for an hour at room temperature with gentle 
rotation. The membrane was then washed in the 1X TBST buffer for 3x 15 minutes to get 
rid of unbound primary antibody and reduce background. After washing, the membrane 
was incubated with the appropriate HRP-conjugated secondary antibody solution (rabbit or 
mouse) using a 1:5000 dilution in 1% blocking solution for 1 hour at room temperate with 
agitation. Following secondary antibody incubation, the membrane was washed in the 
1xTBST buffer 3x 15 minutes to remove unbound secondary antibody.  
 
Finally, the Pierce™ ECL Western Blotting Substrate (Thermo Scientific, Cat no. 32106) 
was used according to the manufacturer’s instructions for development of the membrane. 
This involved the membrane being incubated with the mixture of equal amounts of an 
enhanced luminol solution and a peroxide solution for 2 minutes. In the presence of HRP, 
from the secondary antibody, and the peroxide buffer, luminol oxidises and forms and 
excited state, that emits lights as it decays to a ground state. When oxidised luminol returns 
back to its initial state, light is emitted. The chemiluminescent signal was captured by 
using light sensitive photographic film, CL-XPosure™ Film (Thermo Scientific, Cat no. 
34097) and developed using a Kodak X-OMAT. 
In order to incubate the PVDF membrane with a different primary antibody, such as 
against a housekeeping protein β-Tubulin, the membrane was reactivated in methanol for 2 
minutes then thoroughly washed in 1x TBST for 3x 15 minutes. The membrane was re-
blocked in blocking buffer for 1 hour before incubation with another primary antibody. 
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2.3.9 DNA sequencing 
 
Genomic DNA (gDNA) was extracted from BaF3
Pon-Res
 cells using a QIAamp DNA mini 
kit (Qiagen, Cat no. 51304). PCR was performed using primers designed to cover the 
BCR-ABL splice junction, including the ABL kinase domain, in order to detect any 
common mutatioms which may cause TKI resistance. These primers were designed by Dr. 
Arunima Mukhopadhyay.  
 
Figure ‎2-3: BCR-ABL transcript.  
BCR-ABL indicating known mutations in the kinase domain, which affect TKI binding. It also 
indicates the regions of BCR-ABL that the forward and reverse primers span, allowing the 
sequencing of the kinase domain. 
 
T315I Primer sequence F T315I Primer sequence R 
GTTCCTGATCTCCTCTGACTATGAGCGTG GCATGGGCTGTGTAGGTGTCC 
Table ‎2-2: Forward and reverse BCR-ABL primer sequences. 
For each PCR reaction the following mix was made using the GeneAmp® RNA PCR Core 
Kit (Applied Biosystems, Cat no.  N8080143):  
Reagent Volume (µL) 
10x Buffer 5 
dNTPs (10 mM) 10 
Taq polymerase 2.5 
F Primer (10 µM) 2.5 
R Primer (10 µM) 2.5 
MgCl2 (25 mM) 5 
DNA template 1 µg 
Nuclease free H2O Up to 50 µL 
Table ‎2-3: PCR reaction mix. 
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2.3.9.1 Cycling parameters  
 
The PCR tubes were heated to 95°C for 5 minutes to denature the double stranded DNA, 
and then 35 cycles of 95°C for 30 seconds, 52°C for 1 minute and 72°C for 1 minute were 
set in a PCR Thermo Cycler. After all cycles finished, the tubes were heated to 72°C for 5 
minutes for final extension, and then held at 4°C. 
 
2.3.9.2 Gel electrophoresis 
 
The PCR products were run on an agarose gel in order to visualise the DNA bands. A 1% 
agarose gel was prepared by diluting 1 g of agarose powder in 100 mL of 1x TBE buffer 
(10x TBE buffer - diluted in dH2O). The mixture was heated in a conical flask in a 
microwave for 2 minutes until the agarose powder had completely dissolved. When the gel 
cooled down, 2 µL of ethidium bromide (10 mg/mL) was added and mixed well. The gel 
was poured into a casting tray with a comb inserted to create wells and the gel was left to 
set. The gel was placed in a gel tank and filled with 1x TBE buffer so as to cover 
completely the gel and the comb was removed. 10µL of PCR product mixed with 2µL 
loading dye (6x) was loaded into each well of the gel, 5 µL of 100 bp DNA ladder was 
loaded in a separate lane, and then the gel was run at 100V for 1 hour. After running, the 
gel was viewed by an ultraviolet (UV) transilluminator (ChemiDoc). 
DNA sequencing was performed by DNA Sequencing & Services (MRC I PPU, College of 
Life Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) using Applied 
Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 automated 
capillary DNA sequencer. 
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2.3.10 RNA-seq 
 
RNA-Seq allows for the detection of transcript isoforms, gene fusions, single nucleotide 
variants, allele-specific gene expression in one single assay. 
2.3.10.1 Cell lines 
 
KCL22
WT
 or KCL22
Pon-Res
 cells were seeded at 0.25x10
6
/mL in RPMI and untreated, 
treated with 100 nM ponatinib, 100 nM NVP-Bez235 or a combination of ponatinib and 
NVP-Bez235 for 24 hours at 37°C at 5% CO2. 1x10
6
 cells were harvested from each 
sample and RNA was extracted using an RNeasy Mini kit (Qiagen, Cat no. 74104) as per 
the manufacturer’s instructions. The RNA quantification was analysed by a nanodrop, ND-
2000. 
2.3.10.2 CML samples 
 
MNCs were seeded at 1x10
6
/mL in SFM supplemented physiological growth factors. The 
cells were either untreated or treated with 100 nM ponatinib for 24 hours at 37°C at 5% 
CO2. 2x10
6
 cells were harvested from each sample and RNA was extracted using an 
RNeasy Mini kit (Qiagen, Cat no. 74104) as per the manufacturer’s instructions. The RNA 
quantification was analysed by a nanodrop, ND-2000. 
Quantification of RNA by the qubit revealed DNA contamination; therefore, samples 
underwent DNase treatment using the DNase Set - RNase free kit (Qiagen, Cat no. 79254) 
as per the manufacturer’s instructions. Once again the RNA quantification was analysed by 
a nanodrop, ND-2000. 
The samples were sent to Glasgow Polyomics who performed the RNA-seq experiment. 
Glasgow Polyomics prepared the RNA using polyA selection to enrich for mRNA. 
Subsequently, they prepared libraries by converting the mRNA to double-stranded 
complementary DNA (cDNA) and adding on the Illumina "adaptor" sequences. The 
samples were sequenced using an Illumina NextSeq™500. The samples were sequenced 
using paired end reads, with a read length of 75 and a read depth of 30 million. The 
sequencing data was analysed by Dr. Graham Hamilton and Dr. Lisa Hopcroft. In order to 
analyse the data first the sequences were demultiplexed, filtered, and trimmed. The reads 
were then assembled into transcripts and aligned to reference sequences. The transcripts 
were then annotated and the number of reads per transcript was quantified and a statistical 
comparison of transcript abundance across samples and treatment arms was performed. 
 
112 
 
2.3.11 shRNA constructs 
 
pLKO.1-shATG7-GFP and pLKO.1-shATG7-PURO vectors carrying hairpins targeting 
ATG7 were used along with the packaging vectors; psPAX2 and pCMV-VSV-G (see 
Appendix 9.1 for plasmid maps). Vectors pLKO.1-shSCR-GFP and pLKO.1-shSCR-
PURO carried scrambled - non-targeting- hairpins and were used as control. The plasmid 
pCMV-VSV-G was kindly donated by Professor John Rossi. pLKO.1-PURO-shATG7 was 
donated by Professor Kevin Ryan. Plasmids pLKO.1-GFP-shCtrl and psPAX2 were 
donated by Dr Kamil Kranc. The pLKO.1-shATG7-GFP plasmid was generated in our lab 
by Dr. Maria Karvela.  
 
2.3.12 Lentivirus transfection 
 
Lentivirus was produced by transfecting HEK293 cells using the CaCl2 method.  
1x10
6 
HEK293 cells were plated in a 10 cm
2 
cell culture dish in 10 mL DMEM three days 
prior to the transfection to allow the cells to adhere to the plate. After three days 70% 
confluency should have been achieved and the cell media was replaced by adding 9ml of 
DMEM plus 30 μM of chloroquine, which inhibits DNA degradation by lysosomes by 
raising their pH. 
Lentiviral DNA mixes were made by adding 14.2 μg of the lentiviral vector, 12.45 μg 
psPAX2, and 4.5 μg pCMV-VSV-G into a 1.5 mL eppendorf. This was added to a 15 mL 
falcon tube along with 1280 μL of sterile water and 183 μL 2M CaCl2. This mix was then 
added to 1.5 mL of 2xHBSS and mixed very thoroughly. The transfection mixes were 
incubated at 37°C for 20 minutes and then added dropwise to the HEK293 cells. Each mix 
made was for one 10cm
2 
cell culture dish. After 8 hours the medium was replaced with 8 
mL of DMEM, to wash off the CaCl2 precipitate. The following morning the medium was 
changed again and 6 mL of DMEM was added to the cells. For GFP tagged plasmids, cells 
were checked under an inverted fluorescent microscope for the presence of green cells. 
Virus was harvested at 24 and 48 hours by collecting media, centrifuging at 300 x g for 5 
minutes and filter sterilising the supernatant using a 0.45 μM filter before being used to 
directly transfect KCL22 cell lines. 
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2.3.13 Transduction of CML cell lines 
 
After 24 hours of incubation, the viral DMEM medium was collected from the HEK293 
cells and used for the transduction of KCL22 CML cell lines. 6 mL of fresh medium was 
placed on the HEK293 cells for harvesting at a 48 hour time point. 
The 6 mL of viral medium was filter sterilised and KCL22 cells were resuspended in the 
virus at a cell concentration of 0.25x10
6
/mL and incubated for 24 hours. Following the 
incubation, the viral medium was removed and replaced with the 48 hour viral medium and 
incubated for a further 24 hours. Following these two rounds of infection the cells were 
centrifuged at 300 x g for 5 minutes to remove the viral medium and the cells were 
resuspended in 6 mL of RPMI.  Cells transduced with puromycin resistant selection marker 
would be immediately treated with 2.5 μg/mL puromycin for 72 hours then 5 μg/ml for a 
further 11 days before cells were used experimentally. Cells were continually grown in the 
presence of puromycin. Cells transduced with plasmid constructs tagged with GFP would 
be analysed under an inverted fluorescent microscope for the presence of green fluorescent 
cells.  
2.3.14 CRISPR guide design 
 
Background: See results chapter 4. 
Specific oligonucleotides were designed for ATG7, BCR-ABL, mTOR and MEK CRISPR 
KO. First, the human gene transcripts were identified using Ensembl genome database. 
The transcripts chosen were verified from more than one reference database (Ensembl and 
Havana, yellow labelled merged genes in Ensembl database). Ref-seq was then used to 
gain the coding sequence of the gene (CDS). In order to create Indels that will cause a 
frameshift mutation that will ablate gene function it is important to generate CRISPR 
guides that target coding sequence early in the gene transcript. Therefore, sequences were 
taken from exons from the start of the coding sequence. 23-1000bp of the DNA sequence 
of interest were entered into the CRISPR Design Tool, designed by the Zhang laboratory at 
MIT http://crispr.mit.edu/.  
This tool identifies 20 nucleotide DNA sequences followed by a Cas9 target site (PAM site 
5’ NGG) within the input sequence (Cong et al., 2013). The results provide the user with a 
rank ordered list of target sequences based on their predicted likelihood of off-target 
genome modifications. The algorithm used by the program is based on Hsu et al., Nature 
Biotechnology 2013.  
The 20 nucleotide guide sequences were chosen based on the quality score given by the 
design tool (Hsu et al., 2013). Sequences that scored >90% were chosen and their reverse 
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complimentary strands were established. These sequences were verified using 
NCBI/Nucleotide-Blast (Blastn). In order for those sequences to be cloned into the lenti-
CRISPRv2 (Addgene, Cat no. 52961) or the lenti-Guide-puro (Addgene, Cat no. 52963) 
vectors, the two oligonucleotides must be synthesized with the addition of overhangs 
compatible with BsmBI digestion. Also if the target sequence did not start with guanidine 
(G), a G nucleotide is added 5’ to make the sequence a 20+1 guide RNA. Guanidine will 
improve U6-mediated transcription and will not affect the function of the gRNA. The PAM 
site is not included in the synthesis of the oligos. Therefore, oligos were designed using the 
following format: 
 
 
 
Figure ‎2-4: Design template for targeted guide sequences for CRISPR KO.  
A 20 nucleotide target sequence, with 5’ overhangs added for cloning using BsmBI restriction 
sites. The PAM site has been indicated but is not included in the design of the guide. 
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Name Sequence Exon 
Quality 
score 
Off target sites 
CrispR 
ATG7 1-1 
CACCGGAAGCTGAACGAGTATCGGC 
2 95 
33 
(8 are in 
genes) 
CrispR 
ATG7 1-2 
AAACGCCGATACTCGTTCAGCTTCC 
CrispR 
ATG7 2-1 
CACCGTGCCCCTTTTAGTAGTGCCT 
2 80 
130 
(9 are in 
genes) 
CrispR 
ATG7 2-2 
AAACAGGCACTACTAAAAGGGGCAC 
CrispR 
ATG7 3-1 
CACCGAACTCCAATGTTAAGCGAGC 
3 91 
51 
(8 are in 
genes) 
CrispR 
ATG7 3-2 
AAACGCTCGCTTAACATTGGAGTTC 
CrispR 
mTOR 1-1 
CACCGTGGCCTAAAGAGCCGGAATG 
2 90 
104 
(12 are in 
genes) 
CrispR 
mTOR 1-2 
AAACCATTCCGGCTCTTTAGGCCAC 
CrispR 
mTOR 2-1 
CACCGCACTTTTACCGCTGAGTACG 
4 92 
40 
(5 are in 
genes) 
CrispR 
mTOR 2-2 
AAACCGTACTCAGCGGTAAAAGTGC 
CrispR 
mTOR 3-1 
CACCGGGTGGGAATGCCACCCGAAT 
4 90 
73 
(7 are in 
genes) 
CrispR 
mTOR 3-2 
AAACATTCGGGTGGCATTCCCACCC 
CrispR MEK 
1-1 
CACCGCGTTAACTGCAGAGCCGTCG 
1 
96 
 
27 
(5 are in 
genes) 
CrispR  
MEK 1-2 
AAACCGACGGCTCTGCAGTTAACGC 
CrispR  
MEK 2-1 
CACCGTGGAGATCAAACCCGCAATC 
3 93 
61 
(6 are in 
genes) 
CrispR  
MEK 2-2 
AAACGATTGCGGGTTTGATCTCCAC 
CrispR  
MEK 3-1 
CACCGACATCCTAGTCAACTCCCGT 6 91 
46 
(2 are in 
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CrispR  
MEK 3-2 
AAACACGGGAGTTGACTAGGATGTC 
genes) 
CrispR BCR-
ABL 1-1 
CACCGACGTGTAACTCTTGCCGTTG bcr-
abl1 
e13a2 
90 
40 
(5 are in 
genes) 
CrispR BCR-
ABL 1-2 
AAACCAACGGCAAGAGTTACACGTC 
CrispR BCR-
ABL 2-1 
CACCGGTCTGAGTGAAGCCGCTCGT bcr-
abl1 
e13a2 
96 
54 
(17 are in 
genes) 
CrispR BCR-
ABL 2-2 
AAACACGAGCGGCTTCACTCAGACC 
CrispR BCR-
ABL 3-1 
CACCGATCATTCAACGGTGGCCGAC bcr-
abl1 
e13a2 
93 
31 
(5 are in 
genes) 
CrispR BCR-
ABL 3-2 
AAACGTCGGCCACCGTTGAATGATC 
Table ‎2-4: CRISPR single guide sequences for ATG7, mTOR, MEK and BCR-ABL. 
 
Both vectors have the same BsmBI digestion sites for cloning and therefore the same oligos can be 
used for cloning into lentiCRISPRv2 and lentiGuide-Puro vectors. 
Standard desalted oligonucleotides were ordered for synthesis from IDT. On arrival the DNA was 
resuspended in sterile water at a concentration of 100 μM. 
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2.3.15 Target Guide Sequence Cloning Protocol 
 
In order to clone the guide sequences into the CRISPR lentiviral vectors the ‘targeted guide 
sequence cloning protocol’ was used from the Zhang lab. This protocol gives a detailed 
method of Lentiviral vector digestion, oligo annealing and cloning into digested vector. 
One amendment was made to the protocol; Step 1: vector digestion at 37°C overnight 
instead of for 30 minutes as stated.  
5 μg of lentiCRISPRv2 or lentiGuide-puro were digested and dephosphorylated, using 
FastDigest BsmBI, FastAP, 10xFastDigest Buffer, freshly prepared 100 mM DTT and 
made up to 60 μL with H2O. This reaction was incubated at 37°C overnight, in order to 
ensure cuts were made at the BsmBI digestion sites and to dephosphorylate its overhanging 
complementary ends and inhibit annealing between them. This reaction made two cuts, 
either side of an 1880bp filler sequence of the vectors, leaving this site available for the 
target sequences. The digestion products were then separated on a 1% agarose gel. The 
fragments of interest, lentiCRISPRv2 (12993 bp) and lentiGuide-puro (8297 bp) backbone 
fragments, were isolated under long-wave UV light using a clean scalpel. The products 
were gel-purified by using the QIAquick Gel Extraction Kit (Qiagen, Cat no. 28704) 
according to manufacturer’s instructions. The concentration and quality of extracted DNA 
were measured with a NanoDrop ND-2000 spectrophotometer.  
 
 
Figure ‎2-5: Gel purification of BsmBI digested lentiCRISPRv2 and lentiGuide-puro. 
 
 
 
 
 
118 
 
At the same time each pair of oligonucleotides for the target sequence were annealed and 
phosphorylated. This was performed by setting up a reaction containing; 100 μM oligo 1 
(sense) and 100 μM oligo 2 (antisense), 10x ligation buffer (NEB), T4 Polynucleotide 
Kinase and ddH2O. (10x Ligation buffer from NEB was used as it contains ATP required 
for the phosphorylation reaction). The reaction was put in a thermocycler under the 
following parameters: 37°C for 30 minutes, up to 95°C for 5 minutes and then down 5°C 
every 60 seconds until reaching 25°C. Following the thermocycler, the annealed oligos 
were diluted 1:200 in sterile water.  
The ligation reaction performed by mixing; 50 ng of the BsmBI digested plasmid, 1 μL of 
the diluted oligo duplex, 2x Quick ligase buffer (NEB), ddH2O to make it up to 10 μL and 
1 μL of quick ligase (NEB M2200S). The ligation reaction was incubated at room 
temperature for 10 minutes. A negative control was also performed. 
After the incubation period the ligation was transformed into Subcloning Efficiency™ 
DH5α™ Competent Cells (Thermo Fisher Scientific Cat no. 18265017), following 
manufacturer’s instructions. 5 μL of the ligation reaction was carefully mixed with 50 μL 
of bacteria and incubated on ice for 30 minutes. A positive control was also performed by 
adding 50 ng of undigested plasmid vector to the bacteria for transformation. The bacteria 
and DNA were heat shocked at 42°C for 20 seconds, then immediately placed on ice for 2 
minutes. 950 μL of pre-warmed S.O.C. media (Sigma, Cat no. S1797) was added to the 
tube and incubated at 37°C for 1 hour at 225 rpm. 200 μL from each transformation, 
including the negative controls, was spread out on pre-warmed LB agar plates containing 
100 μg/mL ampicillin. The plates were incubated overnight at 37°C.  After incubation, the 
plates were checked for bacterial growth, the positive control, which had intact plasmid 
DNA had high transformation efficiency with many bacterial colonies grown. The negative 
control contained digested plasmid DNA and the addition of ddH2O, the DNA is therefore 
not intact and the bacteria cannot grow as they do not have the ampicillin resistant gene, 
which comes from the plasmid. The bacteria transformed with the lentiCRISPRv2 
backbone fragment and the ATG7 oligos had a low number of colonies, indicating low 
transformation efficiency. However, 3 single colonies were randomly selected and 
incubated in 5 mL of LB broth for 4 hours at 37°C with constant agitation; the cultures 
were then transferred into 250 mL of LB broth and cultured overnight at 37°C with 
constant agitation. 
The plasmid DNA was collected from the bacterial cells 24 hours later by using the Maxi 
Prep Kit (Qiagen, Cat no. 12163) as described by the manufacturer’s instructions or by the 
Beatson services. 2mL of each culture were stored as bacterial glycerol stock (30% 
glycerol/ sterile H2O).  
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2.3.16 Animal work 
 
2.3.16.1 Ethical issues 
 
All animal work was carried out in accordance with regulations set by the Animals 
Scientific Procedures Act 1986 and UK Home Office regulations. Animals were housed at 
the Beatson Institute for Cancer Research or at the Veterinary Research Facility at the 
University of Glasgow. All experiments were carried out under my personal licence 
(60/12683) and Dr Alison Michie’s project licence (60/4076). Tumour initiating CML cell 
transplants were carried out on animals between 8 and 12 weeks. The details of the 
numbers of animals used and gender for each experiment is provided in each figure legend. 
2.3.16.2 Mouse models 
 
NOD.Cg-Prkdc
scid
Il2rg
tm1Wjl
/SzJ or more commonly known as the NOD scid gamma 
(NSG).  
Background: This animal model combines the characteristics of the NOD/ShiLtJ 
background (deficiencies in innate immunity), severe combined immune deficiency 
mutation, scid, and an IL2 receptor gamma chain deficiency, which disables cytokine 
signalling. As a result, these mice lack mature T cells, B cells, functional NK cells, and are 
also deficient in cytokine signalling, making these mice very good transplant models. 
2.3.16.3 Bioluminescent in vivo imaging of tumour initiating CML cells 
 
KCL22 cells were labelled with lentiviral firefly luciferase, by G. V. Helgason, and 
selected based on antibiotic resistance, hygromycin. The cells were cultured in RPMI at a 
cell concentration of 0.25x10
6
/mL. Cells were untreated or treated with 100 nM ponatinib, 
10 µM HCQ, 100 nM NVP-Bez235 or the combination of 10 µM HCQ and 100 nM NVP-
Bez235. Cells were cultured for 72 hours. In a previous cell titration study performed by 
Dr. L. Mukherjee, 1x10
6
 cells per mouse was the lowest number of cells to transplant to 
maintain efficacy.  Cells were counted and based on the combination treatment; the volume 
of cell suspension required for 1x10
6
 cells per mouse was harvested. Therefore, different 
number of cells will be transplanted per mouse depending on the drug cytotoxicity. Cells 
were centrifuged at 300 x g for 5 minutes and washed in PBS/ 0.5% FBS and centrifuged a 
second time at 300 x g for 5 minutes. Each cell sample was resuspended in 200 µL of PBS/ 
0.5% FBS and filtered through a 30 µM filter cup, before being transplanted via tail vein 
into an 8-12 week old female NSG mouse. In order to activate the bioluminescent reaction, 
the chemical substrate D-Luciferin (Perkin Elmer, Cat no. 122799) must be injected into 
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the mice. The luciferin oxidises under catalytic effects of the firefly luciferase and ATP 
and emits light, which is captured by the IVIS spectral range between 550 nm and 620 nm. 
D-Luciferin was dissolved in PBS and injected subcutaneously at a dose of 3 mg per 
mouse 5 minutes before measuring the light emission. 30 minutes after the transplantation 
of the cells the mice were injected subcutaneously with D-luciferin and analysed by 
luciferase bioimaging via an IVIS Spectrum In Vivo Imaging System (PerkinElmer, Cat no. 
124262), to measure the efficiency of transplantation. The engraftment of these cells was 
subsequently measured weekly, until tumour burden reached the threshold and the animals 
were sacrificed using appropriate schedule 1 methods. 
2.3.16.4 In vivo drug treatment experiments   
 
NSG mice were transplanted with 1×10
6
 KCL22
Pon-Res
 cells per mouse, the cells were 
transplanted via tail vein into 8–12-week-old female NSG mice. The mice were monitored 
as previously described in 2.3.16.3. After 1 week, the mice were treated with vehicle 
control (citrate buffer or NMP/PEG300 (1:10)), ponatinib (5 mg/kg, oral gavage once 
daily), HCQ (60mgkg, intraperitoneally once daily), NVP-Bez235 (40mg/kg, oral gavage 
once daily) or the combination of NVP-Bez235 and HCQ for 4-5 weeks. 5 mice were 
assigned per drug arm per experiment. Results presented represent data from both 
experiments.  
2.3.16.5 Drug formulation 
 
40mg/kg NVP-Bez235 (LC Labs, Cat no. N-4288) 
10ml/kg = 54.67mg/kg BEZ235 salt 
For 7 days of treatment a stock solution of 54.67 mg/mL of N-Methyl-2-pyrrolidone 
(NMP) was prepared.  
Using a small glass beaker, 109.4 mg of NVP-BEZ235 was dissolved in 2 ml NMP by 
heating the solution in a water bath 80°C for 20 minutes followed by sonication. The 
solution was made into 0.25mL aliquots and frozen at -20°C. For each day of treatment, 
one aliquot was defrosted and resuspended in 2.25 mL of Polyethylene glycol 300 (PEG 
300). Each mouse was treated 10 mL/kg, each mouse weighs on average 20g therefore 
each mouse will be treated with ~ 200 µL via oral gavage. 
60 mg/kg HCQ (Sigma, Cat no. 1327000) 
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200 mg vial was dissolved in 40 mL of PBS making a stock solution of 5 mg /mL. Each 
mouse weighs on average 20g, therefore each mouse will be treated with ~ 240 µL of HCQ 
intraperitoneally. 
2.3.16.6 Dissection  
 
Animals were sacrificed using appropriate schedule 1 methods. Femur, tibia, hip bones, 
spleen and tumours were dissected and stored in PBS/2%FBS on ice. Peripheral blood was 
taken from femoral vein post sacrifice and collected into tubes containing EDTA to ensure 
anti-coagulation, stored at RT and analysed within several hours.  
2.3.16.7 Cell extraction 
 
Bones from femur, tibia and hips were crushed in PBS/2% FBS using a mortar and pestle 
and made into a single cells suspension through filtering through a sterile 0.2µm filter. 
Spleen and tumours were homogenised in PBS/2% FCS using a sterile plunger and filtered. 
Peripheral blood (PB) was analysed neat for cellularity analyses.  
2.3.16.8 Analysis  
 
Cell suspensions from each tissue were spun and resuspended in appropriate antibodies and 
analysed by flow cytometry. Tumour and spleen sizes were measure and photographed. 
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3 Results (I): Identification and validation of suitable TKI-
resistant models for the study of BCR-ABL-independent TKI-
resistance 
 
Although the discovery of TKIs has significantly improved the life expectancy of CML 
patients, its success has been marred by the development of drug intolerance, CML stem 
cell insensitivity to TKIs (Graham et al., 2002, Jørgensen et al., 2007a, Copland et al., 
2006b, Corbin et al., 2011, Hamilton et al., 2012) and drug resistance (Karvela et al., 2012). 
Drug resistance affects a significant subset of CML patients and although the most 
common cause of drug resistance is due to mutations within the ABL kinase domain, which 
inhibit TKI binding (Druker et al., 1996), this is being combatted by the development of 
more potent TKIs (Corbin et al., 2002, Lombardo et al., 2004, Brümmendorf et al., 2015, 
O’Hare et al., 2009). However, there is a patient population, which have an acquired TKI 
resistance, which is not due to a kinase domain mutation and yet are resistant to all current 
TKI treatments. These patients are said to have a BCR-ABL-independent mechanism of 
resistance. Evidence shows that BCR-ABL-independent TKI resistance may stem from the 
activation of a secondary oncogenic mechanism (Thomas et al., 2004, Mahon et al., 2003, 
Mahon et al., 2008). These patients are of major clinical concern as a number of 
mechanisms have been proposed, yet not one common mechanism has been discovered, 
which leaves these patients with very limited treatment options. Therefore, increased effort 
is being made to investigate these alternative mechanisms of resistance. Recent studies by 
our laboratory suggest that classic imatinib-resistant cell line models are not ideal to 
investigate acquired resistance to all available TKIs (including ponatinib). Therefore, in 
this chapter we describe the development of ponatinib-resistant cell lines with acquired 
BCR-ABL-independent resistance and attempt to characterise the mechanism of resistance 
using different screening methods.  With the hope that the information gained from these 
experiments will guide us towards the identification of a common weakness in primary 
TKI-resistant CML cells.  By doing so we propose the PI3K-AKT-mTOR pathway as a 
key player responsible for TKI resistance and that pharmacological inhibition of this 
pathway in combination with the inhibition of survival mechanism, autophagy, may 
represent a potential new treatment for TKI-resistant CML patients. 
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3.1 Aims and objectives 
 
I. Generate a suitable ponatinib-resistant model for the study of BCR-ABL-
independent TKI-resistance 
 
II. Characterise the mechanism causing TKI-resistance in the ponatinib-resistant cell 
models 
 
3.2 An assessment of current imatinib-resistant cell line models and their 
relevance for the study of BCR-ABL-independent TKI-resistance 
 
Classically, imatinib is used to generate TKI-resistant cell lines and several CML imatinib-
resistant cell lines have been generated and published such as K562
Im-Res
, KCL22
Im-Res
 and 
LAMA84
Im-Res 
(kindly donated by Bruno Calabretta and Junia Melo). These imatinib-
resistant models have had their mechanisms of resistance previously characterised. K562
Im-
Res
 is a BCR-ABL-independent cell line established by Donato and colleagues (Donato et 
al., 2003), which they established that the over-expression and activation of the SRC-
related kinase, LYN was causing imatinib resistance. LAMA84
Im-Res
 established by Mahon 
and colleagues (Mahon et al., 2000a) showed that these cells developed two mechanisms 
which may owe to imatinib resistance, one being the up-regulation of the BCR-ABL 
protein, associated with amplification of the BCR-ABL gene, and the second is the over-
expression of the multidrug resistance P-glycoprotein (Pgp). The KCL22
Im-Res 
cells were 
also established by Mahon and colleagues (Mahon et al., 2000a), however they were 
unable to establish the exact mechanism causing imatinib resistance in this cell line.  
Although, imatinib is still the first-line therapy for CML patients, the development of more 
efficient and potent TKIs, along with improved drug regimens, has opened the question to 
whether using imatinib resistant cell lines is relevant in order to study BCR-ABL-
independent resistant CML. 
In the clinic, if a patient does not achieve an optimal response to imatinib treatment, they 
can be treated with an increased concentration of imatinib or a 2
nd
 generation TKI such as 
dasatinib or nilotinib. Poor response to 1
st
 and 2
nd
 generation TKIs leads to treatment with 
3
rd
 generation TKI, ponatinib.  
In order to investigate whether imatinib resistant cell lines are suitable models to study 
BCR-ABL-independent TKI-resistant mechanisms, we first wanted to treat these cells such 
as it would occur in the clinic. Therefore, we tested how the imatinib resistant cell lines 
respond to imatinib escalation and more potent TKIs; nilotinib, dasatinib and ponatinib, all 
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treated with concentrations within the maximal tolerated doses (MTDs) achieved in 
patients. Pharmacokinetic studies show that the MTD for imatinib is 800 mg, which 
equates to a maximum measured plasma concentration (cMax) of 3.9 µM (Peng et al., 
2004). Patients treated with 400 mg of nilotinib achieve a cMax of 3.6 µM (Jabbour et al., 
2009a). The maximal concentration achievable for dasatinib shown in phase I trials is 180 
nM (Copland et al., 2006b). Ponatinib has shown to completely supress the emergence of 
BCR-ABL transcripts at concentrations as low as  40 nM (O'Hare et al., 2009), however 
the maximal tolerated dose was 30 mg per day, which equates to a cMax of 120 nM 
(Cortes et al., 2012b). Therefore, for our experiments we used drug concentrations within 
the cMax ranges, imatinib 2 µM, nilotinib 2 µM, dasatinib 150 nM and ponatinib 100 nM. 
In addition, previous experiments in our lab had shown that at these concentrations BCR-
ABL activity is inhibited, as reflected by a reduction in CRKL phosphorylation (Karvela, 
2013). The effectiveness of imatinib, nilotinib dasatinib and ponatinib was also assessed 
with regards to cell proliferation, ability to induce apoptosis and reduce the number of 
leukaemic cells with colony forming potential. 
K562
Im-Res
, KCL22
Im-Res
, and LAMA84
Im-Res
 (figure 3-1) cell lines were treated with TKIs. 
Following 72 hours of continuous treatment the K562
Im-Res 
cell line had significant 
induction of apoptosis in all TKI treatments (figure 3-1). The KCL22
Im-Res
 cell line was 
developed by growing the cells increasing amounts of imatinib up to 1 µM, however the 
KCL22
Im-Res
 cells had retained their resistance even to an increased concentration of 
imatinib (2 µM), shown by no induction of apoptosis over the untreated sample. However, 
the 2
nd
 and 3
rd
 generation TKIs induced a significant apoptotic response (figure 1b). The 
LAMA84
Im-Res
 cell line was resistant to first and second generation TKIs but ponatinib 
induced a striking and highly significant apoptotic affect even at 24 hours (figure 3-1).  
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Figure ‎3-1: Imatinib-resistant cell lines. 
K562Im-res, KCL22Im-res and Lama84Im-res cells were seeded at 0.25x106/mL and treated with 2 μM 
imatinib, 2 μM nilotinib, 150 nM dasatinib, and 100 nM ponatinib. The histogram represents early 
and late apoptosis and numbers are presented as mean±SEM (n=3). The percentage of apoptosis 
was measured following 24-72 hour drug treatment by flow cytometry following annexin V and 
7AAD staining.Statistical analysis was performed by using paired t-test. Annotation above a bar 
refers to statistical significance between the bar and the untreated control. (**; p≤0.01, ***; 
p≤0.001). 
 
Although TKIs have a potent inhibitory affect against BCR-ABL activity, they also have 
the ability to target other tyrosine kinases of similar structure, such as KIT and platelet-
derived growth factor receptor (PDGFR). Each TKI shows slightly different effects in 
terms of cytotoxicity and anti-proliferation, which may be due to their ability to inhibit 
alternative kinases. Particularly dasatinib and ponatinib, which are less specific due to their 
design, which enables them to target mutated forms of BCR-ABL. For example, dasatinib, 
even at low nM concentrations inhibits SCR family kinases, including SRC, LCK, LYN, 
FGR, BLK, FYN, YES and HCK (Deguchi et al., 2008).  
Similarly, ponatinib also inhibits SCR and LYN at low concentrations, as well as members 
of the VEGFR, FGFR, and PDGFR families of receptor tyrosine kinases (O'Hare et al., 
2009). This may explain the increased cytotoxic effect caused by dasatinib and ponatinib 
compared to imatinib treatment against these cell lines. Ponatinib also has activity against 
many mutant forms of BCR-ABL including the T315I mutation and has the ability to 
completely supress the outgrowth of BCR-ABL resistant clones (O'Hare et al., 2009). As 
ponatinib is so effective against imatinib resistant cell models, it puts into question 
whether these models are  relevant for the study of BCR-ABL-independent TKI resistance. 
Therefore, we propose using ponatinib to generate a TKI-resistant model, as it would be 
more likely that the resistant cells selected by ponatinib treatment would have a BCR-
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ABL-independent TKI-resistance. Given the limited availability of primary human TKI-
resistant samples, the generation of TKI-resistant BCR-ABL positive cell line models 
provide us with a relevant tool to perform large-scale screens in order to identify 
mechanism(s) that the cells develop to become TKI-resistant, which would enable us to 
establish an effective drug target for treatment for these patients. 
3.3 The generation of a ponatinib-resistant CML cell model  
 
KCL22
WT
 cells and BaF3
WT
 cells, initially sensitive to TKIs, were grown in increasing 
concentrations of ponatinib over a long period of time (figure 3-2).  
 
 
Figure ‎3-2: Illustrates the time course and increasing concentration of ponatinib used to 
generate the BaF3Pon-Res cell line.  
The parental BaF3WT cell line was treated with 0.1 nM ponatinib in October, once the cells were 
happily proliferating, the cells were exposed to a gradual increase in concentration until they 
were resistant to 100 nM ponatinib. 
 
Our data shows that the original TKI sensitive CML cell lines, KCL22
WT
 and BaF3
WT
, 
were sensitive to ponatinib treatment (figure 3-3 and 3-4). An anti-proliferative effect was 
observed after 48 hours of treatment at concentrations as low as 1 nM of ponatinib for both 
cell lines. 150 nM dasatinib inhibited proliferation of KCL22
WT
 cells after 48 hours of 
treatment. The proliferation IC50 values for ponatinib against KCL22
WT
 and BaF3
WT 
cells, 
based on the cell counts following 72 hour of treatment ponatinib, are 2.5 nM and 0.95 nM 
respectively. The activity of BCR-ABL was analysed by its ability to phosphorylate and 
activate downstream proteins such as CRKL. Western blot analysis revealed that although 
proliferation can be impeded at low concentrations of ponatinib treatment in both cell lines, 
BCR-ABL activity was reduced, but not switched off until 10 nM treatment in KCL22
WT 
and 100 nM
 
in BaF3
WT 
cells. This is in contrast to the newly generated KCL22 ponatinib-
resistant (KCL22
Pon-Res
) and BaF3
WT
 ponatinib-resistant (BaF3
Pon-Res
) clones, which 
continue to proliferate in up to concentrations of 100 nM ponatinib (figure 3-3 and 3-4). In 
addition, 150 nM dasatinib had no effect on proliferation in both the KCL22
Pon-Res
 and 
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BaF3
Pon-Res
 cells (figure 3-3 and 3-4). The proliferation IC50 values for ponatinib against 
KCL22
Pon-Res
 and BaF3
Pon-Res 
cells were 303.6 nM and 987.4 nM respectively. Therefore, 
the new ponatinib-resistant cell line KCL22
Pon-Res
 has over a 120 fold tolerance for 
ponatinib compared to its original counterpart, KCL22
WT
, and BaF3
Pon-Res
 has over 1000 
fold resilience against ponatinib compared to BaF3
WT 
cells. Although BCR-ABL activity is 
much reduced at 10 nM ponatinib treatment, as seen in KCL22
WT
 cells, a complete switch 
off does not occur until 100 nM treatment of ponatinib, despite cellular proliferation being 
unaffected (figure 3-3). The BaF3
Pon-Res
 cells do not show a reduction in signalling until 
1μM ponatinib treatment, which corresponds with the high IC50. However, despite, the 
reduction in BCR-ABL signalling the BaF3
Pon-Res
 cells continue to proliferate at this 
concentration (figure 3-4). (KCL22
Pon-Res
 cell line was generated by G.V. Helgason).  
 
Figure ‎3-3: KCL22WT and KCL22Pon-Res cells were seeded at 0.25x106/mL and treated with 0.1, 1, 
10, 100, 1000 and 10000 nM ponatinib and 150 nM dasatinib.   
Cell proliferation and viability were analysed by trypan blue cell counts at 24, 48 and 72 hours. 
IC50s were calculated using 72 hour cell count data using prism. BCR-ABL kinase activity of 
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KCL22WT and KCL22Pon-Res cells after 24 hours TKI treatment was assessed by the level of 
phosphorylated CRKL protein expression via western blot. (Figures by G. V. Helgason). 
 
 
Figure ‎3-4: BaF3WT and BaF3Pon-Res cells were seeded at 0.25x106/ml and treated with 0.1, 1, 10, 
100, 1000 and 10000 nM ponatinib and 150 nM dasatinib.  
Cell proliferation and viability were analysed by trypan blue cell counts at 24, 48 and 72 hours.  
IC50s were calculated using 72 hour cell count data using prism.  BCR-ABL kinase activity of 
KCL22WT and KCL22Pon-Res cells after 24 hours TKI treatment was assessed by the level of 
phosphorylated CRKL protein expression via western blot. (Figures by Vignir Helgason). 
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To further analyse the level of ponatinib resistance gained by the KCL22
Pon-Res
 and 
BaF3
Pon-Res 
cells we performed XTT assays, to determine how this affected the cell 
viability by measuring the number of metabolically active cells. metabolic activity. The 
assay was carried out using a broad range of equimolar concentrations of ponatinib against 
KCL22
WT
 and KCL22
Pon-Res 
cells. The KCL22
WT
 cells were highly sensitive to ponatinib 
achieving a half maximal effective concentration (EC50) of 0.00004 nM. An EC50 refers 
to concentration of a drug that gives half-maximal response. The KCL22
Pon-Res
 cells had a 
much higher EC50 of 647.3 nM (figure 3-5).  XTT assays were also performed on 
BaF3
parental
, BaF3
WT
 and BaF3
Pon-Res
 cells. The BaF3
parental 
cell line does not express BCR-
ABL and acted as a normal cell control. The BaF3 cells were treated with the same 
equimolar ranges of ponatinib. The BaF3
WT
 cells showed high sensitivity, similar to the 
KCL22
WT 
cells, with an EC50 of 0.0002 nM, which was in comparison to the BaF3
Pon-Res 
cells which had an EC50 of 1598 nM. BaF3
parental 
cells do not express BCR-ABL and 
therefore are not effected by TKIs until much higher doses, which are likely to be causing 
off target affects and inhibiting other important kinase activity. BaF3
parental 
cells exhibited a 
much higher tolerance to ponatinib treatment, with an EC50 of 552.1 nM, which is a 
similar concentration to the ponatinib-resistant cell lines, lower than the BaF3
Pon-Res
, 
further strengthening the evidence that the KCL22
Pon-Res
 and the BaF3
Pon-Res
 no longer use 
BCR-ABL for their survival (figure 3-3 and 3-4).  
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Cell Type Drug 
EC50 
(nM) 
KCL22WT Ponatinib 0.00004 
KCL22Pon-Res Ponatinib 647.3 
BaF3
Parental
 Ponatinib 552.1 
BaF3
WT
 Ponatinib 0.0002 
BaF3
Pon-Res
 Ponatinib 1598 
 
Figure ‎3-5: XTT assay using ponatinib againstKCL22WT, KCL22Pon-Res, BaF3parental, BaF3WT and 
BaF3Pon-Res cells. 
Cells were seeded at 0.2x106/mL and treated with the same equimolar concentration of drug 
ranging from 0.01 nM to 10 μM ponatinib. Cell viability measured after 72 hours using an XTT 
assay and (b) EC50s were calculated using graphpad prism. 
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3.3.1 Ponatinib resistant CML cell model is pan-TKI-resistant  
 
The apoptotic effect of all available TKIs and the highly toxic protein translation inhibitor, 
omacetaxine, which is used in patients as a last resort treatment, were investigated in 
KCL22
Pon-Res
 cells.  KCL22
Pon-Res
 cells were treated with TKIs; imatinib 2 µM, nilotinib 2 
µM, dasatinib 150 nM, ponatinib 100nM and omacetaxine 10 nM for 72 hours. Apoptosis 
was analysed by FACS following annexin V and 7AAD staining. Figure 3-6 shows that 
TKIs did not induce apoptosis in the KCL22
Pon-Res
 cells. The low level of apoptosis shown 
reflects that seen in the untreated cell population. However, although pan-TKI-resistant, 
very low concentrations of omacetaxine are able induce highly significant levels of 
apoptosis within this pan-TKI-resistant cell line highlighting that the KCL22
Pon-Res
 cells 
still remain their ability to activate the apoptotic machinery and undergo programmed cell 
death.   
 
Figure ‎3-6: : KCL22Pon-Res cells were treated with imatinib 2 µM, nilotinib 2 µM, dasatinib 150 nM, 
ponatinib 100 nM and omacetaxine 10 nM for 72 hours, and analysed by flow cytometry 
following annexin V and 7AAD staining.  
The histogram represents early and late apoptosis and numbers are presented as mean±SEM. 
Statistical analysis was performed by using paired t-test. Annotation above a bar refers to 
statistical significance between the bar and the untreated sample. (***; p≤0.001) n=3. The FACS 
plots show the live cell population in the lower left quadrant, early apoptotic cells in the lower 
right quadrant and the late apoptotic cells within the upper right hand quadrant.  
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3.3.2 Pre-clinical BCR-ABL inhibitor, ABL001, is ineffective against KCL22Pon-Res and 
BaF3Pon-Res cells  
The previous experiments demonstrate the TKIs are redundant in the treatment of these 
pan-TKI-resistant cells. A new drug that exhibits an alternative mode of action against 
BCR-ABL is currently being investigated in a Phase I clinical trial, ABL001 (Ottmann et 
al., 2015). Unlike TKIs, which bind to the kinase domain, ABL001 binds to the myristoyl 
pocket of BCR-ABL and forces a conformational change that disables the kinase domain. 
Since this type of drug does not bind within the kinase domain of BCR-ABL, where most 
TKI-resistant mutations occur, it is thought that this could potentially be an alternative 
drug treatment for TKI-resistant patients (Ottmann et al., 2015). Hence, we wanted to 
investigate whether the KCL22
Pon-Res
 and BaF3
Pon-Res 
cells would be sensitive to this 
alternative drug. KCL22
WT 
and KCL22
Pon-Res 
cells were treated for 72 hours with a range of 
concentrations of ABL001. ABL001 proved to have antiproliferative effects in KCL22
WT 
cells in concentrations equal to 10 nM and above. However, ABL001 had no effect on 
proliferation of KCL22
Pon-Res 
cells, even in concentrations up to 1000 nM. In KCL22
WT 
cells, even low concentrations of 1 nM caused a modest induction of apoptosis after 72 
hours of treatment, which significantly increased to 40% in concentrations 10 nM and 
above. Increased concentrations of 100 nM and 1000 nM did not further increase the level 
of apoptosis. ABL001 exhibited no apoptotic effect on the KCL22
Pon-Res 
cells, even at high 
concentrations of 1000 nM. The sensitivity of KCL22
WT 
and the resistance of KCL22
Pon-Res 
cells to ABL001 were reiterated in a XTT assay, which showed that KCL22
WT
 had an 
EC50 of 0.00005 nM and KCL22
Pon-Res 
cells had and EC50 of 6000 nM. 
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Figure ‎3-7: KCL22WT and KCL22Pon-Res cells were seeded at 0.25x106/ml and treated with 0.1, 1, 10, 
100, 1000, 10000 nM ABL001 for 72 hours.  
Apoptosis was analysed via flow cytometry following annexin V and 7AAD staining. The histogram 
represents early and late apoptosis and numbers are presented as mean±SEM (n=3). Statistical 
analysis was performed by using paired t-test. Annotation above a bar refers to statistical 
significance between the bar and the untreated control. (**; p≤0.01, ***; p≤0.001). (c) KCL22WT 
and KCL22Pon-Res cells were seeded at 0.2x106/mL and treated with the same equimolar 
concentration of drug ranging from 0.001 nM to 10 μM ponatinib. Cell viability measured after 72 
hours using an XTT assay and the EC50 was calculated using graphpad prism. 
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An apoptosis assay using a range of concentrations from 0.1 nM to 1000 nM was also 
performed on the BaF3 cell lines; BaF3
parental
, BaF3
WT
, BaF3
T315I 
and BaF3
Pon-Res
 cells. As 
expected, ABL001 had no impact upon the non-BCR-ABL expressing cell line, BaF3
parental
. 
In the BaF3
WT
 cell line a modest induction of apoptosis was caused with 10 nM of 
ABL001, however treatment with 100 nM and 1000 nM of ABL001 induced a significant 
level of apoptosis, 85% and 90% respectively. Due to the design of ABL001, it has been 
shown to have inhibitory effects with CML patients harbouring the T315I mutation. Here 
we showed that 100 nM and 1000 nM induced apoptosis in the BaF3
T315I
 cells, to levels of 
40% and 50% respectively. This is almost a 50% reduction in apoptosis compared to that 
observed in the BaF3
WT
 cells, using the same concentrations. This implies that BCR-ABL 
carrying the T315I mutation is less sensitive to ABL001 and may need treatment with 
higher concentrations to eradicate the cells (Thomas et al., 2015). As seen with the 
KCL22
Pon-Res
 cell line, ABL001 had no apoptotic effect on BaF3
Pon-Res
 cells, even at high 
concentrations of 1000 nM. These observations were supported by a cell viability assay, 
using resazurin. A broad range of equimolar concentrations of ABL001 were used against 
BaF3
parental
, BaF3
WT
 and BaF3
Pon-Res
 cells, which showed that only the BaF3
WT
 cell were 
sensitive to ABL001 with a IC50 of 80 nM. The BaF3
parental
 and BaF3
Pon-Res
 cells did not 
show any response to ABL001 even at 10 µM, the highest concentration used within this 
assay. Even the combination of ABL001 and 100 nM ponatinib had no addition effect on 
the BaF3
Pon-Res
 cells. Given that both KCL22
Pon-Res
 and BaF3
Pon-Res
 cells are highly resistant 
to ABL001 reinforces the evidence that these cell lines do not have a kinase domain 
mutation which may infer the TKI resistance and that these cell line models truly survive 
due to a BCR-ABL-independent mechanism.  
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Figure ‎3-8: BaF3parental, BaF3WT, BaF3T315I and BaF3Pon-Res cells were seeded at 0.25x106/ml and 
treated with 0.1, 1, 10, 100, 1000, 10000 nM ABL001 for 72 hours, and analysed by FACS 
following annexin V and 7AAD staining.  
The histogram represents early and late apoptosis and numbers are presented as mean±SEM 
(n=3). Statistical analysis was performed by using paired t-test. Annotation above a bar refers to 
statistical significance between the bar and the untreated control (*;p≤0.05, **; p≤0.01, ***; 
p≤0.001).. BaF3Parental, BaF3WT, BaF3Pon-Res and BaF3Pon-Res + 100 nM ponatinib cells were seeded at 
0.25x106/ mL and treated with the same equimolar concentration of drug ranging from 0.001 nM 
to 10 μM ABL001. Cell viability measured after 72 hours using a resazurin assay and the IC50 was 
calculated using graphpad prism (Beatson drug screening facility). 
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3.4 Characterisation of the mechanism causing TKI resistance in the 
ponatinib-resistant cell models 
 
In order to understand the molecular mechanism driving the TKI resistance, both the 
KCL22
Pon-Res
 and BaF3
Pon-Res
 cells underwent several screening experiments.  
 
3.4.1 DNA sequencing reveals no kinase domain mutation 
Firstly, to confirm that the ponatinib-resistant cell models did not acquire kinase mutations, 
we sequenced the BCR-ABL kinase domain. As previously discussed, the BCR-ABL 
kinase domain is an area renowned for mutational changes, which affect TKI binding and 
ultimately cause TKI resistance.  This is the most common cause of TKI resistance in CML 
patients. The T315I mutation is the most threatening mutation as 1
st
 and 2
nd
 generation 
TKIs are not able to bind to the BCR-ABL kinase domain due to this change. However, 
ponatinib has now been generated and was specifically designed to treat patients 
harbouring this mutation. The western blot previously showing the BCR-ABL activity of 
the BaF3
Pon-Res 
cells treated with increasing concentrations of ponatinib and dasatinib, 
showed that ponatinib could switch off BCR-ABL signalling, however dasatinib did not. 
Therefore, we were interested to know if during the generation of the BaF3
Pon-Res
 cells a 
T315I mutation had occurred. However, sequencing revealed no mutations within the 
kinase domain in either of the cell lines, which included no T315I mutation. As ponatinib is 
a more potent ABL inhibitor and the cells are highly resistant to ponatinib, perhaps higher 
concentrations of dasatinib are need to inhibit BCR-ABL signalling in the BaF3
Pon-Res
 cell 
model. Data shown for BaF3
Pon-Res 
only (figure 3-9), KCL22
Pon-Res
 sequencing had been 
performed previously within our laboratory. 
 
Figure ‎3-9: Genomic sequencing of BaF3Pon-Res revealed no mutations within the BCR-ABL kinase 
domain. Data shown here is for the position for the T315I mutation and no mutation change has 
occurred.  
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3.4.2 KCL22Pon-Res cells have an impaired transcriptional response to TKI 
As mutational changes of the kinase domain had been ruled out as the mechanism of 
resistance for the TKI-resistant cells, we wanted to understand what mechanism the cells 
were using for their survival. With the recent advancements in sequencing we were 
interested in performing a transcriptomic screen to analyse the differences in gene 
transcription between the original KCL22
WT
 and KCL22
Pon-Res
 cells hoping to find the 
potential mechanism(s) of BCR-ABL-independent TKI resistance. The KCL22
WT
 and 
KCL22
Pon-Res
 cells were left untreated or treated with 100 nM ponatinib for 24 hours to 
switch off BCR-ABL signalling, and subsequently RNA and protein were generated. The 
transcriptomic analysis was performed using RNA-seq (performed by Glasgow Polyomics) 
to gain an understanding of the gene expression patterns between KCL22
WT
 and KCL22
Pon-
Res
 cells and what effect switching off BCR-ABL signalling had to gene transcription in 
these two different cell lines. This analysis identified that KCL22
WT
 cells underwent many 
transcriptional changes, with 1658 genes being significantly up-regulated and significantly 
down-regulated following BCR-ABL inhibition by ponatinib (figure 3-10). However, the 
response in KCL22
Pon-Res
 cells to BCR-ABL inhibition was vastly different, with only two 
genes up-regulated and three down-regulated follow ponatinib treatment (figure 3-10). 
This suggested that although BCR-ABL has been inhibited, signalling pathways for cell 
survival remain unaffected and therefore no transcriptional changes occur, highlighting 
KCL22
Pon-Res
 cells lack of transcriptional response following ponatinib treatment. 
This lack of transcriptional response was also shown clearly in the volcano plot, which 
showed the KCL22
WT 
cells with a large magnitude of fold changes in genes up-regulated 
(pink) and genes down-regulated (green). However, KCL22
Pon-Res
 cells show very few 
changes and what has changed is of very low magnitude. The linear correlation (r) between 
gene expression changes in KCL22
WT
 and KCL22
Pon-Res
 cells following 24 hour ponatinib 
treatment was 0.6. This means that there is no positive correlation between the two samples, 
as anything below 0.7 is deemed meaningless, and therefore this is not a significant 
correlation. Statistically this demonstrates that TKI sensitive KCL22
WT
 cells and TKI-
resistant KCL22
Pon-Res
 cells have very different transcriptional responses to ponatinib 
treatment.  
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Figure ‎3-10: Venn diagram showing the differential gene expression changes between KCL22WT 
and KCL22Pon-Res cells following 24 hours ponatinib treatment.  
A volcano plot showing the fold changes in gene expression patterns in KCL22WT and KCL22Pon-Res 
cells following 24 hours ponatinib treatment, down-regulated genes in green and up-regulated 
genes in pink. Comparison of log changes in gene expression between KCL22WT and KCL22Pon-Res 
cells following 24 hours ponatinib treatment. 
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3.4.3 mTOR activity is sustained in KCL22Pon-Res cells despite BCR-ABL inhibition 
As previously described PI3K/AKT/mTOR pathway is an important signalling pathway 
activated by BCR-ABL to help drive cell growth and proliferation (figure 3-11). Due to 
mTOR’s involvement in protein translation it was hypothesised that deregulation of this 
pathway may have led to the impaired transcriptional response observed in the KCL22
Pon-
Res
 cells following ponatinib treatment as seen in the RNA-seq experiment. In order to 
investigate this concept, we performed a western blot to analyse the activity mTOR in 
ponatinib sensitive CML cells (KCL22
WT
 and KCL22
T315I
) and TKI-resistant CML cells 
(KCL22
Pon-Res
) following treatment with TKIs, dasatinib or ponatinib. Treatment of the 
cells with TKI showed complete inhibition of BCR-ABL, shown by the absence of 
phosphorylated CRKL (KCL22
T315I
 with ponatinib treatment only). In the TKI sensitive 
CML cells, inhibition of BCR-ABL stops the signalling of the PI3K/AKT/mTOR pathway 
shown here by the inhibition of phosphorylated Ribosomal Protein S6 (RPS6), which is 
phosphorylated and activated by the mTOR pathway via S6 kinase (figure 3-11). However, 
we observed in the KCL22
Pon-Res
 cell line, despite the complete inhibition of BCR-ABL, 
there was sustained phosphorylation of RPS6. This indicates that mTOR is still active 
within the KCL22
Pon-Res
 cells. This activation is not via BCR-ABL therefore it suggests an 
alternative survival factor is activating mTOR complex 1 (mTORC1) (Ly et al., 2003), 
which is a common protein involved in  multiple oncogenic signalling pathways. 
 
 
Figure ‎3-11: A diagram of the PI3K/AKT/mTOR pathway, downstream of BCR-ABL.   
KCL22WT, KCL22T315I and KCL22Pon-Res were seeded at 0.25x106/ml and treated with 150 nM 
dasatinib and 100 nM ponatinib for 24 hours. A western blot which assess the activity of BCR-ABL 
shown by phosphorylation of CRKL and mTOR activity shown by the phosphorylation of RPS6 
(figure B by G. V. Helgason however n=3, 2 performed by Rebecca Mitchell). 
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3.5 Key findings 
In this chapter we discuss the use of cellular models to study BCR-ABL independent TKI 
resistance in CML and the potential flaws of the imatinib resistant cell line models. One of 
the most significant results in this chapter was the development of truly BCR-ABL 
independent TKI resistant CML cellular models. We generated two ponatinib resistant cell 
lines; KCL22
Pon-Res
 and BaF3
Pon-Res
, both of these models maintained the ability to 
proliferate under the treatment of high concentrations of 1
st
, 2
nd
 and 3
rd
 generation TKIs as 
well as the pre-clinical BCR-ABL inhibitor, ABL001.  It was also shown that despite 
continued proliferation and survival, under 100 nM ponatinib treatment, BCR-ABL 
signalling was switched off, as seen with the inhibition of the phosphorylation of CRKL by 
western blotting. These findings led us to believe that these CML cells are using an 
alternative survival pathway for their survival.  
In an attempt to characterise the mechanism of TKI resistance both models were screened 
for ABL kinase domain mutations, however both cell lines were negative for any known 
mutations which may cause TKI resistance. A transcriptomic screen was performed on 
KCL22
WT 
and KCL22
Pon-Res
 cells using RNA-seq to determine gene transcriptional changes 
between the two cell lines, which may infer the mechanism of resistance. There were very 
few transcriptional differences between the two cell lines at baseline. However, when 
BCR-ABL is inhibited, by ponatinib the KCL22
WT 
cells had a significant amount of 
transcriptional changes, whereas the KCL22
Pon-Res
 cells had no transcriptional response to 
ponatinib. This impaired response, highlights the redundancy of BCR-ABL signalling as a 
survival mechanism.  
Although results from the RNA-seq were inconclusive, through western blotting we 
discovered of sustained mTOR signalling in the KCL22
Pon-Res
 cells despite the complete 
inhibition of BCR-ABL. Therefore, this led us to believe that mTOR was being activated 
by an alternative survival pathway. This was a very significant result from the chapter and 
led us to continue to investigate the PI3K/AKT/mTOR pathway as a potential drug target 
for BCR-ABL independent TKI resistant CML. 
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4 Results (II): Screening for potential novel drug target 
candidates for the treatment of BCR-ABL-independent TKI-
resistant CML  
 
4.1 Aim and objective 
 
III. Search for potential drug targets for BCR-ABL-independent TKI-resistant CML by 
preforming a drug screen using National Institute of Health (NIH) approved 
oncology drugs 
 
4.2 National Institute of Health (NIH) approved oncology drug screen 
 
As a mutational change in BCR-ABL kinase domain had been ruled out as the mechanism 
of resistance for these TKI-resistant cells, we utilised a large scale screening programme in 
conjunction with the Beatson Drug Screening Facility. This facility possesses a library of 
119 National Institute of Health (NIH) approved oncology drugs, which can be tested 
against cells via high throughput screening methods. This library includes inhibitors that 
target many pathways known to be deregulated in cancer, such as RAS/MEK/ERK and 
PI3K/AKT/mTOR, inhibitors against HDACs and tyrosine kinases and as well as many 
other conventional chemotherapy drugs. We wanted to use this screen not only to find an 
alternative treatment for BCR-ABL-independent TKI resistance, but also as a parallel 
approach to uncover the underlying molecular pathophysiology. The initial experiment was 
an analysis of KCL22
WT 
and KCL22
Pon-Res
 cells against the large library of inhibitors. 
KCL22
Pon-Res
 cells were analysed with and without 100 nM ponatinib treatment. Cells were 
plated at a density of 0.25x10
6
/mL in 96 well plates and treated with 4 concentrations of 
each drug (10 µM, 1µM, 0.1 µM, 0.01 µM) in triplicate (figure 4-1). Following 72 hours of 
incubation, a resazurin cell viability assay was performed (figure 4-2). 
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Figure ‎4-1: Workflow and depiction of the robotics used to pipette the drugs and the cells into 
the 96 well plates. 
 
 
 
 
Figure ‎4-2: Workflow and depiction of the robotics used to pipette the resazurin into the 96 well 
plates and the resazurin plate reader. 
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4.2.1 Confirmation that KCL22Pon-Res cells are pan-TKI-resistant 
Importantly the screen confirmed that KCL22
Pon-Res
 cells are pan-TKI-resistant, as cell 
viability tests against the majority of FDA-approved TKIs never achieving an IC50 under 
10 µM, the maximum drug concentration used in the screen (figure 4-3), with the 
exception of bosutinib, which had an IC50 of 8.123 µM, which would be an unachievable 
in patients and still denoted a resistant phenotype (figure 4-3).    
 
4.2.2 37 clinically approved cancer drugs have the potential to induce cell death in TKI-
resistant CML cells  
The primary aim of this screen was to identify a drug(s) that could kill TKI-resistant CML 
cells. Our secondary aim was to find an inhibitor, which would exhibit a level of 
specificity towards the KCL22
Pon-Res
 cell line to help to uncover the mechanism of 
resistance. However, the results of the screen showed that all of the drugs that were 
effective against KCL22
Pon-Res
 cells also exerted their activity against KCL22
WT
 cells. 
Despite the non-selectivity towards the KCL22
Pon-Res
 cells, of the 119 drugs tested in the 
screen, 37 were shown to have an effect on cell viability of KCL22
Pon-Res
 cells within the 
drug concentration range (0.001-10 µM). Many of these drugs were non-specific 
chemotherapy drugs, such as vincristine sulphate, ixabepilone, docetaxel, cabazitaxel, 
vinblastine sulphate, paclitaxel and dactinomycin. All of these conventional chemotherapy 
treatments were within the top 10 drugs, which were able to reduce cell viability using very 
low drug concentrations. All of the IC50s were under 100 nM (figure 4-3). Another 
chemotherapeutic, omacetaxine, as previously shown in figure 3-6, used as our positive 
control in this assay, was also highly effective against KCL22
Pon-Res
 cells, with an IC50 of 
42 nM (figure 4-3). 
 
4.2.3 KCL22Pon-Res cells are highly sensitive to mTOR inhibitors 
The most prominent target highlighted from the screen was the inhibition of mTOR. 
mTOR had three consistent hits from allosteric inhibitors; everolimus, sirolimus and 
temsirolimus. These drugs were ranked highly for their low IC50s against KCL22
Pon-Res
 
cells (12
th
, 13
th
 and 16
th
) (figure 4-3). The IC50s of everolimus, sirolimus and temsirolimus 
were 115 nM, 118 nM and 158 nM, respectively (figure 4-3). The addition of ponatinib 
treatment to the cells had no additional effect on the IC50s. Of all the drug targets in the 
screen, mTOR was the only target that had 3 consecutive hits from drugs which were 
highly effective in reducing cell viability (figure 4-3). mTOR inhibitors are of great interest, 
as PI3K/AKT mTOR is deregulated in many cancers. Sirolimus is more widely known as 
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rapamycin, and everolimus and temsirolimus are rapamycin analogues. Clinical trials have 
been conducted with mTOR inhibitors, one of which tested the effect of everolimus and 
imatinib in treating patients with CP CML who were not in CCyR after previous imatinib 
treatment (NCT00093639). This trial has now been completed, however no data is 
currently available. While sirolimus and rapamycin analogues have had moderate success 
in cancer therapy for solid tumours, only modest efficacy was achieved in patients, where 
it was thought it would provide great benefit (Sillaber et al., 2008, Wander et al., 2011). It 
is thought that the reason for the suboptimal response is due to rapamycin and its 
analogues only targeting mTORC1 and not the secondary subunit mTORC2, which can 
feedback to AKT and provide further stimulus for activation of mTOR (Choo and Blenis, 
2009). However, this issue is being tackled by the development of catalytic inhibitors, one 
of which is about to open in a phase I clinical trial. This trial is a dose-finding study of 
NVP-Bez235 in adult patients with relapsed or refractory acute leukaemia, which is also 
open to BC CML patients (NCT01756118). NVP-Bez235 is a potent dual inhibitor of PI3K 
and mTOR (Maira et al., 2008). Dual PI3K and mTOR inhibitors are particularly effective 
in blocking PI3K/AKT/mTOR activation because they can also prevent the feedback 
activation of PI3K signalling normally observed with mTORC1 inhibitors, such as 
rapamycin and its analogues (Mukherjee et al., 2012). 
 
4.2.4 KCL22Pon-Res cells are sensitive to HDAC inhibition 
However, very interestingly the drug that showed the highest sensitivity towards the 
KCL22
Pon-Res
 cells was romidepsin. This is a HDAC inhibitor currently approved for the 
treatment of cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas 
(PTCLs) (Iyer and Foss, 2015, Prince and Dickinson, 2012). The IC50 obtained for this 
drug against the KCL22
Pon-Res
 cells was below the lowest drug concentration performed in 
the assay, 10 nM (figure 4-3). Other HDAC inhibitors were also screened against the 
KCL22
Pon-Res
 cells, however belinostat and vorinostat did not show the same level of 
sensitivity, having IC50s of 1.039 µM and 3.41 µM, respectively (figure 4-3). The addition 
of ponatinib treatment to the cells had a varied effect on the IC50s. In the scope of this 
experiment, as the concentration range did not go lower than 10 nM for romidepsin, it was 
unclear whether HDAC inhibition further sensitised cells to ponatinib. The addition of 
ponatinib had very little effect on belinostat, however it reduced the IC50 of vorinostat by 
~ 70% (figure 4-3).  
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4.2.5 KCL22Pon-Res cells are sensitive to MEK inhibition  
Another interesting specific drug target was the MEK inhibitor, trametinib. As previously 
described, MEK is part of the RAS/MEK/ERK signalling pathway, which is an important 
pathway downstream of BCR-ABL. Trametinib was within the top 20 drugs that affected 
KCL22
Pon-Res
 cell viability (figure 4-3). Sensitivity to this drug may be understandable due 
to it being one of the main survival pathways used by BCR-ABL. The main reason we 
found this particular drug so interesting was because as a single treatment it had an IC50 of 
287 nM against KCL22
Pon-Res
 cells. However, when this was combined with 100 nM of 
ponatinib treatment it lowered the IC50 to 34 nM (figure 4-3). Therefore, ponatinib 
treatment further sensitises the KCL22
Pon-Res
 cells to the MEK inhibitor, suggesting that 
there may be a secondary oncogenic source activating MEK for KCL22
Pon-Res
 cell survival. 
This additive effect may allow for a more specific treatment towards TKI-resistant CML 
cells versus normal cells (figure 4-3).  
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Figure ‎4-3:  Heat map of the top IC50 concentrations obtained from NIH approved oncology 
drug screen against KCL22Pon-Res cells with and without ponatinib.  
mTOR inhibitors highlighted by asterisks within the heat map. Dot plot of the drugs with the top 
IC50 concentrations against KCL22Pon-Res cells grouped into their target/mode of action.   
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4.3 Validation of the primary drug screen using the BaF3Pon-Res cell model 
A secondary screen was conducted using the BaF3
Pon-Res
 cell model to validate that the hits 
from the first screen could be translated to other TKI-resistant models and wasn't specific 
to KCL22
Pon-Res
 cells. Several pre-clinical mTOR inhibitors were added to the screen, 
including dual PI3K and mTOR inhibitors, to assess whether they were more effective than 
the rapamycin analogues used in the primary screen. In the secondary screen BaF3
parental
, 
BaF3
WT
 and BaF3
Pon-Res
 cells were analysed. The BaF3
parental
 were used as a “normal” 
haemopoietic cell control in order to understand if the drugs were toxic to normal cells or 
were specific to CML cells. The experiment was set up as previously described. 
4.3.1 mTORC1 inhibition is insufficient to affect cell viability in BaF3Pon-Res cells 
 mTOR inhibitors, everolimus and sirolimus, were very effective in the primary drug 
screen and were able to inhibit 50% of cell growth at 115 nM and 118 nM. However, in the 
BaF3
Pon-Res
 cell model the mTORC1 inhibitors were ineffective (figure 4-4). No IC50 was 
achieved for either sirolimus or everolimus in any of the BaF3 cell lines up to the 
maximum concentration, 10 µM (figure 4-4). Sirolimus in combination with 100 nM 
ponatinib, achieved an IC50 of 7.4 µM in the BaF3
Pon-Res
 cells, however this is a very high 
concentration, which may not be achievable in the clinic. The failure of the mTORC1 
inhibitors in this setting, may be due to the partial effect on the mTOR pathway, which  
therefore once more highlights the need for more effective mTOR inhibitors, such as the 
catalytic inhibitors (Mukherjee et al., 2012).  
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Figure ‎4-4: BaF3parental, BaF3WT, BaF3Pon-Res and BaF3Pon-Res + 100 nM ponatinib cells were seeded 
at 0.25x106/ mL and treated with the same equimolar concentration of drug ranging from 0.001 
nM to 10 μM of sirolimus or everolimus.  
Cell viability was measured after 72 hours using a resazurin assay and the IC50s were calculated 
using graphpad prism  
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4.3.2 BaF3Pon-Res cells are highly sensitive to dual PI3K and mTOR inhibition 
The PI3K-mTOR inhibitors may establish a deeper mTORC1 inhibition due to the 
targeting of both mTORC1 and mTORC2 as well as all PI3K isoforms (Maira et al., 2008). 
Therefore, we analysed the effects of catalytic inhibitors, AZD8055, (an mTORC1 and 
mTORC2 inhibitor that does not affect PI3K at the concentrations used), as well as several 
dual PI3K and mTORC1/2 inhibitors; apitolisib, VS-5584, NVP-Bez235 and gedatolisib. 
The sensitivity of KCL22
WT
 and KCL22
Pon-Res
 to AZD8055 was very similar to the mTOR 
inhibitors used in the primary screen, with the regards to the IC50 drug concentrations. 
More importantly, AZD8055 had a significantly greater effect on growth inhibition in all 
three BaF3 cell lines, shown by the low IC50 compared to the allosteric inhibitors. 
Although AZD8055 also affects the BaF3
parental
, lower concentrations of AZD8055 are 
needed to inhibit the growth of BaF3
WT
 and BaF3
Pon-Res
 cells.  BaF3
parental
 cells have an 
IC50 of 320 nM, BaF3
WT
 cells 150 nM and BaF3
Pon-Res
 cells 240 nM (figure 4-5). The 
addition of ponatinib did not give AZD8055 any increased affect against the ponatinib-
resistant cells (figure 4-5). 
 
Figure ‎4-5: KCL22WT, KCL22Pon-Res, KCL22Pon-Res +100 nM ponatinib, BaF3parental, BaF3WT, BaF3Pon-Res 
and BaF3Pon-Res + 100 nM ponatinib cells were seeded at 0.25x106/mL and treated with the same 
equimolar concentration of drug ranging from 0.001 nM to 10 μM of AZD8055.  
Cell viability was measured after 72 hours using a resazurin assay and the IC50s were calculated 
using graphpad prism. 
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The KCL22
Pon-Res 
and the BaF3
Pon-Res
 cells were also highly sensitive to treatment with dual 
PI3K and mTOR inhibitors; apitolisib, VS-5584, NVP-Bez235 and gedatolisib. KCL22
Pon-
Res
 390 nM, 390 nM, 6 µM and 1.4 µM and BaF3
Pon-Res
 cells 2.2 µM, 1.29 µM, 0.94 µM, 
460 nM, respectively (figure 4-6).  
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Figure ‎4-6: KCL22WT, KCL22Pon-Res, KCL22Pon-Res +100 nM ponatinib, BaF3parental, BaF3WT, BaF3Pon-Res 
and BaF3Pon-Res + 100 nM ponatinib cells were seeded at 0.25x106/ mL and treated with the same 
equimolar concentration of drug ranging from 0.001 nM to 10 μM of Apitolisib, VS-5584, NVP-
Bez235 and Gedatolisib.  
Cell viability was measured after 72 hours using a resazurin assay and the IC50s were calculated 
using graphpad prism.  
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4.3.3 Potential selectivity using trametinib against BaF3Pon-Res cells compared to 
BaF3parental cells 
With the success of trametinib in the primary drug screen we wanted to ensure these results 
translated to the BaF3
Pon-Res
 cell model. This revealed that trametinib was a specific drug 
target for CML cells, as an IC50 for the BaF3
parental 
cells was not achieved within the drug 
concentration range (0.001 to 10 µM) and IC50s for the BCR-ABL expressing cells, 
BaF3
WT
 and BaF3
Pon-Res
 were 230 nM and 1.83 µM respectively (figure 4-7). Once again 
as seen in the KCL22
Pon-Res
 cell model, BaF3
Pon-Res
 cells were further sensitised to MEK 
inhibition with the addition of ponatinib treatment, reducing the IC50 from 1.83 µM to 440 
nM (figure 4-7).  We also wanted to analyse whether MEK inhibition was a reproducible 
target, as only one MEK inhibitor was used in the primary screen. In the secondary screen 
we added selumetinib, which is also referred to as AZD6244. The efficacy of selumetinib 
was tested in the KCL22
WT
, KCL22
Pon-Res
, KCL22
Pon-Res 
+100 nM ponatinib, BaF3
parental
, 
BaF3
WT
, BaF3
Pon-Res 
and BaF3
Pon-Res
 +100 nM ponatinib cells. Selumetinib also showed 
greater efficacy against the KCL22
Pon-Res
 cells, IC50 480 nM, compared to KCL22
WT
, IC50 
>10 µM (figure 4-7). As seen previously with trametinib, the addition of ponatinib 
treatment in combination with selumetinib treatment further sensitised the KCL22
Pon-Res
 
cells to cell death, decreasing the IC50 to 70 nM (figure 4-3). However, this failed to 
translate to the BaF3 cell models, as selumetinib did not reach an IC50 within the drug 
concentration range (0.001 to 10 µM) (figure 4-7).  
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Figure ‎4-7: KCL22WT, KCL22Pon-Res, KCL22Pon-Res +100 nM ponatinib, BaF3parental, BaF3WT, BaF3Pon-Res 
and BaF3Pon-Res + 100 nM ponatinib cells were seeded at 0.25x106/ mL and treated with the same 
equimolar concentration of drug ranging from 0.001 nM to 10 μM of selumetinib and 
trametinib.  
Cell viability was measured after 72 hours using a resazurin assay and the IC50s were calculated 
using graphpad prism. 
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4.4 A tertiary screen was performed to assess toxicity of the drugs to 
normal haemopoietic cells 
 
Due to the similarity in IC50 drug concentrations against BaF3
parental 
cells, TKI-sensitive 
and TKI-resistant CML cells in the cell line models we wanted to repeat the drug screen to 
test the toxicity of the mTOR and MEK inhibitors in primary non-CML CD34
+ 
cells from 
three separate patients. The assay was set up very similarly to the cell line experiments.   
 
4.4.1 Dual PI3K and mTOR inhibitors may have a therapeutic window for treatment 
for BCR-ABL-independent TKI-resistant CML patients 
The results of the screen showed that mTOR inhibitors, sirolimus and everolimus, were not 
toxic to the “normal” cells, as IC50s for sirolimus were in the high micromolar range 4.63, 
2.27 and 8.97 µM for each patient. As for treatment with everolimus a 50% reduction in 
growth was never achieved in any of the patient samples. PI3K/AKT/mTOR is an 
important pathway in normal cells as well as cancer cells, therefore the inhibition of 
mTOR should cause some growth inhibitory response. As this had not been observed 
within the assay, it also reinforces the theory that these allosteric mTOR inhibitors are 
inefficient. Due to their rarity, it would be impossible for us to carry out a drug screen 
using BCR-ABL-independent TKI-resistant CML samples. Therefore, our nearest 
comparison was human cell line, KCL22
Pon-Res
. IC50 concentrations have been plotted 
alongside the non-CML samples as a vague comparison. As seen with the KCL22
Pon-Res
 
cells, the non-CML cells were also very sensitive to AZD8055 with all three samples 
having IC50 concentrations within the nM range. These concentrations were very similar 
to the KCL22
Pon-Res
 model, which demonstrates a level of toxicity. IC50 values for non-
CML samples, < 20 nM, 100 nM and 210 nM compared to160 nM for KCL22
Pon-Res 
cells 
(figure 4-8). The non-CML cells were also sensitive to the dual PI3K and mTOR inhibitors, 
however the IC50 concentrations were higher than that of the KCL22
Pon-Res
 model. 
Apitolisib non-CML samples IC50s: 670 nM, 430 nM and 850 nM compared to 390 nM 
achieved in KCL22
Pon-Res
 cells. VS-5584 IC50s: 1.02 μM, 610 nM, 1.31 μM compared to 
340 nM in KCL22
Pon-Res
 cells. NVP-Bez235: 320 nM, 520 nM, >1 μM compared to 630 
nM in KCL22
Pon-Res
 cells. Gedatolisib: 730 nM, 530 nM, 630 nM compared to 160 nM in 
KCL22
Pon-Res
 cells (figure 4-9). Therefore, this requires further investigation and may be 
best tested in an in vivo model (refer to chapter 6.12). 
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Figure ‎4-8: Non-CML cells from three different samples were seeded at 0.5x106/ mL and treated 
with the same equimolar concentration of drug ranging from 0.001 nM to 10 μM of sirolimus, 
everolimus and AZD8055.  
Cell viability was measured after 72 hours using a resazurin assay and the IC50s were calculated 
using graphpad prism. 
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Figure ‎4-9: Non-CML cells from three different samples were seeded at 0.5x106/ mL and treated 
with the same equimolar concentration of drug ranging from 0.001 nM to 10 μM of apitolisib, 
VS-5584, NVP-Bez235 and gedatolisib.  
Cell viability was measured after 72 hours using a resazurin assay and the IC50s were calculated 
using graphpad. 
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4.4.2 MEK inhibition is not toxic to non-CML haemopoietic cells 
Despite the inconsistent translation between cell line models shown with the MEK 
inhibitors, we thought further investigation was still worthwhile as a potential therapeutic 
against BCR-ABL-independent TKI-resistant CML. Therefore, we also tested the toxicity 
of selumetinib and trametinib against non-CML haemopoietic cells. In this assay it showed 
that selumetinib and trametinib did not reach 50% cell growth inhibition, apart from one 
patient sample treated with trametinib which had a high IC50 of 3.72 μM (figure 4-10). 
Therefore, it suggests that MEK inhibition is not toxic to “normal” haemopoietic cells and 
could be a potential specific drug target for BCR-ABL-independent TKI-resistant CML. 
 
 
Figure ‎4-10: Non-CML cells from three different samples were seeded at 0.5x106/ mL and 
treated with the same equimolar concentration of drug ranging from 0.001 nM to 10 μM 
selumetinib and trametinib.  
Cell viability was measured after 72 hours using a resazurin assay and the IC50s were calculated 
using graphpad prism. 
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4.5 Key findings 
In this chapter we perform a drug screen in conjunction with the Beatson Drug Screening 
Facility. The facility possessed a library of 119 National Institute of Health (NIH) 
approved oncology drugs. 
Our main aim for the screen was to find an alternative treatment for BCR-ABL-
independent TKI resistant CML. By identifying an alternative target we hoped this may 
also lead to uncovering the underlying molecular pathophysiology.  
The initial screen was conducted using KCL22
WT 
and KCL22
Pon-Res
 cells, which identified 
37 clinically approved drugs that had the potential to induce cell death in TKI-resistant 
CML cells. The most significant result from this chapter was that the KCL22
Pon-Res
 cells 
were no longer sensitive to TKI treatment however were highly sensitive to mTORC1 
inhibitors, which complimented data from chapter 3 were we saw sustained mTOR activity 
despite BCR-ABL inhibition. The primary drug screen results were validated using the 
BaF3
Pon-Res
 cell model and although the allosteric mTORC1 inhibitors from the primary 
experiment had a suboptimal effect on BaF3
Pon-Res
 cell viability, the use of novel dual PI3K 
and mTOR catalytic inhibitors, were highly effective at reducing cell viability in the 
BaF3
Pon-Res
 cell model, therefore further strengthening the concept that the 
PI3K/AKT/mTOR pathway may be a potential drug target for BCR-ABL independent TKI 
resistant CML.   
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5 Results (III): Validation of mTOR inhibitors in ponatinib-
resistant cell lines 
 
5.1 Aim and objective 
 
IV. Validation of mTOR inhibitors in ponatinib-resistant cell lines 
 
Although mTOR was not the only target discovered within the drug screen, the positive 
data that was collated from the primary and secondary screen showed that both the 
KCL22
Pon-Res
 and the BaF3
Pon-Res
 cells were highly sensitive to mTOR inhibition. Along 
with the impaired transcriptional response highlighted in the RNA-seq data (figure 3-10), 
as well as the sustained mTOR activity (figure 3-11), all provide a strong rational for 
further investigation into mTOR as a therapeutic target for BCR-ABL-independent TKI-
resistant CML. Therefore, we wanted to gain a deeper understanding of the importance of 
the PI3K/AKT/mTOR pathway’s role in BCR-ABL-independent TKI-resistant CML.  
Initially within the laboratory, we treated the ponatinib-resistant cell lines with clinically 
relevant mTOR inhibitors. As previously described mTORC2 can feed back to AKT to 
further activate mTOR. Therefore, the inhibitors we selected for the assays had slightly 
different targets, to establish whether inhibiting mTOR alone was sufficient to induce cell 
death or if the full PI3K/AKT/mTOR pathway had to be inhibited in order for full response 
to occur (figure 5-1). The inhibitors used included; BKM120, a catalytic inhibitor for class 
IA PI3Ks, rapamycin, a mTORC1 only allosteric inhibitor, AZD8055, acatalytic inhibitor 
that target mTORC1 and mTORC2 complexes of mTOR and NVP-Bez235, a catalytic 
mTOR inhibitor that inhibits both mTOR complexes and also has strong activity against all 
PI3K isoforms (figure 5-1).  By using inhibitors against different proteins within the 
pathway, we were able to establish the best target that would affect cellular survival. 
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Figure ‎5-1: Schematic of the PI3K/AKT/mTOR pathway, downstream of BCR-ABL. It illustrates 
the chosen clinically applicable mTOR inhibitors and their targets. 
 
5.2 Ponatinib resistant CML cells are sensitive to mTOR inhibition  
Preliminary studies tested the efficacy of catalytic inhibitors BKM120 (PI3K), AZD8055 
(mTORC1+2) and NVP-Bez235 (PI3K and mTORC1+2) against the KCL22
Pon-Res
 cell 
model by performing XTT assays and calculating the EC50s The KCL22
Pon-Res
 cells were 
highly sensitive to NVP-Bez235 and AZD8055 treatment. NVP-Bez235 had the greatest 
effect by decreasing proliferation at very low concentrations achieving an EC50 
concentration of 2.22 nM. An EC50 of 28.28 nM was achieved in KCL22Pon-Res cells 
against AZD8055. However, PI3K inhibition alone, by BKM120 required a much higher 
concentration and achieved an EC50 at 1.928 µM. Therefore, mTOR inhibitors are capable 
of reducing cell viability at low concentrations in the KCL22
Pon-Res 
cell model, which 
provides increasing evidence that mTOR is important for TKI-resistant CML cellular 
survival (figure 5-2). 
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Drug EC50 (nM) 
NVP-Bez235 2.22 
AZD8055 28.28 
ponatinib 647.3 
BKM120 1928 
 
Figure ‎5-2: KCL22Pon-Res were seeded at 0.2x106/ mL and treated with the same equimolar 
concentration of drug ranging from 0.01 nM to 10 μM (ponatinib, NVP-Bez235, AZD8055, and 
BKM120).  
Cell viability measured after 72 hours using an XTT assay and EC50 was calculated using graphpad 
prism. 
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5.3 mTOR inhibitors induce apoptosis and reduce CFC output in KCL22Pon-
Res cells 
To further validate the results from the drug screen and the XTT assays we assessed how 
the inhibition of the PI3K/AKT/mTOR survival pathway affected the TKI-resistant cell 
viability following 72 hours of drug treatment by performing apoptosis and long term-
survival assays (figure 5-3). The drug concentrations used in the assay were all clinically 
achievable in patients.  
As expected none of the TKIs, imatinib, nilotinib, dasatinib and ponatinib, had an effect on 
either the induction of apoptotic cell death or the leukaemic colony formation shown from 
CFC assays (Figure 5-3). The efficacy of the panel of mTOR and PI3K inhibitors was 
analysed in parallel. Following the 72 hour drug treatment, rapamycin and BKM120 had 
exerted a very minimal effect on the overall survival of the KCL22
Pon-Res
 cells. However, 
treatment with the mTORC1 and mTORC2 inhibitor AZD8055 and dual inhibitor, NVP-
Bez235, induced apoptosis by 25 and 30%, respectively (Figure 5-3). Although AZD8055 
reduced leukaemic colony formation by 50%, NVP-Bez235 had the most significant effect 
and was able to reduce leukaemic colony forming potential by approximately 66% (Figure 
5-3). The efficiency of NVP-Bez235 of inhibiting the PI3K/AKT/mTOR pathway 
highlights the importance of a complete inhibition of this pathway to switch off pro-
survival signals. Complete inhibition of mTOR signalling by NVP-BEZ235 provided a 
much more effective treatment against BCR-ABL-independent TKI-resistant CML cells. 
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Figure ‎5-3: KCL22Pon-Res were seeded at 0.25x106/ mL and treated with 2 μM imatinib, 2 μM 
nilotinib, 150 nM dasatinib, 100 nM ponatinib, 10 nM rapamycin, 500nM BKM120, AZD8055, 
100 nM NVP-Bez235, 100 nM.  
The percentage of apoptosis and the colony forming potential were measured following a 72 hour 
drug treatment. The numbers are presented as mean±SEM (n=3). Statistical analysis was 
performed by using paired t-test. Annotation above a bar refers to statistical significance between 
the bar and the untreated control. (**; p≤0.01, ***; p≤0.001) 
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5.4 KCL22Pon-Res cells are highly sensitive to catalytic PI3K and mTOR 
inhibitors  
Due to the success of the NVP-Bez235 compound against TKI-resistant cells in our in vitro 
studies, we wanted to validate the NVP-Bez235 effect by testing a further three clinically 
relevant catalytic dual PI3K and mTOR inhibitors against the KCL22
Pon-Res 
cells. The three 
new inhibitors are; gedatolisib, apitolisib and VS-5584. All of these inhibitors are currently 
undergoing investigation in phase I and II clinical trials against numerous blood and solid 
tumour cancers (table 5-1). Efficacy of these new inhibitors were first tested by XTT 
assays to gain an understanding of the drug concentration needed to produce half the 
maximal effective concentration (EC50) (figure 5-4). As it was seen NVP-Bez235, 
KCL22
Pon-Res 
cells were highly sensitive to all of the catalytic PI3K and mTOR inhibitors. 
All the EC50s achieved were comparable to that of NVP-Bez235 (EC50: 2.15 nM), 
gedatolisib; EC50: 0.168 nM, VS-5584; EC50: 1.742 nM and apitolisib; EC50: 29.15 nM. 
All the inhibitors exerted their inhibitory effects at very low concentration.  
Using low nM concentrations of the inhibitors; gedatolisib, apitolisib and VS-5584, and 
treating the KCL22
Pon-Res
 cells for 72 hours, a significant amount of apoptosis was induced 
above the untreated cells for all PI3K and mTOR inhibitors. Additionally, VS-5584 and 
more so NVP-Bez235 and gedatolisib were able to significantly increase apoptotic death of 
KCL22
Pon-Res 
cells above treatment with TKI, ponatinib 18, 35 and 38% respectively 
(figure 5-5). In order to validate the mode of action of the catalytic PI3K and mTOR 
inhibitors in the KCL22
 
cells, we treated the KCL22
WT 
and KCL22
Pon-Res 
cells with 100 nM 
ponatinib, as a control, 100 nM NVP-Bez235 and 100 nM gedatolisib and analysed mTOR 
signalling, through RPS6 phosphorylation and BCR-ABL signalling via the 
phosphorylation of CRKL. This showed that in TKI sensitive, KCL22
WT
 cells that 
ponatinib switches off BCR-ABL signalling (no phosphorylated CRKL), which 
subsequently switches off downstream pathway PI3K/AKT/mTOR signalling, shown by 
the absence of phosphorylated RPS6. This is the part of the mechanism that induces cell 
death in TKI-sensitive cells. However, in the KCL22
Pon-Res 
cells, ponatinib inhibits BCR-
ABL (no phosphorylated CRKL), but mTOR signalling is still present, RPS6 is 
phosphorylated and the cells continue to survive and proliferate. Treatment of both the 
KCL22
WT 
and KCL22
Pon-Res 
cells with NVP-Bez235 and gedatolisib completely inhibits 
mTOR signalling, as shown by the absence of phosphorylated RPS6. The complete 
inhibition of this pathway in the KCL22
Pon-Res
 leads to high levels of cellular death as seen 
in the apoptosis assay (figure 5-5). Therefore, further strengthening the importance of the 
PI3K/AKT/mTOR pathway for KCL22
Pon-Res
 cell survival. As NVP-Bez235 is the most 
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highly investigated catalytic dual PI3K and mTOR inhibitor currently on the market and 
the efficacy seen in the in vitro thus far, we focus on this compound in our experiments for 
the remainder of the study.  
 
 
Figure ‎5-4: KCL22Pon-Res were seeded at 0.2x106/ mL and treated with the same equimolar 
concentration of drug ranging from 0.01 nM to 10 μM (gedatolisib, VS-5584, NVP-Bez235, 
apitolisib, and ponatinib). Colour coded by Table 5-1. 
 Cell viability measured after 72 hours using an XTT assay. 
 
Drug Company EC50 (nM) 
Phase I Clinical  
Trials 
Phase II Clinical  
Trials 
gedatolisib Pfizer 0.168 4 1 
VS-5584 Verastem 1.742 2 - 
NVP-Bez235 Novartis 2.15 10 5 
apitolisib Genentech 29.15 8 4 
ponatinib Ariad 647.3 
  
Table ‎5-1: Clinically applicable dual PI3K and mTOR inhibitors. The drug name, name of 
pharmaceutical company developing the drug, EC50 (nM) in KCL22Pon-Res cells calculated by 
graphpad from (figure 5-4) and the number of phase I and II clinical trials the drug is currently 
involved in. as shown on clinicaltrials.gov.  
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Figure ‎5-5: KCL22Pon-Res were seeded at 0.25x106/ mL and treated with 100 nM ponatinib, 100 
nM apitolisib, 100 nM VS-5584, 100 nM NVP-Bez235, 100 nM gedatolisib for 72 hours. 
Following treatment, the level of apoptosis induced was analysed by flow cytometry. The 
histogram represents early and late apoptosis and numbers are presented as mean±SEM (n=3). 
Statistical analysis was performed by using paired t-test. Annotation above a bar refers to 
statistical significance between the bar and the untreated control  (*;p≤0.05, **; p≤0.01, ***; 
p≤0.001). 
 
Figure ‎5-6: KCL22WT and KCL22Pon-Res were seeded at 0.25x106/mL and treated with and 100 nM 
ponatinib, 100 nM NVP-Bez235 or 100 nM gedatolisib for 24 hours.  
Western blot analysis assessed the activity of BCR-ABL shown by phosphorylation of CRKL and 
mTOR activity shown by the phosphorylation of RPS6.  
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5.5 BaF3Pon-Res cells are highly sensitive to NVP-Bez235 
The efficacy of dual PI3K and mTOR inhibitor; NVP-Bez235 was validated in the 
BaF3
Pon-Res
 cell model.  Previous experiments showed that NVP-Bez235 was the most 
effective mTOR drug against KCL22
Pon-Res
 cells, which is likely due to inhibition of both 
mTOR complexes and PI3K. This should inhibit any regulatory feedback loops within the 
pathway and results in a complete inhibition of PI3K/AKT/mTOR signalling. 
In order to gain further insight into the NVP-Bez235 effect on BaF3
Pon-Res
 cell viability an 
XTT assay was performed and EC50s calculated. This experiment was performed on both 
the original BaF3
WT 
and BaF3
Pon-Res
 cells to establish whether sensitivity to mTOR 
inhibition was a trait gained in the generation of the ponatinib-resistant cell line, or if the 
original BaF3
WT 
cells, which are TKI sensitive, were also sensitive to NVP-Bez235 
treatment. As shown previously, BaF3
WT 
cells were highly sensitive to ponatinib treatment 
with an EC50 of 0.0002 nM and the BaF3
Pon-Res
 cells were much more resistant with on 
EC50 for of 1.598 µM (figure 5-7). The BaF3
WT 
cells also showed some sensitivity to 
NVP-Bez235 treatment, however NVP-Bez235 (EC50:0.24 nM) was not as effective as 
ponatinib (EC50:0.0002 nM) (figure 5-7 and 3-5). 
Most importantly, BaF3
Pon-Res
 cells retain their sensitivity to the NVP-Bez235 compound 
with an EC50: 8.971 nM compared to 1.598 µM with ponatinib, which is an unachievable 
concentration for patient treatment. The increased concentration of NVP-Bez235 needed to 
achieve an EC50 increased from 0.24 nM in BaF3
WT 
cells to 8.971 nM in BaF3
Pon-Res
 cells, 
which may imply increased activation of mTOR signalling in the BaF3
Pon-Res
 cells.  
In parallel with the XTT assay, following 72 hours of treatment, NVP-Bez235 also induced 
a considerable amount of apoptosis in both BaF3
WT 
cells and BaF3
Pon-Res
 cells of 70 and 
60%, respectively. The original BaF3
WT 
cells remain most sensitive to TKI treatment, due 
to their BCR-ABL dependency. Apoptosis levels achieved with imatinib were 45%, 
dasatinib 78% and ponatinib 75%. The BaF3
Pon-Res
 cells lost their sensitivity to all TKIs 
tested as the level of apoptosis achieved was equal or less than the untreated cells (figure 5-
8). However, the BaF3
Pon-Res
 cells retained their sensitivity to the inhibition of 
PI3K/AKT/mTOR.  
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Cell Type Drug 
EC50 
(nM) 
BaF3
Parental
 NVP-Bez235 4.9 35 
BaF3
WT
 NVP-Bez235 0.2435 
BaF3
Pon-Res
 NVP-Bez235 8.971 
 
Figure ‎5-7: (a) BaF3WT and BaF3Pon-Res were seeded at 0.2x106/ mL and treated with the same 
equimolar concentration of drug ranging from 0.01 nM to 10 μM (ponatinib and NVP-Bez235. 
Cell viability measured after 72 hours using an XTT assay and (b) EC50 was calculated using 
graphpad prism. 
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Figure ‎5-8: BaF3WT and BaF3Pon-Res were seeded at 0.25x106/ mL and treated with 2µM imatinib, 
150 nM dasatinib, 100 nM ponatinib or 100 nM NVP-Bez235.  
The percentage of apoptosis was measured following a 72 hour drug treatment. The histogram 
represents early and late apoptosis and numbers are presented as mean±SEM (n=3). Statistical 
analysis was performed by using paired t-test. Annotation above a bar refers to statistical 
significance between the bar and the untreated control (***; p≤0.001). 
 
5.6 KCL22Pon-Res cells transcriptional response is restored upon NVP-Bez235 
treatment 
To gain further insight into how mTOR inhibition induces cell death in BCR-ABL-
independent TKI-resistant CML we performed RNA-seq using KCL22
WT 
and KCL22
Pon-Res 
cells. The cells were treated with 100 nM NVP-Bez235 with or without the combination of 
100 nM ponatinib for 24 hours, to switch off mTOR and BCR-ABL signalling. Inhibition 
of BCR-ABL by ponatinib treatment had no effect on the KCL22
Pon-Res 
cells 
transcriptionally (figure 3-10), however, treatment with NVP-Bez235 caused a large 
number of transcriptional changes in genes up-regulated and down-regulated, similar to 
that number of the number of genes regulated in the KCL22
WT
 cells following ponatinib 
treatment (figure 5-9).  
Of the 5 genes which were upregulated in response to ponatinib treatment, all 5 overlapped 
with the response to NVP-Bez235 treatment, which may imply these transcriptional 
changes were not ponatinib mediated BCR-ABL inhibition specific and occur in the 
response to any drug treatment or are artifacts from the experimental method. 
However, the combination treatment of NVP-Bez235 and ponatinib did not enhance the 
NVP-Bez235 effect, as seen in the volcano plot (figure 5-9). The Venn diagram shows that 
1039 (~88%) genes from the NVP-Bez235 only and the combination treatment overlap 
(figure 5-9), with only just over 10% of genes being upregulated by NVP-Bez235 
treatment alone and 10% with the combination treatment.  
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Figure ‎5-9: A volcano plot showing the fold changes in gene expression patterns in KCL22Pon-Res 
cells following 24 hour NVP-Bez235 treatment or a combination treatment of NVP-Bez235 and 
ponatinib, down-regulated genes in green and up-regulated genes in pink.  
Venn diagram showing the differential gene expression changes between 3 scenarios; KCL22Pon-Res 
cells following 24 hour ponatinib treatment, KCL22Pon-Res cells following 24 hour NVP-Bez235 
treatment and KCL22Pon-Res cells following a 24 hour combination treatment of NVP-Bez235 and 
ponatinib.  
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In a comparison between KCL22
WT 
cells treated with ponatinib and KCL22
Pon-Res 
cells 
treated with NVP-Bez235, the majority of transcription changes that occurred in the 
KCL22
WT 
cells following ponatinib mediated BCR-ABL inhibition also occurred in the 
KCL22
Pon-Res 
cells following NVP-Bez235 mediated mTOR inhibition. Although more 
transcriptional changes occurred following NVP-Bez235 treatment in KCL22
Pon-Res 
cells, 
the proportion of overlap implies that NVP-Bez235 triggers a similar transcriptional 
response as ponatinib does in TKI sensitive cells (figure 5-10). This was corroborated by 
statistical analysis of the linear correlation between gene expression changes in ponatinib 
treated KCL22
WT
 and the NVP-Bez235 treated KCL22
Pon-Res
 cells. This showed a 
correlation (r) = 0.78, which means there was a meaningful positive linear association that 
was statistically significant. Again the importance of mTOR was highlighted in CML when 
further analysis showed that KCL22
WT
 cells treated with NVP-Bez235 had a very similar 
transcriptional response as ponatinib treated KCL22
WT
 and the NVP-Bez235 treated 
KCL22
Pon-Res
 cells (figure 5-10), further demonstrating that targeting mTOR downstream 
of BCR-ABL can rescue the impaired transcription response seen in TKI-resistant cells 
following TKI treatment. Analysis of the KCL22
Pon-Res 
cells treated with both NVP-Bez235 
and ponatinib revealed very few additional gene changes compared to the NVP-Bez235 
only treated cells.  (figure 5-11) (Bioinformatics performed by Graham Hamilton and Lisa 
Hopcroft). 
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Figure ‎5-10: (a) Venn diagram showing the differential gene expression changes between 
KCL22WT following 24 hour ponatinib treatment and KCL22Pon-Res cells following 24 hour NVP-
Bez235 treatment and (b) Relative correlation comparison of log changes in gene expression. 
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Figure ‎5-11: Venn diagram showing the comparison of the differential gene expression changes 
between KCL22WT following 24 hour ponatinib treatment, KCL22WT following 24 hour NVP-
Bez235 treatment and KCL22Pon-Res cells following 24 hour NVP-Bez235 treatment. 
As many of the transcriptional changes that occurred in the KCL22
WT 
cells treated with 
ponatinib also occurred in the KCL22
Pon-Res 
cells treated with NVP-Bez235, we were 
interested to establish whether the same pathways were being induced by NVP-Bez235 in 
the KCL22
Pon-Res 
cells as ponatinib did in the KCL22
WT 
cells. 
Gene ontology enrichment analysis was performed, in which the genes of interest are 
assigned to predefined biological processes depending on their functional characteristics. 
Of the transcriptional changes that occurred in the KCL22
WT 
cells treated with ponatinib, 
which also over lapped with the KCL22
Pon-Res
 treated with NVP-Bez235 only 6 biological 
processes were significantly up-regulated. These processes were involved in apoptosis, 
DNA damage repair and cellular response to stress. These biological processes are all 
pathways expected to be induced following cytotoxic drug treatment. However, 54 
additional biological processes that were up-regulated only in the KCL22
Pon-Res 
cells treated 
with NVP-Bez235, which were processes associated with protein translation and 
metabolism (Table 5-2). The induction of these processes would be expected due to the 
NVP-Bez235 mediated inhibition of mTOR. The difference in biological processes 
upregulated in the two different cell lines seems heavily dependent on the MOA of the 
drugs; ponatinib and NVP-Bez235, as TKIs and mTOR inhibitors have different targets. 
Although, TKIs do inhibit mTOR indirectly, which may account for the lack of differential 
biological processes upregulated in the KCL22
WT 
cells treated with ponatinib compared to 
the KCL22
Pon-Res 
cells treated with NVP-Bez235. The additional biological processes 
enriched in the KCL22
Pon-Res 
cells treated with NVP-Bez235 must be mTOR inhibition 
specific. 
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Sample  Biological Processes 
KCL22
WT
+PON 
and 
KCL22
Pon-Res
+Bez 
Execution phase of apoptosis                                     
Cellular component disassembly involved in the execution of 
apoptosis 
Double-strand break repair via homologous 
recombination                
Recombinational repair                                               
DNA repair                                                              
Cellular response to stress   
KCL22
Pon-Res
+Bez Nuclear-transcribed mRNA catabolic process, nonsense-
mediated decay 
Translational elongation                                           
Protein localization to endoplasmic reticulum                    
Translational termination                                          
Establishment of protein localization to endoplasmic 
reticulum      
Cotranslational protein targeting to membrane                       
SRP-dependent cotranslational protein targeting to 
membrane         
Protein targeting to ER                                            
Translational initiation                                            
Protein targeting to membrane                                      
Nuclear-transcribed mRNA catabolic process                          
mRNA catabolic process                                              
Viral gene expression                                              
Cellular protein complex disassembly                                
Multi-organism metabolic process                                    
Viral transcription                                                 
Amide biosynthetic process                                         
Translation                                                         
Peptide biosynthetic process                                        
RNA catabolic process                                              
Protein complex disassembly                                        
Peptide metabolic process                                           
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Establishment of protein localization to membrane                   
Macromolecular complex disassembly                                  
Establishment of protein localization to organelle                  
Cellular amide metabolic process                                    
Protein transport                                                  
Protein localization                                               
Protein targeting                                                  
Protein localization to organelle                                   
Organonitrogen compound biosynthetic process                        
Macromolecule localization                                          
Viral life cycle                                                    
Protein localization to membrane                                   
Organic substance transport                                         
Establishment of protein localization                              
Protein complex subunit organization                               
Cytoplasmic transport                                               
Intracellular protein transport                                     
Membrane organization                                               
Single-organism membrane organization                               
Nucleobase-containing compound catabolic process                    
Aromatic compound catabolic process                                 
Heterocycle catabolic process                                      
Organic cyclic compound catabolic process                          
Single-organism cellular localization                               
Cellular nitrogen compound catabolic process                        
Cellular protein localization                                      
Cellular macromolecule localization                                 
Cytoplasmic translation                                             
Macromolecular complex subunit organization                         
Cellular localization                                               
Establishment of localization in cell                               
Transport      
Table ‎5-2: A list of the different biological processes that occur in KCL22Pon-Res cells following 24 
hour NVP-Bez235 treatment and KCL22WT following 24 hour ponatinib treatment obtained from 
the gene ontology enrichment analysis. 
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5.7 Key findings 
In this chapter we tested clinically relevant PI3K and mTOR inhibitors against ponatinib 
resistant cell lines to establish the most effective drug target against this pathway. We 
tested several different inhibitors including,  BKM120, a catalytic inhibitor for class IA 
PI3Ks, rapamycin, a mTORC1 only allosteric inhibitor, AZD8055, a catalytic inhibitor that 
targets mTORC1 and mTORC2 complexes of mTOR and NVP-Bez235, a catalytic mTOR 
inhibitor that inhibits both mTOR complexes and also has strong activity against all PI3K 
isoforms (figure 5-1).  
Through different types of cell viability assays we identified the catalytic dual PI3K and 
mTOR inhibitor, NVP-Bez235 as the most effective drug at inducing apoptosis and 
reducing cell viability in ponatinib resistant CML cells. This was validated by testing a 
further three clinically relevant dual PI3K and mTOR inhibitors; gedatolisib, apitolisib and 
VS-5584. Both NVP-Bez235 and gedatolisib induced significant amounts of apoptosis in 
the KCL22
Pon-Res 
cells and despite not effecting BCR-ABL signalling they did switch off 
mTOR signalling, which we saw with the inhibition of phosphorylated RPS6 by western 
blotting.  
Also, importantly we show through RNA-seq analysis that a transcriptional response is 
restored in the KCL22
Pon-Res 
cells upon treatment with NVP-Bez235 and that this response 
to mTOR inhibition caused very similar gene transcription changes as ponatinib does to 
TKI sensitive CML cells, KCL22
WT
 cells. The data from this chapter thereby, increases the 
evidence that the PI3K/AKT/mTOR pathway is important for BCR-ABL independent TKI 
resistant CML cell survival.   
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6 Results (IV): Validation of mTOR inhibitors in primary TKI-
resistant CML cells 
 
6.1 Aim and objective 
 
V. Validation of mTOR inhibitors in primary TKI-resistant CML cells. 
 
6.2 MNCs derived from TKI-resistant CML patients are sensitive to NVP-
Bez235-mediated mTOR inhibition ex vivo 
 
In order to test the predictive value of our cell line model we investigated whether mTOR 
inhibition would also target CML cells from patients known to have BCR-ABL-
independent TKI-resistant CML. To do this, bone marrow was collected from three 
patients who had failed to achieve a CCyR despite treatment with 1
st
, 2
nd
 and 3
rd
 generation 
TKIs. The MNCs were extracted from the samples and the effects of TKIs and catalytic 
mTOR inhibitors were analysed. The cells were treated with the TKIs imatinib or ponatinib, 
and mTOR inhibitors; AZD8055, BKM120 and NVP-Bez235 for 72 hours and apoptosis 
and the colony forming potential of progenitor cells were analysed.  
Importantly, mTOR inhibition mediated by treatment with AZD8055 and more potently 
NVP-Bez235 had a significant effect on the survival of the progenitor cells from these 
patients. In all 3 patients NVP-Bez235 caused an induction of apoptosis, which was 
increased by 12-22% above that of untreated or TKI treated cells. The most dramatic 
results were seen in the reduction in the potential of colony formation following drug 
treatment.   
 
Although the patients have been clinically diagnosed as TKI-resistant and have failed to 
achieve a CCyR with ponatinib treatment, as there are no alternative treatments the patients 
are currently being treated with ponatinib, which has at least enabled a haematological 
response. The partial response to ponatinib may explain the slight reduction in colony 
formation in the cells treated with TKIs imatinib and ponatinib. However, NVP-Bez235 
mediated mTOR inhibition had the greatest affect at reducing colony numbers. 
NVP-Bez235 treatment on MNCs derived from TKI-resistant CML patients 1 and 3 
significantly reduced colony formation by 63 and 88%, respectively. Data from patient 1 
also showed a significant decrease, 83%, in colony numbers compared to ponatinib 
treatment (figure 6-1). The data from the two different cell lines and more importantly the 
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patient samples demonstrate just how important the PI3K/AKT/mTOR pathway is for TKI-
resistant CML cellular survival.  
 
Figure ‎6-1:Bone marrow and peripheral blood derived MNCs from TKI-resistant CML patients 
were cultured in SFM supplemented with physiological growth factors.  
Cells were treated with 2 uM imatinib, 100 nM ponatinib and 100 nM NVP-Bez235 and the 
apoptosis and colony forming potential we were measured following a 72 hour drug treatment. 
n=2 patients. The histogram numbers are presented as mean±SEM. Statistical analysis was 
performed by using paired t-test. Annotation above a bar refers to statistical significance between 
the bar and the untreated control (*;p≤0.05, **; p≤0.01, ***; p≤0.001). 
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Clinical patient information 
Patient 
1 
Resistant to two TKIs. The patient was 
ponatinib naïve at the time the sample was 
taken, with no known kinase domain 
mutation 
Patient 
2 
No response to imatinib. Dasatinib started 
2006. Ponatinib since 2011 (PACE trial). No 
CCyR or MMR on ponatinib. 
Patient 
3 
Dasatinib and nilotinib failure. Achieved 
CHR but no CYR on ponatinib. 
Patient 
4 
CHR but not CyR on imatinib. Dasatinib 
started 2007. BCR-ABL 16% in July 2013. 
 
Table ‎6-1: Clinical patient informations. Details of prior treatments, clinical trials and treatment 
responses. 
6.3 Ponatinib is an effective treatment against BCR-ABL-dependent TKI-
resistant CML cells  
To allow us to compare treatment regimens between patients harbouring a BCR-ABL-
dependent mechanism of TKI-resistant CML or patients with a BCR-ABL-independent 
mechanism of TKI-resistant CML, we collected bone marrow samples from two patients, 
clinically confirmed to have the BCR-ABL T315I mutation. These patients therefore have 
a BCR-ABL-dependent mechanism of TKI-resistant CML. These cells were treated with 
TKIs; dasatinib or ponatinib and mTOR inhibitor, NVP-Bez235 for 72 hours or 6 days. 
Following drug treatment, the cells were assessed for the induction of apoptosis and their 
colony forming potential in a CFC assay. As expected 2
nd
 generation TKI, dasatinib had no 
effect on the T315I samples, as the drug is not able to bind and inhibit BCR-ABL. 
However, ponatinib, which was designed to target CML cells with the BCR-ABL T315I 
mutation, induced apoptosis by 10% within 72 hours and to 20% after 6 days of treatment. 
mTOR inhibition by NVP-Bez235 treatment induced a similar apoptotic response and 
reduction in colony formation to ponatinib. However, although the response to ponatinib 
and NVP-Bez235 was similar in both samples, the treatment with ponatinib was more 
significant statistically, which highlights that TKIs are the most effective treatment for 
patients suffering from a BCR-ABL-dependent form of TKI-resistant CML. 
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Figure ‎6-2: Bone marrow and peripheral blood derived MNCs from CML patients carrying the 
T315I mutation. 
The cells were cultured in SFM supplemented with physiological growth factors and treated with 
150 nM dasatinib, 100 nM ponatinib and 100 nM NVP-Bez235 and the apoptosis and colony 
forming potential we were measured following a 72 hour or 6 days of drug treatment. n=2 
patients. The histogram numbers are presented as mean±SEM. Statistical analysis was performed 
by using paired t-test. Annotation above a bar refers to statistical significance between the bar 
and the untreated control (*;p≤0.05, **; p≤0.01, ***; p≤0.001). 
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6.4 Ponatinib treatment causes different transcriptional responses in TKI 
sensitive CML, T315I CML and BCR-ABL-independent TKI-resistant CML 
 
Access to primary samples gave us a cellular tool to investigate BCR-ABL-independent 
mechanisms of TKI-resistant in current patients CML cells. Although the experiments are 
performed in an ex vivo environment the response would much closer mimic what happens 
to CML cells in patients. However due to the rarity and limited size of these samples we 
were restricted in the type of experiments that could be conducted. However, one screening 
method which was possible was RNA-seq. By performing RNA-seq this allowed us to 
identify potential gene transcriptional changes which may enable us to decipher potential 
mechanism(s) of BCR-ABL-independent TKI resistance. We performed this experiment by 
analysing 3 different CML patient groups (1) TKI sensitive, (2) BCR-ABL-dependent 
TKI-resistant; T315I mutation, (3) BCR-ABL-independent TKI-resistant. Bone marrow 
was collected from these patients and the MNCS were isolated. The cells were untreated or 
ponatinib treated for 24 hours to switch off BCR-ABL signalling and subsequently RNA 
was generated from the samples. BCR-ABL was switched off in the different sample types 
to gain an understanding what additional transcriptional changes, if any, occur in the BCR-
ABL-independent TKI-resistant samples to allow the continued survival and proliferation 
despite BCR-ABL inhibition. Three samples were obtained from each patient group, 
except T315I patients, which has two. Analysis of the gene transcriptional changes from 
the 3 groups showed subtle changes in all groups. The volcano plots for each of the three 
groups showed very low magnitude fold changes in genes up-regulated and down-
regulated (figure 6-2). Gene transcription changes were then compared in all 3 groups 
following ponatinib mediated BCR-ABL inhibition. This revealed that the response in each 
group was vastly different, with the majority of gene changes occurring being specific to 
that patient group, with very little overlap between each group (figure 6-3). Although only 
a low magnitude of gene expression changes occurred in the CML TKI-resistant cells, the 
level of transcriptional response was comparable to the ponatinib sensitive cells; CML TKI 
sensitive and CML T315I samples, which was inconsistent with the cell line data which 
showed KCL22
Pon-Res
 cells have an impaired transcriptional response following 24 hour 
ponatinib treatment (figure 3-10). 
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Figure ‎6-3: Volcano plots showing the fold changes in gene expression patterns in TKI sensitive 
CML cells, BCR-ABL-independent TKI-resistant CML cells and T315I CML cells following 24 hour 
ponatinib treatment, down-regulated genes (left) and up-regulated genes (right). 
 
 
 
 
Figure ‎6-4: Venn diagram showing the differential gene expression changes between TKI 
sensitive CML cells, BCR-ABL-independent TKI-resistant CML cells and T315I CML cells following 
24 hours ponatinib treatment. Genes up-regulated in red and genes down-regulated in green. 
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Despite the disparity in the transcriptional changes between groups gene ontology 
enrichment analysis was performed to assess whether there was an overlap in the 
biological processes regulated in the cells following ponatinib treatment.  
Analysis of gene ontology from data gathered from the BCR-ABL-independent TKI-
resistant CML cell samples significantly upregulate many biological processes following 
ponatinib treatment. These processes included multicellular processes, cell to cell 
signalling, signal transduction, G-coupled receptor signalling, ion transportation and cell 
adhesion. Also one of the processes was ‘response to stimulus’ which implies the cells may 
sense the cytotoxic ponatinib treatment, but have the mechanisms to overcome treatment 
and evade cell death (figure 6-4). 
To understand if TKI-resistant CML cells upregulated different biological processes for 
their survival against TKI a comparison was made between TKI sensitive CML and TKI-
resistant CML following ponatinib treatment. This revealed that the majority of biological 
processes that are activated in the TKI-resistant cells are also activated TKI sensitive CML 
group. Only four biological processes differed despite the differences in gene transcription 
between the two sample groups (figure 6-5 and table 6-2).  However, the TKI-resistant 
CML group had 35 biological processes that were regulated that were not used by the TKI 
sensitive CML sample group, these additional processes may account for the survival of 
the TKI-resistant CML cells. 
In order to identify the differences between a BCR-ABL-dependent TKI-resistant cells and 
BCR-ABL-independent TKI-resistant cells, the same comparison was made between the 
CML T315I group and the TKI-resistant CML following ponatinib treatment. This analysis 
revealed that 22 biological processes were regulated in the CML T315I group that were 
different to the TKI-resistant CML group. These biological processes included; growth 
factor activity, locomotion, movement of cell or subcellular component, differentiation, ion 
transport and regulation of cell proliferation. Similarly, 22 biological processes were 
regulated in the TKI-resistant CML group in response to ponatinib that differed from the 
CML T315I group. These included; antigen binding, cellular response to stimulus, G-
protein coupled receptor binding, G-protein coupled receptor signalling pathway, ligand-
gated ion channel activity, positive regulation of cell adhesion, regulation of ion transport, 
regulation of localization, regulation of secretion and signal transduction. Therefore, 
implying that mechanistically the biological processes used by the CML T315I (BCR-
ABL-dependent TKI-resistant cells and TKI-resistant CML (BCR-ABL-independent TKI-
resistant cells) are vastly different, although small similarities did occur, grey dots in 
(figure 6-6 and table 6-3). 
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Although small changes had occurred between the patient groups, the low magnitude of 
transcriptional changes and the level of disparity have left the results from these 
experiments inconclusive. This is most possibly due to the cell heterogeneity within the 
MNC population, which has “masked” the effect of the TKI treatment. 
 
 
 
Figure ‎6-5: Gene ontology enrichment of the biological processes that occur in KCL22Pon-Res cells 
following 24 hour NVP-Bez235 treatment. 
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Figure ‎6-6: A dot plot showing the functional response to ponatinib in CML TKI sensitive versus 
CML TKI-resistant cells.  
The dots represent a biological response either specifically upregulated in the CML TKI sensitive 
cells (green) or specifically upregulated in the CML TKI-resistant cells (blue), which occur in TKI 
sensitive CML and not BCR-ABL-independent TKI-resistant CML following 24 hour ponatinib 
treatment. 
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CML TKI Sensitive + PON 
Biological  Processes 
Neurological System Process 
Response to Lipid 
Sensory Perception 
System Process 
CML TKI Resistant + PON 
Biological  Processes 
Anatomical Structure Development 
Antigen Binding 
Biological Adhesion 
Cation Channel Activity 
Cation Transport 
Cell Adhesion 
Cell Communication 
Cell-Cell Adhesion 
Cellular Response to Interferon-Gamma 
Cellular Response to Stimulus 
Channel Activity 
G-Protein Coupled Receptor Activity 
G-Protein Coupled Receptor Binding 
G-Protein Coupled Receptor Signaling Pathway 
Hormone Activity 
Ligand-Gated Channel Activity 
Ligand-Gated Ion Channel Activity 
Metal Ion Transmembrane Transporter Activity 
Metal Ion Transport 
MHC Class Ii Receptor Activity 
Multicellular Organismal Development 
Passive Transmembrane Transporter Activity 
Positive Regulation of Cell Adhesion 
Positive Regulation of Cell-Cell Adhesion 
Receptor Binding 
Regulation of Cell-Cell Adhesion 
Regulation of Ion Transport 
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Regulation of Localization 
Regulation of Multicellular Organismal Process 
Response to Stimulus 
Signal Transducer Activity 
Signal Transduction 
Signaling 
Single Organism Signaling 
Single-Organism Process 
Synaptic Transmission 
Table ‎6-2: A differential  list of the biological processes for CML TKI sensitive treated with 
ponatinib  (green) and TKI-resistant CML  treated with ponatinib (blue). 
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Figure ‎6-7: A dot plot showing the functional response to ponatinib in CML T315I versus CML 
TKI-resistant cells.  
The dots represent a biological response either specifically upregulated in the CML T315I cells 
(light blue) or specifically upregulated in the CML TKI-resistant cells (blue), which occur in TKI 
sensitive CML and not BCR-ABL-independent TKI-resistant CML following 24 hour ponatinib 
treatment. 
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CML T315I + PON 
Biological Processes 
Anatomical Structure Morphogenesis 
Blood Circulation 
Circulatory System Process 
Developmental Process 
Generation of Neurons 
Growth Factor Activity 
Locomotion 
Movement of Cell or Subcellular Component 
Myotube Differentiation 
Nervous System Development 
Neurogenesis 
Neurological System Process 
Neuron Differentiation 
Organ Morphogenesis 
Positive Regulation of Developmental Process 
Positive Regulation of Multicellular Organismal Process 
Potassium Ion Transport 
Regulation of Cell Proliferation 
Response to Retinoic Acid 
Response to Wounding 
Single-Organism Developmental Process 
System Process 
CML TKI Resistant + PON 
Biological Processes 
Antigen Binding 
 Cation Transport 
 Cell-Cell Adhesion 
 Cellular Response to Interferon-Gamma 
 Cellular Response to Stimulus 
 G-Protein Coupled Receptor Binding 
 G-Protein Coupled Receptor Signaling Pathway 
 Hormone Activity 
 Ligand-Gated Channel Activity 
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 Ligand-Gated Ion Channel Activity 
 Metal Ion Transmembrane Transporter Activity 
 Metal Ion Transport 
 Negative Regulation of Secretion 
 Positive Regulation of Cell Adhesion 
 Positive Regulation of Cell-Cell Adhesion 
 Regulation of Cell-Cell Adhesion 
 Regulation of Ion Transport 
 Regulation of Localization 
 Regulation of Secretion 
 Regulation of Secretion by Cell 
 Signal Transduction 
 Synaptic Transmission 
Table ‎6-3: A differential  list of the biological processes for CML T315I treated with ponatinib  
(light blue) and TKI-resistant CML  treated with ponatinib (blue). 
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6.5 mTORC1 inhibition induces protective autophagy in KCL22Pon-Res cells  
As discussed previously, mTORC1 not only regulates translation, but is also the main 
regulator of the catabolic process, autophagy.  mTORC1 is a negative regulator of 
autophagy in nutrient rich conditions, however in stressful conditions such as nutrient 
deprivation or following drug stress, autophagy can be induced as a protective mechanism 
for the cell to evade cell death. The induction of protective autophagy has been observed in 
CP CML CD34
+
 cells as a mechanism to evade drug treatment, which leads to drug 
resistance (Bellodi et al., 2009). Therefore, we asked the question whether NVP-Bez235 
would induce protective autophagy in TKI-resistant CML cells (figure 6-7).  
 
 
 
Figure ‎6-8: Schematic of the PI3K/AKT/mTOR pathway, downstream of BCR-ABL and mTORC1’s 
regulation of autophagy.  
This illustrates our hypothesis that NVP-Bez235 may induce autophagy due to the inhibition of 
mTORC1. This may in turn provide opportunities to further sensitise cells to NVP-Bez235 using 
HCQ, a late stage autophagy inhibitor. 
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6.6 NVP-Bez235 mediated mTOR inhibition induces autophagy in 
KCL22Pon-Res cells 
The assessment of autophagy induction can be hard to interpret, however previously in our 
laboratory a cellular tool was developed to help us assess the effects of autophagy flow. 
KCL22
Pon-Res
 cell line that stably expressed fluorescently tagged human LC3B-II, mRFP-
GFP-LC3B enables the visualization of different stages of autophagy by fluorescent 
microscopy (Shunsuke Kimura, 2007). The RFP-GFP signal (red+green=yellow) is 
expressed when the LC3 is bound to the autophagosome. When the autophagy process 
continues and the lysosome binds to the autophagosome the pH is decreased and this 
quenches GFP leaving only an RFP signal (red), which indicates autolysosomes (figure 6-
8). Autophagy flow can be inhibited pharmacologically by HCQ, which prevents the fusion 
of the autophagosome and the lysosome. This leads to an accumulation of autophagosomes 
and therefore a build-up of a yellow fluorescent signal (figure 6-8).  
Using the KCL22
Pon-Res
-RFP-GFP-LC3 cell model to determine if NVP-Bez235 induced 
autophagy, we treated the KCL22
Pon-Res
-RFP-GFP-LC3 cells with 100 nM NVP-Bez235, 
10 µM HCQ and the combination treatment, NVPBez235 and HCQ. Following 24 hours 
treatment the cells were analysed under a fluorescent microscope. The untreated cells 
allowed us to visualise the basal level of autophagy occurring within the KCL22
Pon-Res
 cells 
(figure 6-8). The single treatment of NVP-Bez235 dramatically increased puncta 
expressing a red signal, indicating that a high level of autophagic flow is being completed 
(figure 6-8). HCQ only treatment resulted in the accumulation of yellow puncta, therefore 
providing proof that autophagy can be pharmacologically inhibited in KCL22
Pon-Res
 cells 
(figure 6-8). The combination treatment of NVP-Bez235 and HCQ also resulted in the 
accumulation of yellow puncta. This indicates that NVP-Bez235 mediated inhibition of 
mTORC1 induces autophagy and that protective autophagy can be successfully inhibited 
with combined treatment with HCQ (figure).  
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Figure ‎6-9: Schematic diagram of mRFP-GFP-LC3 system where different stages of autophagy 
can be measured as red+green=yellow puncta indicating autophagosomes and ‘red only’ signal 
indicates autolysosomes.  
KCL22Pon-Res expressing mRFP-GFP-LC3 were treated for 24 hours with 100 nM NVP-Bez235, 10 µM 
HCQ or combination treatment, NVP-Bez235+HCQ. Autophagy flow and inhibition of autophagy 
were visualised using a fluorescent microscope. Image produced by Elaine Allan. 
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6.7 ATG7 knock out mediated autophagy inhibition increases sensitivity of 
KCL22Pon-Res cells to NVP-Bez235 
Next we investigated if autophagy induced by NVP-Bez235 has a protective role following 
drug treatment in TKI-resistant cells. However HCQ is a non-specific autophagy agent and 
has been proposed to affect cancer cells in an autophagy independent manner (Maycotte et 
al., 2012). Therefore, we employed two complimentary approaches; CRISPR-Cas9 and 
RNAi techniques to test if specific inhibition of autophagy could enhance the effects of 
NVP-Bez235 on KCL22
Pon-Res
 cell death. In order to inhibit autophagy, we targeted an 
essential autophagy gene, ATG7, an E1-like enzyme required for the lipidation of LC3B. 
First we generated two CRISPR-Cas9 plasmids containing single guide RNAs specific for 
ATG7 (see methods 2.3.14-15). These plasmids were used to knock out (KO) ATG7 in 
KCL22
Pon-Res
 cells using CRISPR. The level of ATG7 KO was analysed by western blot 
against the ATG7 protein. The complete KO of ATG7 by KO2 and partial KO by KO1 was 
associated with the inhibition of the formation of the lipidated form of LC3, LC3B-II, as 
well as a build-up of the autophagy substrate SQSTM1/p62. The KCL22
Pon-Res
 ATG7 KO 
and the complementary control cells were treated with 100 nM NVP-Bez235, 10 µM HCQ 
and the combination treatment. As the KCL22
Pon-Res
 ATG7 KO cells already had autophagy 
fully inhibited no effect was seen with the treatment with HCQ (figure 6-9). However, in 
the control cells HCQ caused a build-up of LC3BII, due to the inhibition of 
autophagosome degradation, which was complemented with an increase in SQSTM1/p62 
(figure 6-9). The treatment of both the ATG7 KO cells and the control cells with NVP-
Bez235 led to full inhibition of phosphorylated RPS6 and therefore evidence that NVP-
Bez235 can inhibit mTOR signalling within the KCL22
Pon-Res
 ATG7 KO cell model (figure 
6-9). 
This data was complemented with a secondary assay measuring lipidated LC3BII by flow 
cytometry. The assay washes out cytoplasmic LC3BI and detects membrane bound LC3BII 
by using a fluorescent tagged (FITC) antibody. Flow cytometry detected very low levels of 
FITC fluorescent, which correlates with low levels of LC3BII in ATG7 KO cells. This is 
consistent with the protein expression analysis, which shows that ATG7 KO cells no longer 
have the potential to convert LC3BI to LC3BII, which implies that autophagy has been 
inhibited in these cells (figure 6-10). Low levels of fluorescence were observed with all 
treatment conditions in ATG7 KO cells. In comparison, the control cells, when treated with 
HCQ there is a striking increase in LC3BII as seen with an increase in FITC fluorescence 
(figure 6-10). HCQ inhibits the formation of the autolysosome, which causes a build-up of 
autophagosomes and therefore membrane bound LC3BII (figure 6-10). By using these two 
complimentary assays we can show that autophagy flow is impaired in the ATG7 KO cells. 
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Figure ‎6-10: KCL22Pon-Res cells were lentivirally transduced with a CRISPR v2 vector containing an 
ATG7-targeting sequence or an empty vector control with unconcentrated virus.  
The KCL22Pon-Res cells transduced with the control v2 vector, CRISPR v2 ATG7-1 or CRISPR v2 ATG7-
2 were then treated with 100 nM NVP-Bez235, 10 µM HCQ or the combination for 24 hours. 
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Western blot analysis assessed the level of ATG7 KO achieved and other autophagy associated 
proteins, such as LC3B and p62. The mTOR activity was assessed by the phosphorylation of RPS6. 
 
Figure ‎6-11: The measurement of LC3BII in KCL22Pon-Res ATG7 KO and control cells.  
The KCL22Pon-Res cells were seeded at 0.25x106/mL for 24 hours with the appropriate drug; 100 nM 
ponatinib, 100 nM NVP-Bez235 or 4 hours with 10 µM HCQ. The FlowCellect™ Autophagy LC3 
Antibody-based Assay Kit was performed as per the protocol. FITC fluorescence was detected via 
flow cytometry. Statistical analysis was performed by using paired t-test. Annotation above a bar 
refers to statistical significance between the bar and the untreated control (**; p≤0.01)(n=2). 
 
The generation of a specific autophagy null TKI-resistant CML cell line, KCL22
Pon-Res
 
ATG7 KO cells, provided us with a tool to assess whether the inhibition of autophagy 
enhances the NVP-Bez235 mediated cell death in KCL22
Pon-Res
 cells. The KCL22
Pon-Res
 
ATG7 KO cells and the control cells were treated with 100 nM ponatinib or 100 nM NVP-
Bez235 and following 72 hours of treatment apoptosis and CFC assays were performed. 
Ponatinib treatment had no apoptotic effect on either the KCL22
Pon-Res
 ATG7 KO cells or 
the control cells, however caused a modest reduction in colony forming potential in the 
CFC assay (Figure 6-11). NVP-Bez235 caused a high level of apoptosis in both the 
KCL22
Pon-Res
 ATG7 KO cells and the control cells (Figure 6-11). The apoptotic response in 
the controls cells was increased by 32% above the untreated cells, which was enhanced in 
the KCL22
Pon-Res
 ATG7 KO cells as the apoptotic response increased to 42% following 
NVP-Bez235 treatment (Figure 6-11). Therefore, the inhibition of autophagy enhanced the 
apoptotic response to NVP-Bez235 treatment by 10%.  This enhanced effect was mirrored 
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in the CFC.  The ATG7 KO in the KCL22
Pon-Res
 cells significantly reduced the amount of 
colonies formed following NVP-Bez235 treatment compared to KCL22
Pon-Res
 control cells 
treated with NVP-Bez235, which was a 37.5% reduction (figure 6-11). 
 
 
Figure ‎6-12: KCL22Pon-Res cells were lentivirally transduced with a CRISPR v2 vector containing an 
ATG7-targeting sequence or an empty vector control with unconcentrated virus.  
The cells were transduced for 48 hours and underwent puromycin selection for 14 days. The 
KCL22Pon-Res cells transduced with the control v2 vector, CRISPR v2 ATG7-1 or CRISPR v2 ATG7-2 
were treated with 100 nM NVP-Bez235 for 72hrs and apoptosis was measured by staining the 
cells with annexin V and 7AAD and analysed using flow cytometry. The histograms represent the 
average of both the results from ATG7 KO 1 and 2. Statistical analysis was performed by using 
paired t-test. Annotation above a bar refers to statistical significance between the bar and the 
untreated control (*;p≤0.05) (n=3). 
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Due to possibility of off target effects occurring when generating a specific KD or KO, a 
secondary complementary approach was performed, which similarly used a pLKO-GFP 
shRNA vector system to knock down (KD) ATG7 in the KCL22
Pon-Res
 cells. KCL22
Pon-Res
 
cell lines were transduced with either a pLKO-GFP shATG7 vector or a pLKO-GFP 
shSCR (Scrambled) control vector. The level of ATG7 KD obtained was assessed at the 
protein level by western blot, which showed the complete inhibition of ATG7 protein 
expression, indicating that the ATG7 had been silenced in the sh-ATG7 KD KCL22
Pon-Res
 
cells (figure 6-12). To establish whether the ATG7 KD could also enhance the NVP-
Bez235 mediated cell death in the KCL22
Pon-Res
 cells, we treated the cells with 100 nM 
NVP-Bez235 for 72 hours and analysed apoptosis. NVP-Bez235 induced apoptosis in both 
the KCL22
Pon-Res 
control and ATG7 KD cells. However, the level of apoptosis was 
significantly increased within the autophagy redundant cells by more than 20% compared 
to the control cells treated with NVP-Bez235 (figure 6-12). 
 
 
Figure ‎6-13: KCL22Pon-Res cells were lentivirally transduced with a pLKO.1-GFP vector carrying 
either a mock (shSCR) or an ATG7-targeting hairpin (shATG7) with unconcentrated virus.  
Cells were transduced over 48 hours and GFP was measured by flow cytometry analysis, which 
showed >99% transduction efficiency for both vectors. The KCL22Pon-Res cells transduced with 
shSCR or shATG7 were treated with NVP-Bez235 for 72hrs and apoptosis was measured.  The 
level of ATG7 knockdown achieved was assessed by western blot. The histogram represents early 
and late apoptosis and numbers are presented as mean±SEM (n=3). Statistical analysis was 
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performed by using paired t-test. Annotation above a bar refers to statistical significance between 
the bar and the untreated control (**; p≤0.01, ***; p≤0.001).  
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6.8 Pharmacological autophagy inhibition enhances the effect of NVP-
Bez235 against primary TKI-resistant CML cells  
Our previous study using the KCL22
Pon-Res
 cell model showed that NVP-Bez235 mediated 
mTORC1 inhibition induces protective autophagy. We were able to inhibit autophagy in 
the KCL22
Pon-Res
 cells pharmacologically by HCQ treatment or specifically by knocking 
out or knocking down essential autophagy gene, ATG7. The combination of NVP-Bez235 
treatment and autophagy inhibition led to the significant enhancement of NVP-Bez235 
induced cell death.  
As a result of these promising data we wanted to investigate whether autophagy inhibition 
could also enhance NVP-Bez235 induced cell death in primary BCR-ABL-independent 
TKI-resistant CML cells.  
To do this we extracted MNCs from the bone marrow of three patients who have failed to 
achieve CCyR following 1st, 2nd and 3rd generation TKI treatments. We then treated these 
cells with 100 nM ponatinib, as a control for TKI-resistance, 10 µM HCQ, 100 nM NVP-
Bez235 and the combination of NVP-Bez235 and HCQ. Following 72 hours treatment the 
colony forming potential of the leukaemic cells and their ability to form colonies post 
treatment were assessed by performing CFC assays. 
As shown previously NVP-Bez235 had a significantly greater effect at reducing the colony 
forming potential than ponatinib. NVP-Bez235 reduced the number of colonies formed by 
60%, whilst ponatinib reduced colonies by 40-45% (figure 6-13). Most importantly this 
assay confirmed that HCQ treatment could significantly enhance that effect of NVP-
Bez235 by reducing the number of colonies formed by 80%, which was highly significant 
in both patients. This combination treatment proved to be significantly more effective than 
ponatinib treatment and the treatment of NVP-Bez235 alone in all patients analysed (figure 
6-13).   
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Figure ‎6-14: Bone marrow derived MNCs from TKI-resistant CML patients were cultured in SFM 
supplemented with physiological growth factors.  
Cells were treated with 100 nM ponatinib, 10 μM HCQ, 100 nM NVP-Bez235 and combination 
treatment of NVP-Bez235 and HCQ. The colony forming potential was measured following a 72 
hour drug treatment. (n=3 patients). Statistical analysis was performed by using paired t-test. 
Annotation above a bar refers to statistical significance between the bar and the untreated 
control (*;p≤0.05, **; p≤0.01, ***; p≤0.001). 
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6.9 Autophagy inhibition enhances the effect of dual PI3K and mTOR 
inhibitors against primary TKI-resistant CML cells  
 
A preliminary experiment investigating the effect of the novel dual PI3K and mTOR 
inhibitors and combination treatment with HCQ was performed on one patient sample.  
The MNCs were extracted from the patient’s bone marrow and were treated with 100 nM 
ponatinib, 10 µM HCQ, 100 nM NVP-Bez235, 100 nM gedatolisib, 100 nM apitolisib and 
100 nM VS-5584. All the dual PI3K and mTOR inhibitors were analysed as single 
treatments or in combination with 10 µM HCQ. Following 72 hours of treatment cell 
viability was assessed by apoptosis and CFC assays. Ponatinib was used as a control for 
TKI resistance. This experiment showed that ponatinib treatment had no effect on cell 
death or colony forming potential in the primary TKI-resistant CML cells. As single 
treatments, the dual PI3K and mTOR inhibitors all induced a modest level of apoptosis, 
between 5-12% above untreated and ponatinib treatment, NVP-Bez235 being the most 
effective (figure 6-14). However, the most striking effect was seen in the CFC assay, 
which assesses the cells colony forming potential following drug treatment. All single 
treatments with the dual PI3K and mTOR inhibitors reduced the number of colonies 
formed. NVP-Bez235 and gedatolisib had the greatest effects compared to untreated 
control, 70 and 39% reduction, respectively (figure 6-14). However, the combination 
treatment with the PI3K and mTOR inhibitors and HCQ showed the most striking effects, 
all combination treatments significantly reduced the number of colonies. The combination 
of NVP-Bez235 plus HCQ most significantly decreased colony formation (85% reduction), 
which was also significantly reduced compared to ponatinib, the patient’s current treatment. 
The combination treatment of gedatolisib and HCQ also significantly reduced colony 
formation compared to ponatinib treatment alone. The combination of gedatolisib and 
HCQ decreased colony formation by 53%. Apitolisib and HCQ reduced colony formation 
by 65% and VS5585 and HCQ by 61.5% (figure 6-14).  
This experiment highlights the importance of our concept of treatment with dual PI3K and 
mTOR inhibitors in combination with an autophagy inhibitor for treatment against BCR-
ABL-independent TKI-resistant CML. Although all combination treatments effectively 
induced cell death and reduced the long-term survival of the leukaemic cells, NVP-Bez235 
and HCQ remained the most effective drug treatment option.  
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Figure ‎6-15: Bone marrow derived MNCs from a TKI-resistant CML patient were cultured in SFM 
supplemented with physiological growth factors.  
Cells were treated with 100 nM ponatinib, 10 µM HCQ, 100 nM NVP-Bez235, 100 nM gedatolisib, 
100 nM apitolisib and 100 nM VS-5584. All the dual PI3K and mTOR inhibitors were analysed as 
single treatments or in combination with 10 µM HCQ. The induction of apoptosis and the colony 
forming potential was measured following a 72 hour drug treatment. (n=1 patient). Statistical 
analysis was performed by using paired t-test. Annotation above a bar refers to statistical 
significance between the bar and the untreated control  (*;p≤0.05, **; p≤0.01, ***; p≤0.001). 
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6.10 Pharmacological inhibition of autophagy enhances the effect of NVP-
Bez235 in vivo  
Previously we have shown in in vitro and ex vivo studies that the combination of mTOR 
and autophagy inhibition is an effective treatment, which induces high levels of apoptosis 
and also reduces long-term cell viability against BCR-ABL-independent TKI-resistant 
CML cells.  
To analyse this further, we investigated whether the mTOR inhibition, when combined 
with autophagy inhibition, could inhibit leukaemia initiation in TKI-resistant cells. To do 
this we used KCL22
Pon-Res
 cells, expressing firefly luciferase (previously generated by G. V. 
Helgason). These cells were treated in vitro with 10 µM HCQ, 100 nM ponatinib, 100 nM 
NVP-Bez235 and combination treatments of ponatinib and HCQ and NVP-Bez235 and 
HCQ. Following a 72 hours drug treatment cell counts were performed, and taking into 
account cell death, the relative number of cells were transplanted intravenously into sub-
lethally irradiated NOD/SCID/IL-2Rγ-/- (NSG) mice (Ishikawa et al., 2005). Thirty 
minutes after the transplant the mice were injected with D-luciferin substrate to activate the 
firefly luciferase and the mice were imaged using a bioluminescent imager, IVIS, to ensure 
the success of the transplantation and the cell viability. Subsequently the mice were imaged 
weekly to assess leukaemia development. By week 4 there was a significant reduction in 
the luciferase expression in the mice transplanted with the combination treatment of NVP-
Bez235 and HCQ (figure 6-15). This suggests that mTOR and autophagy inhibition can 
delay leukaemia development. The NVP-Bez235 and HCQ drug treatment combination 
also significantly prolonged the survival of the NSG mice, compared to the cohort of mice 
transplanted with untreated control cells and mice transplanted with ponatinib treated cells 
(p=0.0004 and p=0.0054, respectively) (figure 6-15). All 4 mice in the combination arm 
were sacrificed at day 42 with little evidence of leukaemia (figure 6-15). 
The NVP-Bez235 treatment alone also reduced the development of leukaemia significantly 
compared to the untreated cohort of mice, however it only increased survival by 1-5 days 
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(figure 6-15). Ponatinib, HCQ and the combination treatment had very little effect against 
the development of the leukaemia in this model and only prolonged survival by 1 or 2 days 
(figure 6-15).  
 
 
 
Figure ‎6-16: KCL22Pon-Res were labelled with lentiviral firefly luciferase and seeded at 0.25x106/ml 
and treated with 10 μM HCQ, 100 nM Ponatinib, 100 nM NVP-Bez235 or combination, in vitro 
for 72 hours.  
Cell counts were performed to taking into account cell death from the drug treatments. The 
relative numbers of cells compared to the NVP-Bez235+HCQ treatment were injected into 
sublethally irradiated NSG mice (4-7 mice per cohort) i.e. if the untreated cells had expanded 3 
fold over the 72 hour treatment time compared to the NVP-Bez235+HCQ treated cells, the mice in 
the untreated cohort were transplanted with 3x106 cells and the mice in the NVP-Bez235+HCQ 
cohort would receive 1x106 cells.  Leukaemic burden and engraftment was recorded by IVIS 
bioluminescent imaging weekly. Overall survival was monitored and measured by Kaplan-Meier 
analysis using graphpad prism. Annotation above a bar refers to statistical significance between 
the bar and the untreated control  (*;p≤0.05, **; p≤0.01, ***; p≤0.001). 
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6.11 The combination treatment of NVP-Bez235 and HCQ has minimal 
toxicity compared to omacetaxine in non-CML cells 
 
Despite the successful anti-leukaemic effects NVP-Bez235 has shown in this study, 
treatment of NVP-Bez235 in the clinics has taken a precautionary approach, as reports 
have been made that some patients have suffered from adverse effects. NVP-Bez235 is 
currently under investigation in many clinical trials against a wide range of solid and blood 
cancers, to ascertain whether NVP-Bez235 could be an effective and safe treatment for 
patients from different disease backgrounds. Due to the toxicities reported from the clinic 
and some of our preclinical data from the drug screen, which showed non-CML CD34
+
 
cells were sensitive to low drug concentrations of the PI3K and mTOR inhibitors, we 
tested the effect of NVP-Bez235 and the combination treatment of NVP-Bez235 and HCQ 
on normal cells. Firstly, due to lack of clinical material we tested the effects of NVP-Bez 
and gedatolisib on normal BaF3
Parental 
cells and compared it to the cytotoxic effects caused 
in the TKI-resistant BaF3
Pon-Resl 
cells. This preliminary study suggested that NVP-Bez235 
and gedatolisib were more selective towards the TKI-resistant BaF3
Pon-Resl 
cells, by 
increasing apoptosis 25-30% higher in these cells compared to the normal cells (figure 6-
16). Further investigation was performed using non-CML CD34
+
 cells, derived from 
patients with a Ph negative haematological malignancy, lymphoma. The non-CML cells 
were treated with ponatinib, NVP-BEZ235, alone and in combination with HCQ, and 
compared with cytotoxicity of 10 nM omacetaxine treatment. This revealed that 
omacetaxine significantly affected the colony forming potential of normal progenitor cells, 
as no colonies were formed, the combination of NVP-BEZ235 and HCQ had a less than 
maximal effect (figures 6-17). 
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Figure ‎6-17:BaF3Parental and BaF3Pon-Res cells were seeded at 0.25x106/ mL and treated with 100 
nM NVP-Bez235 or 100 nM gedatolisib. The percentage of apoptosis was measured following a 
72 hour drug treatment. 
Statistical analysis was performed by using paired t-test. Annotation above a bar refers to 
statistical significance (*;p≤0.05). 
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Figure ‎6-18: Bone marrow derived MNCs from a non-CML lymphoma patients were cultured in 
SFM supplemented with physiological growth factors. 
Cells were treated with 10 µM HCQ, 100 nM NVP-Bez235, NVP-Bez235 in combination with HCQ 
and 10 nM omacetaxine.  The induction of apoptosis and the colony forming potential was 
measured following a 72 hour drug treatment. (n=3 patients). Statistical analysis was performed 
by using paired t-test. Annotation above a bar refers to statistical significance between the bar 
and the untreated control  (*;p≤0.05, **; p≤0.01, ***; p≤0.001). 
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6.12 The combination treatment of NVP-Bez235 and HCQ was well 
tolerated by NSG mice and significantly extended the survival of TKI-
resistant CML xenograft mice. 
 
As a result of the concerns raised about the toxic effects of NVP-bez235 we tested the 
tolerability and efficacy of this drug combination with HCQ in vivo. In this study we used 
the KCL22
Pon-Res
 luciferase positive cells and transplanted them intravenously into NSG 
mice. Evidence of engraftment of the KCL22
Pon-Res
 cells was assessed 7 days after 
transplantation by bioluminescent imaging. Following confirmation of engraftment, the 
mice were treated with NVP-Bez235, HCQ and the combination treatment. The NVP-
Bez23 treated mice received a daily dose of 45mg/kg by oral gavage and the HCQ treated 
mice received a daily dose of 60 mg/kg by intraperitoneal injection. One mouse in the 
NVP-Bez235 treated arm was culled for reasons unrelated to disease development or drug 
treatment. After 3 weeks of treatment bioluminescent imaging revealed the untreated 
(vehicle control) mice and the HCQ treated mice had a high level of bioluminescent signal, 
indicating the development of leukaemia and by week 4, due to the level of disease burden, 
the untreated and HCQ treated mice were sacrificed (figure 6-18). At week 5, two of the 5 
NVP-Bez235 treated mice were sacrificed due to the leukaemic burden. Bioluminescent 
imaging indicated an increased level of bioluminescence in the remaining NVP-Bez235 
only treated mice compared to the combination treatment mice (figure 6-18). The mice 
treated with the combination of NVP-Bez235 and HCQ tolerated the treatment well with 
no signs of toxicity, observed by weight of the mice, appearance, behaviour, eating and 
drinking. The combination treatment slowed the kinetics of disease development, shown 
by the reduced levels of bioluminescence, and significantly extended the survival of the 
mice compared to the single NVP-Bez235 treatment (figure 6-18).  
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Figure ‎6-19: KCL22Pon-Res were labelled with lentiviral firefly luciferase  intravenously injected 
into NSG mice (5-6 mice per cohort).  
The mice were treated once daily with vehicle control, 60 mg/ml HCQ by IP injection, 45 mg/kg of 
NVP-Bez235 or the combination of NVP-Bez235 and HCQ. (a) Disease burden and engraftment 
were recorded weekly by IVIS bioluminescent imaging. (b) Overall survival was monitored and 
measured by Kaplan-Meier analysis using graphpad prism. Annotation above a bar refers to 
statistical (*;p≤0.05). 
 
Overall our data showed that TKI resistance can occur through the aberrant activation of 
alternative survival pathways. This was observed in our ponatinib-resistant KCL22 cell 
model which no longer required BCR-ABL for survival. Instead this cell model was highly 
dependent on mTOR, which was shown by the sustained mTOR activation and sensitivity 
to mTOR inhibition by catalytic inhibitor NVP-Bez235. We also showed the potent mTOR 
inhibition by NVP-Bez235 induced protective autophagy. Furthermore, pharmacological 
inhibition of autophagy, in combination with NVP-Bez235, enhanced the NVP-Bez235 
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induced cell death, which we therefore propose as an alternative treatment option to tackle 
the problem of BCR-ABL-independent mechanism TKI-resistant CML.  
 
6.13 Key findings 
Very importantly in this chapter we show that MNCs derived from three TKI-resistant 
CML patients, who are thought to have a BCR-ABL independent mechanism of TKI 
resistance, are also sensitive to NVP-Bez235-mediated mTOR inhibition ex vivo. NVP-
Bez235 significantly increased apoptosis above TKI treatment as well as significantly 
reducing colony formation. 
Additionally we showed that NVP-Bez235-mediated mTOR inhibition induces protective 
autophagy in KCL22
Pon-Res 
cells, which could be inhibited via lentiviral KO and KD 
methods targeting essential autophagy gene ATG7 and pharmacologically by treatment 
with HCQ, which increased the sensitivity of KCL22
Pon-Res 
cells to treatment with NVP-
Bez235. Importantly we showed that HCQ mediated autophagy inhibition enhances the 
effect of dual PI3K and mTOR inhibitors against primary TKI-resistant CML cells. This 
was validated in vivo by transplanting KCL22
Pon-Res 
cells tagged with firefly luciferase into 
NSG mice and treating the mice with a combination treatment of NVP-Bez235 and HCQ, 
which significantly reduced the development of leukaemia and prolonged the survival of 
the NSG mice. This study provides strong pre-clinical data that this drug combination 
would improve the treatment of BCR-ABL independent TKI resistant CML compared to 
current drug regimes, which is shown to be a safe and tolerable treatment in vivo. 
Therefore, this study provides a rational for testing this drug combination in the clinic for 
BCR-ABL independent TKI resistant CML patients who are not responding to TKIs.
  
 
7 Results (V): Establishing CRISPR as a genome-wide screening 
tool for the study of BCR-ABL-independent TKI-resistance 
7.1 Gene knock-down  
 
RNA interference is a very powerful tool in cellular biology and a widely used approach to 
study specific gene function (Hannon, 2002). The technique of “knocking down” a gene 
degrades the target’s gene expression and therefore impacts upon the translation of the 
targets protein product. The inhibition of the translation of the protein allows investigations 
into the function of the gene by analysing the resulting change, if any, in the cells 
phenotype. This is carried out by editing the cell’s DNA, through sequence specific 
degradation of the host mRNA, meaning that this gene can no longer be translated into a 
functional protein. Traditionally, this technique uses short-hairpin RNAs (shRNAs), which 
contain a sequence specific to the target gene. The shRNA is delivered into the cells via 
lentiviral vectors and is integrated into the host’s genome, which allows for long-term 
knockdown of the target gene. However, by using this strategy gene function is reduced, 
but not eliminated.  
Therefore, with recent advancements in genome editing using Clustered Regularly 
Interspaced Short Palindromic Repeat (CRISPR) as an exciting tool not only to knockout 
single genes, but with the potential to be used as a whole genome screening tool, we 
established protocols and designed experiments for the use of CRISPR within our 
laboratory. Our intention was to use the CRISPR whole genome knockout screen to infect 
a CML cell line and knock out 1 gene from the whole genome in each cell and treat the 
cells with TKI to assess if the deletion of single gene could cause drug resistance against 
TKIs. We hoped this may provide an effective tool to uncover new gene targets, which 
may be the main cause of BCR-ABL-independent TKI resistance, as so far many different 
mechanisms have been implicated. 
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7.2 Clustered Regularly Interspaced Short Palindromic Repeat 
(CRISPR)/Cas system 
 
Background: The interpretation of gene function and that of their variants requires precise 
genome editing technologies. Although protein-based targeting methods, such as Zinc 
Finger Nucleases (Gonzalez et al., 2010) and Transcription Activator-Like Effector 
Nucleases (TALEN) (Zhang et al., 2011), had enabled targeted genome modifications, a 
need still remained for new technologies that were affordable and easy to design, which 
would not be limited in large scale use.  
In 2013 a new system was introduced to the field, Clustered Regularly Interspaced Short 
Palindromic Repeat (CRISPR)/Cas system (Cong et al., 2013, Hsu et al., 2013, Mali et al., 
2013b). This has given the research community the ability to precisely edit the genome of a 
living cell, which has opened up an exciting range of possibilities for future research, 
including the potential for therapeutic and biotechnological application. 
The new CRISPR technology is based on a naturally occurring biological mechanism, first 
discovered in bacteria and archaea, used as a novel defence mechanism against 
environmental stresses, such as viral infections (Barrangou et al., 2007).  
CRISPR repeat sequences were initially discovered in E.Coli in 1987 (Ishino et al., 1987). 
However, very little was known about them until 2002, when these genomic sequences 
were characterised and subsequently coined ‘CRISPR’ after similar sequences had been 
observed in genomes of various bacteria and archaea (Jansen et al., 2002, Mojica et al., 
2000). At this time the biological function of the CRISPR region had still eluded 
researchers until in silico studies of the spacers revealed sequence homology 
corresponding to foreign elements, such as bacteriophage and plasmid sequences 
(Makarova et al., 2006, Mojica et al., 2005).  These studies hypothesised that the function 
of the CRISPR region was to provide immunity against genetic material, via a RNA 
interference based mechanism. This was confirmed by Barrangou and colleagues in 2007, 
where they reported that after a viral challenge, bacteria integrated new spacer sequences 
derived from phage genomic DNA into the CRISPR region. The CRISPR spacer content 
along with the CRISPR-associated (Cas) enzymatic machinery, provided the bacteria with 
a specific nucleic acid based immunity against phages containing the particular sequence 
(Barrangou et al., 2007). The system is made up of two main components; the CRISPR 
array, which is composed of spacer sequences corresponding to invading viral or plasmid 
sequences and is located on the host genome often next to the Cas genes (Barrangou et al., 
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2007, Ishino et al., 1987, Jansen et al., 2002, Makarova et al., 2006, Mojica et al., 2005, 
Mojica et al., 2000) and the second component: Cas protein complex which is a large and 
heterogeneous family of proteins that carry functional domains typical of nucleases, 
helicases, polymerases, and polynucleotide-binding protein. CRISPR, in combination with 
Cas proteins, forms the CRISPR/Cas systems (Haft et al., 2005, Jansen et al., 2002, 
Makarova et al., 2006). 
Through further study, much more is now known about the CRISPR/Cas system and its 
function in bacteria and archaea. This defence mechanism has the ability to incorporate 
foreign genetic material in specific locations within a CRISPR region of the host genome 
(Barrangou et al., 2007, Ishino et al., 1987, Jansen et al., 2002, Makarova et al., 2006, 
Mojica et al., 2000, Mojica et al., 2005). The foreign gene sequences are processed into 
non-coding RNAs and in conjunction with Cas proteins can bind to invading foreign 
genetic material with the same sequence (Jinek et al., 2012). This sequence recognition 
informs nucleases in the Cas protein complex to cleave the invading nucleic acids and 
prevent the viral attack (Jinek et al., 2012). This exposure provides the host with heritable 
immunity (figure 7-1).  
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Figure ‎7-1: The functional mechanism of the type II CRISPR-Cas systems for adaptive immunity. 
CRISPR can be separated into stages, first is the “immunisation step” or spacer acquisition. This is 
when the host recognises an invading virus and subsequently integrates short sequences of DNA 
from the invading virus’s genome into the CRISPR region of its own genome. These foreign 
‘spacer’ sequences are only 20 nucleotides long and are integrated between two repeat units to 
form the CRISPR array. The corresponding sequence of the spacer on the viral genome is known 
as the ‘protospacer’. In most cases following the protospacer there is a short conserved 
nucleotide sequence, referred to as the Protospacer Adjacent Motif (PAM) and this is a 
recognition motif required for acquisition of the viral DNA fragment. This process requires the use 
of nucleases, which are present in the Cas protein complex. The second stage is ‘CRISPR 
expression’ where, RNA polymerase transcribes the CRISPR array into a pre-CRISPR RNA. The pre-
CRISPR RNA is cleaved by endonucleases into small CRISPR RNAs or otherwise known as guide 
RNAs (gRNA). In the final stage, ‘immunity’, the gRNAs, within the multi protein complex 
recognise and bind specifically with complimentary regions of the foreign DNA. This then initiates 
cleavage of the gRNA and foreign nucleic acid complex. Adapted from (Mali et al., 2013a).   
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7.2.1 CRISPR as a genome editing tool 
 
In 2013 the Feng Zhang and George Church laboratories at the Broad Institute and 
Massachusetts Institute of Technology successfully engineered the CRISPR-Cas9 system 
for mammalian genome editing (Cong et al., 2013, Hsu et al., 2013, Mali et al., 2013b). 
The method consists of the same two components: a gRNA, specific to the gene target and 
the Cas proteins. This particular system uses the type II CRISPR system, which is unique 
as it only uses one Cas protein for gene silencing; Cas9 (Deltcheva et al., 2011, Jinek et al., 
2012).  
The gRNA must contain a 20 nucleotide sequence specific to the target gene, otherwise 
known as the ‘spacer’. The sequence must also be immediately upstream of a PAM 
sequence, as this is crucial for targeted binding (Sternberg et al., 2014, Swarts et al., 2012). 
PAM sequences are specific to the species in which the endonuclease originated. In this 
specific protocol, the Cas9 endonuclease, which was isolated from Streptococcus pyogenes 
is exploited. The PAM sequence for this species is: 5’ NGG 3’ (Cong et al., 2013, Mali et 
al., 2013b). 
Once expressed the Cas9 proteins and gRNA form a riboprotein complex, and Cas9 
undergoes a conformational change, which shifts it from being in an inactive non-DNA 
binding formation, to an active DNA binding formation (Jinek et al., 2012). The ‘spacer’ 
sequence of the gRNA remains available for binding with the target DNA (Nishimasu et 
al., 2014). The gRNA-Cas9 complex will bind any genomic sequence with a PAM site, but 
will only cleave the sequence if there is a high homology between the gRNA and the target 
DNA (Jinek et al., 2012). Once the gRNA-Cas9 complex binds the target, the 3’ end of the 
gRNA anneals to the target DNA in a 3’to 5’ direction. This zipper like annealing 
mechanism starting from the 3’ end may explain why low homology stops Cas9 cleavage, 
as 3’ end pairing needs to be more precise than 5’ pairing, which decreases the chances of 
off target effects. Cas9 has two functional nuclease domains, RuvC and HNH (Jinek et al., 
2012). When Cas9 binds to the target DNA it undergoes a second conformation change 
which positions the nuclease domains to cleave opposite strands of the target DNA, 
resulting in a double stranded break (DSB) around 3-4 nucleotides upstream of the PAM 
site (Jinek et al., 2012).The DSB can be repaired by either (1) an efficient but error-prone 
Non-Homologous End Joining (NHEJ) pathway or (2) the less efficient but high fidelity 
Homology Directed Repair (HDR) pathway (Jinek et al., 2013, Lin et al., 2014). 
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The NHEJ pathway is the most active repair mechanism capable of rapidly repairing 
DSBs, but due to its high activity this process frequently incurs mistakes (Shrivastav et al., 
2008). However, this becomes useful for gene editing. NHEJ most commonly creates small 
insertions or deletions (InDels) in the target DNA, which can cause in-frame insertions or 
deletions, or frameshift mutations leading to premature STOP codons within the open 
reading frame (ORF) (Shrivastav et al., 2008). This can cause a loss-of-function mutation, 
rendering the gene inactive and therefore knock-out the target gene (Jinek et al., 2013).  
CRISPR has opened up many different possibilities for genome editing. It was originally 
thought to be a useful tool to knockout (KO) a target gene in mammalian cells, but has now 
had its use extended to selectively activate or repress target genes, to purify specific 
regions of DNA, to image DNA in live cells using fluorescent tags and also for genome-
wide screens.  
7.2.2 CRISPR as a genome-wide forward screening tool 
 
Due to the simplicity of generating custom gRNAs to repress almost any gene in the 
genome, CRISPR-Cas9 has become an ideal genome editing system for large-scale genetic 
screening. Forward genetic screens are very useful tools to study disease phenotypes, when 
there is no known underlying cause. By using this method, we can take parental cells and 
knockout genes in the cell population to try and identify if any particular gene KO can 
mimic the same phenotype as the disease. Before the discovery of CRISPR, shRNA 
screens were used in this context, but these screens were not so reliable due to incomplete 
knock-downs of the target genes. However, CRISPR is capable of generating a population 
of cells that have a homogenous gene knock-out, which gives it a higher sensitivity for 
screening, especially, in cases where reduced gene expression can still allow gene function, 
as seen with autophagy genes. In 2014, the Zhang lab at MIT showed that by delivery of 
pooled single gRNA-Cas9 CRISPR libraries using lentivirus it was possible to conduct 
both positive and negative loss-of-function screens in mammalian cells (Sanjana et al., 
2014, Shalem et al., 2014). Pooled CRISPR libraries are heterogeneous populations of 
lentiviral vectors, that each contains one gRNA to target a single gene within the genome. 
The gRNAs are designed in silico and synthesised. These individual gRNAs are then 
cloned into CRISPR lentiviral vectors and pooled.  
In this study we used the human Genome-scale CRISPR Knock Out (GeCKO) v2 library to 
help us uncover whether the loss of a single gene may cause TKI resistance in CML cells 
and potentially mimic what is seen with patients in the clinic. The GeCKO v2 library was 
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generated by the Zhang lab (Sanjana et al., 2014, Shalem et al., 2014) and consists of 
122,411 unique gRNAs for gene KO on two separate plasmids, 65,383 in Library A and 
58,028 in Library B. This targets 19,050 genes in the human genome. The two libraries (A 
and B) are used together so there are 6 gRNAs to target each gene to ensure there is 
sufficient coverage of each gene. Both of the libraries contain 1000 control gRNAs 
designed not to target the genome, and library A also contains gRNAs to target 1864 
miRNAs, 4 gRNAs per miRNA (Sanjana et al., 2014, Shalem et al., 2014). Complete 
sequences of all the gRNAs in library A and B are available on the Zhang laboratories 
website http://www.genome-engineering.org/gecko/. 
The GeCKO v2 library is available either in a 1 vector system, using lentiCRISPRv2, 
which has Cas9 in the plasmid constructs, or as a 2 vector system, where first cells are 
made Cas9 competent using the lentiCas9-Blast plasmid, then the gRNA libraries are 
added using lentiGuide-Puro plasmids. Although the 2 vector format requires more steps, 
the lentiGuide-Puro plasmid has the advantage of higher titer for the library virus (figure 7-
2) (Sanjana et al., 2014, Shalem et al., 2014).  
The GeCKO screening systems have been shown to have very high modification 
efficiency, low off target modification, high consistency between unique sgRNAs targeting 
the same genes and high validation rate of screen hits (Sanjana et al., 2014, Shalem et al., 
2014).  
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Figure ‎7-2: Lentiviral expression vectors for the one vector (lentiCRISPRv2) and two vector 
GeCKO systems (lentiCas9-Blast and lentiGuide-puro). 
Puro, puromycin selection marker, Blast, blastocidin selection marker; psi+, psi packaging signal; 
RRE, rev response element; cPPT, central polypurine tract; U6, U6 promoter element; EFS, 
elongation factor-1a short promoter; P2A, 2A self-cleaving peptide; WPRE, posttranscriptional 
regulatory element. Figure from (Sanjana et al., 2014) 
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7.2.3 Method: Genome-wide forward CRISPR screen 
 
GeCKO CRISPR pooled libraries were bought from Addgene. Here I will explain my 
experimental design for a pooled CRISPR screen in KCL22 parental cells. 
7.2.3.1 GeCKO pooled electroporation, plating, determination of transformation efficiency 
and maxi prep 
The pooled libraries are provided at a quantity that is too low for immediate large 
screening application. Therefore, the first step is to amplify the library to a concentration 
that is sufficient to be used to generate lentivirus.  
In order to amplify the DNA of the pooled libraries received from Addgene the ‘GeCKO 
pooled electroporation, plating, and determination of transformation efficiency and maxi 
prep’ protocol was used, which was published by the Zhang lab. 
The following protocol was followed to amplify and prepare each library, A and B 
separately. 
First the DNA concentrations of GeCKO libraries A and B were determined using the 
NanoDrop ND-2000 spectrophotometer. The GeCKO libraries were both diluted to 50 ng/ 
μL in water. DNA was amplified using Lucigen EnduraTM electrocompetent cells and 
electroporation as per the manufacturer’s instructions. Four transformations per library 
were set up. 
The 0.1 cm gap Electroporation cuvettes (Bio-Rad, Cat no. 1652089) and microcentrifuge 
tubes were chilled on ice. 25 μL of the EnduraTM cells were aliquoted into a chilled 
microcentrifuge tube. 100ng of library A and B DNA was electroporated into 25 μL 
aliquots of Lucigen Endura
TM
 electrocompetent cells (Lucigen, Cat no. 60242-1) with 
efficiency 1x10
10 cfu/μg. The mixture was stirred carefully with a pipette tip and 
transferred into a chilled 0.1cm electroporation cuvette. The cuvette was flicked 
downwards to deposit cells at the bottom of the cuvette and electroporated using the 
following instructions: 10 μF, 600 Ohms, 1800 Volts for 3.5 to 4.5 milliseconds. 
Immediately following the pulse 975 μL of room temperature Recovery Medium was 
added to the cuvette, the cells were resuspended and transferred to a culture tube 
containing a further 1 ml of Recovery Medium. The culture tubes were incubated at 37°C 
for 1 hour with constant agitation.  
In order to calculate the transformation efficiency a dilution plate was set up. 8 mL of the 
electroporated cells was pooled and mixed well. 10 μL of cells was transferred to 1 mL of 
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recovery medium, mixed and plated 20 μL onto a pre-warmed LB agar plates containing 
100 μg/mL ampicillin. This was performed separately for library A and B. This was a 
40,000 fold dilution of the transformation and allowed for an estimation of the transform 
efficiency to ensure full representation of the library. 
The rest of the transformation cultures were plated out on 20 10cm
2
 LB agar plates 
containing 100 μg/mL ampicillin. 400 μL of the culture was plated per LB plate. The 
cultures were grown for 14 hours at 32°C; the lower temperature reduces recombination 
between the lentiviral long-term repeats. 
Following a 14 hour incubation the transformation efficiency was calculated. The number 
of colonies was counted for library A and library B. The number of colonies was 
multiplied by 40,000, to correct for the dilution factor. The colony number should be 
3x10
6
, this equates to 50x colonies per construct in the GeCKO library.  
The transformation plates were then harvested by pipetting 500 μL of LB broth onto each 
plate and the colonies were scraped off using a cell scraper. The liquid culture was then 
pipetted into and tube and repeated on the same plate. The culture was then centrifuged at 
6,000 xg for 20 minutes at 4°C and the supernatant was discarded. The bacterial pellets 
were frozen at -20°C and taken to the Beatson services for DNA extraction. 
Following DNA extraction, the gRNA representation was checked using next generation 
sequencing, to ensure no guides have been lost or over amplified, which may introduce 
bias to the screen.  
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7.2.3.2 DNA sequencing 
 
The DNA sequencing protocol was followed from the supplementary methods of improved 
lentiviral vectors and genome-wide libraries for CRISPR screening (Sanjana et al., 2014).  
To analyse the guides from the DNA, 2 PCR steps were performed. The first PCR 
amplifies lentiCRISPR gRNAs and the second PCR step attaches the Illumina adaptors and 
barcodes the samples.  
In the first PCR reaction, two separate reactions were set up for library A and library B.  
The primers sequences used to amplify lentiCRISPR gRNAs were used, which were 
designed by the Zhang lab and the sequences are publicly available on the GeCKO website 
http://genome-engineering.org/gecko/?page_id=15. 
 
v2Adaptor_F: AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG 
v2Adaptor_R: TCTACTATTCTTTCCCCTGCACTGTtgtgggcgatgtgcgctctg 
 
These primers were ordered as standard desalted oligonucleotides from IDT and on arrival 
were resuspended in sterile water at a stock concentration of 100 μM, for the PCR step the 
stock was diluted 1:10 for a working concentration of 10 μM. 
Each PCR reaction was set up with a total volume of 50 μL. First 10 μg of template DNA 
was added to a chilled PCR tube, to this 2.5 μL of 10 μM of v2Adaptor_F and 
v2Adaptor_R, final concentration 0.5 μM. This was made up to 25 μL with Nuclease free 
water (Qiagen, Cat no. 129114) and then 25 μL 2xPhusion Flash High-Fidelity PCR 
Master Mix (Thermo Scientific, F548S) was added and mixed carefully by pipetting.  A 
negative control was also set up minus the template DNA.  
The PCR tubes were immediately put on a thermocycler with conditions: 
Initial denaturation: 98°C for 10 seconds, denaturation: 98°C for 1 second, annealing: 61°C 
for 5 seconds, extension: 72°C for 15 seconds, repeated for 20 cycles. Final extension: 
72°C for 1 minute then held at 4°C. 
The second PCR step was performed to attach the Illumina adaptors and to barcode the 
samples. These primers were ordered as Ultramers from IDT for high-fidelity synthesis of 
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very long oligos. Each sample is set up in 12 reactions using 12 different forward primers 
(F01-F12). The forward primers have a staggered sequence, which are 1-9bp different in 
order to increase the complexity of the library to avoid problems during sequencing. The 
same reverse primer is used in the 12 reactions for 1 sample; therefore, it is specific for that 
biological condition. For example: Sample 1: F01+R01, F02+R01, F03+R01, F04+R01, 
F05+R01, F06+R01, F07+R01, F08+R01, F09+R01, F10+R01, F11+R01 and F12+R01. If 
sequencing multiple samples, different reverse primers are used 12 reverse primer 
sequences (R01-R12) can be found on the GeCKO website.  
Once again this PCR reaction was set up as a 50 μL reaction, and 4 μL of the PCR product 
from the first PCR was used in each of the 12 reactions. Using the entire DNA sample 
from the first step helps to keep representation of the guides.  
Therefore, 4 μL from PCR 1 was added to a chilled PCR tube, as before 2.5 μL of 10 μM 
F01 primer and R01 primer, final concentration 0.5 μM was added. This was made up to 
25 μL with Nuclease free water and then 25 μL 2xPhusion Flash High-Fidelity PCR 
Master Mix was added and mixed carefully by pipetting.  A negative control was also set 
up minus the template DNA. The same thermocycler parameters were used, apart from one 
change which was 24 cycles, instead of 20. 
The resulting amplicon from the second PCR had an expected length of 340bp. This was 
run on a 2% agarose gel, for gel extraction, to remove the excess of primers. The gel was 
stained with SYBR safe and imaged under UV light, the 340bp product was excised, gel 
extracted using a QIAquick gel extraction kit as per the manufacturer’s instructions, 
bearing in mind the instructions for a 2% gel (figure 7-3).  
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Figure ‎7-3: Gel electrophoresis of PCR products from PCR 1 and 2. Gel purification of PCR 2 
product 340pb. 
 
The PCR products from the same biological condition were mixed and the DNA 
concentration was measured using a NanoDrop ND2000.  
The samples were given to Glasgow Polyomics for sequencing on a HiSeq 2500 (Illumina) 
and analysis performed by Dr. Pawel Herzyk. 
Analysis of the sequencing showed 99.98% representation in both Library A and Library 
B. All gRNAs were well represented and no skewed bias was shown (figure 7-4).  
 
 
Figure ‎7-4: The workflow of the GeCKO Library amplification Addgene.  
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7.2.4 CRISPR 2-vector screen 
 
In this study we used the human CML cell line, KCL22
WT
 as our model. The human 
GeCKO v2 library was used to transduce the cells and knockout one gene per cell/ within 
the entire human genome. The cells then underwent ponatinib selection to investigate, 
whether any TKI-resistant clones could overcome ponatinib treatment.  
Our aim in doing so was to uncover whether the loss of a single gene may cause TKI 
resistance in CML cells.  
 
 
Figure ‎7-5: The workflow for the positive selection CRISPR Screen. 
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7.2.4.1 KCL22WT Cas9 competent cells 
 
The first step of the GeCKO CRISPR screen 2 vector is to establish a Cas9 competent cell 
line, by infecting cells with the lentiCas9-Blast construct.  
Lentivirus was produced by transfecting HEK293 cells using the CaCl2 method as 
previously described 2.3.12. The virus was used to transduce the KCL22
WT
 CML cell line, 
using the transduction protocol previously discussed 2.3.13. This construct has a 
blastocidin selection marker; therefore, these cells were selected in 10 μg/ml blastocidin 
for 14 days. To allow for an assessment of Cas9 expression the Cas9 protein was FLAG-
tagged (DYKDDDDK Tag) and the protein expression was analysed by western blot. 
Therefore, follow selection, protein was extracted from the KCL22
WT
 cells, as per 
protocol, and analysed for Cas9 expression via a FLAG antibody (Sigma, Cat no. F3165).  
 
 
Figure ‎7-6: Stable expression of LentiCas9-Blast in KCL22WT cells. 
 
In order to assess the ponatinib treatment period needed to kill TKI-sensitive CML cells, a 
ponatinib treatment time course was performed.  
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7.2.4.2 Ponatinib treatment time course  
 
KCL22
WT
 cells were seeded at 0.25x10
6
/mL grown in RPMI in the presence of 100 nM 
ponatinib. An apoptosis assay was performed every few days to analysis the effect of 
ponatinib on cell death. Cells were also imaged after four weeks to observe the 
morphology of the cells. After 5 weeks of ponatinib treatment, the drug was washed out 
and cultured in RPMI only, for a further 10 days; however, no cells were able to repopulate 
the culture following treatment (figure 7-7). 
 
KCL22WT cells under a ponatinib treatment time course 
 
Figure ‎7-7: KCL22WT cells under a ponatinib treatment time course. 
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7.2.4.3 Lentivirus production 
 
A large quantity of virus was needed to perform the whole screen, including enough for 
replicates. Lentivirus was produced by transfecting HEK293 cells using the CaCl2 method.  
14 cm
2 
cell culture dishes were used for viral production. These plates have a 2.8x bigger 
surface area than a 10 cm
2 
dish, therefore conditions previously discussed for lentivirus 
production were multiplied by 2.8. 
2.8x10
6 
HEK293 cells were plated in eight 14 cm
2 
cell culture dishes in 28 ml DMEM 
three days prior to the transfection to allow the cells to adhere to the plate. After three days 
70% confluency was achieved and the media was replaced by adding 23.8 ml of DMEM 
plus 30 μM of chloroquine. 
Lentiviral DNA mixes were made for each 14 cm
2
 plate by adding 39.76 μg of library A 
and 39.76 μg of library B, 34.86 μg psPAX2 and 12.6 μg pCMV-VSV-G into a 15 mL 
falcon tube. To the DNA mix 2560 μL of sterile water and 512.4 μL 2M CaCl2 were added 
and mixed thoroughly. This mix was then added to 4.2 mL of 2xHBSS and mixed very 
thoroughly. The transfection mixes were incubated at 37°C for 30 minutes and then added 
dropwise to the HEK293 cells. Each mix made was for one 14cm
2 
cell culture dish. This 
was allowed to incubate at 37°C for 8 hours, and then medium was replaced with 28 mL of 
DMEM. The following morning the medium was changed again and 16.8 mL of DMEM 
was added to the cells. The virus was harvested after 48 hours by collecting media, 
centrifuging at 300 xg for 5 minutes and filter sterilising the viral supernatant using a 0.45 
μM filter. The virus was pooled and immediately snap frozen in dry ice and transferred to a 
-80°C for storage. 
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7.2.4.4 CRISPR library virus titration 
 
In order to understand how a single gene knockout will affect a cells phenotype in this 
whole genome targeted format, only one gene can be knocked out per cell. Therefore, a 
very low multiplicity of infection (MOI) is required to ensure only 1 gene is knocked out 
per cell. An MOI of 0.3-0.5 was the recommended infection rate (Shalem et al., 2014). 
To find the optimal virus volumes for achieving an MOI of 0.3-0.5 the Cas9 competent 
cells, KCL22
WT
-Cas9-Blast, were infected with different volumes of virus. 1x10
6 
KCL22
WT
-Cas9-Blast cells were plated per well in a 6 well plate. The frozen virus was 
defrosted and pre-warmed. Six different volumes of virus were added to the cells 0.1 mL, 
0.2 mL, 0.5 mL, 1 mL, 2 mL, 4 mL, total volume of 4 mL per well made up with RPMI 
medium. The cells were incubated with the virus for 24 hours. Following the 24 hour 
incubation the viral medium was removed by centrifugation and replaced with RPMI. Each 
well was split into duplicate wells and one replicate received 5 μg/mL puromycin for 72 
hours. The cells were counted and analysed by FACS using DAPI staining to evaluate the 
% of cells that had died post puromycin selection. A MOI of 0.3-0.5 equates to 50-70% 
cell death. Erring on the side of caution, a virus volume of 0.5 mL was chosen for large-
scale screening (figure 7-8). 
 
 
Figure ‎7-8: Virus titration on KCL22WT-Cas9-Blast after 72 hours 
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7.2.4.5 KCL22WT resistant screen  
 
In order to have good representation of all the guides in a population of cells, a calculation 
was made to ensure 400x coverage for each guide. The GeCKO Library’s A and B together 
contain over 120,000 gRNAs, therefore in theory, 120x10
6 
cells are needed per infection. 
Using an MOI of 0.4, after puromycin selection leaves 48 x10
6
 cells. This equates to over 
400 cells with every single gRNA.  
Therefore, 120x10
6 
KCL22
WT
-Cas9-Blast cells were seeded, at a cell concentration of 
0.5x10
6
/mL. The total volume of media need equates to 240 mL, therefore, cells were 
resuspended in 210 mL of RPMI and 30 mL of viral supernatant. The cells were incubated 
for 24 hours with the virus and following the incubation period the viral medium was 
removed by centrifugation and replaced with RPMI, supplemented with 2.5 μg/mL 
puromycin for selection. The cells were initially incubated for 72 hours and then the 
concentration of puromycin was increased to 5 μg/ml for a further 7 days to ensure a 
thorough selection of cells, which had been transduced with the lentivirus (figure 7-9). 
 
 
Figure ‎7-9: KCL22WT–Cas9–Blast FACS analysis post 10 days puromycin selection. 
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On day 10, 10x10
6 
cells were taken for genomic DNA analysis to ensure the coverage of 
the gRNAs post transduction. 48x10
6 
cells were cultured in RPMI supplemented with 100 
nM ponatinib, with the exception of a control flask without ponatinib treatment. All the 
rest of the cells were frozen down. Another important control for the screen was 
KCL22
WT
-Cas9-Blast cells not transduced with the library treated with ponatinib. The cells 
were either passaged or fresh media and ponatinib replaced every 3 days. Cells were FACS 
analysed with Dapi staining once a week. After 4 weeks of ponatinib treatment a 
population of cells in the GeCKO library transduced KCL22
WT
 cells had survived, unlike 
the non-transduced cells. The surviving cell population was FACS sorted (figure 7-10).  
These cells were allowed to recover overnight in culture and the following day genomic 
DNA was extracted using a QIAamp DNA Mini Kit (Qiagen, Cat no. 51304) as per the 
manufacturer’s instructions. The DNA concentration was measured using a nanodrop 
ND2000 (Table 7-1). 
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Figure ‎7-10: : Ponatinib selection and FACS sorting of the CRISPR screen. 
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Sample DNA concentration ng/µL Quality (260/280) 
CRISPR screen day 0 1 427.4 1.98 
CRISPR Screen day 0 2 457 1.93 
CRISPR screen post ponatinib 1 507.8 1.98 
CRISPR screen post ponatinib 2 884.4 1.91 
CRISPR Screen post ponatinib 3-1 660.2 2 
CRISPR Screen post ponatinib 3-2 1992.9 1.99 
CRISPR Screen post ponatinib 3-3 1935.4 1.95 
CRISPR Screen post ponatinib 3-4 1094.7 1.94 
CRISPR Screen post ponatinib 3-5 1942.2 2 
CRISPR Screen post ponatinib 3-6 1990.2 2 
CRISPR Screen post ponatinib 3-7 1523.6 1.98 
CRISPR Screen post ponatinib 3-8 2036.7 1.99 
CRISPR Screen post ponatinib 3-9 1985.8 1.95 
CRISPR Screen post ponatinib 3-10 2317.5 1.99 
CRISPR Screen post ponatinib 3-11 1948 1.99 
Table ‎7-1: CRISPR screen gDNA concentrations. 
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7.2.4.6 Genomic DNA sequencing 
 
As previously discussed, PCR was performed in two steps. For the first PCR, in order to 
achieve 300x coverage over the GECKO library, the amount of input genomic DNA 
(gDNA) for each sample, the calculation was described by Shalem et al, 2014. It was 
recommended that 130 μg of DNA was used per sample. Therefore, for each sample, 13 
separate 50 μl reactions were performed with 10 μg genomic DNA in each reaction using 
2xPhusion Flash High-Fidelity PCR Master Mix as previously described for PCR 1. 
The second PCR was performed as previously described, in a 50 μL reaction volume using 
5 μl of the product from the first PCR (figure 7-11 and 7-12).  
 
Figure ‎7-11: Gel purification of PCR 2 product 340pb from KCL22WT resistant screen day 0. 
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Figure ‎7-12: Gel purification of PCR 2 product 340pb from KCL22WT resistant screen day 0. 
 
Sample DNA concentration ng/µL 260/280 
CrispR screen day 0 PCR 2 194.0 1.87 
CrispR Screen post ponatinib 1 PCR 2 116.5 1.89 
CrispR Screen post ponatinib 2 PCR 2 170.0 1.89 
Table ‎7-2: CRISPR screen PCR product concentrations. 
Preliminary results 
The resulting PCR products from the second PCR were gel extracted, quantified, mixed 
and sequenced using a HiSeq 2500 (Illumina). The sequencing was single ended and 75 bp 
in length, with a depth of 33 million. 
In the preliminary experiment, sequencing revealed 4 dominant gRNAs from the 
population of KCL22
WT
 cells after 5 weeks of ponatinib treatment (Table 7-3), suggesting 
that loss of these particular genes may contribute to ponatinib resistance.  
 
Top hits 
Gene Reads % of clones in sample 
*EDARADD 16128536.39 Sample 1 - 45 
TBC1D9 9628072.508 Sample 1 - 27 
MRFAP1L1 9595178.017 Sample 1- 27 
CDH4 35415241.35 Sample 2 - 98 
Table ‎7-3: Guide RNAs with the highest reads from the CRISPR Screen. 
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The results from this preliminary screen showed the top hit was EDARADD, which 
comprised 45% of the TKI resistant clones from the samples. No evidence has so far been 
that implicates EDARADD in the development of leukaemia or in drug resistance. 
However, it is associated with NF-κB signalling, RelA, which is involved in 
lymphogenesis, survival and proliferation, the Wnt and BMP signalling and Sonic 
hedgehog (Shh) signalling. NF-κB, Wnt, BMP and Shh signalling pathways have all been 
implicated in TKI resistance or disease persistence in CML.Threfore, pathway modelling 
to help identify the most likely mechanism causing the resistance could be performed, as 
well as in vitro studies to analysis the response of these 3 pathways when EDARADD is 
KO in KCL22
WT
 cells compared to the scrambled control. 
One unexplained result from the screen, which is hard to interpret is the out growth of 
clones with a TBC1D9 KO. This gene is more commonly known as Multi-drug resistance 
1 (MDR1). Overexpression of MDR1 is known to cause TKI resistance in CML due to 
increased drug efflux from the cell causing suboptimal concentrations being achieved 
within the CML cells. Therefore, the reduced expression of this gene causing drug 
resistance is hard to interpret. Purely, speculator, however there is the possibility a 
compensatory mechanism has been activated due to the low levels of MRD1, which may 
lead to the drug resistance.  
27% of the clones that became ponatinib resistant had a MRFAP1L1 KO. MRFAP1L1 has 
not been implicated in the development of leukaemia either, however has been associated 
with the following: Motility factor 1 like 1, Ubiquitin C, smu-1 suppressor of mec-8 and 
unc-52 homolog, transmembrane protein 126B, which is involved in assembly of the 
mitochondrial NADH-ubiquinone oxidoreductase complex, translin-associated factor X; 
protein kinase C, delta binding protein; which seems to have an immune potentiation 
function, cyclin-dependent kinase 2 associated protein 2 and RAD52 motif 1. Some of 
these proteins are associated with CML development such asRAD52 and protein kinase C. 
Therefore, the KO of MRFAP1L1 may also cause TKI resistance indirectly through one of 
these associated pathways. Once again, pathway modelling and in vitro studies would give 
us a better understanding of the resistant mechanism. 
In the second technical replicate cells with a CDH4 KO comprise 98% of the clones in that 
sample. CDH4 encodes R-cadherin, which so far has not been implicated in leukaemia, 
unlike N-cadherin. However, a study in colorectal and gastric cancer showed that promoter 
methylation of CDH4 results in the loss of gene expression, which could be restored with 
the treatment with a demethylating agent. Methylation of CDH4 was not detected in 
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normal patients, and has therefore been considered an early event in tumour progression. 
This study concluded that CDH4 may act as a tumour suppressor gene in human 
gastrointestinal tumours, which may also make sense of the result of our CRISPR screen 
(Miotto et al., 2004). Knocking out a tumour suppressor gene would give the cells a growth 
and survival advantage, which may be strong enough to cause the CML cells to become 
drug resistant.  
However, high variability in the two technical replicates compelled further investigation 
(see appendix 9.2). In light of this the remaining cells from the experiment had been frozen 
down, these cells have now been defrosted and put into culture. The cells underwent the 
same experimental protocol, 100 nM ponatinib selection for 5 weeks, sorted under the 
same parameters, genomic DNA extracted, and PCR reactions were performed as 
previously stated. However, we are still awaiting sequencing to be performed by Glasgow 
Polyomics, which will be performed using the same parameters.  
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7.2.5 Future work  
7.2.5.1 Design a secondary library  
 
The next conventional step would be to validate the hits confirmed from the primary 
screen. In order to do so a secondary screen would be performed, by generating a new 
library that targets the top genes in the analysis of the primary screen.  
The guide sequences from the GeCKO libraries are available publicly, http://genome-
engineering.org/gecko/?page_id=15.   
For construction of the library, the previously published protocol from Shalem et al., 2014, 
would be followed. However, in brief, the oligos would be synthesized, and amplified 
using the following primers:  
Forward: 
TAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGAC
GAAACACCG  
Reverse: 
ACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAG
CTCTAAAAC  
Following amplification, the oligos would then be cloned into the lentiGuide-Puro plasmid 
(Addgene, Cat no. 52963) using the Gibson ligation reaction (NEB, Cat no, E5510S). The 
ligation reaction is performed using molar ratio of 1:5 of the vector to insert. The ligated 
DNA is then transformed into Lucigen Endura
TM 
electrocompetent cells (Lucigen, Cat no. 
60242-1) according to the parameters previously described in GeCKO pooled 
electroporation, plating, determination of transformation efficiency and maxi prep. 10 
parallel transformations are performed and plated onto 10 cm
2
 plates with 100 μg/mL 
ampicillin for 14 hours at 32°C. Following incubation, bacterial colonies would be 
collected and plasmid DNA extracted. Virus production and all subsequent steps would be 
performed as described for the primary screen. 
A secondary screen has greater specificity and sensitivity and therefore represents an 
effective strategy for increasing the rate of true positives. However, as we obtained so few 
dominant clones from our primary screen it would be within our capabilities to generate 
single guide RNAs to KO out each individual gene to validate these hits.   
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7.2.5.2 Negative Screen  
 
A second way of validating the hits in the primary positive screen is to perform a negative 
screen. The negative screen is essentially an inverse of the primary screen. This screen 
would utilise the KCL22
Pon-Res
 cell line, therefore these cells are already TKI-resistant. The 
same whole genome GeCKO library would be used to KO one gene in each cell. The 
KCL22
Pon-Res
 cells would then undergo ponatinib selection and observed by FACS and 
DAPI staining to see if the cells become re-sensitised to the TKI. The remaining cell 
population would then be sequenced and analysed against an untreated population to see 
what guides had been lost and were therefore responsible for the re-sensitisation.  
 
 
Figure ‎7-13: The workflow for a negative CRISPR Screen. 
 
7.2.5.3 Single guide RNAs 
 
Final validation of the hits found through the screening methods will be performed by 
generating 6 single gRNAs for the specific genes as outlined in methods 2.3.14. This will 
allow us to establish a TKI-resistant CML cell line with the specific single gene KO. This 
will provide us with a tool to study the change in the cells phenotype in response to the 
gene silencing and if this re-sensitises the whole population of cells to TKI. 
Performing a thorough screening experiment in cell lines narrows down the potential 
candidates that may be the cause of TKI resistance in CML patients. This makes the 
candidate gene pool smaller, which helps when designing an experiment using TKI-
resistant CML patient samples, as there is a limited number of cells available that would 
make it very difficult to perform a whole genome KO screen in primary samples. 
Therefore, a smaller library or single guide knockouts would be advantageous for 
furthering our research using primary patient samples.   
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If a successful candidate(s) gene is found from the CRISPR screen and could be validated 
by single guide KOs in cell lines and in primary samples this would be considered an 
extremely important gene for the development of TKI resistance in CML and worthy of 
further validation.  
If the KO of this gene can cause TKI resistance, analysis of the gene’s products and their 
interactions may need to be considered, in order to find a mechanism to target that would 
oppose the KO effect. This could have the potential to lead to the discovery of novel drug 
therapies against TKI-resistant CML, which can be further validated by therapeutic 
inhibition in in vitro studies, as well as in in vivo models.  
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8 Discussion  
 
CML is driven by the aberrant tyrosine kinase activity of the fusion oncoprotein BCR-ABL. 
TKIs were designed to target BCR-ABL and inhibit its kinase activity and therefore induce 
cell death within the CML cell population. TKIs were one of the first successful targeted 
drug therapies developed for the treatment of cancer. They proved a very successful 
treatment strategy and clinical trials reported >87% of patients treated with imatinib (1
st
 
generation TKI) achieved MCyR in the IRIS study (O'Brien et al., 2003).  
Although most patients treated with TKIs achieve a MCyR, it has been reported that 
approximately 30% of patients with newly diagnosed CP CML who receive imatinib did 
not achieve a CCyR within 1 year of treatment (O'Brien et al., 2003). In addition, 
approximately 10% of patients experienced relapse during 5 years of follow-up, including 
approximately 10% who had achieved a CCyR (Druker et al., 2006). 
Another limitation of imatinib which hampers successful treatment is minimal residual 
disease (MRD). This has been observed in a number of patients who fail to achieve CMR 
due to the continued detection of BCR-ABL transcripts (Druker et al., 2006). Imatinib is 
also much less effective in treating more advanced stages of CML, if any response to 
imatinib does occur it is only transient (Druker et al., 2001a).  
Unfortunately, the development of resistance has become the Achilles’ heel of TKIs, with 
both primary and acquired TKI resistance remaining major clinical problems. Due to no 
alternative targeted treatment the disease may progress and become harder to treat. The 
only effective treatment options for these patients are either an invasive stem cell 
transplantation, but this is only if the patient is eligible and has a matched donor available 
or treatment with omacetaxine, which is highly toxic.  
So far, many mechanisms have been reported to lead to imatinib resistance, which is most 
commonly due to BCR-ABL kinase domain mutations that affect imatinib binding. 
Acquired resistance can also arise due to BCR-ABL-independent mechanisms, such as 
activation of alternative survival pathways, as discussed in more detail below. In an 
attempt to overcome these issues, increasing the dose of imatinib was suggested in resistant 
CML patients, i.e. patients originally treated with 400 mg/day were treated with up to 800 
mg/day (Kantarjian et al., 2003, Jabbour et al., 2009b). However, although response rates 
were often improved, this was not sufficient to eliminate resistance in many cases. 
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In the aim to overcome imatinib resistance, 2
nd
 generation TKIs dasatinib and nilotinib 
were developed, which were much more potent and designed to target BCR-ABL mutants 
and conformations of the drug pocket which were unattainable by imatinib. Both the 2
nd
 
generation TKIs had a superior affect compared to the standard dose of imatinib in the 
clinic, shown in the DASISION and the ENESTnd clinical trials. However, some patients 
still had primary resistance or acquired resistance to both dasatinib and nilotinib. One 
reason for this was that neither of the 2
nd
 generation TKIs were effective in targeting the 
T315I mutation (Shah et al., 2004, O’Hare et al., 2005). 
This has led to the more recently developed 3
rd
 generation TKI ponatinib, which was 
specifically designed to inhibit BCR-ABL and its mutant form, T315I. Ponatinib is a pan-
TKI inhibitor and has been shown to exert its effects on additional targets, such as SRC 
kinases. It has also been shown to be highly effective in suppressing the emergence of any 
BCR-ABL mutations, even at low concentrations, such as 40 nM (O’Hare et al., 2009). 
The PACE clinical trial reported that ponatinib induced rapid and durable responses in CP 
CML patients, as well as, having significant anti-leukaemic activity in patients harbouring 
the T315I mutation and patients in more advanced disease stages (Cortes et al., 2013). 
Despite promising results from clinical trials such as PACE, which showed that ponatinib 
induced rapid and durable responses in CP CML patients, there is still a significant number 
of patients which are unresponsive to all current TKIs. For these patients it is thought that 
they have developed a mechanism of resistance that is not related to BCR-ABL, i.e. BCR-
ABL-independent mechanism of TKI resistance. Such mechanisms of resistance are often 
thought to occur due to the activation of alternative oncogenic mechanisms (Quentmeier et 
al., 2011, Hentschel, 2011), which protect CML cells against cell death by maintaining 
pro-survival pathways, even when BCR-ABL signalling is inhibited. Patients diagnosed 
with BCR-ABL-independent TKI-resistant CML currently have very few treatment options 
and therefore have a poor prognosis. With further research it is hoped that an alternative 
drug target can be identified, that is shared by this patient population, and could be 
inhibited by a novel drug therapy. 
Many studies that have been conducted so far investigating BCR-ABL-independent TKI 
resistance have used cell line models that have had prolonged exposure to imatinib in order 
to acquire TKI resistance. Studies using imatinib resistant CML cell lines have led to the 
implication of many different mechanistic pathways that contribute to TKI-resistance. One 
of which was the over-expression of SRC kinases, such as LYN, HCK and FYN, which 
promote survival and proliferation (Donato et al., 2003, Grosso et al., 2009). However, in 
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our study we have shown that even though imatinib resistant CML cell lines have a durable 
imatinib resistance they are sensitive to imatinib dose escalation, nilotinib, dasatinib and 
ponatinib (figure 3-1). The primary reason may be that while TKIs have a potent inhibitory 
effect against BCR-ABL activity, they also have the ability to target other tyrosine kinases 
of similar structure, such as KIT and platelet-derived growth factor receptor (PDGFR). 
Each TKI shows slightly different effects in terms of cytotoxicity and anti-proliferative 
activities, which are due to their ability to inhibit alternative kinases. Particularly dasatinib 
and ponatinib, which are less specific due to their design, which enables them to target 
mutated forms of BCR-ABL. For example dasatinib, even at low nanomolar concentrations, 
is able to inhibit SCR family kinases, including SRC, LCK, LYN, FGR, BLK, FYN, YES 
and HCK (Deguchi et al., 2008).  
Similarly, ponatinib can also inhibit SRC and LYN at low concentrations, as well as 
members of the VEGFR, FGFR, and PDGFR families of receptor tyrosine kinases (O'Hare 
et al., 2009). This may explain the increased cytotoxic effect caused by dasatinib and 
ponatinib compared to imatinib treatment against these cell lines. Ponatinib also has 
activity against many mutant forms of BCR-ABL, including the T315I mutation and has 
the ability to completely suppress the outgrowth of BCR-ABL resistant clones (O'Hare et 
al., 2009). Due to ponatinib’s effectiveness against imatinib resistant cell models, the 
question arises as to whether imatinib models are currently relevant to study BCR-ABL-
independent TKI resistance. Therefore, we proposed that using ponatinib to generate a 
TKI-resistant model would be more likely to result in a pan-TKI-resistant BCR-ABL-
independent phenotype.  
Consequently, to allow us to investigate the exact mechanism(s) of BCR-ABL-independent 
TKI-resistance, we generated a TKI-resistant cell model using the human KCL22
WT
 cell 
line and the murine BaF3
WT
 cell line (KCL22
Pon-Res
 and BaF3
Pon-Res
) by growing them in 
increasing concentrations of ponatinib for a prolonged period of time until the cells showed 
a resistant phenotype. To the best of our knowledge this is the first time that ponatinib-
resistant CML cell lines have been generated for the study of TKI resistance. The BaF3
Pon-
Res
 and KCL22
Pon-Res 
cell lines were validated as TKI-resistant CML cell models due to 
their tolerance of up to 100 nM ponatinib and 150 nM dasatinib, which under these 
conditions would be toxic to the original parental cells. 
Most importantly this study showed that 100 nM ponatinib switched off BCR-ABL 
signalling in KCL22
Pon-Res
 cells and 1 µM switched off BCR-ABL in the BaF3
Pon-Res
 cells; 
however, the cells continued to proliferate, despite the absence of BCR-ABL activity 
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(figure 3-11). This infers that both of these cell lines have adapted and are using a 
mechanism independent of BCR-ABL for their cellular survival.  
In addition, we convincingly showed that BCR-ABL inhibition via TKIs (imatinib, 
nilotinib, dasatinib, or ponatinib) or the experimental BCR-ABL inhibitor ABL001, which 
inhibits BCR-ABL via a different binding pocket, had no effect on the KCL22
Pon-Res
 and 
BaF3
Pon-Res
 cell lines. An exhaustive series of cell viability assays showed that TKI or 
ABL001 mediated BCR-ABL inhibition was unable to induce apoptosis, reduce cell 
proliferation or inhibit colony forming potential of TKI-resistant CML cells (Figures 3-3 – 
3-8).  
The implication that the BaF3
Pon-Res
 and KCL22
Pon-Res 
cell lines were utilising BCR-ABL-
independent mechanisms for their survival was strengthened by genomic DNA sequencing 
of the ABL kinase domain, which was negative for any mutation which may confer a 
BCR-ABL-dependent TKI resistance. 
The generation of these ponatinib-resistant CML cell models therefore provided us with a 
unique tool to investigate the mechanism(s) which drive a truly BCR-ABL-independent 
resistance in CML. 
In an effort to tease out the molecular mechanism(s) which may be the driving force for 
survival of the ponatinib-resistant cells, a transcriptomics analysis was performed to 
investigate the gene transcription differences between the original KCL22
WT
 cell line and 
the KCL22
Pon-Res
 cell line at basal levels and following ponatinib mediated BCR-ABL 
inhibition. By analysing the transcriptional response with and without BCR-ABL 
signalling we hoped to see genes responses that were normalised in KCL22
WT
 following 
ponatinib treatment, which were still being aberrantly expressed in the KCL22
Pon-Res
 cell 
line despite BCR-ABL inhibition. Results showed that, although, there were very few 
differences comparatively at basal level, following 24 hours of ponatinib treatment, 
unsurprisingly a vast number of genes were up-regulated or down-regulated in the 
KCL22
WT
 cell line. Gene ontology analysis revealed that the genes were associated with 
biological processes involved in apoptosis, DNA damage repair and cellular response to 
stress. These biological processes are all typical pathways expected to be induced 
following cytotoxic drug treatment. However, no transcriptional response was observed in 
the KCL22
Pon-Res
 cells following ponatinib treatment. The lack of transcriptional response 
added to the evidence that BCR-ABL signalling is redundant in the KCL22
Pon-Res
 due to the 
gain of an alternative survival pathway. There may be a possibility mTOR is involved as 
although, mTOR is known to be a major regulator of translation, it also has links to gene 
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transcription regulation (Laplante and Sabatini, 2013, Mayer and Grummt, 0000, Yecies 
and Manning, 2011).  
The PI3K/AKT/mTOR pathway is a downstream pathway in BCR-ABL signalling and is 
known to be deregulated in a number of different types of cancers. PI3K/AKT/mTOR 
signalling plays a central role in regulating proliferation, survival and differentiation events 
in haemopoiesis and has also been linked with functions of HSCs and the process of 
lineage commitment (Martelli et al., 2010). PI3K/AKT/mTOR signalling is involved in 
many important processes and any change in the signal transduction could have dramatic 
effects on the phenotype of the cell, which is the possible reason why deregulation of this 
pathway is so common in cancer, including leukaemia.  
In our model, western blot analysis of the KCL22
Pon-Res
 cells revealed sustained mTOR 
activity despite TKI mediated BCR-ABL inhibition. This data is in agreement with 
previous studies, which showed that the PI3K/AKT/mTOR pathway was activated by 
imatinib treatment in LAMA84 cells as well as primary leukaemia cells in vitro, and also 
mediated the early stages of imatinib resistance (Burchert et al., 2005). More recently it has 
been shown that PI3K and mTOR inhibition can re-sensitise both CML progenitors and 
stem cells to nilotinib (Airiau et al., 2013). It has also been reported that PI3K is 
constitutively activated in a high percentage of patients with chronic leukaemia 
(Ringshausen et al., 2002).  
Therefore this data implies that the generation of the KCL22
Pon-Res
 cell line has resulted in 
the BCR-ABL-independent activation of mTORC1, which is in agreement with other 
studies which have also disclosed that the activation of PI3K/AKT/mTOR may be the 
cause of TKI resistance and sub-optimal response to TKIs in CML cells (Burchert et al., 
2005, Airiau et al., 2013, Ringshausen et al., 2002). This makes the PI3K/AKT/mTOR 
pathway an attractive potential therapeutic target for CML patients.  
In order to facilitate the identification of clinically relevant drugs with potential efficacy 
and selectivity against TKI-resistant CML cells, we screened a panel of NIH approved 
anti-cancer drugs. This screen included inhibitors that target signalling pathways known to 
be deregulated in cancer, such as RAS/MEK/ERK and PI3K/AKT/mTOR, inhibitors 
against tyrosine kinases as well as many other conventional chemotherapy drugs. The 
results of this screen pulled out 37 drugs which had inhibitory effects against the 
KCL22
Pon-Res 
cells. Most of the hits were non-specific chemotherapy drugs, such as 
vincristine sulphate, ixabepilone, docetaxel, cabazitaxel, vinblastine sulphate and paclitaxel. 
The mechanism of action of these drugs is to bind to tubulin, which then affects the 
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microtubule formation in the mitotic spindle and results in a cell cycle arrest. Other 
chemotherapies that showed a high efficacy against the KCL22
Pon-Res 
cells were protein 
translation inhibitors, such as omacetaxine and dactinomycin. However, none of these 
chemotherapy drugs target the actual mechanism driving the leukaemia and are non-
selective as they also target normal cells so create high levels of toxicity and side effects 
for patients.  
In spite of this, three specific drug targets were discovered from the initial drug screen; 
HDAC, MEK and mTOR inhibitors.  The top hit in the drug screen was to an HDAC 
inhibitor, romidepsin, which is currently approved for the treatment of CTCL and PTCLs 
(Iyer and Foss, 2015, Prince and Dickinson, 2012). HDAC inhibitors have previously been 
reported to have a synergistic effect when combined with BCR-ABL inhibition in 
treatment against imatinib resistant CML cells (Nguyen et al., 2011). In this study the 
HDAC inhibitor vorinostat was used which was also used in our drug screen as well as 
belinostat. Both vorinostat and belinostat had much higher IC50s, both within the µM 
range compared to romidepsin. Although as a single treatment vorinostat had a very high 
IC50 (>5 µM), when combined with ponatinib it was reduced to 1.5 µM, which may just 
be achievable. As cMax for vorinostat in studies have ranged from 1-1.5 µM (Rubin et al., 
2006, Ramalingam et al., 2010, Doi et al., 2013). 
A second promising target that was highlighted in the drug screen was MEK. In the initial 
screen the MEK inhibitor trametinib was the 19
th
 most effective drug against the 
KCL22
Pon-Res 
cell line, having an IC50 of 287 nM. A second MEK inhibitor was added to 
the screen, selumetinib, which had a greater efficacy against the TKI-resistant cells than 
the TKI sensitive cells. However, this was not translated to the BaF3
Pon-Res
 cell model, 
where only trametinib was effective and required a much higher concentration to achieve 
an IC50: 1.86 µM. Despite the inconsistency between the inhibitors and the cell models, 
neither of the MEK inhibitors affected the non-CML cells, which never reached an IC50 
within the 10 µM concentration range, suggesting that this could be a potential specific 
treatment for TKI-resistant CML. However, subsequent experiments in the laboratory 
showed that despite 72 hours of MEK inhibition it had very little effect on the apoptotic 
response and colony forming potential TKI-resistant CML cells. This is in keeping with 
previous studies, which have also reported that TKI-resistant CML cells (or CML cells 
having a sub-optimal response to TKIs), are sensitive to MEK inhibition, due to re-
activation of the RAS-MEK-ERK signalling pathway (Pietarinen et al., 2015, Packer et al., 
2011, Asmussen et al., 2014, Ma et al., 2014). In line with our study they also witnessed a 
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synergistic affect with combination MEK inhibition and TKI treatment (Ma et al., 2014, 
Packer et al., 2011).  
In addition, it has also been reported that there is cross-talk between the MEK/ERK and 
PI3K/AKT/mTOR pathways, which is involved in the maintenance of self-renewal and 
tumourigenicity of glioblastoma stem-like cells (Sunayama et al., 2010). Due to the 
sensitivity of the KCL22
Pon-Res 
cell to both mTOR and MEK inhibition, aberrant activity of 
these two pathways, working together, may be the potential mechanism driving survival 
and growth of these TKI-resistant CML cells.  
The most conclusive data obtained from the drug screen was the sensitivity of TKI-
resistant CML cells to mTOR inhibition. Three different allosteric mTOR inhibitors were 
all tested against the TKI-resistant cells and had strong anti-proliferative effects at very 
low drug concentrations. The three mTOR inhibitors from the drug screen were everolimus, 
sirolimus and temsirolimus, each achieving similar IC50s at 115 nM, 118 nM and 158 nM, 
respectively. Three consecutive hits for the same target suggests the importance of this 
pathway to the TKI-resistant CML cells. This was in line with the fact that mTOR was still 
active despite BCR-ABL inhibition (figure 3-11), strengthening the concept that activation 
of the mTOR signalling pathway was promoting cell proliferation and survival in the TKI-
resistant CML cells.  
Currently the only mTOR inhibitors that are FDA approved are the allosteric inhibitors; 
everolimus, sirolimus and temsirolimus. These inhibitors are currently approved for the 
treatment of renal cancer, and have been deemed safe and have been relatively well 
tolerated (Teachey et al., 2009). A very small trial was conducted assessing the efficacy of 
mTOR inhibition in patients suffering with imatinib-resistant CML. Four of the subjects 
were treated with 2 mg of sirolimus for 14 days. Due to the low number of subjects the 
results were inconclusive; two patients achieving a major response and two others 
achieving a minor response (Sillaber et al., 2008). Larger trials have been conducted in 
CML to gain more conclusive data but the results are not yet available; sirolimus 
(rapamycin) (NCT00780104) and rapamycin derivative, everolimus (RAD001) 
(NCT00093639 and NCT00081874).  
However, there are results available from clinical trials analysing the effect of allosteric 
mTOR inhibitors against other types of malignancies, such as breast cancer, a cancer 
known for its high frequency of patients with a deregulated PI3K/AKT/mTOR pathway. 
These trials reported surprisingly poor response rates, when it was expected to provided 
significant benefit (Wander et al., 2011).  
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Although the allosteric mTOR inhibitors showed great efficacy in our initial drug screen, 
subsequent validation of the mTOR inhibitors in the secondary screen using the BaF3
Pon-Res
 
cell model was unsuccessful, as both everolimus and sirolimus failed to achieve an IC50 
within 10 µM. This poor response rate is similar to the results we observed in our in vitro 
studies, in which rapamycin induced minimal apoptosis compared to our untreated control 
and had no effect on the colony forming potential of BaF3
Pon-Res
 cells or the KCL22
Pon-Res 
cells. The insensitivity of cells to rapamycin may be explained by its selective inhibitory 
action against only one of the mTOR complexes, mTORC1, and its inability to fully inhibit 
phosphorylation of downstream targets, such as 4EBP1 (Choo et al., 2008), which 
therefore gives an incomplete inhibition of the mTOR pathway. It has also been suggested 
that because mTORC2 is still active it creates a feedback loop, which actives AKT and 
allows further phosphorylation of both the mTOR complexes therefore opposing the effect 
of rapamycin (O’Reilly et al., 2006).  
Due to the suboptimal response of allosteric inhibitors observed in the clinic, new catalytic 
mTOR inhibitors have now been developed; PP242 and AZD8055, which target both 
mTOR complexes and NVP-Bez235, which is a dual inhibitor that targets PI3K and both 
the mTOR complexes. By using catalytic inhibitors against mTOR we hoped to increase 
efficacy of mTOR inhibition as they utilise competitive inhibition and directly inhibit 
kinase activity rather than a non-competitive method of inhibition used by allosteric 
inhibitors.  
The drug screen showed that the increased potency of the catalytic inhibitors AZD8055 
and NVP-Bez235 against mTOR kinase activity was more effective as the inhibitors were 
able to exert their anti-proliferative effects on both the KCL22
Pon-Res
 and BaF3
Pon-Res
 cells. 
In order to further test the efficacy of the PI3K/mTOR inhibitors, subsequent analysis was 
performed in the laboratory to gain an understanding of which target within the 
PI3K/AKT/mTOR pathway would provide the most effective inhibition. XTT assays were 
performed testing AZD8055, BKM120 and NVP-Bez235 against the human KCL22
Pon-Res
 
cells. This showed that the TKI-resistant cells were very sensitive to mTOR inhibition 
(AZD8055 EC50:28.28 nM) and even more so to the mTOR and PI3K inhibition (NVP-
Bez235 EC50:2.22 nM). The reduced sensitivity of AZD8055 compared to NVP-Bez235 
may be due to a feedback mechanism between mTORC2 and PI3K as the inhibition of 
mTOR leads to a feedback activation of PI3K
 
(Carracedo and Pandolfi, 2008), which may 
have a role in imposing resistance against AZD8055.  However, AZD8055 may just be less 
efficient at inhibiting mTOR. These cells were less affected by PI3K inhibition alone 
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(BKM120 EC50:1928 nM). This highlights the sensitivity of TKI-resistant CML cells to 
catalytic mTOR inhibition. 
These results correlate with apoptosis data, where rapamycin (mTORC1 only inhibitor) 
and BKM120 (PI3K only inhibitor) had a very minimal effect on cell death. AZD8055 
(mTORC1+2 inhibitor) increased apoptosis to more than 40%, which is almost double that 
in response to rapamycin. However, NVP-Bez235, induced the highest levels of apoptosis 
and significantly reduced the leukaemic colony forming potential of the TKI-resistant cells 
following 72 hours of treatment. Rapamycin and BKM120 had a minimal effect on CFC. 
AZD8055 reduced the CFC by ~50%. However, NVP-Bez235 had the ability to reduce 
CFC by approximately 66% (Figure 5-3). This data was supported by a second TKI-
resistant cell line BaF3
Pon-Res
, where mTORC1 inhibition by rapamycin showed a minimal 
increase in apoptosis compared to untreated, but no effect on CFC of CML cells. PP242 
(mTORC1+2 inhibitor) surprisingly, unlike AZD8055, had no effect on cell death nor CFC, 
which may be due to its decreased efficacy (IC50: 8 nM (Apsel et al., 2008)) compared to 
AZD8055 (IC50: 0.8 nM (Chresta et al., 2010)) against mTOR activity. However, even 
low concentrations of NVP-Bez235 caused a striking and very significant increase in 
apoptotic events and significantly reduced the CFC potential of these TKI-resistant CML 
cells.  
Importantly, this translated to clinical samples, as NVP-Bez235 was also highly effective 
in both inducing cell death and reducing clonogenic growth in primary TKI-resistant CML 
patient samples. Therefore, treating TKI-resistant cells with NVP-Bez235 became more 
attractive as this targets both mTOR and PI3K and may be able to overcome the feedback 
mechanisms within this pathway and produce a better inhibitory action against the whole 
PI3K/AKT/mTOR pathway.  
Due to the success of PI3K and mTOR inhibitors, such as NVP-Bez235, at inhibiting the 
PI3K/AKT/mTOR pathway, more dual inhibitors were developed such as apitolisib, VS-
5584 and gedatolisib. Therefore, we used these inhibitors to validate that the effects of 
NVP-Bez235 were due to PI3K and mTOR inhibition and not off target effects, which 
should not occur due to the low concentrations used in the assays. XTT assays revealed 
that the human KCL22
Pon-Res
 cells were just as sensitive to apitolisib (EC50: 29.15 nM), 
VS-5584 (EC50: 1.742 nM) and gedatolisib (EC50: 0.168 nM) as they were to NVP-
Bez235 (EC50: 2.15 nM). This data also corresponded with a significant induction in 
apoptosis, especially with gedatolisib, which achieved a similarly high level of apoptosis as 
NVP-Bez235. Once again this data successfully transferred to clinical samples, where we 
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showed at low concentrations that apitolisib, VS-5584 and gedatolisib can induce apoptosis 
and reduce clonogenic growth in primary TKI-resistant CML patient samples, increasingly 
more so than ponatinib.   
Subsequent testing of catalytic mTOR inhibitors revealed that NVP-Bez235 treatment led 
to the complete inhibition of RPS6 phosphorylation, indicating a potent inhibition of 
mTOR activity and therefore an effective inhibition of protein translation. This suggests 
that the cell death occurring in the TKI-resistant CML cells when treated with NVP-
Bez235 is due to mTOR inhibition.  
The importance of targeting mTOR was again highlighted in the RNA-seq experiment. 
KCL22
Pon-Res
 cells were shown to have an impaired transcriptional response when treated 
with ponatinib, however NVP-Bez235-mediated mTOR inhibition had a dramatic impact 
on the cells causing a large number of transcriptional changes, which mimicked the 
response seen in TKI sensitive CML cells following BCR-ABL inhibition (as many of the 
transcriptional changes that occurred in the KCL22
WT 
cells following ponatinib mediated 
BCR-ABL inhibition also occurred in the KCL22
Pon-Res 
cells following NVP-Bez235 
mediated mTOR inhibition). 
The ability of these compounds to inhibit proliferation at low nanomolar concentrations 
and induce a high apoptotic response further enhances the notion that TKI-resistant CML 
cells are highly dependent on mTOR signalling for their survival. Taken together, this 
therefore provides a rationale for testing dual PI3K/mTOR inhibitors in the clinic, for 
patients that don’t respond to BCR-ABL inhibitors. 
8.1 mTOR and autophagy 
It is evident that the depth of response to TKI is insufficient in TKI-resistant patients to 
inhibit leukaemic burden and therefore there is a clinical need for treatments which target 
the resistant clones or preferably target the primitive CML stem cells from which TKI-
resistant clones may arise (Bolton-Gillespie et al., 2013).  
In addition to the survival signals previously described, the PI3K/AKT/mTOR pathway is 
also linked to another survival mechanism; autophagy. Autophagy maintains cellular 
homeostasis by regulating recycling of intracellular waste in order to generate energy and 
new materials needed for cell survival (DeBerardinis et al., 2008, Amaravadi et al., 2011). 
This process is a fundamental cellular pathway for the survival and maintenance of HSCs 
(Warr et al., 2013b). Autophagy is specifically regulated by mTORC1, which when active, 
binds to the initiation complex to inhibit the induction of autophagy (Kim et al., 2011). 
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Therefore, by treating the TKI-resistant cells with mTOR inhibitors it may induce 
autophagy and protect cells against cell death and lead to a sub-optimal response to mTOR 
inhibitors.  
We tested this hypothesis using the KCL22
Pon-Res
-RFP-GFP-LC3 cell model and observed 
that treatment with NVP-Bez235 induced a striking increase in autophagy flow. Moreover, 
the NVP-Bez235 mediated autophagy induction could be inhibited through 
pharmacological intervention by HCQ. For this reason, we examined the response of TKI-
resistant cells to the combination of autophagy inhibition and NVP-Bez235 treatment and 
whether this could enhance the effects of NVP-Bez235 treatment alone.  
To address our hypothesis and test whether this effect could be reproduced in primary 
patient samples, we tested the combination treatment of NVP-Bez235 and HCQ on bone 
marrow derived MNCs from three different TKI-resistant CML patients. The combination 
treatment caused a dramatic and highly significant reduction in clonogenic growth by ~80% 
in both patients. Autophagy inhibition, using HCQ, enhanced the effect of NVP-Bez235 
alone, which had a great impact on cell survival.   
HCQ mediated autophagy inhibition also enhanced the efficacy of NVP-Bez235 in an in 
vivo xenograft model of TKI-resistant CML. The NVP-Bez235 and HCQ combination 
treatment had a significant impact on reducing the number of leukaemia initiating cells, 
which significantly reduced disease progression, tumour burden and prolonged survival 
rates beyond that of ponatinib +/- HCQ and NVP-Bez235 as a single agent treatment in 
NSG mice. The combination treatment of NVP-Bez235 and HCQ was also well tolerated 
by NSG mice, which makes it a promising treatment for going forward to clinical trial.  
HCQ is currently being tested in 27 active clinical trials for autophagy inhibition 
(Helgason et al., 2013). However, HCQ is not a specific autophagy inhibitor and exerts its 
effect by inhibiting lysosomal function and therefore has the potential to influence other 
pathways and cellular processes. Therefore, to validate that the effects of HCQ treatment 
were due to autophagy inhibition, we used two complimentary approaches; CRISPR and 
shRNA, to KO/KD the essential autophagy gene ATG7 in the KCL22
Pon-Res
 cells. ATG7 
plays an essential role in the lipidation of LC3; which is vital for the complete formation of 
the autophagosome.  
KCL22
Pon-Res 
transduced with CRISPR-ATG7 or shATG7 were treated with NVP-Bez235, 
which caused significant apoptosis in both the control cells and the ATG7 knockdown cells. 
However, the addition of ATG7 knockdown mediated autophagy inhibition greatly 
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enhanced the apoptotic response and reduced CFC potential when compared with the 
control cells treated with NVP-Bez235.  Importantly, this shows that autophagy inhibition 
further sensitises CML cells to NVP-Bez235 induced cell death, which confirms that 
autophagy was induced following NVP-Bez235 mediated mTOR inhibition and that 
autophagy was causing a cytoprotective effect against NVP-Bez235 treatment. This also 
suggests that the additive effect of HCQ, when used in combination with mTOR inhibitors, 
was due to blocking the autophagy process. 
8.2 NVP-Bez235 and toxicity 
As mTOR has many important roles in normal physiological conditions, such as protein 
translation, there are concerns that mTOR inhibition will also effect viability of normal 
cells as well as the leukaemic cells, which may cause a level of toxicity in patients. Results 
from the drug screen do infer a level of toxicity due to the sensitivity of the primary non-
CML cells to the dual PI3K and mTOR inhibitors, however not having a direct comparison 
with primary TKI-resistant CML cells makes it hard to assess whether there may still be a 
therapeutic window for treatment using the catalytic dual PI3K and mTOR inhibitors. 
However, drug concentrations needed to achieve an IC50 were higher in non-CML cell 
than in the TKI-resistant cell line models. Further assessment of NVP-Bez235 treatment on 
non-CML cells did result in an 80% induction of apoptosis and a reduction in colony 
formation, only 40% of colonies remained compared to untreated. This outcome not 
optimal however it may have potential as it was less toxic than last resort treatment 
omacetaxine, which at extremely low concentrations, 10 nM, induced 90% apoptosis and 
affected “normal” cell viability to the point that no cells survived to form colonies within 
the CFC assay.  
Additionally, there are concerns that mTOR inhibitors may also cause immunosuppression 
in the clinic. Critically, our primary objective for using mTOR inhibitors was to modulate 
aberrant mTOR activity in the TKI-resistant cells; however, mTOR inhibitors were 
originally developed as antifungal agents, which were later found to have 
immunosuppressive and anti-proliferative properties. The mode of action of sirolimus and 
its analogues is to target mTOR activity, which then inhibits interleukin-2 signal 
transduction, which inevitably results in a G1/S phase cell cycle arrest (Hardinger et al., 
2004, Kelly et al., 1997). Due to the inhibition of interleukin-2 and the subsequent cytokine 
production they also block the activation of T-cells and B-cells, causing 
immunosuppression (Kelly et al., 1997). However, previous clinical trials with allosteric 
inhibitors; everolimus, sirolimus and temsirolimus have considered them safe and 
relatively well tolerated (Teachey et al., 2009) and have subsequently been FDA approved. 
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Currently, many early phase clinical trials are being conducted to test the safety and 
efficacy of the catalytic inhibitors. AZD8055 has been tested in 4 trials for solid and 
advanced phase tumours. The dual PI3K and mTOR inhibitors are also undergoing early 
phase safety testing in clinical trials; NVP-Bez235 is currently being tested in 13 trials, one 
of which is recruiting CML patients (NCT01756118), gedatolisib is being tested in two 
trials for breast cancer, VS-5584 is also being tested in two trials, one of which is 
recruiting lymphoma patients, and apitolisib has been tested in 12 clinical trials, 2 of which 
included non-Hodgkin’s lymphoma patients.  
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8.3 Conclusion 
In this study we have reported that TKI-resistant cells are highly sensitive to inhibition of 
the PI3K/AKT/mTOR pathway. Moreover, NVP-Bez235 is most effective at targeting 
TKI-resistant cells by inducing apoptosis and reducing the survival of TKI-resistant cells, 
which was shown in both
 
ponatinib-resistant cell line models, in cells derived from a TKI-
resistant CML patients as well as in an in vivo model. Importantly, our data also suggests 
that NVP-Bez235 is more effective against TKI-resistant cells compared to current TKI 
treatments dasatinib and ponatinib.  
As NVP-Bez235 is the most effective PI3K/AKT/mTOR inhibitor it highlights the 
importance of a complete inhibition of the pathway, as targeting mTOR and PI3K together 
is more effective against TKI-resistant cell survival compared to mTOR or PI3K inhibition 
alone, as seen with rapamycin, PP242, AZD8055 and BKM120 treatments. In addition, our 
results demonstrate that NVP-Bez235 treatment can be enhanced with the pharmacological 
inhibition of autophagy, providing a rationale for testing this combination in the clinic for 
CML patients with BCR-ABL-independent resistance mechanisms.  
 
Figure ‎8-1: Our proposed drug treatment strategy for BCR-ABL-independent mechanism 
TKI-resistant CML 
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8.4 Future work 
 
Despite our attempts to identify the underlying mechanism causing BCR-ABL independent 
TKI resistance, we were unable to find the source of the aberrant pro-survival and 
proliferation signalling. Different experimental approaches were tried such as the (1) NIH 
repurposing drug screen, which included many inhibitors that target pathways that are 
already deregulated in cancer, (2) RNA-seq was performed to understand the differential 
gene expression between TKI-sensitive and TKI-resistant CML, and (3) CRISPR whole 
genome KO screen was carried out using TKI-sensitive CML cells (KCL22
WT
), which 
were subsequently treated with ponatinib to assess whether a single gene KO (a secondary 
genetic hit) could cause TKI resistance.  
With the development of CRISPR protocols within the lab an attempt was made to KO 
mTOR in the KCL22
Pon-Res 
cells, to gain a more specific mTOR inhibition. Due to the 
sensitivity of KCL22
Pon-Res 
cells to mTOR inhibition it is hypothesised that this may results 
in 100% death. However, despite successful transduction of the virus containing CRISPR 
gRNAs against mTOR, no KO was achieved. This is presumably due to complications in 
the generation of gRNAs against mTOR.  In order to generate an mTOR KO KCL22
Pon-Res
 
model more time will need to be invested to design guides which are more efficient.  
In keeping with this study, we also made an attempt to further validate the BCR-ABL 
independent TKI-resistant CML model, by designing gRNAs, which would KO BCR-ABL 
only, in KCL22
Pon-Res 
cells, as these cells can survive without BCR-ABL signalling. 
Despite designing 3 gRNAs against the BCR-ABL junction, none of the gRNA were 
efficient to KO BCR-ABL signalling, which was analysed by the phosphorylation of 
CRKL via western blot. Once again further experiments are required to understand the 
BCR-ABL sequence in more detail and find and optimum target sequence. However, if this 
approach is successful, we will have generated a CML cell line, which can grow and 
proliferate despite not expressing BCR-ABL, which will give us a true BCR-ABL 
independent CML model.  
The most substantial data we gathered during our study was that mTOR activity is 
sustained, despite BCR-ABL inhibition, possibly leading to the aberrant transcriptional 
response following TKI treatment. In an attempt to answer the question whether primary 
cells had aberrant transcriptional response following BCR-ABL inhibition we performed 
RNA-seq on MNCs from TKI-resistant patients.  However, the results from these 
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experiments were inconclusive, possibly due to the cell heterogeneity within the MNC 
population, which “masked” the effect of the TKI treatment. 
The majority of our screening processes focussed on gene transcription, however with the 
advancements technology in large proteomics screens there could be a potential to analyse 
differential protein expression between TKI-sensitive and TKI-resistant CML using mass 
spectrometry. This data can then be processed and used to identify any functionally active 
proteins and networks.  
It is also possible to perform phosphoproteomic analysis on the TKI-resistant cells, which 
is a method that has already gained some success in investigating drug resistance in breast 
cancer (Oyama et al., 2011, Rexer et al., 2011). Protein phosphorylation, is involved in 
signal transduction and it requires coherent activation of protein kinases and phosphatases, 
which leads to the defined functions. In imatinib-resistant CML many kinases have already 
been implicated in development of TKI-resistance, therefore this could be an interesting 
experiment to perform understanding the signalling pathways involved in BCR-ABL 
independent TKI-resistance CML and how mTOR fits into the scenario. 
Another screening method, which is of high priority, to facilitate the characterisation of the 
resistance mechanism in the KCL22
Pon-Res
 cells is whole genome sequencing (WGS). This 
technology has the potential to give us invaluable data such as; potential sequence variants, 
mutations, gene copy numbers, as well as structural changes such as chromosomal 
translocations and fusion genes, which may be the source of pro- survival signalling. A 
comparison between the original KCL22
WT 
and the TKI-resistant KCL22
Pon-Res
 to see what 
mutations have been gained to cause TKI-resistance. BCR-ABL independent TKI-
resistance CML samples are scarce, however if a mechanism of resistance is found in the 
cell lines, validating this using WGS in primary patient cells would be the next step.  
From translational point of view, we hope to continue the search for the most suitable 
catalytic mTOR inhibitor and initiate discussion with pharmaceutical companies and 
clinical scientist about ways to test our hypothesis in the clinic. In this setting, the most 
likely clinical trial scenario would involve testing tolerability of adding mTOR inhibitors 
to TKI treatment in patients who are failing 1-3
rd
 gen TKIs. Although TKI are not effective 
in this group of patients, being granted ethical approval to stop TKI and give them a 
treatment that does not target BCR-ABL specifically would be challenging and require an 
in depth screening process to track disease progression or regression in these patients, 
which would require a lot of resources. However, progressing this study to a clinical trial 
has already been briefly discussed with my second supervisor Tessa Holyoake, who is 
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involved in designing and leading clinical trials in CML and therefore already has the 
knowledge and expertise to help guide this project to the level required to translate it into a 
clinical trial.   
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9 Appendices 
9.1 Plasmid maps 
 
9.1.1 pLKO.1 puro  
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9.1.2 psPAX2 – Addgene (12260) 
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9.1.3 pCMV-VSV-G – Addgene (8454) 
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9.1.4 LentiCRISPR v2 Addgene (52961)
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9.1.5 LentiCas9-Blast – Addgene (52962)  
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9.1.6 LentiGuide-Puro – Addgene (52963) 
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9.2 CRISPR data  
9.2.1 gRNA lists from the KCL22WT screen sample 1 
Gene WGKO-S1 WGKO-S1 % 
EDARADD 16128536.39 45.34378387 
TBC1D9 9628072.508 27.068373 
MRFAP1L1 9595178.017 26.97589339 
MAP3K7 4345.029167 0.012215619 
OR5D14 621.5791667 0.001747508 
C6 618.5666667 0.001739039 
HCAR1 614.55 0.001727747 
PRPS1 607.5208333 0.001707985 
CCKAR 600.4916667 0.001688223 
DFNB31 586.4333333 0.001648699 
TMEM200C 578.4 0.001626114 
KIAA0513 574.3833333 0.001614822 
SNTB1 568.3583333 0.001597883 
HS6ST3 565.3458333 0.001589414 
NARG2 565.3458333 0.001589414 
TRIM58 564.3416667 0.001586591 
TMEM55A 563.3375 0.001583768 
ABCB6 555.3041667 0.001561183 
F2R 543.2541667 0.001527305 
OXA1L 541.2458333 0.001521659 
ZNF283 539.2375 0.001516013 
GJA8 537.2291667 0.001510367 
RYBP 534.2166667 0.001501897 
HIPK4 524.175 0.001473666 
ZCCHC17 523.1708333 0.001470843 
NR4A1 522.1666667 0.00146802 
hsa-mir-618 522.1666667 0.00146802 
ITCH 520.1583333 0.001462374 
FRG2B 516.1416667 0.001451081 
ACTL8 515.1375 0.001448258 
CXCR1 512.125 0.001439789 
GFOD1 510.1166667 0.001434143 
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NRTN 507.1041667 0.001425673 
RUSC1 499.0708333 0.001403088 
ARG1 498.0666667 0.001400265 
GFER 497.0625 0.001397442 
RPL32 496.0583333 0.001394619 
PHF16 495.0541667 0.001391796 
RPRM 495.0541667 0.001391796 
FAM107B 492.0416667 0.001383326 
ZNF517 492.0416667 0.001383326 
RBMY1D 488.025 0.001372034 
JKAMP 487.0208333 0.001369211 
FOXK1 487.0208333 0.001369211 
CCDC97 483.0041667 0.001357918 
ALS2CL 480.9958333 0.001352272 
RAD21L1 480.9958333 0.001352272 
MED11 479.9916667 0.001349449 
RPH3AL 479.9916667 0.001349449 
CYP4A22 478.9875 0.001346626 
HECTD1 477.9833333 0.001343803 
FXR2 476.9791667 0.00134098 
DEFB133 468.9458333 0.001318395 
SPATA9 468.9458333 0.001318395 
SLC19A2 468.9458333 0.001318395 
TCF3 463.925 0.001304279 
FAM216A 459.9083333 0.001292987 
hsa-mir-548a-3 454.8875 0.001278871 
LRRC40 453.8833333 0.001276048 
VCX2 453.8833333 0.001276048 
ELMOD1 451.875 0.001270402 
EEA1 450.8708333 0.001267579 
SBNO2 448.8625 0.001261932 
ATP6V1C1 447.8583333 0.001259109 
ISOC1 447.8583333 0.001259109 
PDCD6 447.8583333 0.001259109 
FARSA 446.8541667 0.001256286 
267 
 
hsa-mir-7-3 443.8416667 0.001247817 
ITM2C 442.8375 0.001244994 
OLFML3 441.8333333 0.001242171 
PPCDC 439.825 0.001236524 
GCSAM 438.8208333 0.001233701 
LOC100287036 429.7833333 0.001208293 
KREMEN1 428.7791667 0.00120547 
OR52H1 428.7791667 0.00120547 
RORC 423.7583333 0.001191355 
PPP3CB 420.7458333 0.001182885 
TBX15 420.7458333 0.001182885 
YPEL1 418.7375 0.001177239 
C2orf44 415.725 0.00116877 
HIST1H2AA 415.725 0.00116877 
SUPT20HL1 415.725 0.00116877 
GRIN2B 411.7083333 0.001157477 
DAAM2 409.7 0.001151831 
DUSP7 408.6958333 0.001149008 
LOC81691 408.6958333 0.001149008 
NLRP8 408.6958333 0.001149008 
ATXN1 407.6916667 0.001146185 
SF1 404.6791667 0.001137715 
SLC12A5 404.6791667 0.001137715 
POLN 403.675 0.001134892 
KIDINS220 402.6708333 0.001132069 
TCTN1 399.6583333 0.0011236 
C1QBP 396.6458333 0.001115131 
C7orf60 394.6375 0.001109484 
NR1I3 393.6333333 0.001106661 
MCOLN3 391.625 0.001101015 
CES5A 390.6208333 0.001098192 
FKBP15 390.6208333 0.001098192 
SLC17A9 389.6166667 0.001095369 
CACNA1G 388.6125 0.001092546 
IL10RB 386.6041667 0.001086899 
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PTPN3 384.5958333 0.001081253 
PSPH 383.5916667 0.00107843 
ZNF558 379.575 0.001067138 
CD300A 378.5708333 0.001064314 
KIAA1704 377.5666667 0.001061491 
SLC25A35 375.5583333 0.001055845 
FGFR1 374.5541667 0.001053022 
LIPT1 374.5541667 0.001053022 
DIAPH2 372.5458333 0.001047376 
FAM60A 372.5458333 0.001047376 
KPNA3 371.5416667 0.001044553 
FBXW12 362.5041667 0.001019145 
MS4A7 362.5041667 0.001019145 
OR4K14 361.5 0.001016321 
CHRNB3 361.5 0.001016321 
ZCCHC16 360.4958333 0.001013498 
CLDN17 358.4875 0.001007852 
HELB 357.4833333 0.001005029 
WNT5B 355.475 0.000999383 
ACLY 355.475 0.000999383 
GCSH 354.4708333 0.00099656 
CEP57 352.4625 0.000990913 
TTC29 351.4583333 0.00098809 
IQCB1 349.45 0.000982444 
TYRP1 346.4375 0.000973975 
MCM9 345.4333333 0.000971152 
SNCB 345.4333333 0.000971152 
CEP170 344.4291667 0.000968329 
SRBD1 343.425 0.000965505 
GHSR 342.4208333 0.000962682 
MCM3 342.4208333 0.000962682 
C6orf57 341.4166667 0.000959859 
AP1G2 340.4125 0.000957036 
STON1-GTF2A1L 335.3916667 0.00094292 
ZDHHC13 335.3916667 0.00094292 
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C4orf19 330.3708333 0.000928805 
MTMR12 330.3708333 0.000928805 
TMEM39A 330.3708333 0.000928805 
CTNNBIP1 330.3708333 0.000928805 
LRRC19 329.3666667 0.000925982 
ARPC4-TTLL3 327.3583333 0.000920336 
SFTPD 327.3583333 0.000920336 
CIAO1 326.3541667 0.000917512 
RPUSD2 324.3458333 0.000911866 
TBC1D24 324.3458333 0.000911866 
FBXW8 323.3416667 0.000909043 
COMMD2 322.3375 0.00090622 
SALL2 321.3333333 0.000903397 
hsa-mir-597 321.3333333 0.000903397 
C1orf198 320.3291667 0.000900574 
TDGF1 320.3291667 0.000900574 
COMP 318.3208333 0.000894928 
NR4A1 318.3208333 0.000894928 
hsa-mir-3689f 316.3125 0.000889281 
MRGPRD 315.3083333 0.000886458 
DNAJB3 315.3083333 0.000886458 
hsa-mir-8074 314.3041667 0.000883635 
HP 313.3 0.000880812 
POP1 312.2958333 0.000877989 
RNF4 312.2958333 0.000877989 
WDR4 312.2958333 0.000877989 
SESN3 311.2916667 0.000875166 
SH3RF3 311.2916667 0.000875166 
ZNF280D 311.2916667 0.000875166 
ATP6V0E1 310.2875 0.000872343 
CD6 310.2875 0.000872343 
PLA2R1 310.2875 0.000872343 
SLAIN1 310.2875 0.000872343 
hsa-mir-6073 310.2875 0.000872343 
OTOP1 309.2833333 0.000869519 
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EAPP 308.2791667 0.000866696 
MPPED1 308.2791667 0.000866696 
SMIM15 307.275 0.000863873 
DRC1 306.2708333 0.00086105 
LHFPL2 306.2708333 0.00086105 
PSMC6 306.2708333 0.00086105 
PCDHGB6 305.2666667 0.000858227 
SUPT4H1 304.2625 0.000855404 
ATRX 303.2583333 0.000852581 
FAM193A 303.2583333 0.000852581 
TRIM40 303.2583333 0.000852581 
C19orf26 302.2541667 0.000849758 
CDCA3 302.2541667 0.000849758 
EBP 302.2541667 0.000849758 
PRH1 302.2541667 0.000849758 
CCR3 301.25 0.000846935 
RRH 301.25 0.000846935 
OR7D4 300.2458333 0.000844111 
UGT2B7 300.2458333 0.000844111 
NonTargetingControlGuideForHuman_0068 300.2458333 0.000844111 
C6orf48 300.2458333 0.000844111 
USP30 300.2458333 0.000844111 
GAL3ST1 299.2416667 0.000841288 
GDPD2 299.2416667 0.000841288 
GYLTL1B 299.2416667 0.000841288 
MSX2 299.2416667 0.000841288 
OR6K6 299.2416667 0.000841288 
S100A4 299.2416667 0.000841288 
TNFSF11 299.2416667 0.000841288 
AEBP1 298.2375 0.000838465 
MRPL22 298.2375 0.000838465 
TCTN2 298.2375 0.000838465 
SEC24A 298.2375 0.000838465 
CACNB3 297.2333333 0.000835642 
CRIP1 297.2333333 0.000835642 
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NRARP 297.2333333 0.000835642 
TMEM167B 297.2333333 0.000835642 
TRAPPC8 297.2333333 0.000835642 
ITGA7 296.2291667 0.000832819 
CNTN1 295.225 0.000829996 
KLK3 295.225 0.000829996 
NonTargetingControlGuideForHuman_0755 295.225 0.000829996 
COPRS 294.2208333 0.000827173 
LMTK2 294.2208333 0.000827173 
STRIP1 294.2208333 0.000827173 
HAPLN4 294.2208333 0.000827173 
GJA3 293.2166667 0.00082435 
HTR3A 293.2166667 0.00082435 
INSRR 293.2166667 0.00082435 
PPP1R21 293.2166667 0.00082435 
TRA2A 293.2166667 0.00082435 
hsa-mir-4519 293.2166667 0.00082435 
GAR1 293.2166667 0.00082435 
UCHL1 293.2166667 0.00082435 
EVC2 292.2125 0.000821527 
SIGLEC8 292.2125 0.000821527 
TMEM258 292.2125 0.000821527 
ACTG1 291.2083333 0.000818703 
C9orf117 291.2083333 0.000818703 
CHMP1B 291.2083333 0.000818703 
ETV2 291.2083333 0.000818703 
NDUFB11 291.2083333 0.000818703 
PPP1R13B 291.2083333 0.000818703 
ZKSCAN3 291.2083333 0.000818703 
GPD2 290.2041667 0.00081588 
INS 290.2041667 0.00081588 
OTUB2 290.2041667 0.00081588 
ACTG1 289.2 0.000813057 
SFXN1 289.2 0.000813057 
GAB1 289.2 0.000813057 
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C1orf229 288.1958333 0.000810234 
ZNF775 288.1958333 0.000810234 
NonTargetingControlGuideForHuman_0191 288.1958333 0.000810234 
CD59 287.1916667 0.000807411 
ID2 287.1916667 0.000807411 
SLC25A21 287.1916667 0.000807411 
POLR2G 287.1916667 0.000807411 
hsa-mir-4787 286.1875 0.000804588 
CDC45 286.1875 0.000804588 
FAM110C 285.1833333 0.000801765 
C22orf42 285.1833333 0.000801765 
MYL7 285.1833333 0.000801765 
Sep-08 285.1833333 0.000801765 
TRAPPC13 285.1833333 0.000801765 
FOXA2 284.1791667 0.000798942 
GHRH 284.1791667 0.000798942 
SQRDL 284.1791667 0.000798942 
YTHDC2 284.1791667 0.000798942 
KIAA0101 283.175 0.000796118 
C7orf57 282.1708333 0.000793295 
C9orf114 282.1708333 0.000793295 
LY6D 282.1708333 0.000793295 
SIGLEC8 282.1708333 0.000793295 
TRMT2B 282.1708333 0.000793295 
ADCK4 281.1666667 0.000790472 
MAP3K6 281.1666667 0.000790472 
MORN5 281.1666667 0.000790472 
MYLK4 281.1666667 0.000790472 
GAGE12D 281.1666667 0.000790472 
PPP5D1 281.1666667 0.000790472 
ZNF506 281.1666667 0.000790472 
MUC12 280.1625 0.000787649 
UBQLNL 280.1625 0.000787649 
hsa-mir-374c 280.1625 0.000787649 
ECI1 279.1583333 0.000784826 
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IZUMO1 279.1583333 0.000784826 
NIPBL 279.1583333 0.000784826 
PRKAG1 279.1583333 0.000784826 
hsa-mir-4781 279.1583333 0.000784826 
PCID2 279.1583333 0.000784826 
GALNT16 278.1541667 0.000782003 
GPX8 278.1541667 0.000782003 
HYOU1 278.1541667 0.000782003 
TNFSF14 278.1541667 0.000782003 
NEU3 277.15 0.00077918 
OARD1 277.15 0.00077918 
PCF11 277.15 0.00077918 
CYP4A11 276.1458333 0.000776357 
MSGN1 276.1458333 0.000776357 
OR51Q1 276.1458333 0.000776357 
TTC19 276.1458333 0.000776357 
hsa-mir-181d 276.1458333 0.000776357 
HNRNPL 276.1458333 0.000776357 
NINJ1 275.1416667 0.000773534 
SLC29A2 275.1416667 0.000773534 
hsa-mir-503 275.1416667 0.000773534 
hsa-mir-548an 275.1416667 0.000773534 
PMM1 275.1416667 0.000773534 
LIPA 274.1375 0.00077071 
CFHR5 274.1375 0.00077071 
GPR37 274.1375 0.00077071 
KRTAP16-1 274.1375 0.00077071 
NME4 274.1375 0.00077071 
SDR9C7 274.1375 0.00077071 
EEF2 274.1375 0.00077071 
SLC1A3 274.1375 0.00077071 
FTH1 273.1333333 0.000767887 
CDY2B 273.1333333 0.000767887 
PLOD3 273.1333333 0.000767887 
hsa-mir-3973 273.1333333 0.000767887 
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PDLIM4 273.1333333 0.000767887 
KCNQ2 272.1291667 0.000765064 
OXR1 272.1291667 0.000765064 
RGS22 271.125 0.000762241 
KDSR 270.1208333 0.000759418 
BEND2 269.1166667 0.000756595 
FARSB 269.1166667 0.000756595 
TSHZ3 269.1166667 0.000756595 
ZNF697 269.1166667 0.000756595 
TMEM74B 269.1166667 0.000756595 
CARD16 268.1125 0.000753772 
DDIT4L 268.1125 0.000753772 
EPHX1 268.1125 0.000753772 
KCNN4 268.1125 0.000753772 
LCN6 268.1125 0.000753772 
P2RX6 268.1125 0.000753772 
APOL3 268.1125 0.000753772 
DSC2 267.1083333 0.000750949 
MS4A14 267.1083333 0.000750949 
hsa-mir-4255 267.1083333 0.000750949 
LUZP2 266.1041667 0.000748126 
RPAP2 266.1041667 0.000748126 
AKIRIN2 265.1 0.000745302 
CRYBA1 265.1 0.000745302 
NRDE2 265.1 0.000745302 
NTSR1 265.1 0.000745302 
RHBDD3 265.1 0.000745302 
TRAT1 265.1 0.000745302 
DPPA5 264.0958333 0.000742479 
OR2B3 264.0958333 0.000742479 
PTPRJ 264.0958333 0.000742479 
RIMS1 264.0958333 0.000742479 
HOXA11 263.0916667 0.000739656 
LCAT 263.0916667 0.000739656 
NDUFB6 263.0916667 0.000739656 
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ZNF729 263.0916667 0.000739656 
hsa-mir-548e 263.0916667 0.000739656 
C14orf183 263.0916667 0.000739656 
FCER1G 263.0916667 0.000739656 
NXPE3 263.0916667 0.000739656 
CACUL1 262.0875 0.000736833 
COL22A1 262.0875 0.000736833 
GTPBP4 262.0875 0.000736833 
TCEAL8 262.0875 0.000736833 
DFFA 261.0833333 0.00073401 
EFS 261.0833333 0.00073401 
LIN54 261.0833333 0.00073401 
VGF 261.0833333 0.00073401 
ZNF189 261.0833333 0.00073401 
LGALS7 261.0833333 0.00073401 
REPIN1 261.0833333 0.00073401 
CST2 260.0791667 0.000731187 
DDX19A 260.0791667 0.000731187 
SMN2 260.0791667 0.000731187 
IDNK 259.075 0.000728364 
KCNMB2 259.075 0.000728364 
OR8G5 259.075 0.000728364 
C19orf44 258.0708333 0.000725541 
NPAS3 258.0708333 0.000725541 
RGPD4 258.0708333 0.000725541 
DPAGT1 257.0666667 0.000722717 
KLK1 257.0666667 0.000722717 
P2RX1 257.0666667 0.000722717 
SP5 257.0666667 0.000722717 
NonTargetingControlGuideForHuman_0301 257.0666667 0.000722717 
CHSY3 256.0625 0.000719894 
HRASLS5 256.0625 0.000719894 
KIAA1239 256.0625 0.000719894 
VGLL2 256.0625 0.000719894 
hsa-mir-16-2 256.0625 0.000719894 
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hsa-mir-4470 256.0625 0.000719894 
CHRNB4 256.0625 0.000719894 
BAG5 255.0583333 0.000717071 
EIF4E2 255.0583333 0.000717071 
LRFN2 255.0583333 0.000717071 
MMP8 255.0583333 0.000717071 
MRPL2 255.0583333 0.000717071 
PDHA2 255.0583333 0.000717071 
hsa-mir-6740 255.0583333 0.000717071 
BEND7 254.0541667 0.000714248 
LACTB2 254.0541667 0.000714248 
TBC1D2B 254.0541667 0.000714248 
hsa-mir-4288 254.0541667 0.000714248 
FBXO9 253.05 0.000711425 
KIAA0895 253.05 0.000711425 
MAP2K7 253.05 0.000711425 
PRSS16 253.05 0.000711425 
KCNJ15 253.05 0.000711425 
GRN 252.0458333 0.000708602 
PRB2 252.0458333 0.000708602 
hsa-mir-6764 252.0458333 0.000708602 
EXOSC9 252.0458333 0.000708602 
MLL3 252.0458333 0.000708602 
NCOR2 252.0458333 0.000708602 
PPP1R10 252.0458333 0.000708602 
GLIS3 251.0416667 0.000705779 
MVP 251.0416667 0.000705779 
WASH1 251.0416667 0.000705779 
ZNHIT6 251.0416667 0.000705779 
hsa-mir-4452 251.0416667 0.000705779 
FAM177B 251.0416667 0.000705779 
MTL5 250.0375 0.000702956 
PRELID1 250.0375 0.000702956 
STAG3 250.0375 0.000702956 
TBK1 250.0375 0.000702956 
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TTC40 250.0375 0.000702956 
hsa-mir-5096 249.0333333 0.000700133 
BANF1 248.0291667 0.000697309 
DISP2 248.0291667 0.000697309 
HKR1 248.0291667 0.000697309 
CD1D 248.0291667 0.000697309 
CPSF7 248.0291667 0.000697309 
ATP6V1G3 247.025 0.000694486 
CCL23 247.025 0.000694486 
LONP1 247.025 0.000694486 
WIPI1 247.025 0.000694486 
TMEM159 247.025 0.000694486 
CSN3 246.0208333 0.000691663 
CST9L 246.0208333 0.000691663 
DOC2B 246.0208333 0.000691663 
MCM4 246.0208333 0.000691663 
NPW 246.0208333 0.000691663 
HMGN1 245.0166667 0.00068884 
MAT1A 245.0166667 0.00068884 
WWC3 245.0166667 0.00068884 
hsa-mir-1-2 245.0166667 0.00068884 
C16orf78 245.0166667 0.00068884 
SLC16A5 245.0166667 0.00068884 
ZIC3 245.0166667 0.00068884 
C1orf61 244.0125 0.000686017 
CHRM4 244.0125 0.000686017 
SEC31B 244.0125 0.000686017 
ASIC1 244.0125 0.000686017 
H2AFX 243.0083333 0.000683194 
LAMB3 243.0083333 0.000683194 
OR6C6 243.0083333 0.000683194 
PUS3 243.0083333 0.000683194 
RPL5 243.0083333 0.000683194 
hsa-mir-7112-1 243.0083333 0.000683194 
TMEM11 243.0083333 0.000683194 
278 
 
UNC79 242.0041667 0.000680371 
ANKRD7 242.0041667 0.000680371 
ITGB1 242.0041667 0.000680371 
TAS2R4 242.0041667 0.000680371 
USP18 242.0041667 0.000680371 
USE1 242.0041667 0.000680371 
CDAN1 241 0.000677548 
KRT3 241 0.000677548 
RNF166 241 0.000677548 
hsa-mir-6859-2 241 0.000677548 
ACOT6 239.9958333 0.000674725 
ACTR2 239.9958333 0.000674725 
HIST1H2AJ 239.9958333 0.000674725 
SLC25A39 239.9958333 0.000674725 
SH3BGRL2 239.9958333 0.000674725 
FOXK1 238.9916667 0.000671901 
OR6F1 238.9916667 0.000671901 
PPP1R11 238.9916667 0.000671901 
PRAMEF2 238.9916667 0.000671901 
TNFSF14 238.9916667 0.000671901 
TRA2A 238.9916667 0.000671901 
ZFC3H1 238.9916667 0.000671901 
C10orf76 238.9916667 0.000671901 
CYP2F1 238.9916667 0.000671901 
OPRD1 237.9875 0.000669078 
TAGLN2 237.9875 0.000669078 
FAM45A 237.9875 0.000669078 
ASB17 236.9833333 0.000666255 
MICALCL 236.9833333 0.000666255 
FTSJD2 236.9833333 0.000666255 
GTPBP6_X 236.9833333 0.000666255 
G6PC2 235.9791667 0.000663432 
GJA10 235.9791667 0.000663432 
NODAL 235.9791667 0.000663432 
hsa-mir-7111 235.9791667 0.000663432 
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KCNJ13 234.975 0.000660609 
P2RY1 234.975 0.000660609 
POLR2K 234.975 0.000660609 
SMC1A 234.975 0.000660609 
hsa-mir-635 234.975 0.000660609 
NonTargetingControlGuideForHuman_0207 234.975 0.000660609 
DMXL2 234.975 0.000660609 
MOB1B 234.975 0.000660609 
CACNA1S 233.9708333 0.000657786 
CRIPAK 233.9708333 0.000657786 
PRAMEF8 233.9708333 0.000657786 
TEX14 233.9708333 0.000657786 
TVP23C-CDRT4 233.9708333 0.000657786 
BPIFB2 233.9708333 0.000657786 
FKBP1A 233.9708333 0.000657786 
ATP13A2 232.9666667 0.000654963 
PAIP2 232.9666667 0.000654963 
PAXBP1 232.9666667 0.000654963 
SYN2 232.9666667 0.000654963 
hsa-mir-3689c 232.9666667 0.000654963 
TMEM129 232.9666667 0.000654963 
ZNF610 232.9666667 0.000654963 
DEPTOR 231.9625 0.00065214 
NPLOC4 231.9625 0.00065214 
PBK 231.9625 0.00065214 
BCAS3 230.9583333 0.000649316 
UGT2A1 230.9583333 0.000649316 
SPRTN 230.9583333 0.000649316 
OPRM1 229.9541667 0.000646493 
C13orf45 229.9541667 0.000646493 
SAPCD2 229.9541667 0.000646493 
C7orf34 228.95 0.00064367 
CLEC1A 228.95 0.00064367 
CRHR1 228.95 0.00064367 
KCNK4 228.95 0.00064367 
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PLGRKT 228.95 0.00064367 
SLC30A6 228.95 0.00064367 
hsa-mir-4298 228.95 0.00064367 
hsa-mir-562 228.95 0.00064367 
LYRM2 227.9458333 0.000640847 
PCGF5 227.9458333 0.000640847 
UGT3A2 227.9458333 0.000640847 
FAM64A 227.9458333 0.000640847 
HYKK 227.9458333 0.000640847 
BAG2 226.9416667 0.000638024 
EPS8L2 226.9416667 0.000638024 
MUC2 226.9416667 0.000638024 
TMEM130 226.9416667 0.000638024 
PMPCB 226.9416667 0.000638024 
CCNI 225.9375 0.000635201 
DNTTIP1 225.9375 0.000635201 
FFAR1 225.9375 0.000635201 
STX2 225.9375 0.000635201 
FAM25G 224.9333333 0.000632378 
BEST4 224.9333333 0.000632378 
COL3A1 224.9333333 0.000632378 
MAGEB18 224.9333333 0.000632378 
ZNF585A 224.9333333 0.000632378 
NonTargetingControlGuideForHuman_0221 224.9333333 0.000632378 
hsa-mir-26b 223.9291667 0.000629555 
SCO1 223.9291667 0.000629555 
DGKD 222.925 0.000626732 
UTF1 222.925 0.000626732 
CYP4F3 221.9208333 0.000623908 
HGFAC 221.9208333 0.000623908 
LARP6 221.9208333 0.000623908 
RFNG 221.9208333 0.000623908 
RSPO4 221.9208333 0.000623908 
TUSC3 221.9208333 0.000623908 
MAN2A1 220.9166667 0.000621085 
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MMP1 220.9166667 0.000621085 
CCL25 220.9166667 0.000621085 
EPPIN 220.9166667 0.000621085 
CDH8 219.9125 0.000618262 
TMPRSS6 219.9125 0.000618262 
hsa-mir-126 219.9125 0.000618262 
hsa-mir-1915 219.9125 0.000618262 
DLL3 219.9125 0.000618262 
ABCG4 218.9083333 0.000615439 
BSG 218.9083333 0.000615439 
F2RL2 218.9083333 0.000615439 
PDE2A 218.9083333 0.000615439 
CASP12 217.9041667 0.000612616 
DPH3P1 217.9041667 0.000612616 
FCAMR 217.9041667 0.000612616 
NHEJ1 217.9041667 0.000612616 
USP25 217.9041667 0.000612616 
LIPA 217.9041667 0.000612616 
MAGED2 216.9 0.000609793 
OR6F1 216.9 0.000609793 
TNFRSF13C 216.9 0.000609793 
hsa-mir-542 216.9 0.000609793 
ENTPD1 215.8958333 0.00060697 
hsa-mir-6815 215.8958333 0.00060697 
EIF4E1B 215.8958333 0.00060697 
OXSR1 214.8916667 0.000604147 
WFDC2 214.8916667 0.000604147 
FRMD3 213.8875 0.000601324 
LRBA 213.8875 0.000601324 
hsa-mir-582 213.8875 0.000601324 
HIGD2A 213.8875 0.000601324 
OR4K15 213.8875 0.000601324 
TRIM74 213.8875 0.000601324 
FRMPD1 212.8833333 0.0005985 
HOXC10 212.8833333 0.0005985 
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LSM12 212.8833333 0.0005985 
MMRN1 212.8833333 0.0005985 
USP28 212.8833333 0.0005985 
WDR49 212.8833333 0.0005985 
hsa-mir-4712 212.8833333 0.0005985 
DDX11 212.8833333 0.0005985 
MYBPC3 212.8833333 0.0005985 
OR2T4 211.8791667 0.000595677 
ABLIM2 211.8791667 0.000595677 
EIF3D 211.8791667 0.000595677 
GID4 210.875 0.000592854 
ZNF335 210.875 0.000592854 
HIST1H2BK 208.8666667 0.000587208 
NOXO1 208.8666667 0.000587208 
LRP4 208.8666667 0.000587208 
C6orf201 207.8625 0.000584385 
TUBE1 207.8625 0.000584385 
SLC30A9 207.8625 0.000584385 
DTNBP1 206.8583333 0.000581562 
ENDOG 206.8583333 0.000581562 
ARFRP1 206.8583333 0.000581562 
CRYZL1 206.8583333 0.000581562 
KIAA1430 206.8583333 0.000581562 
MAGEB1 206.8583333 0.000581562 
SLC25A22 206.8583333 0.000581562 
SPARCL1 206.8583333 0.000581562 
PKN3 205.8541667 0.000578739 
ASB8 205.8541667 0.000578739 
OSTM1 205.8541667 0.000578739 
SLC38A2 205.8541667 0.000578739 
CACFD1 205.8541667 0.000578739 
HBA1 205.8541667 0.000578739 
OR6K6 205.8541667 0.000578739 
RPH3AL 205.8541667 0.000578739 
PLCE1 204.85 0.000575916 
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TNKS 204.85 0.000575916 
MAP1LC3B 203.8458333 0.000573092 
RAB2B 203.8458333 0.000573092 
SYNDIG1L 203.8458333 0.000573092 
ZNF804B 203.8458333 0.000573092 
MAGOHB 201.8375 0.000567446 
TMED10 201.8375 0.000567446 
NKX2-3 201.8375 0.000567446 
CT47A5 200.8333333 0.000564623 
TCEA1 200.8333333 0.000564623 
TP53TG3B 200.8333333 0.000564623 
ADAM33 199.8291667 0.0005618 
DACT2 199.8291667 0.0005618 
DMRTC1B 199.8291667 0.0005618 
EIF4G3 199.8291667 0.0005618 
ITGA8 198.825 0.000558977 
OR13C8 198.825 0.000558977 
PGK1 198.825 0.000558977 
AGGF1 198.825 0.000558977 
STAMBPL1 198.825 0.000558977 
ATP6V0A4 197.8208333 0.000556154 
COX14 197.8208333 0.000556154 
HNRNPH3 196.8166667 0.000553331 
FFAR2 195.8125 0.000550507 
hsa-let-7a-1 195.8125 0.000550507 
DEPDC1 195.8125 0.000550507 
SCNN1A 195.8125 0.000550507 
hsa-mir-432 194.8083333 0.000547684 
EBP 193.8041667 0.000544861 
CNIH4 193.8041667 0.000544861 
FASTK 193.8041667 0.000544861 
hsa-mir-3174 192.8 0.000542038 
DCXR 192.8 0.000542038 
INSIG1 192.8 0.000542038 
INSM2 192.8 0.000542038 
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LRIT3 191.7958333 0.000539215 
NPHP4 191.7958333 0.000539215 
CLTB 190.7916667 0.000536392 
RAD18 189.7875 0.000533569 
ERMP1 188.7833333 0.000530746 
R3HCC1L 188.7833333 0.000530746 
HHIP 186.775 0.000525099 
TRMT5 186.775 0.000525099 
FATE1 185.7708333 0.000522276 
MATN1 185.7708333 0.000522276 
TBX19 185.7708333 0.000522276 
TTC19 185.7708333 0.000522276 
IRX3 184.7666667 0.000519453 
NAV2 183.7625 0.00051663 
C10orf54 183.7625 0.00051663 
PITRM1 183.7625 0.00051663 
ACP6 182.7583333 0.000513807 
BOC 182.7583333 0.000513807 
GSTO1 181.7541667 0.000510984 
KIAA1191 181.7541667 0.000510984 
LEPROTL1 181.7541667 0.000510984 
NAE1 180.75 0.000508161 
RHOT1 180.75 0.000508161 
C4orf33 179.7458333 0.000505338 
DISP1 179.7458333 0.000505338 
UEVLD 179.7458333 0.000505338 
MPHOSPH6 177.7375 0.000499691 
SEMA5A 177.7375 0.000499691 
ITGA1 177.7375 0.000499691 
DEPDC1 176.7333333 0.000496868 
GUF1 176.7333333 0.000496868 
MOSPD1 176.7333333 0.000496868 
ZNF25 175.7291667 0.000494045 
VPS37A 173.7208333 0.000488399 
MED31 173.7208333 0.000488399 
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hsa-mir-585 172.7166667 0.000485576 
UNC13B 171.7125 0.000482753 
OIP5 171.7125 0.000482753 
hsa-mir-4799 170.7083333 0.00047993 
ARSF 170.7083333 0.00047993 
OGT 170.7083333 0.00047993 
RNF6 170.7083333 0.00047993 
hsa-mir-6723 169.7041667 0.000477106 
KLF12 167.6958333 0.00047146 
METTL21A 165.6875 0.000465814 
OR11H12 165.6875 0.000465814 
TENM2 162.675 0.000457345 
CA2 160.6666667 0.000451698 
FABP5 159.6625 0.000448875 
OR6K6 158.6583333 0.000446052 
BRINP2 155.6458333 0.000437583 
NLRP13 153.6375 0.000431937 
MLX 153.6375 0.000431937 
XPO1 152.6333333 0.000429114 
NRG3 150.625 0.000423467 
NR4A3 150.625 0.000423467 
TRIM34 149.6208333 0.000420644 
ARL8A 147.6125 0.000414998 
PRKRA 145.6041667 0.000409352 
BCKDK 145.6041667 0.000409352 
MYOD1 144.6 0.000406529 
UBE2L6 144.6 0.000406529 
CPNE5 144.6 0.000406529 
HMGB2 143.5958333 0.000403705 
SETD5 143.5958333 0.000403705 
COL5A3 142.5916667 0.000400882 
IFITM5 142.5916667 0.000400882 
SMIM22 142.5916667 0.000400882 
ACTN4 142.5916667 0.000400882 
KRT24 141.5875 0.000398059 
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PICALM 138.575 0.00038959 
CMYA5 137.5708333 0.000386767 
KCNMA1 137.5708333 0.000386767 
FAM153B 136.5666667 0.000383944 
ABL2 135.5625 0.000381121 
hsa-mir-151b 134.5583333 0.000378297 
EIF2B4 133.5541667 0.000375474 
ZMAT2 133.5541667 0.000375474 
CYP26A1 131.5458333 0.000369828 
SIGLEC12 131.5458333 0.000369828 
TIGD1 129.5375 0.000364182 
SERPINB9 128.5333333 0.000361359 
hsa-mir-4795 127.5291667 0.000358536 
SLC47A2 127.5291667 0.000358536 
SGPP1 125.5208333 0.000352889 
DPEP2 123.5125 0.000347243 
TMEM33 123.5125 0.000347243 
ZNF442 122.5083333 0.00034442 
OR8U1 122.5083333 0.00034442 
TP73 120.5 0.000338774 
CSMD2 119.4958333 0.000335951 
TTC33 119.4958333 0.000335951 
PYCRL 118.4916667 0.000333128 
ZFP90 116.4833333 0.000327481 
APOB 115.4791667 0.000324658 
FLNB 114.475 0.000321835 
BAI1 113.4708333 0.000319012 
NPC1L1 113.4708333 0.000319012 
RHOJ 113.4708333 0.000319012 
SETD4 113.4708333 0.000319012 
SMTN 113.4708333 0.000319012 
NUDT15 112.4666667 0.000316189 
CEP128 110.4583333 0.000310543 
DCAF8L2 105.4375 0.000296427 
LBP 103.4291667 0.000290781 
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IL27RA 102.425 0.000287958 
FERMT3 101.4208333 0.000285135 
hsa-mir-3913-2 101.4208333 0.000285135 
ZNF213 101.4208333 0.000285135 
OR5V1 100.4166667 0.000282312 
INSL6 96.4 0.000271019 
NonTargetingControlGuideForHuman_0578 96.4 0.000271019 
hsa-mir-3682 95.39583333 0.000268196 
hsa-mir-513b 91.37916667 0.000256903 
PTGES3L-AARSD1 90.375 0.00025408 
REV3L 89.37083333 0.000251257 
ZSCAN21 87.3625 0.000245611 
REV1 85.35416667 0.000239965 
MSRB3 84.35 0.000237142 
TBC1D10C 82.34166667 0.000231495 
DISC1 79.32916667 0.000223026 
RLF 77.32083333 0.00021738 
KIAA0930 76.31666667 0.000214557 
CRTAM 74.30833333 0.000208911 
OOEP 73.30416667 0.000206087 
ADSS 71.29583333 0.000200441 
NonTargetingControlGuideForHuman_0631 71.29583333 0.000200441 
CCHCR1 68.28333333 0.000191972 
CAMTA2 67.27916667 0.000189149 
LPAR6 67.27916667 0.000189149 
ARAF 66.275 0.000186326 
DDX49 65.27083333 0.000183502 
SLC39A13 63.2625 0.000177856 
ARL2BP 61.25416667 0.00017221 
FAM184A 60.25 0.000169387 
SLC15A4 57.2375 0.000160918 
PAFAH2 55.22916667 0.000155271 
hsa-mir-4679-1 52.21666667 0.000146802 
HADH 50.20833333 0.000141156 
LOC100144595 50.20833333 0.000141156 
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OR14I1 50.20833333 0.000141156 
TRIM15 50.20833333 0.000141156 
TSPAN9 50.20833333 0.000141156 
SLC7A11 50.20833333 0.000141156 
BCL2L1 49.20416667 0.000138333 
GM2A 48.2 0.00013551 
HNF1A 48.2 0.00013551 
PDE4B 47.19583333 0.000132686 
CARS2 44.18333333 0.000124217 
GNRH2 44.18333333 0.000124217 
MYOZ2 44.18333333 0.000124217 
VPS11 44.18333333 0.000124217 
MTRNR2L5 41.17083333 0.000115748 
CCL2 40.16666667 0.000112925 
PITPNM2 37.15416667 0.000104455 
C4orf32 35.14583333 9.8809E-05 
LHFPL5 35.14583333 9.8809E-05 
LOC391322 34.14166667 9.59859E-05 
OR5K4 33.1375 9.31628E-05 
CDKL3 32.13333333 9.03397E-05 
MON1B 32.13333333 9.03397E-05 
CYHR1 31.12916667 8.75166E-05 
IFNL3 30.125 8.46935E-05 
ATP1A1 27.1125 7.62241E-05 
KIAA1967 27.1125 7.62241E-05 
POU2F3 26.10833333 7.3401E-05 
MBD3L2 25.10416667 7.05779E-05 
CNRIP1 22.09166667 6.21085E-05 
ESYT2 21.0875 5.92854E-05 
RAB11FIP2 21.0875 5.92854E-05 
HMGN3 19.07916667 5.36392E-05 
USP7 19.07916667 5.36392E-05 
MTRNR2L7 18.075 5.08161E-05 
OR10A2 17.07083333 4.7993E-05 
MXRA7 16.06666667 4.51698E-05 
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XPNPEP1 16.06666667 4.51698E-05 
ZNF812 16.06666667 4.51698E-05 
hsa-mir-105-1 16.06666667 4.51698E-05 
CLMP 16.06666667 4.51698E-05 
OR2G3 15.0625 4.23467E-05 
POLR3H 15.0625 4.23467E-05 
NDUFS5 14.05833333 3.95236E-05 
ZMAT5 13.05416667 3.67005E-05 
hsa-mir-512-2 13.05416667 3.67005E-05 
ACPT 11.04583333 3.10543E-05 
PGAP1 11.04583333 3.10543E-05 
IMMT 11.04583333 3.10543E-05 
RUNDC3B 11.04583333 3.10543E-05 
HBD 10.04166667 2.82312E-05 
HMMR 10.04166667 2.82312E-05 
KCNK16 10.04166667 2.82312E-05 
CEACAM7 8.033333333 2.25849E-05 
WWP1 8.033333333 2.25849E-05 
DDOST 8.033333333 2.25849E-05 
PSORS1C2 8.033333333 2.25849E-05 
SFTPC 8.033333333 2.25849E-05 
CDH4 7.029166667 1.97618E-05 
GNAT3 7.029166667 1.97618E-05 
HTR1F 7.029166667 1.97618E-05 
USP17L20 7.029166667 1.97618E-05 
VSTM4 7.029166667 1.97618E-05 
hsa-mir-4491 7.029166667 1.97618E-05 
CYP4Z1 7.029166667 1.97618E-05 
HEYL 7.029166667 1.97618E-05 
DAZ2 6.025 1.69387E-05 
MAPK13 6.025 1.69387E-05 
MCM4 6.025 1.69387E-05 
SNCAIP 6.025 1.69387E-05 
PPIL2 6.025 1.69387E-05 
HMCES 5.020833333 1.41156E-05 
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DDB1 5.020833333 1.41156E-05 
CTH 4.016666667 1.12925E-05 
IFI30 4.016666667 1.12925E-05 
KPNA2 4.016666667 1.12925E-05 
CHRFAM7A 4.016666667 1.12925E-05 
MRGPRD 4.016666667 1.12925E-05 
FBXW4 3.0125 8.46935E-06 
C7orf10 3.0125 8.46935E-06 
GPATCH8 3.0125 8.46935E-06 
KRTAP5-5 3.0125 8.46935E-06 
PLB1 3.0125 8.46935E-06 
PRPF31 3.0125 8.46935E-06 
SLC20A1 3.0125 8.46935E-06 
WDR96 3.0125 8.46935E-06 
hsa-mir-920 3.0125 8.46935E-06 
BAGE2 3.0125 8.46935E-06 
C19orf81 3.0125 8.46935E-06 
SERPINB1 3.0125 8.46935E-06 
EFCAB4B 2.008333333 5.64623E-06 
ETV3 2.008333333 5.64623E-06 
RBM45 2.008333333 5.64623E-06 
SPATA31A5 2.008333333 5.64623E-06 
TTK 2.008333333 5.64623E-06 
CENPP 2.008333333 5.64623E-06 
COMMD9 2.008333333 5.64623E-06 
E2F3 2.008333333 5.64623E-06 
PAPOLB 2.008333333 5.64623E-06 
SLC51A 2.008333333 5.64623E-06 
TTC3 2.008333333 5.64623E-06 
CBFA2T3 1.004166667 2.82312E-06 
DNMT1 1.004166667 2.82312E-06 
KCNT2 1.004166667 2.82312E-06 
SF3B4 1.004166667 2.82312E-06 
SLC9B1 1.004166667 2.82312E-06 
STK36 1.004166667 2.82312E-06 
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TMOD2 1.004166667 2.82312E-06 
ZNF212 1.004166667 2.82312E-06 
hsa-mir-3130-2 1.004166667 2.82312E-06 
hsa-mir-4487 1.004166667 2.82312E-06 
hsa-mir-7152 1.004166667 2.82312E-06 
ADRA2C 1.004166667 2.82312E-06 
HP1BP3 1.004166667 2.82312E-06 
OR2F2 1.004166667 2.82312E-06 
PTRH2 1.004166667 2.82312E-06 
QDPR 1.004166667 2.82312E-06 
RANBP6 1.004166667 2.82312E-06 
UBE3C 1.004166667 2.82312E-06 
UGT2B28 1.004166667 2.82312E-06 
UHRF2 1.004166667 2.82312E-06 
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9.2.2 gRNA lists from the KCL22WT screen sample 2 
Gene WGKO-S2 WGKO-S2 % 
CDH4 35415241.35 98.98672400 
FAM3A 55706.65448 0.15570187 
MRFAP1L1 43845.00914 0.12254819 
TBC1D9 38425.11883 0.10739943 
ATG13 15337.98903 0.04287017 
ZBTB38 1316.402194 0.00367939 
ID3 1309.389397 0.00365978 
DEPTOR 1234.252285 0.00344977 
ZNF135 1205.199269 0.00336857 
CALU 1203.195612 0.00336297 
XAF1 1180.153565 0.00329857 
VWA3B 1172.13894 0.00327617 
ZFAND3 1169.133455 0.00326777 
ENKUR 1168.131627 0.00326496 
TTI1 1158.113346 0.00323696 
DMRT3 1157.111517 0.00323416 
AMIGO3 1152.102377 0.00322016 
IRX5 1136.073126 0.00317536 
TEX14 1130.062157 0.00315856 
CHST11 1127.056673 0.00315016 
RSPH10B 1106.018282 0.00309136 
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AURKA 1086.983547 0.00303815 
GABARAPL1 1081.974406 0.00302415 
S1PR2 1080.972578 0.00302135 
NonTargetingControlGuideForHuman_0696 1080.972578 0.00302135 
ARHGEF4 1077.967093 0.00301295 
SEPHS2 1077.967093 0.00301295 
KRT26 1074.961609 0.00300455 
NonTargetingControlGuideForHuman_0447 1066.946984 0.00298215 
MMP9 1054.925046 0.00294855 
CNTROB 1053.923218 0.00294575 
PSMB5 1051.919561 0.00294015 
C3orf83 1047.912249 0.00292895 
NPFFR2 1043.904936 0.00291775 
UCN3 1033.886654 0.00288975 
SLC12A4 1031.882998 0.00288415 
KIF6 1014.85192 0.00283654 
KAAG1 1010.844607 0.00282534 
EPS8L3 1004.833638 0.00280854 
GAST 1003.83181 0.00280574 
FZD6 1001.828154 0.00280014 
KLK8 999.8244973 0.00279454 
DNAJC3 997.820841 0.00278894 
EEF2K 996.8190128 0.00278614 
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LHFPL5 994.8153565 0.00278054 
hsa-mir-648 985.7989031 0.00275534 
PRSS56 976.7824497 0.00273014 
ANKH 976.7824497 0.00273014 
GRID2IP 973.7769653 0.00272174 
OR6N2 966.7641682 0.00270214 
CCL4L2 964.7605119 0.00269654 
FBXL4 960.7531993 0.00268534 
DCAF5 956.7458867 0.00267414 
ZNF383 954.7422303 0.00266853 
LRP5L 953.7404022 0.00266573 
hsa-mir-7849 951.7367459 0.00266013 
KLRC2 951.7367459 0.00266013 
MAP2K6 948.7312614 0.00265173 
TMED7-TICAM2 946.7276051 0.00264613 
MMGT1 941.7184644 0.00263213 
HSD17B8 938.7129799 0.00262373 
SKA2 929.6965265 0.00259853 
LFNG 923.6855576 0.00258173 
PCDH19 919.678245 0.00257053 
CNNM3 913.6672761 0.00255373 
OR51B2 905.6526508 0.00253133 
ZCCHC24 902.6471664 0.00252293 
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CAPZB 899.6416819 0.00251453 
LOC100652824 896.6361974 0.00250613 
hsa-mir-4478 894.6325411 0.00250053 
hsa-mir-642a 894.6325411 0.00250053 
CDKN2AIP 870.5886654 0.00243332 
SAAL1 863.5758684 0.00241372 
C16orf80 858.5667276 0.00239972 
FAM189B 857.5648995 0.00239692 
hsa-mir-5572 855.5612431 0.00239132 
CDY2A 843.5393053 0.00235772 
ACVRL1 842.5374771 0.00235492 
NonTargetingControlGuideForHuman_0694 842.5374771 0.00235492 
MTRNR2L7 840.5338208 0.00234932 
RBM14 831.5173675 0.00232412 
HLTF 824.5045704 0.00230452 
MFSD2B 823.5027422 0.00230172 
PDGFB 822.5009141 0.00229892 
NOTUM 820.4972578 0.00229332 
NEFM 819.4954296 0.00229052 
XPO7 817.4917733 0.00228492 
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